In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register.

The following guiding principles have been applied to the disclosure:

- *Information will be excluded in order to protect the privacy of patients and all named persons associated with the study*
- *Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the* ***GSK Clinical Study Register****.*
- *Aggregate data will be included; with any direct reference to individual patients excluded*

**Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered*

TITLE PAGE

Division:	ViiV Healthcare Global Medical Sciences	**eTrack Number:**	208674
		Compound number	GR109714+ GR63367
Information Type:	*Post hoc* Clinical Data Analysis	**Total No. of Pages**	566

Title:	Development of AntiRetroviral Therapy in Africa (DART) study *post hoc* safety data analysis comparing safety outcomes of study participants with baseline creatinine clearance of 30-49 mL/min vs participants with creatinine clearance of ≥50 mL/min

Description: This report describes the *post-hoc* analyses for the 96 week safety outcome comparison of study participants with baseline creatinine clearance (CLcr) of 30-49 mL/min vs participants with CLcr of ≥50 mL/min from the open-label Development of AntiRetroviral Therapy in Africa trial (DART), a randomized study where 3316 participants received an antiretroviral therapy regimen containing 150 mg twice daily dose of lamivudine; dosed as a fixed dose combination of lamivudine and zidovudine (COMBIVIR) plus a third antiretroviral drug of either tenofovir, abacavir or nevirapine.

Subject: DART, COMBIVIR, lamivudine, creatinine clearance, eGFR

Copyright 2018 ViiV Healthcare. All rights reserved. Unauthorized copying or use of this information is prohibited.

Table of Contents

Page

TITLE PAGE 1
SIGNATURE PAGES 4
ABBREVIATIONS 7
SUMMARY 9
1. INTRODUCTION 10
1.1. The DART Subgroup Analysis on Study Participants with Renal Dysfunction . 11
2. METHODS 12
2.1. Data Analysis 12
2.1.1. Methods for DART Data Analysis 12
3. RESULTS 13
3.1. DART Post hoc Study Population 13
3.2. DART Post hoc Clinical Laboratory Evaluations 16
3.2.1. DART Renal Function 16
3.2.2. DART Hematology 17
3.2.3. DART Clinical Chemistry 19
3.2.4. DART CD4+ Cell Counts 19
3.3. DART Post hoc Analysis of AEs 20
4. DISCUSSION 31
5. CONCLUSIONS 33
6. REFERENCES 34
SAFETY DATA SOURCE FIGURES 35
Figure 2.1 Plot of Mean Change from Baseline in eGFR (CGF) by Visit and Baseline CLcr (mL/min) (DART Subjects Population) 35
Figure 2.2 Plot of Mean Change from Baseline in CD4 Cell Counts by Visit, Treatment and Baseline CLcr (mL/min) (DART Subjects Population) 36
Figure 2.3 Plot of Mean Change from Baseline in Serum Creatinine by Visit, Treatment and Baseline CLcr (mL/min) (DART Subjects Population) 37
Figure 2.4 Plot of Mean (95% CI) eGFR (CGF) by Visit and Baseline CLcr (mL/min) (DART Subjects Population) 38
Figure 2.5 Plot of Mean (95% CI) eGFR (BSA-Adjusted CGF) by Visit and Baseline CLcr (mL/min) (DART Subjects Population) 39
Figure 2.6 Plot of Mean (95% CI) eGFR (MDRD) by Visit and Baseline CLcr (mL/min) (DART Subjects Population) 40
Figure 2.7 Plot of Mean (95% CI) eGFR (BSA-Adjusted MDRD) by Visit and Baseline CLcr (mL/min) (DART Subjects Population) 41
Figure 2.8 Plot of Common Adverse Events and Relative Risk - Any ART CLcr 30-49 vs Any ART CLcr>=50 (DART Subjects Population) 42
SAFETY DATA SOURCE TABLES 43
Table 2.1 Summary of Baseline ART regimens by Baseline CLcr (mL/min) (DART Subjects Population) 43
Table 2.2 Disposition of DART Safety Population by Treatment and Baseline CLcr (mL/min) (DART Subjects Population) 44

Table 2.3 Summary of Demographic Characteristics by Treatment and Baseline CLcr (mL/min) (DART Subjects Population) 45
Table 2.4 Summary of Frequency of Grade 3-4 AEs, SAEs and Deaths by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 48
Table 2.5 Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr (DART Subjects Population) 49
Table 2.6 Summary of Grade 3-4 Adverse Events Impacting >=5% of Subjects by System Organ Class and Baseline CLcr (DART Subjects Population) ... 56
Table 2.7 Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr (DART Subjects Population) 57
Table 2.8 Summary of Subject Visit Maximum Lab Toxicity Grade by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 64
Table 2.9 Summary of Change from Baseline over Time in Renal Function (eGFR) by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 68
Table 2.10 Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 72
Table 2.11 Summary of Subject Visit Maximum eGFR Toxicity Grade (NKF) by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 78
Table 2.12 Summary of Lab Measurements by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 80
Table 2.13 Summary of Change from Baseline over Time in CD4 Cell Counts by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 84
Table 2.14 Summary of Change from Baseline over Time in Serum Creatinine (mg/dL) by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 85
Table 2.15 Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min) (DART Subjects Population) 86
Table 2.16 Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min) (DART Subjects Population)..... 94
Table 2.17 Summary of Hematology Toxicity Shifts from Baseline (DART Subjects Population)..... 100
Table 2.18 Summary of Maximum Treatment Emergent Hematology Toxicities by Intensity (DART Subjects Population)..... 120
OTHER DATA LISTINGS..... 122
Listing 2.1 Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks (DART Subjects Population) 122
Listing 2.2 Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96 (DART Subjects Population) 198
Listing 2.3 Listing of all Deaths and SAEs up to 96 Weeks (DART Subjects Population)..... 245
Listing 2.4 Listing of All Clinical Grade 3 or 4 AEs (DART Subjects Population) 340
SDAP AMENDMENT 01 521

Authors:

PPD

PPD M.S.
Senior Investigator, ViiV Healthcare Global Medical Sciences

April 4, 2018
Date

PPD

PPD M.S.
Associate Director Biostatistics, PAREXEL International,

April 16, 2018
Date

PPD
Mature Marketed Products Pharmacovigilance Safety Scientist, GlaxoSmithKline

Date

PPD

PPD PharmD.
Global Medical Lead, ViiV Healthcare Global Medical Sciences

4/4/18
Date

Approved by

PPD

4April 18
Harmony Garges, M.D., M.P.H.
Vice President, ViiV Healthcare Global Medical Sciences

Effective Date

Nassrin Payvandi, PhD.,
Vice President, ViiV Healthcare Safety and Pharmacovigilance

Effective Date

Copyright 2018 ViiV Healthcare. All rights reserved. Unauthorized copying or use of this information is prohibited.

PPD

Authors:

PPD M.S.
Senior Investigator, ViiV Healthcare Global Medical Sciences

Date

PPD M.S.
Associate Director Biostatistics, PAREXEL International,

Date

PPD
PPD
Mature Marketed Products Pharmacovigilance Safety Scientist, GlaxoSmithKline

06/04/2018.
Date

PPD PharmD.
Global Medical Lead, ViiV Healthcare Global Medical Sciences

Date

Approved by

Harmony Garges, M.D., M.P.H.
Vice President, ViiV Healthcare Global Medical Sciences

Effective Date

Nassrin Payvandi, PhD.,
Vice President, ViiV Healthcare Safety and Pharmacovigilance

Effective Date

Copyright 2018 ViiV Healthcare. All rights reserved. Unauthorized copying or use of this information is prohibited.

PPD

Authors:

PPD M.S.
Senior Investigator, ViiV Healthcare Global Medical Sciences

Date

PPD M.S.
Associate Director Biostatistics, PAREXEL International,

Date

PPD
Mature Marketed Products Pharmacovigilance Safety Scientist, GlaxoSmithKline

Date

PPD PharmD.
Global Medical Lead, ViiV Healthcare Global Medical Sciences

Date

Approved by

Harmony Garges, M.D., M.P.H.
Vice President, ViiV Healthcare Global Medical Sciences

Effective Date

PPD

6/4/2018

Nassrin Payvandi, PhD.,
Vice President, ViiV Healthcare Safety and Pharmacovigilance

Effective Date

Copyright 2018 ViiV Healthcare. All rights reserved. Unauthorized copying or use of this information is prohibited.

PPD

ABBREVIATIONS

3TC	Lamivudine, EPIVIR
ABC	Abacavir sulfate, ZIAGEN
AE	Adverse Event
AIDS	Acquired immunodeficiency syndrome
ALT	Alanine aminotransferase
ART	Antiretroviral therapy
ARV	Antiretroviral drug
AST	Aspartate aminotransferase
AUC(0-∞)	area under the time curve from time zero (pre-dose) to infinity
BID	Twice-daily
BSA	Body surface area
CDM	Clinically driven monitoring
CGF	Cockcroft Gault Formula
CI	Confidence Interval
CLcr	Creatinine clearance
CL/F	Clearance following oral dosing
CNS	Central nervous system
DAIDS	United States Government Division of AIDS
DART	Development of AntiRetroviral Therapy in Africa
dL	Deciliter
eGFR	Estimated glomerular filtration rate
FDC	Fixed dose combination
g	Gram
GSK	GlaxoSmithKline
HIV	Human immunodeficiency virus
LCM	Laboratory clinical monitoring
MCV	Mean corpuscular volume
MDRD	Modification of diet in renal disease
MedDRA	Medical Dictionary for Regulatory Activities
mg	Milligram
min	minute
mL	Milliliter
mm^3	Cubic millimeter
MRC	Medical Research Council
NKF	National Kidney Foundation
NVP	Nevirapine
QD	Once-daily
SAE	Serious adverse event
SDAP	Summary document analysis plan
SOC	System organ class
STI	Structured treatment interruption
TDF	Tenofovir disoproxil fumarate
UK	United Kingdom
UTI	Urinary tract infection
vs	versus

WHO	World Health Organization
ZDV	Zidovudine, RETROVIR

Trademark Information

Trademarks of ViiV Healthcare
COMBIVIR
EPIVIR
RETROVIR
ZIAGEN

Trademarks not owned by ViiV Healthcare
None

SUMMARY

To evaluate the safety of increased lamivudine (3TC) exposure for patients with creatinine clearance (CLcr) 30-49 mL/minute (min), a *post hoc* safety analysis was conducted using data from the DART study (Development of AntiRetroviral Therapy in Africa), in which study participants received standard dosing of the fixed-dose combination (FDC) of lamivudine/zidovudine (3TC/ZDV; COMBIVIR) in combination with tenofovir (TDF), abacavir (ABC) or nevirapine (NVP). This study was sponsored and conducted by the United Kingdom (UK) Medical Research Council (MRC) at 4 sites in Africa. The study primary objective was to compare the impact of routine laboratory and clinical monitoring versus (vs) only clinical monitoring on long term clinical outcomes. This *post hoc* analysis stratified the study results by treatment regimen and baseline CLcr and compared the results from study participants with baseline CLcr 30-49 mL/min (n=168) vs those with baseline CLcr ≥50 mL/min (n=3,132).

Overall, the *post hoc* analysis demonstrated comparable safety outcomes over a period of 96 weeks for study participants that entered the study with baseline CLcr 30-49 mL/min compared to those with baseline CLcr ≥50 mL/min. The incidence of Grade 3-4 adverse events (AEs) and serious adverse events (SAEs) for hematological, hepatic and gastrointestinal events, the maximal toxicities for liver enzymes, serum creatinine and bilirubin (over time) and the maximum treatment emergent hematology toxicities were comparable in the group of DART participants with moderate renal impairment (CLcr 30-49 mL/min) vs those with higher CLcr (≥50 mL/min), with no meaningful trends identified in these parameters. The only organ system class in which Grade 3-4 AEs were reported in ≥5% of study participants in any treatment group was in hematology, and ranged from 21-24% of participants. Within this class, the proportion of some AEs or laboratory assessments was higher for patients with CLcr 30-49 mL/min vs those with CLcr >50 mL/min, which could be reflective of the small number of participants in these treatment groups or could be due to the poorer health typically observed in patients with moderate renal impairment.

No new risks or trends were identified from this dataset. Based on these results, it is expected that human immunodeficiency virus (HIV)-infected patients with CLcr of 30-49 mL/min would have similar AE risks in comparison to patients with CLcr ≥50 mL/min when using 3TC- containing FDCs.

1. INTRODUCTION

DART was an open label, non-inferiority, randomized study comparing two strategic approaches for the management of antiretroviral therapy (ART) in symptomatic HIV-infected adults in Africa. The study was conducted at three centers in Uganda and one in Zimbabwe and was funded by the UK MRC, the UK Department for International Development and the Rockefeller Foundation. GlaxoSmithKline (GSK), Gilead and Boehringer-Ingelheim provided study drugs; GSK also provided some of the study funding. All 3,316 participants were symptomatic, ART naive, HIV-infected African adults with CD4 counts less than 200 cells/mm^3. Each participant received 3TC/ZDV twice-daily (BID) as COMBIVIR (150 mg 3TC and 300 mg ZDV) in combination with a third drug. The third drug was TDF (245 mg) once-daily (QD) for 2,469 study participants, NVP (200 mg QD for 14 days followed by 200 mg BID thereafter) for 547 study participants and ABC (300 mg BID) for 300 study participants [DART, 2008; DART, 2010].

The initial randomization compared the use of clinically driven monitoring (CDM; n=1,660) to laboratory and clinical monitoring (LCM; n=1,656). The primary efficacy endpoint was progression to a new World Health Organization (WHO)-defined HIV Stage 4 disease or death. In both groups, study participants had hematology and liver function tests performed, but these results were not returned to clinicians caring for participants in the CDM group unless they were indicative of a Grade 4 AE or the results were requested by the clinician for a clinical reason.

There was also an additional sub-study randomization within DART. At Week 28, the initial 100 DART participants whose CD4+ cell counts were ≥300 cells/mm^3 were invited to participate in a small non-randomized pilot sub-study within DART. These participants then underwent a structured treatment interruption (STI) for 12 weeks. Following this pilot, the second randomization strategy compared STI (12 weeks on antiretroviral therapy (ART), 12 weeks off ART with continuous ART in study participants who had achieved CD4 cell counts ≥300 cell/mm^3 after 48 or 72 weeks. That portion of the study was terminated early in March 2006 due to demonstration that the STI arm was inferior (as demonstrated by a two-fold increase in the rate of disease progression) to continuous ART [DART, 2008]. As further described in Section 2.1.1, for these STI participants (n=225), data from study visits that occurred after the start of their first STI were excluded from this *post-hoc* analysis.

Due to the large number of study participants and the long-running nature of this study there have been multiple publications that have summarized various aspects of the DART results. One subsequent publication [DART, 2010] evaluated the 5-year survival rate, which was 87% in the CDM group and 90% in the LCM group. In the CDM group, 28% of participants and 21% in the LCM group developed a new WHO Stage 4 event or died. Differences in disease progression between treatment groups were observed from the third year on ART onwards, whereas higher rates of switch to second-line treatment occurred in LCM from the second year onwards in the study. The authors concluded that in resource constrained countries, such as Africa, ART may be delivered safely without routine laboratory monitoring for toxic effects. The authors did observe that there were differences in disease progression when evaluated long term (i.e. from second year

onwards) between the two groups and suggested a role for targeted monitoring of CD4-cell count from the second year of ART to guide the switch to second-line ART treatment.

1.1. The DART Subgroup Analysis on Study Participants with Renal Dysfunction

The recommended dose of 3TC of 300 mg once-daily or 150 mg twice-daily for patients with CLcr ≥50 mL/min and the current dose recommendations for 3TC by other CLcr categories was established on the basis of pharmacokinetic (PK) data obtained from the NUCA1004 study [Glaxo Report Number UCP/95/004, 1995; Heald, 1996], a phase 1 single dose study of HIV-infected study participants with impaired renal function. The results demonstrated that 3TC concentrations were increased in participants with varying degrees of renal impairment compared to those with normal renal function. The NUCA1004 findings were further supported by findings from a second phase 1 single dose PK study, NUCB1003 [Glaxo Report Number GCP/95/060, 1996] conducted to inform 3TC dosing in Hepatitis B-infected patients based on renal function (including hemodialysis). Adjustment of the 3TC dose was recommended for patients with CLcr <50 mL/min as determined from the linear relationship between 3TC clearance following oral dosing (CL/F) and CLcr based on renal function as 3TC is primarily eliminated as unchanged drug in the urine. Dose recommendations for 3TC were determined based on the linear relationship between 3TC clearance following oral dosing (CL/F) and CLcr in order to achieve a similar 3TC area under the time curve from time zero (pre-dose) to infinity [AUC(0-∞)] values across CLcr categories as detailed in the NUCA1004 and NUCB1003 study reports and was implemented for patients with reduced CLcr in the 3TC product labeling. For patients with CLcr 30-49 mL/min, the current recommended dose of 3TC is 150 mg once-daily (i.e., 50% reduced dose), since an approximately 2-fold increase in 3TC exposure was observed in this CLcr range. Since both NUCA1003 and NUCB1003 were single dose studies, these dosing recommendations were based on PK and did not address long term safety or toxicity.

A prior DART publication had reported that a total of 1492 (45%) of enrolled DART participants had mild reductions in estimated glomerular filtration rate (eGFR) (≥60 but <90 mL/min/1.73 m^2) while 237 participants (7%) had moderate (≥30 but <60 mL/min/1.73 m^2) reductions in eGFR [Reid, 2008]. Since each participant received 3TC/ZDV as a FDC (COMBIVIR) in combination with a third drug, in order to better evaluate the risk: benefit ratio of using standard doses of 3TC in patients with CLcr 30-49 mL/min, a *post hoc* analysis of the safety data from this study was performed.

2. METHODS

2.1. Data Analysis

A *post hoc* analysis was conducted to evaluate safety outcomes for DART study participants using datasets provided by the MRC to ViiV Healthcare. The MRC had not previously performed analyses evaluating safety outcomes for DART study participants with baseline CLcr of 30-49 mL/min compared to study participants with baseline CLcr of ≥50 mL/min.

The DART study participants were not randomized or stratified based on baseline CLcr categories [DART, 2010]. The DART study team had previously published comparisons of the treatment regimens by the following baseline CLcr categories: CLcr <30 mL/min/1.73 m^2; CLcr ≥30 but <60 mL/min/1.73 m^2 and CLcr ≥60 but <90 mL/min/1.73 m^2 [Reid, 2008; Stohr, 2011] publications. As this was a *post-hoc* subgroup analysis of data from the DART study participants using the currently approved 3TC label defined CLcr categories (<30 mL/min; 30-49 mL/min; ≥50 mL/min), limited statistical evaluation was performed.

2.1.1. Methods for DART Data Analysis

The DART demographic and safety data though 96 weeks was obtained from the MRC and subsequently analyzed by the GSK and ViiV statistics team as detailed in the summary document analysis plan (SDAP). The original study internal DART study designation was COL30515, however for purposes of *post hoc* analysis reporting a separate designation (study number 208674) has subsequently been assigned; however, the SAS files have utilized the original designation (COL30515). Baseline eGFRs were calculated by the DART team using the baseline serum creatinine measurements, and multiple methods including the Cockcroft and Gault formula (CGF) [Cockcroft, 1976] and modification of diet in renal disease (MDRD) formulas. CLcr calculations were conducted with or without adjustment/normalization for body surface area (BSA).

The safety data have been analyzed and summarized by ART regimen and by the following baseline CLcr categories: ≥50 mL/min, 30-49 mL/min and <30 mL/min. The CLcr groups created in this *post hoc* analysis used baseline (unadjusted for BSA) CGF CLcr values.

There are several limitations with regards to this data set. This was not a ViiV sponsored trial and all data analyzed here was obtained *post hoc* after trial completion. This trial investigated whether routine toxicity and efficacy measures of HIV-infected study participants receiving ART had an important long-term effect on clinical outcomes in Africa. Routine viral load, as measured by HIV-1 RNA, and resistance testing were not performed prospectively. Treatment switches were guided by immunological (CD4+ cell counts) and clinical parameters only. Additionally, as the randomization was to either CDM (i.e. limited local laboratory values provided unless a Grade 4 toxicity or physician request for a clinical reason) vs LCM, there may have been a bias in the study between the two randomized groups with regards to AE reporting. However, within this *post hoc* analysis, the data have been summarized by baseline CLcr levels without regard to the

original CDM vs LCM randomization. Assuming random distribution of both groups throughout the CLcr categories, some of this reporting bias against a single group may have been reduced.

Data from participants who took part in an STI were excluded from this *post-hoc* analysis after the start of their STI (if it occurred within the first 96 weeks of treatment). In this study, serum calcium and phosphate and urinalysis were not routinely performed. Local laboratories were used for measurement of serum creatinine and no specific calibration was undertaken across centers. Limitations with respect to the AE reporting and coding system are further detailed in Section 3.3.

3. RESULTS

3.1. DART *Post hoc* Study Population

The summary of baseline ART regimens by baseline CLcr for the HIV-infected, ART-naive DART study participants is summarized in Table 1.

Table 1 Summary of Baseline ART regimens by Baseline CLcr (mL/min) in the DART Study

Regimen	CLcr ≥50 (n=3132) n (%)	CLcr 30-49 (n=168) n (%)	Any CLcr <30 (n=13) n (%)	Total (n=3316)[1]
3TC/ZDV + TDF	2335 (75)	122 (73)	9 (69)	2469 (74)
3TC/ZDV + ABC	272 (9)	27 (16)	1 (8)	300 (9)
3TC/ZDV + NVP	525 (17)	19 (11)	3 (23)	547 (16)

Source Table 2.1

1. There were 3 participants with missing baseline CLcr and these were only included in total column

All study participants received 3TC/ZDV as COMBIVIR, in combination with a third antiretroviral drug (ARV; either TDF or ABC or NVP). Study enrollment occurred between January, 2003 through October, 2004. The study continued for a period of 5 years.

There were 168 participants enrolled into DART with CLcr 30-49 mL/min, of which 46 participants received either ABC or NVP as the third ARV. These 168 participants constitute the group of particular interest in order to assess long term safety of a standard dose of 150 mg BID 3TC (administered as COMBIVIR) in HIV-1 infected study participants with impaired renal function with CLcr 30-49 mL/min. Since TDF is known to impact renal function and TDF plasma levels are affected by renal function, the TDF-treated participants were analyzed separately.

The demographics of the DART study participants were summarized by treatment regimen and by baseline CLcr (Table 2). All study participants were African (from Uganda or Zimbabwe). Overall, demographic characteristics were well balanced across the CLcr defined treatment groups. The majority were women (65%); women who had previously received only short-course ART to prevent mother-to-child transmission were considered ART-naïve for purposes of enrollment into DART. The median age of the

participants was 36.8 years. The median BSA adjusted baseline eGFR was 89 mL/min/1.73 m^2 (Table 3).

Overall, approximately half of the participants had positive test results at screening for Hepatitis B (53%), while 56% had advanced HIV disease (WHO Stage 3). The ABC or NVP baseline CLcr 30-49 mL/min treatment group had a higher percentage (63%) of participants with WHO Stage 3 status at entry than the TDF baseline CLcr 30-49 mL/min group. This baseline information and overall the median entry CD4 cell count of 86 cells/mm^3 were indicative of a population which was sicker at entry, when compared to ART-naïve HIV-infected study participants in resource rich countries [Elion, 2006, Squires, 2010]. As the primary objective of the full DART trial was to assess whether routine toxicity and efficacy monitoring had important long term effects on clinical outcomes, no baseline HIV viral loads were prospectively reported.

Table 2 DART Study Demographic Characteristics Summarized by Treatment Regimen and by Baseline CLcr (mL/min)

Baseline[1]	TDF containing ART		ABC or NVP containing ART		ANY ART			Overall (N=3316)
	CLcr ≥50 (n=2335)	CLcr 30-49 (n=122)	CLcr ≥50 (n=797)	CLcr 30-49 (n=46)	Any CLcr ≥50 (n=3132)	Any CLcr 30-49 (n=168)	Any CLcr <30 (n=13)	
Median Age (year)	36.5	41.2	36.6	44.1	36.5	41.3	38.2	36.8
Sex, n (%)								
Male	860 (37)	33 (27)	252 (32)	10 (22)	1112 (36)	43 (26)	3 (23)	1160 (35)
Female	1475 (63)	89 (73)	545 (68)	36 (78)	2020 (64)	125 (74)	10 (77)	2156 (65)
Median CD4 cells/mm^3	81.0	85.5	98.0	102.5	85.0	89.0	101.0	86.0
World Health Organization Disease Stage, n (%)	2335	122	797	46	3132	168	13	3316
Stage 2	449 (19)	26 (21)	189 (24)	7 (15)	638 (20)	33 (20)	1 (8)	673 (20)
Stage 3	1294 (55)	55 (45)	476 (60)	29 (63)	1770 (57)	84 (50)	8 (62)	1864 (56)
Stage 4	592 (25)	41 (34)	132 (17)	10 (22)	724 (23)	51 (30)	4 (31)	779 (23)
Hepatitis B Status n (%)	2335	122	797	46	3132	168	13	3316
Positive	1236 (53)	65 (53)	443 (56)	24 (52)	1679 (54)	89 (53)	5 (38)	1774 (53)
Negative	1097 (47)	57 (47)	352 (44)	22 (48)	1449 (46)	79 (47)	7 (54)	1537 (46)
Missing	2 (<1)	0	2 (<1)	0	4 (<1)	0	1 (8)	5 (<1)

Source Table 2.3

1. Race is not captured as all participants were African. Viral load at baseline was not reported.

Baseline eGFR for the DART participants had previously been calculated by the MRC with and without normalization for BSA using the CGF or MDRD formulas and these

were used to calculate the median values when grouped by ART treatment and by baseline CLcr and as summarized in Table 3.

Table 3 DART Participants Baseline eGFRs as Summarized by Treatment Regimen and by Baseline CLcr (mL/min) category

Baseline	TDF containing ART		ABC or NVP containing ART		ANY ART			Overall
	CLcr ≥50 (n=2335)	CLcr 30-49 (n=122)	CLcr ≥50 (n=797)	CLcr 30-49 (n=46)	CLcr ≥50 (n=3132)	CLcr 30-49 (n=168)	CLcr <30 (n=13)	Total (n=3316)
Median eGFR (CGF) (mL/min)	85.4	44.3	81.8	44.9	84.4	44.4	27.4	82.8
Median BSA-adjusted-eGFR (CGF) (mL/min/1.73 m^2)	91.6	52.3	87.9	52.7	90.3	52.5	30.7	88.9
Median MDRD (mL/min)	106.9	62.0	100.6	64.6	105.2	63.2	32.9	103.4
Median BSA-adjusted MDRD (mL/min/1.73 m^2)	100.0	53.6	93.6	54.6	98.1	54.2	29.4	96.3

Source Table 2.3

As summarized in Table 4, 71% of the 3,316 DART participants remained in the study through Week 96. Seven percent of the DART participants (225 of the 3316 participants) had an STI prior to Week 96 (including the initial pilot and the second randomization); data from these STI participants were excluded from this *post-hoc* analysis for all study visits after the start of their first STI.

Table 4 Disposition of the DART Safety Population Summarized by Treatment Regimen and by Baseline CLcr (mL/min)

	TDF CLcr ≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr ≥50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)	Total (N=3316)
Visit at Week 0 n (%)	2335 (100%)	122 (100%)	797 (100%)	46 (100%)	13 (100%)	3316 (100%)
Visit at Week 24 n (%)	2206 (94%)	112 (92%)	758 (95%)	39 (85%)	8 (62%)	3126 (94%)
Visit at Week 48 n (%)	2168 (93%)	109 (89%)	747 (94%)	37 (80%)	9 (69%)	3073 (93%)
Visit at Week 96 n (%)	1660 (71%)	90 (74%)	566 (71%)	27 (59%)	4 (31%)	2349 (71%)
Had STI during 96 weeks n (%)	162 (7%)	5 (4%)	53 (7%)	3 (7%)	2 (15%)	225 (7%)

Source Table 2.2

3.2. DART *Post hoc* Clinical Laboratory Evaluations

All available clinical laboratory data for study participants was summarized for Week 0, 24, 48 and Week 96. As previously noted, STI participant data were censored after the start of their STI (if it occurred within the first 96 weeks) and per DART study design, laboratory results were routinely returned to the physicians for the participants who were randomized to the LCM group but not provided for the CDM group. Results for CDM participants were only provided upon request by physician or if there was a Grade 4 laboratory toxicity effect. The DAIDS grading scale [DART, 2010] was used for laboratory grading and the National Kidney Foundation (NKF) grading scale was used for the eGFR grading for the DART study participants [Levy, 2003].

3.2.1. DART Renal Function

The *post hoc* analysis of the mean change in eGFR (BSA-adjusted CGF) over time and by treatment group is presented in Figure 1. The dotted lines represent the upper limit of each of the NKF toxicity grades of BSA-adjusted eGFR. The NKF eGFR Grade 1 is 60-<90 mL/min/1.73m^2, Grade 2 is 30-60 mL/min/1.73m^2 and Grade 3 is 15 to <30 mL/min/1.73m^2. The study participants who enrolled with CLcr ≥50 mL/min had very small mean changes (<7 mL/min) in adjusted eGFR values over 96 weeks; however, there was a substantial increase (>25 mL/min) in the mean eGFR of the participants entering the study with CLcr<30-49 mL/min.

Figure 1 Figure of mean (95% CI) eGFR (BSA-adjusted CGF) by Visit and Baseline CLcr



CI - Confidence Interval
Source Figure 2.1

The median change from baseline in eGFR using both the CGF and the MDRD, adjusted and unadjusted for BSA are summarized in Table 5. Substantial increases in the median eGFR (>22 mL/min) were observed over time by each of the formulas for calculating eGFR for the participants who entered the study with CLcr 30-49 mL/min, while no increase or smaller median changes in eGFR (9 mL/min) were observed by any of these formulas in those participants who entered the study with CLcr ≥50 mL/min.

Table 5 Summary of eGFR Median Change from Baseline By Treatment and Baseline CLcr (mL/min) Categories with CGF and MDRD Calculations

	TDF CLcr≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr≥50 (N=797)	ABC or NVP CLcr 30-49 (N=46)
CGF at Week 24	2.8	17.1	5.9	22.5
CGF at Week 48	3.3	18.8	7.5	24.7
CGF at Week 96	2.4	23.9	8.6	26.6
BSA-adjusted CGF at Week 24	0.4	16.7	3.8	23.4
BSA-adjusted CGF at Week48	-0.7	18.0	4.2	24.8
BSA-adjusted CGF at Week 96	-0.9	22.9	5.7	27.8
MDRD at Week 24	-4.6	19.7	1.1	30.1
MDRD at Week 48	-6.9	16.2	-0.5	29.9
MDRD at Week 96	-6.3	25.8	2.6	30.9
BSA-adjusted MDRD at Week 24	-1.1	19.1	3.6	27.9
BSA-adjusted MDRD at Week 48	-2.5	19.5	3.0	26.8
BSA-adjusted MDRD at Week 96	-2.6	26.0	6.0	29.0
Source Table 2.9				

3.2.2. DART Hematology

The hematology panel performed in the DART study included measurements of hemoglobin, lymphocytes, mean corpuscular volume (MCV), neutrophils, platelets and white blood cells. The change from baseline results at Week 96 are shown in Table 6 and the maximum toxicity through Week 96 are shown in Table 7. The change in hematology laboratory values were very similar when comparing the treatment groups of participants with baseline CLcr 30-49 mL/min to those participants with baseline CLcr ≥50 mL/min, except for hemoglobin, which had higher mean increases in the participants with CLcr 30-49 mL/min. This difference is likely due to differences in baseline mean hemoglobin across group.

This hematology data demonstrates that for this population, use of the standard dose of 3TC administered as COMBIVIR did not have an adverse impact on these parameters.

Table 6 Summary of Hematology Labs Mean Change from Baseline Through Week 96 by Treatment and Baseline CLcr (mL/min) Categories

	TDF CLcr≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr≥50 (N=797)	ABC or NVP CLcr 30-49 (N=46)
Number of participants at Week 96	1713	90	582	27
Hemoglobin (g/dL) (min, max)	1.37 (-6.4, 9.4)	1.98 (-7.6, 6.0)	1.27 (-6.4, 6.8)	1.89 (-1.2, 7.2)
Number of participants at Week 96	1709	90	582	27
Lymphocytes (x10^3 cells/µL) (min, max)	0.18 (-3.8, 5.4)	0.11 (-2.5, 2.8)	0.14 (-2.7, 4.8)	0.22 (-0.8, 2.0)
Number of participants at Week 96	1711	90	582	27
MCV (femtoliters/cell) (min, max)	14.5 (-54.5, 78.9)	17.8 (-16.0, 79.4)	18.9 (-12.5, 86.1)	19.2 (-3.0, 39.0)
Number of participants at Week 96	1705	90	578	27
Neutrophils (x10^3 cells/µL) (min, max)	0.00 (-11.5, 10.1)	0.02 (-7.2, 6.6)	0.00 (-6.2, 5.8)	-0.01 (-1.6, 1.8)
Number of participants at Week 96	1710	90	581	27
Platelets (x10^3 cells/µL) (min, max)	55.5 (-367.0, 543.0)	55.8 (-189.0, 328.0)	40.5 (-467.0, 323.0)	14.6 (-201.0, 166.0)
Number of participants at Week 96	1711	90	582	27
White Blood Cells (x10^3 cells/µL) (min, max)	0.17 (-13.4, 13.6)	-0.09 (-8.0, 6.1)	-0.02 (-8.8, 6.7)	0.07 (-1.8, 3.5)

MCV: Mean Corpuscular Volume
Source Table 2.16

A small number of patients had Grade 3 or 4 maximal laboratory toxicity measurements for the hematology laboratory assessments (Table 7). The maximal toxicity (grades 3 and 4) for neutrophils was slightly higher in the CLcr 30-49 mL/min group, but these differences between groups for maximum hematology laboratory toxicity measurement were not consistent or were likely due to small numbers in some of the treatment groups.

Table 7 Summary of Maximum Hematology Laboratory Toxicity Over 96 Weeks by Treatment and Baseline CLcr(mL/min) Categories

	TDF CLcr≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr≥50 (N=797)	ABC or NVP CLcr 30-49 (N=46)
Hemoglobin (g/dL)				
Grade 3 n (%)	8 (<1%)	0	3 (<1%)	1 (2%)
Grade 4 n (%)	19 (<1%)	2 (2%)	7 (<1%)	0
Neutrophils (x 10^3cells/µl)				
Grade 3 n (%)	228 (10%)	15 (12%)	84 (11%)	6 (13%)
Grade 4 n (%)	112 (5%)	9 (7%)	28 (4%)	4 (9%)
Platelets (x 10^3cells/µl)				
Grade 3 n (%)	17 (<1%)	1 (<1%)	9 (1%)	2 (4%)
Grade 4 n (%)	3 (<1%)	0	2 (<1%)	0

	TDF CLcr≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr≥50 (N=797)	ABC or NVP CLcr 30-49 (N=46)
White Blood Cells (x 10^3cells/µl)				
Grade 3 n (%)	119 (5%)	10 (8%)	33 (4%)	1 (2%)
Grade 4 n (%)	2 (<1%)	1 (<1%)	0	1 (2%)

Source Table 2.18

3.2.3. DART Clinical Chemistry

The maximal DAIDS toxicity grading during the 96-week treatment period for the laboratory values for alanine aminotransferase (ALT) aspartate aminotransferase (AST), serum creatinine and bilirubin have been summarized in Table 8. Overall, the maximal toxicities reported across the treatment and CLcr groups were similar, with very few incidences of Grades 3 and 4 laboratory toxicities and no trend of increase in toxicities grades over time.

Table 8 Summary of Maximum Toxicity at Week 96 of ALT, AST, Serum Creatinine and Bilirubin by Treatment and Baseline CLcr (mL/min) Categories

Analyte	TDF CLcr≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr≥50 (N=797)	ABC or NVP CLcr 30-49 (N=46)
ALT				
Grade 3 n (%)	2 (1<%)	0	0	1 (2%)
Grade 4 n (%)	1 (1<%))	0	0	0
AST				
Grade 3 n (%)	0	0	1 (<1%)	1 (2%)
Grade 4 n (%)	2 (<1%)	0	0	0
Serum Creatinine				
Grade 3 n (%)	1(1<%)	0	0	0
Grade 4 n (%)	0	0	0	0
Bilirubin				
Grade 3 n (%)	8 (<1%)	1 (<1%)	1 (<1%)	0
Grade 4 n (%)	1 (<1%)	0	1 (<1%)	0

Source: Table 2.8

3.2.4. DART CD4+ Cell Counts

Immunologic activity over time was compared using changes from baseline at each visit. There were similar increases in CD4+ cell counts from baseline over time in all treatment groups. The mean change from baseline to Week 96 in CD4+ cells counts was 167.6 cells/mm^3 in the 3TC/ZDV + TDF baseline CLcr 30-49 mL/min -treated group and 181.2 cells/mm^3 in the 3TC/ZDV + ABC or NVP baseline CLcr 30-49 mL/min-treated group (Source Table 2.13; Figure 2).

Figure 2 Mean Change from Baseline in CD4 Cell Counts over 96 Weeks of Treatment



Source Figure 2.2

3.3. DART *Post hoc* Analysis of AEs

The AE/SAE coding system used in the DART trial was developed specifically for that trial by physicians in Africa based on diseases likely to occur in that setting. For all AE/SAEs, the DART team provided the coded terms; Medical Dictionary for Regulatory Activities (MedDRA) coding was not used. The DART protocol explicitly exempted any AEs and SAEs judged by the investigator to be a consequence of HIV-infection alone to avoid double counting disease events in their primary analysis and they only collected Grade 3-4 AEs. Per communication from the DART team, often the AE/SAE terms would be associated with additional terms by the treating physician (such as diagnosis, signs and symptoms) and for such instances, the first term would represent the primary event which would then be coded to the system organ class. These additional terms (such as diagnosis, signs and symptoms) were not coded separately. SAEs and deaths which were judged by the physician to be solely HIV-related were not reported as SAEs.

Overall, 28% of participants experienced Grade 3-4 AEs, 9% reported SAEs and 5% of participants died during the 96-week treatment period. These rates were similar across treatment groups (Table 9) with differences between treatment groups due to the small numbers in the treatment groups with CLcr 30-49mL/min. Over 96 weeks of treatment,

the AE profile of 3TC/ZDV with ABC NVP or TDF in participants with baseline CLcr of 30-49 mL/min was comparable to the overall safety profile in the other treatment groups.

Table 9 Summary of Number of Participants Experiencing G3-4 AEs, SAEs or Death for by Treatment and Baseline CLcr (mL/min) Categories

	TDF CLcr 30-49 (n=122)	ABC or NVP CLcr 30-49 (n=46)	Any ART CLcr ≥50 (n=3132)	Any ART CLcr 30-49 (n=168)	Overall (n=3316)
Grade 3-4 AEs n (%)	41 (34)	14 (30)	850 (27)	55 (33)	912 (28)
SAEs n (%)	12 (10)	7 (15)	261 (8)	19 (11)	283 (9)
Deaths n (%)	10 (8)	5 (11)	136 (4)	15 (9)	155 (5)
Deaths with no associated SAEs	5 (4)	1 (2)	76 (2)	6 (4)	84 (3)

Source Table 2.4

Table 10 presents a summary of the Grade 3-4 events reported in the trial for those AEs which occurred in ≥5% of study participants in any treatment group. Hematological AEs were the only organ system class where these events were reported in ≥5% of study participants in any treatment group, with the most frequent AE reported within this class being neutropenia. The incidence of Grade 3-4 hematological AEs were comparable across treatment groups (21-24%), as was the incidence of specific events for neutropenia (16-18%) and anemia (7-9%).

Table 10 Summary of Grade 3-4 AEs Occurring in ≥5% of Participants in any Treatment Group

DART Defined System Organ Class Preferred Term[1]	TDF CLcr ≥50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr ≥50 (N=797	ABC or NVP CLcr 30-49 (N=46)
ANY EVENT n (%)	632 (27%)	41 (34%)	218 (27%)	14 (30%)
Hematological				
Any Event n (%)	518 (22%)	29 (24%)	171 (21%)	11 (24%)
Neutropenia n (%)	371 (16%)	22 (18%)	130 (16%)	8 (17%)
Anemia with clinical symptoms n (%)	181 (8%)	8 (7%)	53 (7%)	4 (9%)

Source Table 2.6.

1. DART defined the first term as the primary term which was coded to the system organ class and when study physicians' reported additional diagnoses, signs and symptoms, these were listed after the primary term and were not coded separately

Table 11 presents a summary of the Grade 3-4 events reported in the trial, which occurred in at least 2% of study participants in any treatment group by system organ class and for specific AEs within these classes (including AEs occurring in ≥5% of participants described in Table 10). Hematological AEs occurred most frequently in all groups. In addition to neutropenia and anemia with clinical symptoms, pancytopenia with possible bone marrow depression and thrombocytopenia were reported in incidences ≤2% in at least one treatment group, but the incidence was comparable across treatment groups (<1-

2% across treatment groups for both events). In addition to hematological AEs, Grade 3-4 AEs were reported for any treatment group for cardiovascular and gastrointestinal organ classes with comparable incidence (0-2% by treatment group for any specific event within these classes) and in small numbers of participants. The overall incidence of grade 3-4 AEs for all other system organ classes was comparable across treatment groups and number of study participants with specific events within each class were small.

Table 11 Summary of Grade 3-4 AEs Occurring in ≥2% of Participants of any Treatment Group

DART Defined System Organ Class Preferred Term[1]	**TDF CLcr ≥50 (N=2335)** n (%)	**TDF CLcr 30-49 (N=122)** n (%)	**ABC or NVP CLcr ≥50 (N=797** n (%)	**ABC or NVP CLcr 30-49 (N=46)** n (%)
ANY EVENT	632 (27%)	41 (34%)	218 (27%)	14 (30%)
Hematological				
Any Event	518 (22%)	29 (24%)	171 (21%)	11 (24%)
Neutropenia	371 (16%)	22 (18%)	130 (16%)	8 (17%)
Anemia with clinical symptoms	181 (8%)	8 (7%)	53 (7%)	4 (9%)
Pancytopenia, bone marrow depression	11 (<1%)	2 (2%)	3 (<1%)	1 (2%)
Thrombocytopenia	8 (<1%)	1 (<1%)	1 (<1%)	1 (2%)
Cardiovascular				
Any event	29 (1%)	5 (4%)	6 (<1%)	1 (2%)
Deep vein thrombosis	7 (<1%)	0	6 (<1%)	1 (2%)
Hypotension/shock/toxic shock	4 (<1%)	2 (2%)	0	0
Hepatic				
Any event	29 (1%)	0	12 (2%)	1 (2%)
Lactic acidosis	14 (<1%)	0	3 (<1%)	1 (2%)
Gastrointestinal				
Any event	30 (1%)	5 (4%)	5 (<1%)	0
Vomiting	13 (<1%)	3 (2%)	2 (<1%)	0
Systemic[2]				
Any event	8 (<1%)	0	12 (2%)	0
Renal				
Any event	12 (<1%)	2 (2%)	1 (<1%)	0
Renal failure – chronic	1 (<1%)	2 (2%)	0	0
Specific Infections				
Any event	14 (<1%)	1 (<1%)	1 (<1%)	1 (2%)
P Falciparum malaria	14 (<1%)0	0	1 (<1%)	1 (2%)
Lower respiratory tract				
Any event	6 (<1%)	2 (2%)	1 (<1%)	0
Other[3]				
Any event	3 (<1%)	0	0	1 (2%)
Overdose (not suicide attempt)	0	0	0	1 (2%)

Source Table 2.5
1. DART defined the first term as the primary term which was coded to the system organ class and when study physicians' reported additional diagnoses, signs and symptoms, these were listed after the primary term and were not coded separately.
2. Systemic events as defined by the DART team include events of hypersensitivity reaction, malaise, tiredness, acute febrile episode, dehydration, recurrent fever and Stevens-Johnson syndrome
3. Other events as defined by the DART team include non-fatal trauma and overdose (not suicide attempt).

Table 12 presents a summary of the Grade 3-4 events reported in the trial for those AEs, which occurred in at least one study participant with baseline CLcr 30-49 mL/min. If there were no events reported in those participants, only the overall incidence in that particular system organ class (SOC) was reported. Hematological AEs occurred most frequently in all groups. The incidence was 24% for participants with CLcr 30-49 mL receiving either TDF or non-TDF containing regimens, while similar frequencies of hematological events were also observed for participants with CLcr ≥50 mL/min (22% and 21% for TDF or non-TDF containing regimen respectively). Neutropenia and anemia with clinical symptoms were frequently reported in both groups but were overall comparable (16% vs. 17% for neutropenia and 7% vs. 9% for anemia with clinical symptoms in groups CLcr ≥50 and CLcr 30-49, respectively). The incidence of other Grade 3-4 AES by organ class were comparable across treatment groups and included small numbers of study participants for specific events.

Table 12 Summary of Grade 3-4 AEs in ≥1 Participants with Baseline CLcr 30-49 (mL/min) and AE by Treatment and by Baseline CLcr (mL/min)

DART Defined System Organ Class Preferred Term[1]	TDF CLcr ≥50 (N=2335) n (%)	TDF CLcr 30-49 (N=122) n (%)	ABC or NVP CLcr ≥50 (N=797 n (%)	ABC or NVP CLcr 30-49 (N=46) n (%)
ANY EVENT	632 (27%)	41 (34%)	218 (27%)	14 (30%)
Hematological				
Any Event	518 (22%)	29 (24%)	171 (21%)	11 (24%)
Neutropenia	371 (16%)	22 (18%)	130 (16%)	8 (17%)
Anemia with clinical symptoms	181 (8%)	8 (7%)	53 (7%)	4 (9%)
Pancytopenia, bone marrow depression	11 (<1%)	2 (2%)	3 (<1%)	1 (2%)
Thrombocytopenia	8 (<1%)	1 (<1%)	1 (<1%)	1 (2%)
CNS				
Any event	30 (1%)	1 (<1%)	11 (1%)	0
Hemiparesis	0	1 (<1%)	0	0
Cardiovascular				
Any event	29 (1%)	5 (4%)	6 (<1%)	1 (2%)
Deep vein thrombosis	7 (<1%)	0	6 (<1%)	1 (2%)
Congestive cardiac failure	9 (<1%)	1 (<1%)	0	0
Hypotension/shock/toxic shock	4 (<1%)	2 (2%)	0	0
Other cardiovascular	2 (<1%)	1 (<1%)	0	0
Chest pain	0	1 (<1%)	0	0
Hepatic				
Any event	29 (1%)	0	12 (2%)	1 (2%)
Lactic acidosis	14 (<1%)	0	3 (<1%)	1 (2%)
Jaundice	3 (<1%)	0	1 (<1%)	0
Gastrointestinal				
Any event	30 (1%)	5 (4%)	5 (<1%)	0
Vomiting	13 (<1%)	3 (2%)	2 (<1%)	0
Acute diarrhea no pathogen, idiopathic AIDS enteropathy	6 (<1%)	1 (<1%)	0	0
Indigestion, esophageal reflux, gastritis, ulcerative esophagitis	0	1 (<1%)	0	0
Biochemical				
Any event	26 (1%)	1 (<1%)	8 (1%)	0
Raised liver enzymes	13 (<1%)	1 (<1%)	6 (<1%)	0
Systemic[2]				
Any event	8 (<1%)	0	12 (2%)	0
Renal				
Any event	12 (<1%)	2 (2%)	1 (<1%)	0
Renal failure – acute	9 (<1%)	0	1 (<1%)	0
Renal failure – chronic	1 (<1%)	2 (2%)	0	0
Glomerulonephritis	0	0	0	0
Hematuria	1 (<1%)	0	0	0
Lower urinary tract infection (UTI), cystitis	1 (<1%)	0	0	0
Renal colic, renal stones, uroliathiasis	1 (<1%)	0	0	0
Specific Infections				
Any event	14 (<1%)	1 (<1%)	1 (<1%)	1 (2%)

DART Defined System Organ Class Preferred Term[1]	**TDF CLcr ≥50 (N=2335)** n (%)	**TDF CLcr 30-49 (N=122)** n (%)	**ABC or NVP CLcr ≥50 (N=797** n (%)	**ABC or NVP CLcr 30-49 (N=46)** n (%)
P Falciparum malaria	14 (<1%	0	1 (<1%)	1 (2%)
Pregnancy associated				
Any event	**11 (<1%)**	**0**	**5 (<1%)**	**0**
Musculoskeletal				
Any event	9 (<1%)	1 (<1%)	3 (<1%)	0
Bone fracture	5 (<1%)	1 (<1%)	0	0
Skin				
Any event	4 (<1%)	0	8 (1%)	0
Lower respiratory tract				
Any event	6 (<1%)	2 (2%)	1 (<1%)	0
Pneumonia no organism identified, aspiration pneumonia	1 (<1%)	1 (<1%)	1 (<1%)	0
Bronchospasm/Asthma	1 (<1%)	1 (<1%)	0	0
Non HIV related deaths[3]				
Any event	5 (<1%)	0	0	0
Tumors				
Any event	2 (<1%)	1 (<1%)	2 (<1%)	0
Other Solid tumor	0	1 (<1%)	1 (<1%)	0
Any event[4]	3 (<1%)	0	1 (<1%)	0
Other[5]				
Any event	3 (<1%)	0	0	1 (2%)
Non-fatal trauma	3 (<1%)	0	0	0
Overdose (not suicide attempt)	0	0	0	1 (2%)
Endocrine				
Any event	2 (<1%)	1 (<1%)	0	0
Diabetes - Type II	1 (<1%)	1 (<1%)	0	0
Fat redistribution				
Any event	2 (<1%)	1 (<1%)	0	0
Fat wasting or loss of fat	2 (<1%)	1 (<1%)	0	0
Eye				
Any event	1 (<1%)	0	0	0
Genitourinary				
Any event	1 (<1%)	0	0	0
Psychiatric				
Any event	1 (<1%)	0	0	0

CNS: Central nervous system; AIDS: Acquired immunodeficiency syndrome
Source Table 2.5
1. DART defined the first term as the primary term which was coded to the system organ class and when study physicians' reported additional diagnoses, signs and symptoms, these were listed after the primary term and were not coded separately.
2. Systemic events as defined by the DART team include events of hypersensitivity reaction, malaise, tiredness, acute febrile episode, dehydration, recurrent fever and Stevens-Johnson syndrome
3. Non-HIV related deaths as defined by the DART team include obstetric, traumatic and suicide terms
4. Any event as coded by the DART team and these events had no preferred terms associated with the event.
5. Other events as defined by the DART team include non-fatal trauma and overdose (not suicide attempt).

Table 13 summarizes SAEs that were reported in ≥2% of participants in any treatment group. Overall, 283 participants reported an SAE, with the most common event being anemia. Anemia occurred at a slightly higher frequency in the baseline CLcr 30-49 mL/min group for the ZDV/3TC plus ABC or NVP treatment group compared to those with baseline CLcr ≥50 mL/min but the overall hematological events were comparable (4% vs. 3%). For the other system organ classes, the incidence of individual SAEs by organ class or by specific event were comparable and ranged from 0 to ≤2% across the treatment groups except for the DART investigator defined category of "other". There were a total of 7 SAEs reported in the 3TC/ZDV with ABC or NVP CLcr baseline CLcr 30-49 mL/min treatment group, including one case of P. Falciparum malarial infection and two cases with unknown causes of death (4%) and 12 SAEs reported in the 3TC/ZDV with TDF CLcr 30-49 mL/min treatment group, including 2 cases of chronic renal failure.

Table 13 Summary of SAEs by DART Defined Preferred Terms and SAEs Reported in ≥2%of Participants in any Treatment Group

DART Defined System Organ Class Preferred Term[1]	TDF CLcr ≥50 (N=2335) n (%)	TDF CLcr 30-49 (N=122) n (%)	ABC or NVP CLcr ≥50 (N=797) n (%)	ABC or NVP CLcr 30-49 (N=46) n (%)
ANY EVENT	185 (8%)	12 (10%)	77 (10%)	7 (15%)
Hematological				
Any event	78 (3%)	4 (3%)	20 (3%)	2 (4%)
Anemia	64 (3%)	3 (2%)	13 (2%)	2 (4%)
Cardiovascular				
Any event	19 (<1%)	2 (2%)	6 (<1%)	1 (2%)
Deep vein thrombosis	5 (<1%)	0	6 (<1%)	1 (2%)
Systemic[2]				
Any event	4 (<1%)	0	18 (2%)	0
Hypersensitivity reaction	2 (<1%)	0	18 (2%)	0
Specific infections				
Any event	14 (<1%)	1 (<1%)	1 (<1%)	1 (2%)
P falciparum malaria	14 (<1%)	0	1 (<1%)	1 (2%)
Skin				
Any event	0	0	15 (2%)	0
Rash, maculopapular	0	0	13 (2%)	0
Gastrointestinal				
Any event	9 (<1%)	1 (<1%)	3 (<1%)	1 (2%)
Indigestion, esophageal reflux, gastritis, ulcerative esophagitis	1 (<1%)	1 (<1%)	0	0
Hematemesis+Peptic/gastric/duodenal ulcer	0	0	1 (<1%)	0
Renal				
Any event	9 (<1%)	2 (2%)	1 (<1%)	0
Renal failure – chronic	1 (<1%)	2 (2%)	0	0
Other				
Any Event	8 (<1%)	0	2 (<1%)	2 (4%)
Death (cause unknown)	6 (<1%)	0	0	2 (4%)

Source Table 2.7

1. DART defined the first term as the primary term which was coded to the system organ class and when study physicians' reported additional diagnoses, signs and symptoms, these were listed after the primary term and were not coded separately.
2. Systemic events as defined by the DART team include events of hypersensitivity reaction, febrile episode and Stevens-Johnson syndrome

Table 14 summarizes SAEs that were reported at least once for participants with baseline CLcr 30-49 mL/min (i.e. any event that occurred exclusively in participants with baseline CLcr ≥50 mL/min is not shown here but is reported in Source Table 2.7 owing to size limitations given the very large numbers of patients in the overall study who were enrolled with CLcr ≥50 mL/min). The incidence of SAEs across all treatment groups in Table 14 is comparable.

Table 14 Summary of SAEs by DART Defined Preferred Terms and SAE in Reported in ≥1 Participants with Baseline CLcr 30-49 mL/min

DART Defined System Organ Class Preferred Term[1]	TDF CLcr ≥50 (N=2335) n (%)	TDF CLcr 30-49 (N=122) n (%)	ABC or NVP CLcr ≥50 (N=797) n (%)	ABC or NVP CLcr 30-49 (N=46) n (%)
ANY EVENT	185 (8%)	12 (10%)	77 (10%)	7 (15%)
Hematological				
Any event	78 (3%)	4 (3%)	20 (3%)	2 (4%)
Anemia	64 (3%)	3 (2%)	13 (2%)	2 (4%)
Pancytopenia, bone marrow depression	2 (<1%)	0	1 (<1%)	0
Cardiovascular				
Any event	19 (<1%)	2 (2%)	6 (<1%)	1 (2%)
Deep vein thrombosis	5 (<1%)	0	6 (<1%)	1 (2%)
Congestive cardiac failure	5 (<1%)	1 (<1%)	0	0
Chest pain	0	1 (<1%)	0	0
Systemic[2]				
Any event	4 (<1%)	0	18 (2%)	0
Hepatic				
Any event	14 (<1%)	0	6 (<1%)	0
CNS				
Any event	13 (<1%)	1 (<1%)	3 (<1%)	0
Hemiparesis	0	1 (<1%)	0	0
Skin				
Any event	0	0	15 (2%)	0
Gastrointestinal				
Any event	9 (<1%)	1 (<1%)	3 (<1%)	1 (2%)
Indigestion, esophageal reflux, gastritis, ulcerative esophagitis	1 (<1%)	1 (<1%)	0	0
Hematemesis+Peptic/gastric/duodenal ulcer	0	0	1 (<1%)	0
Renal				
Any event	9 (<1%)	2 (2%)	1 (<1%)	0
Renal failure – acute	6 (<1%)	0	1 (<1%)	0
Renal failure – chronic	1 (<1%)	2 (2%)	0	0
Hematuria	1 (<1%)	0	0	0
Renal failure - acute+Pancytopenia, bone marrow depression	1 (<1%)	0	0	0
Renal failure - chronic+congestive cardiac failure	0	0	0	0
Specific infections				
Any event	14 (<1%)	1 (<1%)	1 (<1%)	1 (2%)
P falciparum malaria	14 (<1%)	0	1 (<1%)0	1 (2%)
Musculoskeletal				
Any event	7 (<1%)	1 (<1%)	1 (<1%)	0
Bone fracture	5 (<1%)	1 (<1%)	0	0
Tumors				
Any event	4 (<1%)	1 (<1%)	4 (<1%)	0
Lower respiratory tract				
Any event	3 (<1%)	0	1 (<1%)	0
Pneumonia no organism identified, aspiration pneumonia	0	0	1 (<1%)	0
Endocrine				
Any event	2 (<1%)	1 (<1%)	0	0

DART Defined System Organ Class Preferred Term[1]	TDF CLcr ≥50 (N=2335) n (%)	TDF CLcr 30-49 (N=122) n (%)	ABC or NVP CLcr ≥50 (N=797) n (%)	ABC or NVP CLcr 30-49[3] (N=46) n (%)
Diabetes - Type II	1 (<1%)	1 (<1%)	0	0
Biochemical				
Any event	2 (<1%)	0	0	0
Congenital abnormality				
Any event	2 (<1%)	0	0	0
Pregnancy associated				
Any event	1 (<1%)	0	1 (<1%)	0
Genitourinary				
Any event	1 (<1%)	0	0	0
Other				
Any Event	8 (<1%)	0	2 (<1%)	2 (4%)
Death (cause unknown)	6 (<1%)	0	0	2 (4%)

Source Table 2.7

1. DART defined the first term as the primary term which was coded to the system organ class and when study physicians' reported additional diagnoses, signs and symptoms, these were listed after the primary term and were not coded separately.

2. Systemic events as defined by the DART team include events of hypersensitivity reaction, febrile episode and Stevens-Johnson syndrome

In Figure 3, the AE event rates for participants treated with any ART with baseline CLcr 30-49 mL/min and those with baseline CLcr ≥50 mL/min) are presented in the left panel and relative risk and 95% confidence intervals (CI) are presented on the right panel. As 95% CI ranges encompass 1, none of the rates were statistically significant between the groups, though this is not a powered study and no multiple comparisons were adjusted.

Figure 3 Plot of Common AEs and Relative Risk for Any ART-Treated Participants with Baseline CLcr 30-49 mL/min vs those with Baseline CLcr ≥50 mL/min



Source Figure 2.8
1. Relative risk is the ratio of the probability of an event occurring in one group comparing with other group.

4. DISCUSSION

Overall, the incidence of Grade 3-4 AEs and for hematological, hepatic and gastrointestinal events through 96 weeks of treatment were comparable for the DART participants who had moderate renal impairment (CLcr 30-49 mL/min) at baseline compared with those participants with higher baseline CLcr (≥50 mL/min).

There were more substantial increases in the mean eGFR over 96 weeks after initiation of ART for both groups of participants who enrolled with impaired renal function (CLcr 30-49 mL/min) when compared to participants who enrolled with CLcr ≥50 mL/min, possibly due to treatment of the underlying HIV infection resulting in improved patient renal function.

These results were in agreement with those previously reported by the DART team over 96 weeks of treatment using slightly different baseline renal impairment subgroupings, [Reid, 2008]. The incidence of severe decreases in eGFR (<30 mL/min/1.73 m^2) and changes in eGFR over 96 weeks of treatment were analyzed. The majority of participants with moderate renal impairment at baseline (CLcr 30-≤60 mL/min/1.73 m^2) showed improvements in their eGFR after starting ART compared to those with higher baseline eGFRs (≥60 mL/min at entry). A total of 1.6% of study participants (52 of 3,316) developed severe reductions in eGFR by week 96.

Another longitudinal analysis conducted by the DART team of investigators evaluated renal function as assessed by eGFR change from baseline for DART study participants through 4 years (week 204) and found modest increases in eGFR (1, 9 and 6 mL/min/1.73 m^2) for regimens containing COMBIVIR in combination with TDF, ABC or NVP, respectively; (P<0.001). Similar to the results at 96 weeks, those participants with eGFR <60 mL/min/1.73 m^2 at ART initiation had significantly greater increases in eGFR over time over 4 years [Stohr, 2011]. There were 21/3316 study participants with renal SAEs over the 5 year period; all 21 were either on or had previously been taking TDF at the time of the event.

The maximal toxicities of all hematology laboratory parameters, ALT, AST, serum creatinine and bilirubin over 96 weeks of treatment were comparable across treatment groups with moderate renal impairment (CLcr 30-49 mL/min) compared with those participants with higher CLcr (≥50 mL/min). Although the percentages of any grade 3 /4 hematological events were comparable for participants with CLcr 30-49 mL/min vs those with CLcr ≥50 mL/min (Figure 3), there were some slightly higher rates in participants with moderate renal impairment, which could be reflective of the small number of participants in the treatment groups with CLcr 30-49 mL/min or due to the poorer health typically observed in patients with moderate renal impairment.

There are several limitations with respect to this data analysis. The data were obtained by ViiV Healthcare *post hoc* after trial completion. The sample size for study participants with baseline CLCR of 30-49 mL/min was small, relative to the overall population. There are additional limitations which have previously been noted, including that given the primary objective, routine HIV-1 RNA and resistance testing were not prospectively undertaken and therefore treatment switches were guided by immunological (CD4+ cell

counts) and clinical parameters only, and so there may have been a bias between groups with regards to AE reporting, as the CDM group was not provided with results of the laboratory evaluations (unless requested or there was a Grade 4 abnormality). However, since the data were stratified by baseline CLcr levels and not by the original CDM vs LCM randomization, this may have reduced the likelihood of bias. Data from some of the 225 participants who took part in the additional strategic treatment interruption (STI) randomization was excluded from this post-hoc analysis after participants started their STI. Limited safety data were collected and serum calcium and phosphate and urinalysis were not routinely performed; the local labs used for measurement of serum creatinine had no specific calibration undertaken across centers and AE event coding was developed by the DART Team of investigators. based on diseases likely to occur in the African setting. Despite these limitations, these data provide useful information regarding the safety of the use of a lamivudine-containing FDC in patients with CLcr 30-49 mL/min compared with the safety of lamivudine-containing FDC in patients with CLcr >50 mL/min.

In summary, this DART *post hoc* analysis has identified no additional risk to the use of standard dose of a 3TC-containing FDC in study participants with moderate renal impairment of 30-49 mL/min. The results from this *post hoc* analysis support the safety of a standard 3TC dose in patients with a CLcr ≥30 mL/min.

5. CONCLUSIONS

- Overall, the *post hoc* analysis demonstrated comparable safety outcomes over a period of 96 weeks of administration for the standard 300 mg total daily dose of 3TC, administered as part of the COMBIVIR FDC, for study participants that entered the study with baseline renal function of CLcr 30-49 mL/min to those with baseline CLcr ≥50 mL/min.

- The Grade 3-4 AEs and SAEs (for hematological, hepatic and gastrointestinal events), maximal toxicities for liver enzymes, serum creatinine and bilirubin (over time) and maximum treatment emergent hematology toxicities were comparable in the group of DART participants with moderate renal impairment (baseline CLcr 30-49 mL/min) to those participants with higher baseline CLcr (≥50 mL/min). The only organ system class in which Grade 3-4 AEs were reported in ≥5% of study participants in any treatment group was in hematology, and ranged from 21-24% of participants. Within this class, the proportion of some AEs or laboratory assessments was higher for patients with CLcr 30-49 mL/min vs those with CLcr >50 mL/min, which could be reflective of the small number of participants in these treatment groups or could be due to the poorer health typically observed in patients with moderate renal impairment. No new risks or trends were identified from this dataset.

- An improvement in renal function was observed over the 96 weeks following ART initiation for participants who enrolled with impaired renal function (baseline CLcr 30-49 mL/min), as evidenced by substantial increases in the mean eGFR, when compared to those with baseline CLcr ≥50 mL/min.

- Therefore, based on these results, it is expected that HIV-infected patients with CLcr of 30-49 mL/min would have similar AE risks in comparison to patients with CLcr ≥50 mL/min when using 3TC- containing FDCs delivering the standard total daily 3TC dose of 300 mg.

6. REFERENCES

Cockcroft D, Gault M. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41.

DART Trial team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <200 cells/µl. *AIDS* 2008; 22: 237-247.

DART Trial team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferior trial. *Lancet* 2010; 375: 123-131.

Elion R, Cohen C, deJesus E, Redfield R, Gathe J, Hsu R, et al. Once-daily Abacavir/Lamivudine/Zidovudine plus Tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48 week pilot study. *HIV Clin Trials* 2006; 7: 324-333.

Glaxo Report Number UCP/95/004. Study ID NUCA1004. A Single-Dose study of GR109714X (3TC™) in HIV-infected study participants with impaired renal function. Effective Date: May 29, 1995.

Glaxo Report Number GCP/95/060. Study ID NUCB1003. A study to investigate the pharmacokinetics of lamivudine (GR109714X) following oral dosing in subjects with impaired renal function. Effective Date: June 18, 1996.

Heald A, Hsyu P., Yuen J, Robinson P, Mydlow P and Bartlett JA et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected study participants with renal dysfunction. *Antimicrobial Agents and Chemotherapy* 1996; 40: 1514-1519.

Levy S, Coresh J, Balk E, Kausz A, Levin A, Steffes M, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification. *Ann Intern Med* 2003; 139: 137-47.

Reid, A, Stohr W, Walker S, Williams I, Kityo C, Hughes P, et al. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. *CID* 2008; 46:1271-1281.

Squires K, Young B, deJesus E, Bellos N, Murphy D, Sutherland-Phillips D, et al. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected study participants. *HIV Clin Trials* 2010; 11: 69-79

Stohr W, Reid A, Walker S, Ssali F, Munderi P, Mambule I, et al. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. *Antiviral Therapy* 2011; 16: 1011-1020.

Protocol: COL30515
Population: DART Subjects

Figure 2.1
Plot of Mean Change from Baseline in eGFR (CGF) by Visit and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Figure 2.2
Plot of Mean Change from Baseline in CD4 Cell Counts by Visit, Treatment and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Figure 2.3
Plot of Mean Change from Baseline in Serum Creatinine by Visit, Treatment and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Figure 2.4
Plot of Mean (95% CI) eGFR (CGF) by Visit and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Figure 2.5
Plot of Mean (95% CI) eGFR (BSA-Adjusted CGF) by Visit and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
NKF Toxicity Guidelines (2003) G1: 60 to <90 mL/min/1.73 m2,G2: 30 to <60 mL/min/1.73 m2,
G3, 15 to <30 mL/min/1.73 m2, and G4: <15 mL/min/1.73 m2

PPD

Protocol: COL30515
Population: DART Subjects

Figure 2.6
Plot of Mean (95% CI) eGFR (MDRD) by Visit and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Figure 2.7
Plot of Mean (95% CI) eGFR (BSA-Adjusted MDRD) by Visit and Baseline CLcr (mL/min)



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Figure 2.8
Plot of Common Adverse Events and Relative Risk - Any ART CLcr 30-49 vs Any ART CLcr>=50



NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.1
Summary of Baseline ART regimens by Baseline CLcr (mL/min)

		CLcr>=50 (N=3132)	CLcr 30-49 (N=168)	Any CLcr<30 (N=13)	CLcr missing (N=3)	Total (N=3316)
Regimen	n	3132	168	13	3	3316
	3TC/ZDV+TDF	2335 (75%)	122 (73%)	9 (69%)	3 (100%)	2469 (74%)
	3TC/ZDV+ABC	272 (9%)	27 (16%)	1 (8%)	0	300 (9%)
	3TC/ZDV+NVP	525 (17%)	19 (11%)	3 (23%)	0	547 (16%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.2
Disposition of DART Safety Population by Treatment and Baseline CLcr (mL/min)

	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)	Total (N=3316)
Visit at Week 0	2335 (100%)	122 (100%)	797 (100%)	46 (100%)	13 (100%)	3316 (100%)
Visit at Week 24	2206 (94%)	112 (92%)	758 (95%)	39 (85%)	8 (62%)	3126 (94%)
Visit at Week 48	2168 (93%)	109 (89%)	747 (94%)	37 (80%)	9 (69%)	3073 (93%)
Visit at Week 96	1660 (71%)	90 (74%)	566 (71%)	27 (59%)	4 (31%)	2349 (71%)
Had STI during 96 weeks	162 (7%)	5 (4%)	53 (7%)	3 (7%)	2 (15%)	225 (7%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI includes both randomized and non-randomized pilot STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.3
Summary of Demographic Characteristics by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr>=50 (N=3132)	Any CLcr 30-49 (N=168)	Any CLcr<30 (N=13)	Total (N=3316)
Age (y)	n	2335	122	797	46	3132	168	13	3316
	Mean	37.4	41.6	37.0	43.1	37.3	42.0	41.6	37.6
	SD	7.67	8.70	7.49	8.46	7.63	8.64	9.72	7.76
	Median	36.5	41.2	36.6	44.1	36.5	41.3	38.2	36.8
	Min.	19	25	18	20	18	20	30	18
	Max.	71	65	73	56	73	65	62	73
Gender	n	2335	122	797	46	3132	168	13	3316
	Male	860 (37%)	33 (27%)	252 (32%)	10 (22%)	1112 (36%)	43 (26%)	3 (23%)	1160 (35%)
	Female	1475 (63%)	89 (73%)	545 (68%)	36 (78%)	2020 (64%)	125 (74%)	10 (77%)	2156 (65%)
Baseline CD4 (cells/ mm**3)	n	2335	122	797	46	3132	168	13	3316
	Mean	84.8	86.1	95.9	94.1	87.6	88.3	114.8	87.8
	SD	59.55	60.71	59.48	59.18	59.72	60.22	54.65	59.72
	Median	81.0	85.5	98.0	102.5	85.0	89.0	101.0	86.0
	Min.	0	1	1	1	0	1	15	0
	Max.	199	199	199	197	199	199	197	199

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. Race is not captured as all are African. Viral load at baseline was not reported.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.3
Summary of Demographic Characteristics by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr>=50 (N=3132)	Any CLcr 30-49 (N=168)	Any CLcr<30 (N=13)	Total (N=3316)
Baseline eGFR (CGF) (mL/min)	n	2335	122	797	46	3132	168	13	3313
	Mean	92.2	43.4	85.3	44.0	90.4	43.6	25.3	87.8
	SD	34.67	5.22	22.76	4.44	32.20	5.01	4.86	33.21
	Median	85.4	44.3	81.8	44.9	84.4	44.4	27.4	82.8
	Min.	50	31	50	36	50	31	17	17
	Max.	459	50	235	50	459	50	30	459
BL BSA-Adj eGFR (CGF) (mL/min/ 1.73m**2)	n	2326	122	797	46	3123	168	12	3303
	Mean	98.1	51.2	90.6	51.6	96.2	51.4	28.8	93.6
	SD	33.57	7.64	21.43	6.25	31.10	7.27	5.78	32.09
	Median	91.6	52.3	87.9	52.7	90.3	52.5	30.7	88.9
	Min.	46	29	54	37	46	29	21	21
	Max.	441	68	258	62	441	68	36	441
Baseline MDRD (mL/min)	n	2335	122	797	46	3132	168	13	3313
	Mean	116.0	62.4	104.9	63.2	113.1	62.6	29.7	110.2
	SD	45.29	13.12	28.60	12.28	41.95	12.87	9.24	42.67
	Median	106.9	62.0	100.6	64.6	105.2	63.2	32.9	103.4
	Min.	50	26	52	37	50	26	17	17
	Max.	645	103	400	90	645	103	45	645

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. Race is not captured as all are African. Viral load at baseline was not reported.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.3
Summary of Demographic Characteristics by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr>=50 (N=3132)	Any CLcr 30-49 (N=168)	Any CLcr<30 (N=13)	Total (N=3316)
Baseline BSA-Adj MDRD (mL/min/ 1.73m**2)	n	2326	122	797	46	3123	168	12	3303
	Mean	108.7	52.6	98.1	53.6	106.0	52.9	27.7	103.0
	SD	44.18	9.09	27.31	8.62	40.80	8.95	7.09	41.66
	Median	100.0	53.6	93.6	54.6	98.1	54.2	29.4	96.3
	Min.	48	28	52	38	48	28	16	16
	Max.	647	71	368	69	647	71	37	647
WHO Disease Stage	n	2335	122	797	46	3132	168	13	3316
	Stage 2	449 (19%)	26 (21%)	189 (24%)	7 (15%)	638 (20%)	33 (20%)	1 (8%)	673 (20%)
	Stage 3	1294 (55%)	55 (45%)	476 (60%)	29 (63%)	1770 (57%)	84 (50%)	8 (62%)	1864 (56%)
	Stage 4	592 (25%)	41 (34%)	132 (17%)	10 (22%)	724 (23%)	51 (30%)	4 (31%)	779 (23%)
Hepatitis B Status	n	2335	122	797	46	3132	168	13	3316
	Positive	1236 (53%)	65 (53%)	443 (56%)	24 (52%)	1679 (54%)	89 (53%)	5 (38%)	1774 (53%)
	Negative	1097 (47%)	57 (47%)	352 (44%)	22 (48%)	1449 (46%)	79 (47%)	7 (54%)	1537 (46%)
	Missing	2 (<1%)	0	2 (<1%)	0	4 (<1%)	0	1 (8%)	5 (<1%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. Race is not captured as all are African. Viral load at baseline was not reported.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.4
Summary of Frequency of Grade 3-4 AEs, SAEs and Deaths by Treatment and Baseline CLcr (mL/min)

	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr>=50 (N=3132)	Any CLcr 30-49 (N=168)	Any CLcr<30 (N=13)	Total (N=3316)
Grade 3-4 AEs	632 (27%)	41 (34%)	218 (27%)	14 (30%)	850 (27%)	55 (33%)	7 (54%)	912 (28%)
SAEs	184 (8%)	12 (10%)	77 (10%)	7 (15%)	261 (8%)	19 (11%)	2 (15%)	283 (9%)
All Deaths	114 (5%)	10 (8%)	22 (3%)	5 (11%)	136 (4%)	15 (9%)	4 (31%)	155 (5%)
Deaths with no associated SAEs reported	63 (3%)	5 (4%)	13 (2%)	1 (2%)	76 (2%)	6 (4%)	2 (15%)	84 (3%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
ANY EVENT	632 (27%)	41 (34%)	218 (27%)	14 (30%)	7 (54%)
Haematological					
Any event	518 (22%)	29 (24%)	171 (21%)	11 (24%)	6 (46%)
Neutropenia	371 (16%)	22 (18%)	130 (16%)	8 (17%)	6 (46%)
Anaemia with clinical symptoms	181 (8%)	8 (7%)	53 (7%)	4 (9%)	2 (15%)
Pancytopenia, bone marrow depression	11 (<1%)	2 (2%)	3 (<1%)	1 (2%)	0
Thrombocytopenia	8 (<1%)	1 (<1%)	1 (<1%)	1 (2%)	0
Leucopenia	3 (<1%)	0	1 (<1%)	0	0
Nose bleed, epistaxis	1 (<1%)	0	1 (<1%)	0	0
CNS					
Any event	30 (1%)	1 (<1%)	11 (1%)	0	1 (8%)
Epilepsy, fits, convulsions	11 (<1%)	0	4 (<1%)	0	0
Peripheral neuropathy - sensory only	7 (<1%)	0	1 (<1%)	0	0
Stroke, cerebrovascular accident	4 (<1%)	0	2 (<1%)	0	1 (8%)
Peripheral neuropathy - sensory & motor	3 (<1%)	0	2 (<1%)	0	0
Acute altered conscious level	1 (<1%)	0	1 (<1%)	0	0
Parathesia, transient numbness, tingling	2 (<1%)	0	0	0	0
Headache	1 (<1%)	0	0	0	0
Hemiparesis	0	1 (<1%)	0	0	0
Meningitis - other	0	0	1 (<1%)	0	0
Other neuropathy, not peripheral, not diabetic or HIV related	1 (<1%)	0	0	0	0
Pyogenic meningitis - organism	0	0	1 (<1%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Cardiovascular					
Any event	29 (1%)	5 (4%)	6 (<1%)	1 (2%)	1 (8%)
Deep vein thrombosis	7 (<1%)	0	6 (<1%)	1 (2%)	0
Congestive cardiac failure	9 (<1%)	1 (<1%)	0	0	1 (8%)
Cardiomyopathy	7 (<1%)	0	0	0	0
Hypotension/shock/toxic shock	4 (<1%)	2 (2%)	0	0	0
Other cardiovascular	2 (<1%)	1 (<1%)	0	0	0
Pericarditis not TB or bacterial or no cause identified	2 (<1%)	0	0	0	0
Chest pain	0	1 (<1%)	0	0	0
Hypertension	1 (<1%)	0	0	0	0
Hepatic					
Any event	29 (1%)	0	12 (2%)	1 (2%)	0
Lactic acidosis	14 (<1%)	0	3 (<1%)	1 (2%)	0
Hepatic failure	6 (<1%)	0	3 (<1%)	0	0
Acute hepatitis	3 (<1%)	0	5 (<1%)	0	0
Hepatitis cause unknown	3 (<1%)	0	1 (<1%)	0	0
Jaundice	3 (<1%)	0	1 (<1%)	0	0
Cirrhosis	1 (<1%)	0	0	0	0
Gastrointestinal					
Any event	30 (1%)	5 (4%)	5 (<1%)	0	0
Vomiting	13 (<1%)	3 (2%)	2 (<1%)	0	0
Acute diarrhoea no pathogen, idiopathic AIDS enteropathy	6 (<1%)	1 (<1%)	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Pancreatitis	4 (<1%)	0	0	0	0
Haematemesis	1 (<1%)	0	2 (<1%)	0	0
Abdominal or epigastric pain	2 (<1%)	0	0	0	0
Gall stones, cholecystitis, cholelithiasis	2 (<1%)	0	0	0	0
Chronic diarrhoea with no pathogen	1 (<1%)	0	0	0	0
Indigestion, oesophageal reflux, gastritis, ulcerative oesophagitis	0	1 (<1%)	0	0	0
Nausea	1 (<1%)	0	0	0	0
Paralitic ileus, ileitis	0	0	1 (<1%)	0	0
Peptic/gastric/duodenal ulcer	1 (<1%)	0	0	0	0
Biochemical					
Any event	26 (1%)	1 (<1%)	8 (1%)	0	1 (8%)
Raised liver enzymes	13 (<1%)	1 (<1%)	6 (<1%)	0	0
Raised ALT	4 (<1%)	0	2 (<1%)	0	0
Raised AST	4 (<1%)	0	0	0	0
Raised bilirubin	2 (<1%)	0	0	0	0
Raised creatinine	1 (<1%)	0	0	0	1 (8%)
Hyperglycaemia	1 (<1%)	0	0	0	0
Hyperkalaemia	0	0	0	0	1 (8%)
Hypocalcaemia - clinically symptomatic	1 (<1%)	0	0	0	0
Hypokalaemia	1 (<1%)	0	0	0	0
Hyponatraemia	1 (<1%)	0	0	0	0
Systemic					
Any event	8 (<1%)	0	12 (2%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Hypersensitivity reaction	1 (<1%)	0	11 (1%)	0	0
Malaise, tiredness, lethargy, fatigue, generalised body weakness	4 (<1%)	0	0	0	0
Acute febrile episode - undiagnosed	1 (<1%)	0	0	0	0
Dehydration	1 (<1%)	0	0	0	0
Recurrent fever - no diagnosis	0	0	1 (<1%)	0	0
Stevens-Johnson Syndrome	1 (<1%)	0	0	0	0
Renal					
Any event	12 (<1%)	2 (2%)	1 (<1%)	0	2 (15%)
Renal failure - acute	9 (<1%)	0	1 (<1%)	0	0
Renal failure - chronic	1 (<1%)	2 (2%)	0	0	1 (8%)
Glomerulonephritis	0	0	0	0	1 (8%)
Haematuria	1 (<1%)	0	0	0	0
Lower urinary tract infection (UTI), cystitis	1 (<1%)	0	0	0	0
Renal colic, renal stones, uroliathiasis	1 (<1%)	0	0	0	0
Specific Infections					
Any event	14 (<1%)	1 (<1%)	1 (<1%)	1 (2%)	0
P falciparum malaria	14 (<1%)	0	1 (<1%)	1 (2%)	0
Presumed septicaemia/bacteremia - not investigated	0	1 (<1%)	0	0	0
Pregnancy associated					
Any event	11 (<1%)	0	5 (<1%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Induced abortion	5 (<1%)	0	4 (<1%)	0	0
Spontaneous abortion (complete or incomplete)	4 (<1%)	0	0	0	0
Still birth	2 (<1%)	0	1 (<1%)	0	0
Musculoskeletal					
Any event	9 (<1%)	1 (<1%)	3 (<1%)	0	0
Bone fracture	5 (<1%)	1 (<1%)	0	0	0
Myopathy, muscle wasting	2 (<1%)	0	3 (<1%)	0	0
Myalgia, pain in muscles	2 (<1%)	0	0	0	0
Skin					
Any event	4 (<1%)	0	8 (1%)	0	0
Rash, maculopapular	0	0	6 (<1%)	0	0
Rash, urticaria	4 (<1%)	0	0	0	0
Rash, erythematous	0	0	3 (<1%)	0	0
Lower respiratory tract					
Any event	6 (<1%)	2 (2%)	1 (<1%)	0	0
Pneumonia no organism identified, aspiration pneumonia	1 (<1%)	1 (<1%)	1 (<1%)	0	0
Bronchospasm/Asthma	1 (<1%)	1 (<1%)	0	0	0
Pulmonary embolism	2 (<1%)	0	0	0	0
Pneumothorax	1 (<1%)	0	0	0	0
Tuberculosis - pulmonary - smear positive	1 (<1%)	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Non HIV related deaths					
Any event	5 (<1%)	0	0	0	0
Obstetric	2 (<1%)	0	0	0	0
Traumatic	2 (<1%)	0	0	0	0
Suicide	1 (<1%)	0	0	0	0
Tumours					
Any event	2 (<1%)	1 (<1%)	2 (<1%)	0	0
Cervical carcinoma	1 (<1%)	0	1 (<1%)	0	0
Other Solid tumour	0	1 (<1%)	1 (<1%)	0	0
Hepatocellular carcinoma	1 (<1%)	0	0	0	0
<Unknown>					
Any event	3 (<1%)	0	1 (<1%)	0	0
<Unknown>	3 (<1%)	0	1 (<1%)	0	0
Other					
Any event	3 (<1%)	0	0	1 (2%)	0
Non-fatal trauma	3 (<1%)	0	0	0	0
Overdose (not suicide attempt)	0	0	0	1 (2%)	0
Endocrine					
Any event	2 (<1%)	1 (<1%)	0	0	0
Diabetes - Type II	1 (<1%)	1 (<1%)	0	0	0
Diabetes - Type I	1 (<1%)	0	0	0	0
Fat redistribution					

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.5
Summary of Number of Subjects with Grade 3-4 Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Any event	2 (<1%)	1 (<1%)	0	0	0
Fat wasting or loss of fat	2 (<1%)	1 (<1%)	0	0	0
Eye					
Any event	1 (<1%)	0	0	0	0
Conjunctivitis, blepharitis, keratitis - allergic	1 (<1%)	0	0	0	0
Genitourinary					
Any event	1 (<1%)	0	0	0	0
Urinary retention	1 (<1%)	0	0	0	0
Psychiatric					
Any event	1 (<1%)	0	0	0	0
Depression	1 (<1%)	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.6
Summary of Grade 3-4 Adverse Events Impacting >=5% of Subjects by System Organ Class and Baseline CLcr

System Organ Class Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
ANY EVENT	632 (27%)	41 (34%)	218 (27%)	14 (30%)	7 (54%)
Haematological					
Any event	518 (22%)	29 (24%)	171 (21%)	11 (24%)	6 (46%)
Neutropenia	371 (16%)	22 (18%)	130 (16%)	8 (17%)	6 (46%)
Anaemia with clinical symptoms	181 (8%)	8 (7%)	53 (7%)	4 (9%)	2 (15%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
ANY EVENT	185 (8%)	12 (10%)	77 (10%)	7 (15%)	2 (15%)
Haematological					
Any event	78 (3%)	4 (3%)	20 (3%)	2 (4%)	0
Anaemia	64 (3%)	3 (2%)	13 (2%)	2 (4%)	0
Neutropenia	6 (<1%)	0	4 (<1%)	0	0
Pancytopenia, bone marrow depression	2 (<1%)	0	1 (<1%)	0	0
Anaemia+Congestive cardiac failure	1 (<1%)	0	0	0	0
Anaemia+Neutropenia	1 (<1%)	0	0	0	0
Anaemia+P falciparum malaria	0	0	1 (<1%)	0	0
Anaemia+Pancytopenia, bone marrow depression	1 (<1%)	0	0	0	0
Anaemia+Thrombocytopenia	1 (<1%)	0	0	0	0
Anaemia+Thrombocytopenia+Neutropenia	0	0	1 (<1%)	0	0
Neutropenia+Leucopenia	1 (<1%)	0	0	0	0
Neutropenia+Thrombocytopenia	1 (<1%)	0	0	0	0
Nose bleed, epistaxis	1 (<1%)	0	0	0	0
P falciparum malaria+Anaemia	0	0	1 (<1%)	0	0
Pancytopenia, bone marrow depression+Acute diarrhoea no pathogen, idiopathic AIDS enteropathy	0	1 (<1%)	0	0	0
Cardiovascular					
Any event	19 (<1%)	2 (2%)	6 (<1%)	1 (2%)	0
Deep vein thrombosis	5 (<1%)	0	6 (<1%)	1 (2%)	0
Cardiomyopathy	7 (<1%)	0	0	0	0
Congestive cardiac failure	5 (<1%)	1 (<1%)	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Chest pain	0	1 (<1%)	0	0	0
Hypotension/shock/toxic shock	1 (<1%)	0	0	0	0
Pulmonary embolism+Deep vein thrombosis	1 (<1%)	0	0	0	0
Systemic					
Any event	4 (<1%)	0	18 (2%)	0	0
Hypersensitivity reaction	2 (<1%)	0	18 (2%)	0	0
Acute febrile episode - undiagnosed	1 (<1%)	0	0	0	0
Stevens-Johnson Syndrome	1 (<1%)	0	0	0	0
Hepatic					
Any event	14 (<1%)	0	6 (<1%)	0	0
Lactic acidosis	7 (<1%)	0	0	0	0
Hepatic failure	3 (<1%)	0	2 (<1%)	0	0
Acute hepatitis	1 (<1%)	0	3 (<1%)	0	0
Cirrhosis	1 (<1%)	0	0	0	0
Hepatitis cause unknown	1 (<1%)	0	0	0	0
Jaundice	0	0	1 (<1%)	0	0
Lactic acidosis+Peripheral neuropathy - sensory & motor	1 (<1%)	0	0	0	0
Recurrent fever - no diagnosis+Acute hepatitis	0	0	1 (<1%)	0	0
CNS					
Any event	13 (<1%)	1 (<1%)	3 (<1%)	0	0
Epilepsy, fits, convulsions	3 (<1%)	0	1 (<1%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Stroke, cerebrovascular accident	3 (<1%)	0	1 (<1%)	0	0
Cranial nerve lesion+Jaundice+Epilepsy, fits, convulsions	1 (<1%)	0	0	0	0
Epilepsy, fits, convulsions+Acute altered conscious level	1 (<1%)	0	0	0	0
Epilepsy, fits, convulsions+Acute focal neurological event without fever	1 (<1%)	0	0	0	0
Headache+Acute altered conscious level	0	0	1 (<1%)	0	0
Hemiparesis	0	1 (<1%)	0	0	0
Parathesia, transient numbness, tingling+Diabetes - Type I+Metabolic disorder - other	1 (<1%)	0	0	0	0
Peripheral neuropathy - sensory & motor	1 (<1%)	0	0	0	0
Peripheral neuropathy - sensory only	1 (<1%)	0	0	0	0
Stroke, cerebrovascular accident+Raised liver enzymes	1 (<1%)	0	0	0	0
Specific Infections					
Any event	14 (<1%)	1 (<1%)	1 (<1%)	1 (2%)	0
P falciparum malaria	14 (<1%)	0	1 (<1%)	1 (2%)	0
Presumed septicaemia/bacteremia - not investigated	0	1 (<1%)	0	0	0
Skin					
Any event	0	0	15 (2%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Rash, maculopapular	0	0	13 (2%)	0	0
Rash, erythematous	0	0	1 (<1%)	0	0
Rash, urticaria	0	0	1 (<1%)	0	0
Gastrointestinal					
Any event	9 (<1%)	1 (<1%)	3 (<1%)	1 (2%)	0
Abdominal or epigastric pain	2 (<1%)	0	0	0	0
Haematemesis	1 (<1%)	0	1 (<1%)	0	0
Indigestion, oesophageal reflux, gastritis, ulcerative oesophagitis	1 (<1%)	1 (<1%)	0	0	0
Pancreatitis	2 (<1%)	0	0	0	0
Anorexia, loss of appetite+Depression	1 (<1%)	0	0	0	0
Gall stones, cholecystitis, cholelithiasis+Hepatitis B	1 (<1%)	0	0	0	0
Haematemesis+Peptic/gastric/duodenal ulcer	0	0	1 (<1%)	0	0
Paralitic ileus, ileitis	1 (<1%)	0	0	0	0
Peptic/gastric/duodenal ulcer	0	0	0	1 (2%)	0
Vomiting	0	0	1 (<1%)	0	0
Other					
Any event	8 (<1%)	0	2 (<1%)	2 (4%)	1 (8%)
Death, cause unknown	6 (<1%)	0	0	2 (4%)	1 (8%)
Non-fatal trauma	2 (<1%)	0	1 (<1%)	0	0
Hysterectomy	0	0	1 (<1%)	0	0
Renal					

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Any event	9 (<1%)	2 (2%)	1 (<1%)	0	1 (8%)
Renal failure - acute	6 (<1%)	0	1 (<1%)	0	0
Renal failure - chronic	1 (<1%)	2 (2%)	0	0	0
Haematuria	1 (<1%)	0	0	0	0
Renal failure - acute+Pancytopenia, bone marrow depression	1 (<1%)	0	0	0	0
Renal failure - chronic+Congestive cardiac failure	0	0	0	0	1 (8%)
Musculoskeletal					
Any event	7 (<1%)	1 (<1%)	1 (<1%)	0	0
Bone fracture	5 (<1%)	1 (<1%)	0	0	0
Myalgia, pain in muscles	1 (<1%)	0	0	0	0
Myopathy, muscle wasting	1 (<1%)	0	0	0	0
Pyomyositis - infection	0	0	1 (<1%)	0	0
Tumours					
Any event	4 (<1%)	1 (<1%)	4 (<1%)	0	0
Cervical carcinoma	2 (<1%)	0	2 (<1%)	0	0
Other Solid tumour	1 (<1%)	1 (<1%)	1 (<1%)	0	0
Hepatocellular carcinoma	1 (<1%)	0	1 (<1%)	0	0
Non HIV related deaths					
Any event	5 (<1%)	0	0	0	0
Obstetric	2 (<1%)	0	0	0	0
Traumatic	2 (<1%)	0	0	0	0
Suicide	1 (<1%)	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Lower respiratory tract					
Any event	3 (<1%)	0	1 (<1%)	0	0
Pulmonary embolism	2 (<1%)	0	0	0	0
Bronchospasm/Asthma	1 (<1%)	0	0	0	0
Pneumonia no organism identified, aspiration pneumonia	0	0	1 (<1%)	0	0
Endocrine					
Any event	2 (<1%)	1 (<1%)	0	0	0
Diabetes - Type II	1 (<1%)	1 (<1%)	0	0	0
Diabetes - Type I	1 (<1%)	0	0	0	0
Biochemical					
Any event	2 (<1%)	0	0	0	0
Hyperglycaemia	1 (<1%)	0	0	0	0
Raised liver enzymes	1 (<1%)	0	0	0	0
Congenital abnormality					
Any event	2 (<1%)	0	0	0	0
Club foot	1 (<1%)	0	0	0	0
Hydrocephalus, congenital intersusception bowel	1 (<1%)	0	0	0	0
Pregnancy associated					
Any event	1 (<1%)	0	1 (<1%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.7
Summary of Number of Subjects with Serious Adverse Events by System Organ Class and Baseline CLcr

DART Study-Defined Event by Clinician Preferred Term	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Other gram positive sepsis+Spontaneous abortion (complete or incomplete)	1 (<1%)	0	0	0	0
Still birth	0	0	1 (<1%)	0	0
Genitourinary					
Any event	1 (<1%)	0	0	0	0
Urinary retention	1 (<1%)	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. AEs judged to be HIV-related only were not counted as AEs as the DART protocol explicitly exempted these AEs and SAEs (including deaths).

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.8
Summary of Subject Visit Maximum Lab Toxicity Grade by Treatment and Baseline CLcr (mL/min)

Lab	Week	Toxicity Grade	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
ALT	0	1	223 (10%)	9 (7%)	59 (7%)	2 (4%)	1 (8%)
		2	49 (2%)	5 (4%)	9 (1%)	0	0
		3	1 (<1%)	0	0	1 (2%)	0
		4	0	0	0	0	0
	24	1	127 (5%)	8 (7%)	33 (4%)	3 (7%)	0
		2	20 (<1%)	0	8 (1%)	1 (2%)	0
		3	4 (<1%)	0	1 (<1%)	0	0
		4	4 (<1%)	0	0	0	0
	48	1	109 (5%)	6 (5%)	29 (4%)	1 (2%)	0
		2	8 (<1%)	1 (<1%)	5 (<1%)	2 (4%)	0
		3	2 (<1%)	0	0	0	0
		4	0	0	0	0	0
	96	1	78 (3%)	1 (<1%)	18 (2%)	1 (2%)	0
		2	8 (<1%)	0	5 (<1%)	0	0
		3	2 (<1%)	0	0	1 (2%)	0
		4	1 (<1%)	0	0	0	0
AST	0	1	311 (13%)	31 (25%)	73 (9%)	8 (17%)	0
		2	51 (2%)	2 (2%)	6 (<1%)	2 (4%)	0
		3	1 (<1%)	0	0	1 (2%)	0
		4	0	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.8
Summary of Subject Visit Maximum Lab Toxicity Grade by Treatment and Baseline CLcr (mL/min)

Lab	Week	Toxicity Grade	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
AST	24	1	112 (5%)	5 (4%)	22 (3%)	1 (2%)	1 (8%)
		2	21 (<1%)	3 (2%)	6 (<1%)	1 (2%)	0
		3	5 (<1%)	0	0	0	0
		4	2 (<1%)	0	2 (<1%)	0	0
	48	1	84 (4%)	9 (7%)	20 (3%)	1 (2%)	0
		2	16 (<1%)	0	3 (<1%)	1 (2%)	0
		3	6 (<1%)	0	0	0	0
		4	2 (<1%)	1 (<1%)	0	0	0
	96	1	62 (3%)	4 (3%)	13 (2%)	1 (2%)	0
		2	15 (<1%)	0	1 (<1%)	0	0
		3	0	0	1 (<1%)	1 (2%)	0
		4	2 (<1%)	0	0	0	0
Serum creatinine	0	1	55 (2%)	48 (39%)	18 (2%)	12 (26%)	5 (38%)
		2	0	5 (4%)	0	3 (7%)	8 (62%)
		3	0	0	0	0	0
		4	0	0	0	0	0
	24	1	60 (3%)	9 (7%)	17 (2%)	0	2 (15%)
		2	4 (<1%)	4 (3%)	1 (<1%)	0	1 (8%)
		3	0	1 (<1%)	0	0	1 (8%)
		4	0	1 (<1%)	1 (<1%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.8
Summary of Subject Visit Maximum Lab Toxicity Grade by Treatment and Baseline CLcr (mL/min)

Lab	Week	Toxicity Grade	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Serum creatinine	48	1	85 (4%)	11 (9%)	8 (1%)	0	3 (23%)
		2	2 (<1%)	4 (3%)	0	0	0
		3	0	0	0	0	1 (8%)
		4	0	1 (<1%)	0	0	0
	96	1	45 (2%)	3 (2%)	6 (<1%)	1 (2%)	2 (15%)
		2	1 (<1%)	6 (5%)	0	0	0
		3	1 (<1%)	0	0	0	0
		4	0	0	0	0	0
Bilirubin	0	1	46 (2%)	1 (<1%)	15 (2%)	1 (2%)	0
		2	5 (<1%)	0	4 (<1%)	0	0
		3	2 (<1%)	0	1 (<1%)	0	0
		4	0	0	0	0	0
	24	1	85 (4%)	3 (2%)	16 (2%)	0	0
		2	32 (1%)	2 (2%)	4 (<1%)	1 (2%)	0
		3	8 (<1%)	0	1 (<1%)	0	0
		4	1 (<1%)	0	0	0	0
	48	1	118 (5%)	8 (7%)	19 (2%)	0	0
		2	41 (2%)	2 (2%)	6 (<1%)	0	0
		3	8 (<1%)	0	3 (<1%)	0	0
		4	3 (<1%)	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.8
Summary of Subject Visit Maximum Lab Toxicity Grade by Treatment and Baseline CLcr (mL/min)

Lab	Week	Toxicity Grade	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Bilirubin	96	1	87 (4%)	3 (2%)	11 (1%)	1 (2%)	0
		2	35 (1%)	2 (2%)	5 (<1%)	0	0
		3	8 (<1%)	1 (<1%)	1 (<1%)	0	0
		4	1 (<1%)	0	1 (<1%)	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.9
Summary of Change from Baseline over Time in Renal Function (eGFR) by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
CGF at Week 24	n	2195	112	756	39	8
	Mean	0.2	19.0	5.2	25.0	18.5
	SD	34.09	19.62	21.39	18.69	19.48
	Median	2.8	17.1	5.9	22.5	15.5
	Min.	-338	-31	-148	-5	-7
	Max.	372	76	88	100	43
CGF at Week 48	n	2036	106	744	37	8
	Mean	-0.1	21.2	9.0	30.9	32.4
	SD	31.30	20.54	25.97	29.61	26.97
	Median	3.3	18.8	7.5	24.7	26.1
	Min.	-325	-27	-160	4	-1
	Max.	111	94	228	173	86
CGF at Week 96	n	1713	89	579	27	5
	Mean	1.4	25.1	10.5	31.3	34.1
	SD	32.61	22.28	28.70	21.99	19.92
	Median	2.4	23.9	8.6	26.6	26.9
	Min.	-330	-14	-155	5	15
	Max.	296	128	289	104	62

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.9
Summary of Change from Baseline over Time in Renal Function (eGFR) by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted CGF at Week 24	n	2193	112	756	39	8
	Mean	-2.3	19.0	2.8	25.3	19.5
	SD	34.68	20.70	21.81	18.98	20.59
	Median	0.4	16.7	3.8	23.4	16.1
	Min.	-340	-36	-164	-6	-8
	Max.	353	82	88	98	45
BSA-adjusted CGF at Week 48	n	2036	106	744	37	8
	Mean	-4.2	20.2	5.3	31.2	31.1
	SD	31.35	21.72	25.85	28.80	26.85
	Median	-0.7	18.0	4.2	24.8	25.6
	Min.	-313	-25	-177	0	-2
	Max.	89	97	208	163	85
BSA-adjusted CGF at Week 96	n	1713	89	579	27	5
	Mean	-2.3	24.3	6.9	30.9	32.0
	SD	32.19	24.07	27.77	22.98	16.34
	Median	-0.9	22.9	5.7	27.8	31.1
	Min.	-332	-19	-172	2	14
	Max.	269	139	248	103	55

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Table 2.9
Summary of Change from Baseline over Time in Renal Function (eGFR) by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
MDRD at Week 24	n	2195	112	756	39	8
	Mean	-8.0	21.4	-1.2	29.5	22.2
	SD	48.99	26.84	29.41	23.46	21.85
	Median	-4.6	19.7	1.1	30.1	20.9
	Min.	-532	-39	-282	-9	-8
	Max.	567	96	154	104	46
MDRD at Week 48	n	2036	106	744	37	8
	Mean	-12.8	21.0	0.0	36.9	31.6
	SD	43.16	28.69	34.76	35.09	26.01
	Median	-6.9	16.2	-0.5	29.9	26.4
	Min.	-493	-29	-303	-7	-3
	Max.	122	132	312	171	82
MDRD at Week 96	n	1713	89	579	27	5
	Mean	-9.4	26.8	2.9	36.9	32.3
	SD	43.82	32.59	37.25	33.91	10.25
	Median	-6.3	25.8	2.6	30.9	35.7
	Min.	-524	-31	-296	-4	20
	Max.	314	171	331	138	43

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.9
Summary of Change from Baseline over Time in Renal Function (eGFR) by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted MDRD at Week 24	n	2193	112	756	39	8
	Mean	-4.8	21.6	1.7	29.2	20.9
	SD	46.99	24.43	27.57	22.00	20.62
	Median	-1.1	19.1	3.6	27.9	19.7
	Min.	-531	-34	-256	-7	-7
	Max.	582	88	116	107	43
BSA-adjusted MDRD at Week 48	n	2036	106	744	37	8
	Mean	-7.9	22.6	4.5	36.2	32.9
	SD	41.54	26.13	33.42	33.74	26.11
	Median	-2.5	19.5	3.0	26.8	26.7
	Min.	-493	-26	-275	-2	-2
	Max.	123	126	342	182	83
BSA-adjusted MDRD at Week 96	n	1713	89	579	27	5
	Mean	-4.9	27.9	7.1	37.2	34.3
	SD	42.53	28.73	36.53	29.89	13.42
	Median	-2.6	26.0	6.0	29.0	30.8
	Min.	-522	-22	-268	1	21
	Max.	345	156	384	118	49

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.10
Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
CGF at Baseline	n	2335	122	797	46	13
	Mean	92.2	43.4	85.3	44.0	25.3
	SD	34.67	5.22	22.76	4.44	4.86
	Median	85.4	44.3	81.8	44.9	27.4
	Min.	50	31	50	36	17
	Max.	459	50	235	50	30
CGF at Week 24	n	2195	112	756	39	8
	Mean	92.2	62.5	90.7	69.1	44.6
	SD	28.40	20.66	20.80	18.22	20.32
	Median	88.2	62.6	88.7	67.2	44.2
	Min.	21	5	8	44	14
	Max.	463	122	196	145	72
CGF at Week 48	n	2036	106	744	37	8
	Mean	91.5	64.7	94.5	75.1	58.5
	SD	24.11	21.24	26.06	29.48	29.04
	Median	89.2	62.6	91.0	67.6	50.6
	Min.	33	4	41	51	19
	Max.	251	143	300	218	116

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.10
Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
CGF at Week 96	n	1713	89	579	27	5
	Mean	93.0	68.5	96.4	75.7	60.6
	SD	27.44	23.41	28.43	21.52	22.26
	Median	89.0	66.2	91.1	72.2	49.2
	Min.	20	25	42	43	41
	Max.	398	174	351	149	92
BSA-adjusted CGF at Baseline	n	2326	122	797	46	12
	Mean	98.1	51.2	90.6	51.6	28.8
	SD	33.57	7.64	21.43	6.25	5.78
	Median	91.6	52.3	87.9	52.7	30.7
	Min.	46	29	54	37	21
	Max.	441	68	258	62	36
BSA-adjusted CGF at Week 24	n	2193	112	756	39	8
	Mean	95.3	70.1	93.5	76.9	48.8
	SD	27.24	21.93	18.40	17.33	22.40
	Median	91.5	71.2	91.7	77.5	49.4
	Min.	25	7	9	51	14
	Max.	446	138	176	145	79

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.10
Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted CGF at Week 48	n	2036	106	744	37	8
	Mean	93.1	71.5	96.0	82.8	60.2
	SD	21.58	22.49	23.15	27.97	30.22
	Median	91.0	67.7	91.6	79.2	55.0
	Min.	28	3	43	53	19
	Max.	230	152	280	210	120
BSA-adjusted CGF at Week 96	n	1713	89	579	27	5
	Mean	94.9	75.2	97.5	82.0	61.1
	SD	25.28	25.27	25.34	21.74	19.47
	Median	91.2	74.4	93.7	79.9	52.8
	Min.	17	27	47	47	40
	Max.	378	194	308	151	90
MDRD at Baseline	n	2335	122	797	46	13
	Mean	116.0	62.4	104.9	63.2	29.7
	SD	45.29	13.12	28.60	12.28	9.24
	Median	106.9	62.0	100.6	64.6	32.9
	Min.	50	26	52	37	17
	Max.	645	103	400	90	45

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.10
Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
MDRD at Week 24	n	2195	112	756	39	8
	Mean	107.2	83.3	103.5	92.2	53.3
	SD	35.57	27.37	21.81	19.72	23.64
	Median	102.2	84.3	101.3	92.7	55.2
	Min.	30	6	8	56	11
	Max.	674	165	274	149	78
MDRD at Week 48	n	2036	106	744	37	8
	Mean	102.1	83.6	104.6	98.2	62.4
	SD	23.98	28.14	27.50	33.10	29.85
	Median	99.3	81.9	100.0	92.0	57.1
	Min.	27	2	45	57	16
	Max.	251	173	407	215	115
MDRD at Week 96	n	1713	89	579	27	5
	Mean	105.7	88.7	107.4	99.0	62.9
	SD	29.04	32.84	30.48	31.23	11.51
	Median	100.8	86.2	102.2	94.8	61.1
	Min.	16	23	49	49	49
	Max.	438	230	400	206	76

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.10
Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted MDRD at Baseline	n	2326	122	797	46	12
	Mean	108.7	52.6	98.1	53.6	27.7
	SD	44.18	9.09	27.31	8.62	7.09
	Median	100.0	53.6	93.6	54.6	29.4
	Min.	48	28	52	38	16
	Max.	647	71	368	69	37
BSA-adjusted MDRD at Week 24	n	2193	112	756	39	8
	Mean	103.2	74.1	99.9	82.6	48.7
	SD	34.72	24.86	21.47	19.72	21.49
	Median	98.8	72.9	97.9	83.1	48.3
	Min.	23	5	8	50	11
	Max.	700	140	204	149	71
BSA-adjusted MDRD at Week 48	n	2036	106	744	37	8
	Mean	99.9	75.5	102.5	88.6	60.7
	SD	24.79	25.96	28.47	32.25	28.62
	Median	97.4	73.1	97.8	80.3	54.6
	Min.	32	2	45	54	16
	Max.	268	163	436	224	111

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.10
Summary of eGFR Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted MDRD at Week 96	n	1713	89	579	27	5
	Mean	103.1	80.3	105.6	90.8	62.3
	SD	29.31	29.14	31.44	27.90	15.00
	Median	98.7	77.9	100.1	85.5	56.9
	Min.	19	22	45	45	48
	Max.	461	205	455	177	79

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. BSA-adjusted eGFR (either CGF or MDRD) units are mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.11
Summary of Subject Visit Maximum eGFR Toxicity Grade (NKF) by Treatment and Baseline CLcr (mL/min)

Lab	Week	NKF Toxicity Grade	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted eGFR (CGF)	0	1	1441 (62%)	18 (15%)	551 (69%)	3 (7%)	0
		2	64 (3%)	103 (84%)	20 (3%)	43 (93%)	7 (54%)
		3	0	1 (<1%)	0	0	5 (38%)
		4	0	0	0	0	0
	24	1	1372 (59%)	67 (55%)	482 (60%)	31 (67%)	4 (31%)
		2	67 (3%)	29 (24%)	16 (2%)	6 (13%)	3 (23%)
		3	2 (<1%)	4 (3%)	1 (<1%)	0	1 (8%)
		4	0	0	0	0	0
	48	1	1303 (56%)	65 (53%)	475 (60%)	28 (61%)	2 (15%)
		2	73 (3%)	27 (22%)	11 (1%)	4 (9%)	4 (31%)
		3	1 (<1%)	3 (2%)	0	0	1 (8%)
		4	0	0	0	0	0
	96	1	1071 (46%)	58 (48%)	341 (43%)	19 (41%)	2 (15%)
		2	48 (2%)	16 (13%)	11 (1%)	4 (9%)	3 (23%)
		3	2 (<1%)	3 (2%)	0	0	0
		4	0	0	0	0	0
BSA-adjusted MDRD	0	1	786 (34%)	22 (18%)	331 (42%)	12 (26%)	0
		2	39 (2%)	99 (81%)	18 (2%)	34 (74%)	5 (38%)
		3	0	1 (<1%)	0	0	7 (54%)
		4	0	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. NKF (2003) G1: 60 to <90 mL/min/1.73 m2, G2: 30 to <60 mL/min/1.73 m2; G3, 15 to <30 mL/min/1.73 m2, and G4: <15 mL/min/1.73 m2.

PPD

Table 2.11
Summary of Subject Visit Maximum eGFR Toxicity Grade (NKF) by Treatment and Baseline CLcr (mL/min)

Lab	Week	NKF Toxicity Grade	TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
BSA-adjusted MDRD	24	1	736 (32%)	61 (50%)	247 (31%)	21 (46%)	3 (23%)
		2	45 (2%)	21 (17%)	11 (1%)	6 (13%)	4 (31%)
		3	1 (<1%)	3 (2%)	0	0	0
		4	0	2 (2%)	1 (<1%)	0	1 (8%)
	48	1	711 (30%)	51 (42%)	253 (32%)	23 (50%)	2 (15%)
		2	51 (2%)	26 (21%)	9 (1%)	3 (7%)	4 (31%)
		3	0	1 (<1%)	0	0	1 (8%)
		4	0	1 (<1%)	0	0	0
	96	1	550 (24%)	46 (38%)	182 (23%)	15 (33%)	2 (15%)
		2	39 (2%)	14 (11%)	8 (1%)	2 (4%)	3 (23%)
		3	2 (<1%)	2 (2%)	0	0	0
		4	0	0	0	0	0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI. All CGF and MDRD values calculated and reported by DART team for weeks 0, 24, 48 and up to Week 96. NKF (2003) G1: 60 to <90 mL/min/1.73 m2, G2: 30 to <60 mL/min/1.73 m2; G3, 15 to <30 mL/min/1.73 m2, and G4: <15 mL/min/1.73 m2.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.12
Summary of Lab Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
ALT at Week 0	n	2335	122	797	46	13
	Mean	31.7	30.7	28.7	30.6	19.9
	SD	23.43	24.54	19.40	29.92	14.00
	Median	26.0	24.0	24.0	25.0	17.0
	Min.	1	4	2	9	2
	Max.	332	140	181	198	58
ALT at Week 24	n	2196	111	755	39	8
	Mean	29.4	26.2	24.6	27.3	22.4
	SD	31.25	16.89	22.68	30.61	8.62
	Median	24.0	20.0	20.0	17.0	22.5
	Min.	4	7	4	8	11
	Max.	741	100	399	176	33
ALT at Week 48	n	2035	105	743	37	8
	Mean	26.3	25.1	23.9	24.1	17.6
	SD	18.31	16.59	17.01	23.96	8.00
	Median	22.0	20.0	19.0	17.0	16.0
	Min.	4	9	5	8	8
	Max.	381	107	185	121	33
ALT at Week 96	n	1713	89	579	27	5
	Mean	27.2	20.1	24.3	26.9	16.4
	SD	21.49	9.31	17.30	37.98	8.65
	Median	23.0	18.0	20.0	16.0	15.0
	Min.	2	7	3	9	9
	Max.	466	59	197	210	31

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.12
Summary of Lab Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
AST at Week 0	n	1604	106	555	42	10
	Mean	41.9	45.1	36.2	50.5	32.1
	SD	24.86	27.35	18.09	55.09	10.33
	Median	35.0	36.0	31.0	37.0	30.5
	Min.	7	14	10	15	20
	Max.	224	177	145	364	50
AST at Week 24	n	1519	95	529	36	7
	Mean	35.0	35.6	28.8	31.3	34.0
	SD	35.48	25.02	29.20	27.80	17.70
	Median	29.0	29.0	23.0	23.5	31.0
	Min.	2	14	8	14	17
	Max.	895	194	411	174	69
AST at Week 48	n	1380	91	521	34	7
	Mean	36.4	42.6	25.2	27.9	26.1
	SD	124.49	92.99	14.44	20.69	11.74
	Median	27.0	28.0	22.0	23.0	23.0
	Min.	9	15	10	13	12
	Max.	4487	905	168	120	46
AST at Week 96	n	1169	77	401	24	4
	Mean	31.3	26.8	25.3	33.6	22.5
	SD	30.14	11.44	15.07	44.75	0.58
	Median	27.0	25.0	22.0	22.0	22.5
	Min.	6	14	10	15	22
	Max.	669	83	211	237	23

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.12
Summary of Lab Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Bilirubin at Week 0	n	2335	122	797	46	13
	Mean	0.5	0.4	0.5	0.4	0.4
	SD	0.26	0.21	0.25	0.27	0.18
	Median	0.4	0.3	0.4	0.3	0.3
	Min.	0	0	0	0	0
	Max.	4	1	3	1	1
Bilirubin at Week 24	n	2196	110	755	39	8
	Mean	0.6	0.5	0.5	0.4	0.4
	SD	0.36	0.31	0.28	0.23	0.10
	Median	0.5	0.4	0.4	0.3	0.4
	Min.	0	0	0	0	0
	Max.	5	2	5	2	1
Bilirubin at Week 48	n	2036	105	744	37	8
	Mean	0.6	0.6	0.5	0.4	0.4
	SD	0.55	0.31	0.37	0.16	0.23
	Median	0.5	0.5	0.4	0.4	0.4
	Min.	0	0	0	0	0
	Max.	17	2	6	1	1
Bilirubin at Week 96	n	1711	89	579	27	5
	Mean	0.6	0.6	0.5	0.4	0.4
	SD	0.38	0.53	0.82	0.22	0.21
	Median	0.6	0.5	0.4	0.4	0.3
	Min.	0	0	0	0	0
	Max.	6	4	19	1	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.12
Summary of Lab Measurements by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Serum creatinine at Week 0	n	2335	122	797	46	13
	Mean	0.9	1.4	0.9	1.3	2.7
	SD	0.21	0.37	0.19	0.28	0.82
	Median	0.9	1.3	0.9	1.2	2.4
	Min.	0	1	0	1	2
	Max.	2	3	2	2	4
Serum creatinine at Week 24	n	2196	112	756	39	8
	Mean	0.9	1.2	0.9	1.0	2.0
	SD	0.21	1.04	0.36	0.17	1.59
	Median	0.9	1.0	0.9	0.9	1.4
	Min.	0	1	0	1	1
	Max.	3	10	10	1	6
Serum creatinine at Week 48	n	2036	106	744	37	8
	Mean	0.9	1.4	0.9	0.9	1.7
	SD	0.21	2.66	0.18	0.21	1.09
	Median	0.9	1.0	0.9	0.9	1.5
	Min.	0	1	0	0	1
	Max.	3	28	2	1	4
Serum creatinine at Week 96	n	1713	89	580	27	5
	Mean	0.9	1.1	0.9	0.9	1.3
	SD	0.24	0.45	0.19	0.22	0.37
	Median	0.9	1.0	0.9	0.9	1.2
	Min.	0	0	0	1	1
	Max.	5	3	2	2	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.13
Summary of Change from Baseline over Time in CD4 Cell Counts by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
CD4 at Week 24	n	2193	108	751	39	8
	Mean	104.2	100.3	123.7	133.8	122.6
	SD	85.47	95.21	96.07	78.75	89.36
	Median	91.0	93.0	106.0	128.0	108.0
	Min.	-158	-96	-58	-5	16
	Max.	615	399	776	293	266
CD4 at Week 48	n	2027	105	743	37	8
	Mean	123.3	122.6	159.7	162.3	128.6
	SD	94.90	100.20	113.56	118.28	66.23
	Median	110.0	104.0	146.0	133.0	157.0
	Min.	-150	-41	-69	-75	43
	Max.	616	467	892	411	227
CD4 at Week 96	n	1709	90	582	27	5
	Mean	155.6	167.6	179.6	181.2	206.0
	SD	119.34	125.08	126.82	94.29	88.50
	Median	139.0	148.0	162.0	183.0	203.0
	Min.	-108	-64	-128	-10	88
	Max.	780	544	836	375	335

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.14
Summary of Change from Baseline over Time in Serum Creatinine (mg/dL) by Treatment and Baseline CLcr (mL/min)

		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Serum Creatinine at Week 24	n	2196	112	756	39	8
	Mean	0.04	-0.16	0.00	-0.38	-0.50
	SD	0.229	0.941	0.364	0.313	1.225
	Median	0.03	-0.25	-0.01	-0.34	-0.64
	Min.	-0.9	-2.0	-0.7	-1.2	-2.1
	Max.	1.7	8.1	8.6	0.1	2.1
Serum Creatinine at Week 48	n	2036	106	744	37	8
	Mean	0.06	-0.03	-0.01	-0.42	-0.89
	SD	0.230	2.469	0.207	0.318	0.709
	Median	0.05	-0.23	0.00	-0.33	-0.95
	Min.	-0.7	-2.3	-0.8	-1.4	-1.8
	Max.	1.6	24.8	1.0	0.1	0.6
Serum Creatinine at Week 96	n	1713	89	580	27	5
	Mean	0.04	-0.30	-0.03	-0.44	-1.17
	SD	0.241	0.462	0.224	0.352	0.484
	Median	0.04	-0.33	-0.02	-0.32	-1.12
	Min.	-0.8	-2.0	-1.1	-1.3	-1.9
	Max.	3.2	1.5	0.7	0.1	-0.6

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. Subjects with missing Baseline CLcr only included in total column. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Hemoglobin (g/dL) at Week 0	n	2335	122	797	46	13
	Mean	11.52	10.57	11.60	10.78	10.28
	SD	1.734	1.582	1.740	1.475	1.866
	Median	11.50	10.45	11.50	11.00	10.40
	Min.	5.8	7.8	8.0	8.0	6.9
	Max.	18.5	19.2	18.6	13.8	13.8
Hemoglobin (g/dL) at Week 24	n	2194	110	758	39	8
	Mean	12.17	11.38	12.26	11.39	9.79
	SD	1.909	1.626	1.697	1.753	1.855
	Median	12.20	11.50	12.30	11.20	10.20
	Min.	3.1	5.5	6.3	6.6	6.5
	Max.	18.8	15.2	19.9	14.8	12.3
Hemoglobin (g/dL) at Week 48	n	2035	106	741	37	8
	Mean	12.68	12.13	12.62	11.89	11.00
	SD	1.814	1.592	1.726	1.479	1.043
	Median	12.60	12.20	12.60	11.70	11.15
	Min.	6.1	8.4	2.5	9.2	9.7
	Max.	19.8	16.7	17.5	16.9	12.7
Hemoglobin (g/dL) at Week 96	n	1713	90	582	27	5
	Mean	12.90	12.42	12.98	12.52	10.52
	SD	1.838	1.734	1.711	1.703	1.224
	Median	12.90	12.30	13.00	12.40	10.40
	Min.	4.4	4.7	5.6	10.0	8.9
	Max.	18.8	16.7	17.6	16.3	12.0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Lymphocytes (x10**3 cells/uL) at Week 0	n	2335	122	797	46	13
	Mean	1.39	1.49	1.48	1.33	2.05
	SD	0.716	0.792	0.717	0.589	1.132
	Median	1.28	1.24	1.35	1.25	1.85
	Min.	0.2	0.3	0.2	0.4	0.7
	Max.	6.4	5.2	4.7	2.8	4.9
Lymphocytes (x10**3 cells/uL) at Week 24	n	2194	110	757	39	8
	Mean	1.55	1.51	1.63	1.55	1.80
	SD	0.613	0.632	0.800	0.668	1.209
	Median	1.45	1.42	1.53	1.37	1.39
	Min.	0.2	0.4	0.2	0.3	0.8
	Max.	5.5	4.0	15.0	3.8	4.5
Lymphocytes (x10**3 cells/uL) at Week 48	n	2035	106	741	37	8
	Mean	1.57	1.49	1.63	1.58	1.66
	SD	0.610	0.597	0.631	0.565	1.110
	Median	1.48	1.35	1.53	1.56	1.31
	Min.	0.2	0.4	0.2	0.4	0.8
	Max.	5.4	3.5	4.7	3.0	4.3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Lymphocytes (x10**3 cells/uL) at Week 96	n	1709	90	582	27	5
	Mean	1.55	1.54	1.62	1.55	2.26
	SD	0.620	0.687	0.653	0.666	1.579
	Median	1.48	1.42	1.51	1.43	1.79
	Min.	0.1	0.2	0.2	0.6	0.7
	Max.	6.4	4.3	6.8	3.4	4.8
MCV at Week 0	n	2335	122	797	46	13
	Mean	86.42	86.11	84.01	80.32	86.23
	SD	8.870	10.164	8.487	7.710	8.625
	Median	86.00	86.00	84.00	79.00	87.90
	Min.	3.6	27.6	7.9	60.0	71.0
	Max.	125.0	121.0	109.6	97.0	99.0
MCV at Week 24	n	2194	110	757	39	8
	Mean	100.01	102.22	100.47	96.76	110.38
	SD	10.562	11.168	10.294	10.786	11.476
	Median	101.00	103.00	101.00	97.90	113.50
	Min.	11.4	76.0	55.0	72.0	90.0
	Max.	131.0	138.0	136.1	118.0	124.0
MCV at Week 48	n	2035	106	741	37	8
	Mean	99.09	102.16	101.29	98.67	105.05
	SD	9.909	9.753	10.410	11.415	13.002
	Median	100.00	103.45	102.00	100.00	106.00
	Min.	64.5	77.0	34.4	74.0	87.0
	Max.	139.3	121.0	126.4	118.7	120.0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
MCV at Week 96	n	1711	90	582	27	5
	Mean	100.85	104.33	102.89	100.31	111.60
	SD	10.765	10.613	10.362	12.147	13.446
	Median	102.00	107.00	104.00	103.00	111.00
	Min.	37.9	74.0	68.0	73.0	96.0
	Max.	139.4	140.0	133.0	121.1	127.0
Neutrophils (x10**3 cells/uL) at Week 0	n	2335	122	797	46	13
	Mean	1.78	1.92	1.71	1.53	2.14
	SD	1.021	1.223	0.884	0.657	1.082
	Median	1.54	1.70	1.52	1.45	1.65
	Min.	0.1	0.3	0.3	0.3	0.7
	Max.	13.9	7.8	7.1	3.2	4.4
Neutrophils (x10**3 cells/uL) at Week 24	n	2195	110	756	39	8
	Mean	1.63	1.51	1.61	1.39	1.07
	SD	0.933	1.007	1.104	1.051	0.544
	Median	1.44	1.35	1.39	1.22	0.79
	Min.	0.1	0.1	0.2	0.2	0.6
	Max.	14.3	7.3	20.0	6.7	1.8

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Neutrophils (x10**3 cells/uL) at Week 48	n	2035	106	740	37	8
	Mean	1.72	1.67	1.68	1.78	1.71
	SD	1.026	0.840	0.840	1.020	0.801
	Median	1.53	1.43	1.50	1.58	1.56
	Min.	0.1	0.5	0.1	0.6	1.0
	Max.	15.4	4.9	7.4	6.1	3.5
Neutrophils (x10**3 cells/uL) at Week 96	n	1705	90	578	27	5
	Mean	1.76	1.87	1.74	1.52	1.68
	SD	0.887	1.099	0.829	0.603	1.055
	Median	1.61	1.73	1.56	1.47	1.24
	Min.	0.1	0.2	0.3	0.6	0.6
	Max.	11.1	9.6	6.8	2.6	3.1
Platelets (x10**3 cells/uL) at Week 0	n	2335	122	797	46	13
	Mean	210.17	222.43	221.03	237.24	261.31
	SD	84.767	110.720	86.349	106.601	168.027
	Median	200.00	200.00	214.00	227.00	224.00
	Min.	8.0	14.0	19.0	42.0	51.0
	Max.	584.0	840.0	808.0	555.0	754.0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Platelets (x10**3 cells/uL) at Week 24	n	2191	110	757	39	8
	Mean	262.44	268.45	248.76	240.15	229.00
	SD	91.374	107.893	86.094	121.369	77.694
	Median	252.00	271.00	237.00	226.00	236.00
	Min.	14.0	31.0	23.0	43.0	122.0
	Max.	785.0	760.0	641.0	750.0	354.0
Platelets (x10**3 cells/uL) at Week 48	n	2035	105	741	37	8
	Mean	252.79	268.97	249.09	241.62	258.25
	SD	83.137	108.802	78.825	97.760	89.915
	Median	245.00	254.00	244.00	241.00	233.50
	Min.	14.0	90.0	1.0	24.0	174.0
	Max.	726.0	854.0	590.0	498.0	448.0
Platelets (x10**3 cells/uL) at Week 96	n	1710	90	581	27	5
	Mean	264.49	276.59	259.22	249.37	257.00
	SD	86.084	99.705	79.463	95.045	75.336
	Median	258.00	277.00	250.00	247.00	253.00
	Min.	22.0	55.0	1.0	45.0	174.0
	Max.	733.0	651.0	603.0	443.0	349.0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
White Blood Cells (x10**3 cells/uL) at Week 0	n	2335	122	797	46	13
	Mean	3.88	4.24	3.98	3.67	5.02
	SD	1.529	1.556	1.384	1.046	1.951
	Median	3.60	4.10	3.80	3.70	4.30
	Min.	0.6	1.2	0.7	1.4	3.0
	Max.	16.6	10.2	10.6	5.6	8.9
White Blood Cells (x10**3 cells/uL) at Week 24	n	2194	110	757	39	8
	Mean	3.97	4.00	4.05	3.70	3.44
	SD	1.410	1.639	2.001	1.579	1.734
	Median	3.80	3.60	3.70	3.50	2.90
	Min.	0.8	1.3	1.2	0.9	1.7
	Max.	18.8	11.3	39.6	10.5	6.9
White Blood Cells (x10**3 cells/uL) at Week 48	n	2035	106	741	37	8
	Mean	4.02	3.88	4.07	4.19	3.86
	SD	1.488	1.230	1.425	1.389	1.811
	Median	3.80	3.70	3.80	4.10	3.50
	Min.	1.0	1.2	1.3	1.8	2.4
	Max.	19.4	7.3	17.6	7.5	8.2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.15
Summary of Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
White Blood Cells (x10**3 cells/uL) at Week 96	n	1711	90	582	27	5
	Mean	4.02	4.08	4.00	3.78	4.42
	SD	1.407	1.573	1.326	1.200	1.608
	Median	3.80	3.90	3.80	3.60	4.50
	Min.	0.7	0.7	1.4	2.1	2.3
	Max.	16.4	11.8	11.6	6.4	6.2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.16
Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Hemoglobin (g/dL) at Week 24	n	2194	110	758	39	8
	Mean	0.63	0.81	0.63	0.58	-0.56
	SD	1.750	1.947	1.676	1.787	2.287
	Median	0.60	0.70	0.60	0.30	-0.30
	Min.	-10.2	-7.0	-7.4	-2.9	-4.7
	Max.	8.4	5.4	9.3	5.7	2.0
Hemoglobin (g/dL) at Week 48	n	2035	106	741	37	8
	Mean	1.13	1.56	1.00	1.19	0.39
	SD	1.691	1.726	1.770	1.694	2.455
	Median	1.00	1.50	0.90	0.80	0.30
	Min.	-6.4	-2.5	-6.5	-1.3	-2.7
	Max.	7.8	5.9	8.0	6.0	5.0
Hemoglobin (g/dL) at Week 96	n	1713	90	582	27	5
	Mean	1.37	1.98	1.27	1.89	-0.08
	SD	1.832	2.091	1.859	1.973	2.668
	Median	1.30	2.10	1.30	1.70	-0.10
	Min.	-6.4	-7.6	-6.4	-1.2	-3.5
	Max.	9.4	6.0	6.8	7.2	3.0
Lymphocytes (x10**3 cells/uL) at Week 24	n	2194	110	757	39	8
	Mean	0.14	0.01	0.14	0.14	-0.29
	SD	0.670	0.760	0.835	0.489	0.369
	Median	0.16	0.08	0.16	0.06	-0.35
	Min.	-3.1	-2.1	-2.4	-0.6	-0.8
	Max.	4.6	2.5	13.7	1.2	0.4

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.16
Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Lymphocytes (x10**3 cells/uL) at Week 48	n	2035	106	741	37	8
	Mean	0.17	0.04	0.15	0.17	-0.41
	SD	0.718	0.831	0.723	0.661	0.324
	Median	0.19	0.06	0.17	0.02	-0.24
	Min.	-3.9	-2.6	-2.5	-1.3	-0.9
	Max.	4.2	2.0	3.2	1.6	-0.1
Lymphocytes (x10**3 cells/uL) at Week 96	n	1709	90	582	27	5
	Mean	0.18	0.11	0.14	0.22	-0.01
	SD	0.774	0.819	0.789	0.638	0.441
	Median	0.19	0.14	0.15	0.29	-0.09
	Min.	-3.8	-2.5	-2.7	-0.8	-0.5
	Max.	5.4	2.8	4.8	2.0	0.6
MCV at Week 24	n	2194	110	757	39	8
	Mean	13.52	15.92	16.37	15.69	22.34
	SD	9.469	12.750	8.475	7.971	9.430
	Median	14.00	17.00	16.30	16.00	24.00
	Min.	-73.6	-21.0	-13.8	-5.0	5.1
	Max.	91.9	85.4	82.1	33.0	36.0
MCV at Week 48	n	2035	106	741	37	8
	Mean	12.60	16.01	17.23	17.69	17.06
	SD	8.829	11.647	8.943	8.207	11.888
	Median	12.90	18.00	17.00	16.00	18.20
	Min.	-31.5	-21.0	-57.0	5.0	-4.0
	Max.	81.9	76.4	81.1	35.0	37.0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.16
Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
MCV at Week 96	n	1711	90	582	27	5
	Mean	14.45	17.82	18.87	19.19	23.22
	SD	9.867	12.883	8.852	8.874	14.096
	Median	14.90	18.00	19.10	17.50	28.00
	Min.	-54.5	-16.0	-12.5	-3.0	3.1
	Max.	78.9	79.4	86.1	39.0	40.0
Neutrophils (x10**3 cells/uL) at Week 24	n	2195	110	756	39	8
	Mean	-0.16	-0.37	-0.10	-0.09	-1.23
	SD	1.179	1.473	1.247	1.183	1.317
	Median	-0.11	-0.32	-0.16	-0.32	-0.91
	Min.	-13.1	-6.6	-5.2	-1.7	-3.8
	Max.	13.1	4.8	18.6	5.7	0.5
Neutrophils (x10**3 cells/uL) at Week 48	n	2035	106	740	37	8
	Mean	-0.06	-0.21	-0.03	0.36	-0.48
	SD	1.253	1.375	1.092	0.943	1.396
	Median	-0.03	-0.17	-0.02	0.15	-0.12
	Min.	-13.0	-6.7	-5.7	-1.3	-3.4
	Max.	11.9	3.7	4.1	3.5	1.1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.16
Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Neutrophils (x10**3 cells/uL) at Week 96	n	1705	90	578	27	5
	Mean	-0.00	0.02	-0.00	-0.01	-0.57
	SD	1.203	1.586	1.107	0.874	1.482
	Median	0.04	0.18	0.04	-0.13	-0.23
	Min.	-11.5	-7.2	-6.2	-1.6	-3.1
	Max.	10.1	6.6	5.8	1.8	0.8
Platelets (x10**3 cells/uL) at Week 24	n	2191	110	757	39	8
	Mean	53.07	44.41	29.77	8.82	-39.25
	SD	88.729	98.769	90.054	104.380	169.494
	Median	50.00	59.00	27.00	16.00	10.50
	Min.	-355.0	-216.0	-498.0	-234.0	-400.0
	Max.	487.0	321.0	416.0	195.0	108.0
Platelets (x10**3 cells/uL) at Week 48	n	2035	105	741	37	8
	Mean	43.63	44.97	28.94	16.84	-34.75
	SD	85.089	107.743	85.832	94.268	174.727
	Median	44.00	53.00	31.00	20.00	1.50
	Min.	-384.0	-348.0	-444.0	-221.0	-428.0
	Max.	453.0	564.0	391.0	214.0	138.0

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.16
Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
Platelets (x10**3 cells/uL) at Week 96	n	1710	90	581	27	5
	Mean	55.54	55.82	40.53	14.63	-1.80
	SD	88.452	99.518	87.944	105.714	73.042
	Median	56.00	62.00	43.00	43.00	-6.00
	Min.	-367.0	-189.0	-467.0	-201.0	-118.0
	Max.	543.0	328.0	323.0	166.0	65.0
White Blood Cells (x10**3 cells/uL) at Week 24	n	2194	110	757	39	8
	Mean	0.08	-0.25	0.07	0.00	-1.60
	SD	1.639	2.063	2.039	1.337	1.849
	Median	0.10	-0.20	-0.10	-0.10	-1.60
	Min.	-14.2	-7.3	-6.9	-2.5	-5.2
	Max.	14.3	6.7	33.5	5.7	0.3
White Blood Cells (x10**3 cells/uL) at Week 48	n	2035	106	741	37	8
	Mean	0.13	-0.34	0.09	0.50	-1.13
	SD	1.712	1.790	1.608	1.275	1.568
	Median	0.20	-0.30	0.00	0.30	-0.80
	Min.	-14.3	-6.6	-6.5	-1.6	-4.5
	Max.	14.3	4.8	9.6	3.2	0.8

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.16
Summary of Change from Baseline in Hematology Measurements by Treatment and Baseline CLcr (mL/min)

Parameter / Week		TDF CLcr>=50 (N=2335)	TDF CLcr 30-49 (N=122)	ABC or NVP CLcr>=50 (N=797)	ABC or NVP CLcr 30-49 (N=46)	Any CLcr<30 (N=13)
White Blood Cells (x10**3 cells/uL) at Week 96	n	1711	90	582	27	5
	Mean	0.17	-0.09	-0.02	0.07	-0.64
	SD	1.761	1.919	1.680	1.318	1.537
	Median	0.20	0.10	0.00	0.00	-0.30
	Min.	-13.4	-8.0	-8.8	-1.8	-3.2
	Max.	13.6	6.1	6.7	3.5	0.8

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.
PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Hemoglobin (g/dL)
Treatment: TDF CLcr>=50 (N=2335)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	1834	(93%)	100	(5%)	19	(<1%)	5	(<1%)	15	(<1%)	1973	(89%)
Grade 1	181	(72%)	54	(21%)	10	(4%)	3	(1%)	4	(2%)	252	(11%)
Grade 2	0		1	(50%)	1	(50%)	0		0		2	(<1%)
Grade 4	1	(100%)	0		0		0		0		1	(<1%)
Total	2016	(90%)	155	(7%)	30	(1%)	8	(<1%)	19	(<1%)	2228	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Hemoglobin (g/dL)
Treatment: TDF CLcr 30-49 (N=122)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	73	(89%)	6	(7%)	1	(1%)	0		2	(2%)	82	(74%)
Grade 1	23	(82%)	3	(11%)	2	(7%)	0		0		28	(25%)
Grade 2	1	(100%)	0		0		0		0		1	(<1%)
Total	97	(87%)	9	(8%)	3	(3%)	0		2	(2%)	111	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Hemoglobin (g/dL)
Treatment: ABC or NVP CLcr>=50 (N=797)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	648	(94%)	29	(4%)	5	(<1%)	3	(<1%)	5	(<1%)	690	(90%)
Grade 1	67	(84%)	8	(10%)	3	(4%)	0		2	(3%)	80	(10%)
Total	715	(93%)	37	(5%)	8	(1%)	3	(<1%)	7	(<1%)	770	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Hemoglobin (g/dL)
Treatment: ABC or NVP CLcr 30-49 (N=46)

	Maximum On-treatment Category					
Baseline Category	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Total
Grade 0	30 (94%)	2 (6%)	0	0	0	32 (80%)
Grade 1	5 (63%)	2 (25%)	0	1 (13%)	0	8 (20%)
Total	35 (88%)	4 (10%)	0	1 (3%)	0	40 (100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Hemoglobin (g/dL)
Treatment: Any CLcr<30 (N=13)

	Maximum On-treatment Category					
Baseline Category	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Total
Grade 0	3 (50%)	2 (33%)	0	1 (17%)	0	6 (67%)
Grade 1	2 (100%)	0	0	0	0	2 (22%)
Grade 3	0	0	1 (100%)	0	0	1 (11%)
Total	5 (56%)	2 (22%)	1 (11%)	1 (11%)	0	9 (100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Neutrophils (x10**3 cells/uL)
Treatment: TDF CLcr>=50 (N=2335)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	447	(38%)	426	(36%)	188	(16%)	83	(7%)	38	(3%)	1182	(53%)
Grade 1	144	(21%)	249	(37%)	152	(22%)	105	(15%)	32	(5%)	682	(31%)
Grade 2	31	(14%)	67	(30%)	62	(28%)	40	(18%)	20	(9%)	220	(10%)
Grade 3	12	(9%)	46	(33%)	25	(18%)	33	(24%)	22	(16%)	138	(6%)
Grade 4	1	(17%)	2	(33%)	0		0		3	(50%)	6	(<1%)
Total	635	(29%)	790	(35%)	427	(19%)	261	(12%)	115	(5%)	2228	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Neutrophils (x10**3 cells/uL)
Treatment: TDF CLcr 30-49 (N=122)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	18	(29%)	22	(35%)	13	(21%)	6	(10%)	3	(5%)	62	(56%)
Grade 1	3	(14%)	9	(41%)	4	(18%)	4	(18%)	2	(9%)	22	(20%)
Grade 2	1	(6%)	6	(33%)	3	(17%)	5	(28%)	3	(17%)	18	(16%)
Grade 3	1	(13%)	2	(25%)	2	(25%)	2	(25%)	1	(13%)	8	(7%)
Grade 4	0		1	(100%)	0		0		0		1	(<1%)
Total	23	(21%)	40	(36%)	22	(20%)	17	(15%)	9	(8%)	111	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Neutrophils (x10**3 cells/uL)
Treatment: ABC or NVP CLcr>=50 (N=797)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	136	(34%)	149	(38%)	67	(17%)	35	(9%)	9	(2%)	396	(51%)
Grade 1	22	(10%)	107	(47%)	65	(29%)	30	(13%)	4	(2%)	228	(30%)
Grade 2	19	(18%)	35	(34%)	22	(21%)	19	(18%)	8	(8%)	103	(13%)
Grade 3	3	(8%)	15	(38%)	5	(13%)	10	(25%)	7	(18%)	40	(5%)
Grade 4	1	(50%)	1	(50%)	0		0		0		2	(<1%)
Total	181	(24%)	307	(40%)	159	(21%)	94	(12%)	28	(4%)	769	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Neutrophils (x10**3 cells/uL)
Treatment: ABC or NVP CLcr 30-49 (N=46)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	9	(56%)	2	(13%)	3	(19%)	1	(6%)	1	(6%)	16	(40%)
Grade 1	2	(13%)	4	(25%)	5	(31%)	3	(19%)	2	(13%)	16	(40%)
Grade 2	1	(25%)	0		0		2	(50%)	1	(25%)	4	(10%)
Grade 3	0		1	(33%)	1	(33%)	1	(33%)	0		3	(8%)
Grade 4	0		1	(100%)	0		0		0		1	(3%)
Total	12	(30%)	8	(20%)	9	(23%)	7	(18%)	4	(10%)	40	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Neutrophils (x10**3 cells/uL)
Treatment: Any CLcr<30 (N=13)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	2	(33%)	0		1	(17%)	3	(50%)	0		6	(67%)
Grade 1	0		1	(50%)	0		1	(50%)	0		2	(22%)
Grade 3	0		0		0		1	(100%)	0		1	(11%)
Total	2	(22%)	1	(11%)	1	(11%)	5	(56%)	0		9	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Platelets (x10**3 cells/uL)
Treatment: TDF CLcr>=50 (N=2335)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	2027	(98%)	20	(<1%)	13	(<1%)	7	(<1%)	2	(<1%)	2069	(93%)
Grade 1	77	(83%)	7	(8%)	2	(2%)	7	(8%)	0		93	(4%)
Grade 2	29	(76%)	1	(3%)	4	(11%)	3	(8%)	1	(3%)	38	(2%)
Grade 3	14	(64%)	1	(5%)	4	(18%)	3	(14%)	0		22	(<1%)
Grade 4	3	(50%)	0		0		3	(50%)	0		6	(<1%)
Total	2150	(96%)	29	(1%)	23	(1%)	23	(1%)	3	(<1%)	2228	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Platelets (x10**3 cells/uL)
Treatment: TDF CLcr 30-49 (N=122)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4	Total		
Grade 0	97	(94%)	4	(4%)	1	(<1%)	1	(<1%)	0	103	(93%)	
Grade 1	2	(67%)	0		1	(33%)	0		0	3	(3%)	
Grade 2	2	(100%)	0		0		0		0	2	(2%)	
Grade 3	2	(100%)	0		0		0		0	2	(2%)	
Grade 4	0		1	(100%)	0		0		0	1	(<1%)	
Total	103	(93%)	5	(5%)	2	(2%)	1	(<1%)	0	111	(100%)	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Platelets (x10**3 cells/uL)
Treatment: ABC or NVP CLcr>=50 (N=797)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	705	(97%)	7	(<1%)	6	(<1%)	5	(<1%)	2	(<1%)	725	(94%)
Grade 1	24	(83%)	2	(7%)	1	(3%)	2	(7%)	0		29	(4%)
Grade 2	3	(60%)	0		0		2	(40%)	0		5	(<1%)
Grade 3	6	(60%)	0		2	(20%)	2	(20%)	0		10	(1%)
Grade 4	1	(100%)	0		0		0		0		1	(<1%)
Total	739	(96%)	9	(1%)	9	(1%)	11	(1%)	2	(<1%)	770	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Platelets (x10**3 cells/uL)
Treatment: ABC or NVP CLcr 30-49 (N=46)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4	Total		
Grade 0	31	(89%)	1	(3%)	2	(6%)	1	(3%)	0	35	(88%)	
Grade 1	3	(75%)	0		0		1	(25%)	0	4	(10%)	
Grade 3	1	(100%)	0		0		0		0	1	(3%)	
Total	35	(88%)	1	(3%)	2	(5%)	2	(5%)	0	40	(100%)	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: Platelets (x10**3 cells/uL)
Treatment: Any CLcr<30 (N=13)

	Maximum On-treatment Category					
Baseline Category	Grade 0	Grade 1	Grade 2	Grade 3	Grade 4	Total
Grade 0	8 (100%)	0	0	0	0	8 (89%)
Grade 2	1 (100%)	0	0	0	0	1 (11%)
Total	9 (100%)	0	0	0	0	9 (100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: White Blood Cells (x10**3 cells/uL)
Treatment: TDF CLcr>=50 (N=2335)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	388	(43%)	336	(37%)	171	(19%)	17	(2%)	0		912	(41%)
Grade 1	133	(19%)	288	(41%)	242	(35%)	34	(5%)	0		697	(31%)
Grade 2	53	(10%)	168	(32%)	232	(44%)	68	(13%)	2	(<1%)	523	(23%)
Grade 3	10	(11%)	21	(22%)	42	(45%)	21	(22%)	0		94	(4%)
Grade 4	0		1	(50%)	0		0		1	(50%)	2	(<1%)
Total	584	(26%)	814	(37%)	687	(31%)	140	(6%)	3	(<1%)	2228	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: White Blood Cells (x10**3 cells/uL)
Treatment: TDF CLcr 30-49 (N=122)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	12	(20%)	26	(44%)	18	(31%)	2	(3%)	1	(2%)	59	(53%)
Grade 1	5	(16%)	12	(39%)	11	(35%)	3	(10%)	0		31	(28%)
Grade 2	2	(10%)	9	(45%)	4	(20%)	5	(25%)	0		20	(18%)
Grade 3	0		0		1	(100%)	0		0		1	(<1%)
Total	19	(17%)	47	(42%)	34	(31%)	10	(9%)	1	(<1%)	111	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: White Blood Cells (x10**3 cells/uL)
Treatment: ABC or NVP CLcr>=50 (N=797)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4	Total		
Grade 0	124	(37%)	132	(39%)	72	(21%)	10	(3%)	0	338	(44%)	
Grade 1	43	(16%)	115	(43%)	95	(36%)	12	(5%)	0	265	(34%)	
Grade 2	22	(15%)	48	(32%)	67	(45%)	11	(7%)	0	148	(19%)	
Grade 3	1	(6%)	8	(44%)	7	(39%)	2	(11%)	0	18	(2%)	
Grade 4	0		0		1	(100%)	0		0	1	(<1%)	
Total	190	(25%)	303	(39%)	242	(31%)	35	(5%)	0	770	(100%)	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: White Blood Cells (x10**3 cells/uL)
Treatment: ABC or NVP CLcr 30-49 (N=46)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	5	(31%)	9	(56%)	2	(13%)	0		0		16	(40%)
Grade 1	2	(14%)	8	(57%)	4	(29%)	0		0		14	(35%)
Grade 2	0		1	(17%)	3	(50%)	1	(17%)	1	(17%)	6	(15%)
Grade 3	0		1	(25%)	1	(25%)	2	(50%)	0		4	(10%)
Total	7	(18%)	19	(48%)	10	(25%)	3	(8%)	1	(3%)	40	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.17
Summary of Hematology Toxicity Shifts from Baseline

Lab Parameter: White Blood Cells (x10**3 cells/uL)
Treatment: Any CLcr<30 (N=13)

	Maximum On-treatment Category											
Baseline Category	Grade 0		Grade 1		Grade 2		Grade 3		Grade 4		Total	
Grade 0	2	(40%)	1	(20%)	2	(40%)	0		0		5	(56%)
Grade 1	0		1	(25%)	1	(25%)	2	(50%)	0		4	(44%)
Total	2	(22%)	2	(22%)	3	(33%)	2	(22%)	0		9	(100%)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.18
Summary of Maximum Treatment Emergent Hematology Toxicities by Intensity

	TDF CLcr>=50 (N=2335)		TDF CLcr 30-49 (N=122)		ABC or NVP CLcr>=50 (N=797)		ABC or NVP CLcr 30-49 (N=46)		Any CLcr<30 (N=13)	
ALL PARAMETERS										
Grades 1 to 4	1380	(59%)	88	(72%)	492	(62%)	28	(61%)	8	(62%)
Grades 2 to 4	911	(39%)	55	(45%)	332	(42%)	21	(46%)	7	(54%)
Grades 3 to 4	406	(17%)	27	(22%)	132	(17%)	10	(22%)	5	(38%)
Grade 1	469	(20%)	33	(27%)	160	(20%)	7	(15%)	1	(8%)
Grade 2	505	(22%)	28	(23%)	200	(25%)	11	(24%)	2	(15%)
Grade 3	276	(12%)	17	(14%)	95	(12%)	6	(13%)	5	(38%)
Grade 4	130	(6%)	10	(8%)	37	(5%)	4	(9%)	0	
Hemoglobin (g/dL)										
Grades 1 to 4	156	(7%)	11	(9%)	47	(6%)	3	(7%)	3	(23%)
Grades 2 to 4	56	(2%)	5	(4%)	18	(2%)	1	(2%)	1	(8%)
Grades 3 to 4	27	(1%)	2	(2%)	10	(1%)	1	(2%)	1	(8%)
Grade 1	100	(4%)	6	(5%)	29	(4%)	2	(4%)	2	(15%)
Grade 2	29	(1%)	3	(2%)	8	(1%)	0		0	
Grade 3	8	(<1%)	0		3	(<1%)	1	(2%)	1	(8%)
Grade 4	19	(<1%)	2	(2%)	7	(<1%)	0		0	
Neutrophils (x10**3 cells/uL)										
Grades 1 to 4	1106	(47%)	63	(52%)	393	(49%)	20	(43%)	5	(38%)
Grades 2 to 4	680	(29%)	41	(34%)	244	(31%)	18	(39%)	5	(38%)
Grades 3 to 4	340	(15%)	24	(20%)	112	(14%)	10	(22%)	4	(31%)
Grade 1	426	(18%)	22	(18%)	149	(19%)	2	(4%)	0	
Grade 2	340	(15%)	17	(14%)	132	(17%)	8	(17%)	1	(8%)
Grade 3	228	(10%)	15	(12%)	84	(11%)	6	(13%)	4	(31%)
Grade 4	112	(5%)	9	(7%)	28	(4%)	4	(9%)	0	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Table 2.18
Summary of Maximum Treatment Emergent Hematology Toxicities by Intensity

	TDF CLcr>=50 (N=2335)		TDF CLcr 30-49 (N=122)		ABC or NVP CLcr>=50 (N=797)		ABC or NVP CLcr 30-49 (N=46)		Any CLcr<30 (N=13)	
Platelets (x10**3 cells/uL)										
Grades 1 to 4	55	(2%)	7	(6%)	25	(3%)	5	(11%)	0	
Grades 2 to 4	35	(1%)	3	(2%)	18	(2%)	4	(9%)	0	
Grades 3 to 4	20	(<1%)	1	(<1%)	11	(1%)	2	(4%)	0	
Grade 1	20	(<1%)	4	(3%)	7	(<1%)	1	(2%)	0	
Grade 2	15	(<1%)	2	(2%)	7	(<1%)	2	(4%)	0	
Grade 3	17	(<1%)	1	(<1%)	9	(1%)	2	(4%)	0	
Grade 4	3	(<1%)	0		2	(<1%)	0		0	
White Blood Cells (x10**3 cells/uL)										
Grades 1 to 4	870	(37%)	66	(54%)	332	(42%)	17	(37%)	6	(46%)
Grades 2 to 4	534	(23%)	40	(33%)	200	(25%)	8	(17%)	5	(38%)
Grades 3 to 4	121	(5%)	11	(9%)	33	(4%)	2	(4%)	2	(15%)
Grade 1	336	(14%)	26	(21%)	132	(17%)	9	(20%)	1	(8%)
Grade 2	413	(18%)	29	(24%)	167	(21%)	6	(13%)	3	(23%)
Grade 3	119	(5%)	10	(8%)	33	(4%)	1	(2%)	2	(15%)
Grade 4	2	(<1%)	1	(<1%)	0		1	(2%)	0	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. STI participants data is censored after the start of their STI.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr 30-49	PPD	PPD		ALT	29APR2003	0	33.00	
					28OCT2003	24	51.00	1
					13APR2004	48	68.00	1
					15MAR2005	96	18.00	
				AST	29APR2003	0	66.00	1
					28OCT2003	24	62.00	1
					13APR2004	48	905.00	4
					15MAR2005	96	26.00	
				Bilirubin	29APR2003	0	0.20	
					28OCT2003	24	0.30	
					13APR2004	48	0.14	
					15MAR2005	96	0.31	
				Creatinine	29APR2003	0	1.56	1
					28OCT2003	24	1.02	
					13APR2004	48	0.80	
					15MAR2005	96	1.04	
				ALT	27MAY2003	0	64.00	1
					01DEC2003	24	39.00	
				AST	27MAY2003	0	60.00	1
					01DEC2003	24	47.00	
				Bilirubin	27MAY2003	0	0.14	
					01DEC2003	24	0.17	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr 30-49	P P	PPD		Creatinine	27MAY2003	0	3.45	2
					01DEC2003	24	6.38	3
					03MAY2004	48	28.25	4
				ALT	04JUL2003	0	16.00	
					29DEC2003	24	16.00	
					14JUN2004	48	29.00	
					09MAY2005	96	8.00	
				AST	04JUL2003	0	21.00	
					29DEC2003	24	24.00	
					14JUN2004	48	25.00	
					09MAY2005	96	19.00	
				Bilirubin	04JUL2003	0	0.22	
					29DEC2003	24	0.39	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr 30-49	P P	PPD		Bilirubin	14JUN2004	48	0.30	
					09MAY2005	96	4.46	3
				Creatinine	04JUL2003	0	1.24	1
					29DEC2003	24	1.18	
					14JUN2004	48	0.80	
					09MAY2005	96	0.73	
				ALT	08OCT2003	0	58.00	1
				AST	08OCT2003	0	91.00	1
				Bilirubin	08OCT2003	0	0.62	
				Creatinine	08OCT2003	0	1.67	1
					26FEB2004	24	9.79	4

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	04JUL2003	0	32.00	
					29DEC2003	24	13.00	
					11JUN2004	48	15.00	
					13MAY2005	96	20.00	
				AST	04JUL2003	0	40.00	
					29DEC2003	24	18.00	
					11JUN2004	48	30.00	
					13MAY2005	96	32.00	
				Bilirubin	04JUL2003	0	0.88	
					29DEC2003	24	2.67	3
					11JUN2004	48	2.25	2
					13MAY2005	96	1.82	2
				Creatinine	04JUL2003	0	1.27	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	29DEC2003	24	1.22	
					11JUN2004	48	1.16	
					13MAY2005	96	1.27	
				ALT	28JUL2003	0	19.00	
					30JAN2004	24	30.00	
					16JUL2004	48	22.00	
					17JUN2005	96	38.00	
				AST	28JUL2003	0	27.00	
					30JAN2004	24	23.00	
					16JUL2004	48	25.00	
					17JUN2005	96	109.00	2
				Bilirubin	28JUL2003	0	0.25	
					30JAN2004	24	1.37	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	16JUL2004	48	0.52	
					17JUN2005	96	5.79	4
				Creatinine	28JUL2003	0	1.24	
					30JAN2004	24	1.20	
					16JUL2004	48	1.03	
					17JUN2005	96	1.12	
				ALT	03SEP2003	0	23.00	
					15MAR2004	24	49.00	
					02SEP2004	48	24.00	
					01AUG2005	96	16.00	
				AST	03SEP2003	0	34.00	
					15MAR2004	24	53.00	1
					02SEP2004	48	32.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	01AUG2005	96	27.00	
				Bilirubin	03SEP2003	0	1.20	1
					15MAR2004	24	1.29	1
					02SEP2004	48	1.09	1
					01AUG2005	96	2.62	3
				Creatinine	03SEP2003	0	0.96	
					15MAR2004	24	1.05	
					02SEP2004	48	0.88	
					01AUG2005	96	1.07	
				ALT	24SEP2003	0	45.00	
					24MAR2004	24	13.00	
					08SEP2004	48	13.00	
					10AUG2005	96	9.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	24SEP2003	0	82.00	1
					24MAR2004	24	28.00	
					08SEP2004	48	23.00	
					10AUG2005	96	19.00	
				Bilirubin	24SEP2003	0	0.55	
					24MAR2004	24	2.92	3
					08SEP2004	48	1.73	2
					10AUG2005	96	0.86	
				Creatinine	24SEP2003	0	0.69	
					24MAR2004	24	0.90	
					08SEP2004	48	0.88	
					10AUG2005	96	0.92	
				ALT	08OCT2003	0	26.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	01APR2004	24	741.00	4
					15SEP2004	48	27.00	
					17AUG2005	96	35.00	
				AST	08OCT2003	0	46.00	
					01APR2004	24	895.00	4
					15SEP2004	48	32.00	
					17AUG2005	96	35.00	
				Bilirubin	08OCT2003	0	0.29	
					01APR2004	24	0.49	
					15SEP2004	48	0.79	
					17AUG2005	96	0.70	
				Creatinine	08OCT2003	0	0.92	
					01APR2004	24	1.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	15SEP2004	48	1.07	
					17AUG2005	96	1.13	
				ALT	10OCT2003	0	27.00	
					05APR2004	24	595.00	4
					20SEP2004	48	30.00	
					22AUG2005	96	46.00	
				AST	10OCT2003	0	41.00	
					05APR2004	24	51.00	
					20SEP2004	48	25.00	
					22AUG2005	96	74.00	1
				Bilirubin	10OCT2003	0	0.29	
					05APR2004	24	0.25	
					20SEP2004	48	0.52	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	22AUG2005	96	0.35	
				Creatinine	10OCT2003	0	1.05	
					05APR2004	24	0.96	
					20SEP2004	48	1.88	1
					22AUG2005	96	1.18	
				ALT	21OCT2003	0	74.00	1
					20APR2004	24	24.00	
					05OCT2004	48	10.00	
					06SEP2005	96	12.00	
				AST	21OCT2003	0	88.00	1
					20APR2004	24	37.00	
					05OCT2004	48	20.00	
					06SEP2005	96	21.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	21OCT2003	0	0.36	
					20APR2004	24	0.63	
					05OCT2004	48	2.63	3
					06SEP2005	96	2.75	3
				Creatinine	21OCT2003	0	1.02	
					20APR2004	24	1.10	
					05OCT2004	48	1.26	
					06SEP2005	96	1.16	
				ALT	11NOV2003	0	98.00	2
					05MAY2004	24	132.00	2
					19OCT2004	48	72.00	1
					20SEP2005	96	179.00	2
				AST	11NOV2003	0	153.00	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	05MAY2004	24	133.00	2
					19OCT2004	48	72.00	1
					20SEP2005	96	159.00	2
				Bilirubin	11NOV2003	0	2.96	3
					05MAY2004	24	1.63	2
					19OCT2004	48	1.86	2
					20SEP2005	96	0.98	
				Creatinine	11NOV2003	0	0.79	
					05MAY2004	24	0.78	
					19OCT2004	48	0.87	
					20SEP2005	96	0.88	
				ALT	11DEC2003	0	106.00	2
					27MAY2004	24	136.00	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	10NOV2004	48	271.00	3
					13OCT2005	96	77.00	1
				AST	11DEC2003	0	98.00	1
					27MAY2004	24	163.00	2
					10NOV2004	48	356.00	3
					13OCT2005	96	70.00	1
				Bilirubin	11DEC2003	0	0.23	
					27MAY2004	24	0.40	
					10NOV2004	48	0.48	
					13OCT2005	96	0.54	
				Creatinine	11DEC2003	0	1.02	
					27MAY2004	24	0.89	
					10NOV2004	48	0.71	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	13OCT2005	96	0.66	
				ALT	26NOV2003	0	7.00	
					07JUN2004	24	20.00	
					19NOV2004	48	32.00	
					21OCT2005	96	48.00	
				AST	26NOV2003	0	18.00	
					07JUN2004	24	26.00	
					19NOV2004	48	15.00	
					21OCT2005	96	50.00	
				Bilirubin	26NOV2003	0	0.51	
					07JUN2004	24	0.92	
					19NOV2004	48	0.26	
					21OCT2005	96	2.74	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	26NOV2003	0	0.85	
					07JUN2004	24	0.84	
					19NOV2004	48	0.78	
					21OCT2005	96	0.74	
				ALT	15DEC2003	0	123.00	1
					06JUL2004	24	51.00	
					20DEC2004	48	53.00	
					15NOV2005	96	42.00	
				AST	15DEC2003	0	77.00	1
					06JUL2004	24	62.00	1
					20DEC2004	48	57.00	1
					15NOV2005	96	55.00	1
				Bilirubin	15DEC2003	0	0.52	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	06JUL2004	24	0.60	
					20DEC2004	48	1.16	1
					15NOV2005	96	3.06	3
				Creatinine	15DEC2003	0	0.84	
					06JUL2004	24	0.76	
					20DEC2004	48	1.12	
					15NOV2005	96	1.14	
				ALT	01MAR2004	0	33.00	
					09SEP2004	24	36.00	
					24FEB2005	48	14.00	
					25JAN2006	96	20.00	
				AST	01MAR2004	0	52.00	
					09SEP2004	24	153.00	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	24FEB2005	48	22.00	
					25JAN2006	96	24.00	
				Bilirubin	01MAR2004	0	0.37	
					09SEP2004	24	3.65	3
					24FEB2005	48	1.52	2
					25JAN2006	96	1.04	1
				Creatinine	01MAR2004	0	1.07	
					09SEP2004	24	1.78	1
					24FEB2005	48	1.49	
					25JAN2006	96	1.27	
				ALT	19APR2004	0	36.00	
					12OCT2004	24	10.00	
					29MAR2005	48	14.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	28FEB2006	96	13.00	
				AST	19APR2004	0	58.00	1
					12OCT2004	24	19.00	
					29MAR2005	48	18.00	
					28FEB2006	96	19.00	
				Bilirubin	19APR2004	0	0.32	
					12OCT2004	24	0.75	
					29MAR2005	48	1.71	2
					28FEB2006	96	2.68	3
				Creatinine	19APR2004	0	0.90	
					12OCT2004	24	0.94	
					29MAR2005	48	1.20	
					28FEB2006	96	1.13	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	06JUL2004	0	197.00	2
					13JAN2005	24	11.00	
					28JUN2005	48	20.00	
					01JUN2006	96	29.00	
				AST	06JUL2004	0	224.00	3
					13JAN2005	24	19.00	
					28JUN2005	48	25.00	
					01JUN2006	96	35.00	
				Bilirubin	06JUL2004	0	0.75	
					13JAN2005	24	1.01	1
					28JUN2005	48	0.47	
					01JUN2006	96	1.11	1
				Creatinine	06JUL2004	0	1.05	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	13JAN2005	24	1.10	
					28JUN2005	48	1.19	
					01JUN2006	96	1.14	
				ALT	16JUL2003	0	20.00	
					20JAN2004	24	14.00	
					02JUL2004	48	92.00	1
				AST	16JUL2003	0	50.00	
					20JAN2004	24	26.00	
					02JUL2004	48	416.00	3
				Bilirubin	16JUL2003	0	0.56	
					20JAN2004	24	0.25	
					02JUL2004	48	2.01	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	16JUL2003	0	0.87	
					20JAN2004	24	0.74	
					02JUL2004	48	0.71	
			08SEP2004	ALT	01SEP2003	0	28.00	
					23FEB2004	24	228.00	3
					09AUG2004	48	24.00	
				AST	01SEP2003	0	42.00	
					23FEB2004	24	230.00	3
					09AUG2004	48	30.00	
				Bilirubin	01SEP2003	0	0.46	
					23FEB2004	24	0.45	
					09AUG2004	48	0.35	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD	08SEP2004	Creatinine	01SEP2003	0	0.88	
					23FEB2004	24	0.83	
					09AUG2004	48	0.84	
				ALT	01OCT2003	0	51.00	1
					31MAR2004	24	444.00	4
					15SEP2004	48	35.00	
					17AUG2005	96	24.00	
				AST	01OCT2003	0	77.00	1
					31MAR2004	24	688.00	4
					15SEP2004	48	37.00	
					17AUG2005	96	25.00	
				Bilirubin	01OCT2003	0	0.32	
					31MAR2004	24	0.47	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	15SEP2004	48	0.69	
					17AUG2005	96	0.61	
				Creatinine	01OCT2003	0	1.16	
					31MAR2004	24	1.18	
					15SEP2004	48	0.90	
					17AUG2005	96	1.04	
				ALT	03NOV2003	0	29.00	
					03MAY2004	24	526.00	4
				AST	03NOV2003	0	60.00	1
					03MAY2004	24	354.00	3
				Bilirubin	03NOV2003	0	0.17	
					03MAY2004	24	5.37	4

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	03NOV2003	0	0.85	
					03MAY2004	24	1.97	1
				ALT	12NOV2003	0	9.00	
					12MAY2004	24	22.00	
					29OCT2004	48	16.00	
					26SEP2005	96	13.00	
				AST	12NOV2003	0	20.00	
					12MAY2004	24	35.00	
					29OCT2004	48	27.00	
					26SEP2005	96	24.00	
				Bilirubin	12NOV2003	0	2.13	2
					12MAY2004	24	3.16	3
					29OCT2004	48	2.19	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	26SEP2005	96	1.85	2
				Creatinine	12NOV2003	0	1.10	
					12MAY2004	24	1.22	
					29OCT2004	48	1.18	
					26SEP2005	96	1.58	1
			09NOV2005	ALT	07MAY2004	0	29.00	
					10NOV2004	24	16.00	
					27APR2005	48	22.00	
				AST	07MAY2004	0	50.00	
					10NOV2004	24	20.00	
					27APR2005	48	22.00	
				Bilirubin	07MAY2004	0	0.56	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD	09NOV2005	Bilirubin	10NOV2004	24	2.39	2
					27APR2005	48	6.06	4
				Creatinine	07MAY2004	0	1.15	
					10NOV2004	24	0.81	
					27APR2005	48	0.85	
				ALT	27AUG2004	0	23.00	
					16FEB2005	24	31.00	
					03AUG2005	48	56.00	
				AST	27AUG2004	0	36.00	
					16FEB2005	24	33.00	
					03AUG2005	48	76.00	1
				Bilirubin	27AUG2004	0	0.87	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	16FEB2005	24	0.30	
					03AUG2005	48	8.34	4
				Creatinine	27AUG2004	0	0.87	
					16FEB2005	24	1.62	1
					03AUG2005	48	1.05	
				ALT	13SEP2004	0	39.00	
					17MAR2005	24	17.00	
					30AUG2005	48	23.00	
					04AUG2006	96	20.00	
				AST	13SEP2004	0	70.00	1
					17MAR2005	24	31.00	
					30AUG2005	48	39.00	
					04AUG2006	96	34.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	PPD	PPD		Bilirubin	13SEP2004	0	0.95	
					17MAR2005	24	2.42	2
					30AUG2005	48	2.16	2
					04AUG2006	96	2.57	3
				Creatinine	13SEP2004	0	1.11	
					17MAR2005	24	1.03	
					30AUG2005	48	0.96	
					04AUG2006	96	1.19	
				ALT	23MAY2003	0	79.00	1
					25NOV2003	24	109.00	2
					11MAY2004	48	53.00	1
					12APR2005	96	52.00	1
				AST	23MAY2003	0	104.00	2

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	25NOV2003	24	90.00	1
					11MAY2004	48	53.00	1
					12APR2005	96	34.00	
				Bilirubin	23MAY2003	0	0.33	
					25NOV2003	24	0.22	
					11MAY2004	48	16.78	4
					12APR2005	96	0.63	
				Creatinine	23MAY2003	0	0.68	
					25NOV2003	24	0.66	
					11MAY2004	48	0.75	
					12APR2005	96	0.74	
				ALT	17JUN2003	0	26.00	
					15DEC2003	24	11.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	31MAY2004	48	13.00	
					02MAY2005	96	12.00	
				AST	17JUN2003	0	31.00	
					15DEC2003	24	13.00	
					31MAY2004	48	17.00	
					02MAY2005	96	18.00	
				Bilirubin	17JUN2003	0	0.11	
					15DEC2003	24	0.25	
					31MAY2004	48	0.92	
					02MAY2005	96	2.92	3
				Creatinine	17JUN2003	0	1.18	
					15DEC2003	24	0.95	
					31MAY2004	48	0.75	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	02MAY2005	96	0.89	
				ALT	15AUG2003	0	99.00	1
					17FEB2004	24	26.00	
					04AUG2004	48	29.00	
					06JUL2005	96	466.00	4
				AST	15AUG2003	0	94.00	1
					17FEB2004	24	49.00	
					04AUG2004	48	35.00	
					06JUL2005	96	622.00	4
				Bilirubin	15AUG2003	0	0.30	
					17FEB2004	24	0.84	
					04AUG2004	48	0.89	
					06JUL2005	96	1.21	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	15AUG2003	0	0.96	
					17FEB2004	24	0.86	
					04AUG2004	48	0.80	
					06JUL2005	96	0.76	
			03MAY2005	ALT	07NOV2003	0	53.00	1
					04MAY2004	24	30.00	
					19OCT2004	48	17.00	
				AST	07NOV2003	0	45.00	
					04MAY2004	24	38.00	
					19OCT2004	48	20.00	
				Bilirubin	07NOV2003	0	0.22	
					04MAY2004	24	0.99	
					19OCT2004	48	2.63	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD	03MAY2005	Creatinine	07NOV2003	0	0.90	
					04MAY2004	24	1.04	
					19OCT2004	48	1.29	1
				ALT	04AUG2004	0	28.00	
					02FEB2005	24	133.00	2
					21JUL2005	48	26.00	
					21JUN2006	96	17.00	
				AST	04AUG2004	0	30.00	
					02FEB2005	24	232.00	3
					21JUL2005	48	30.00	
					21JUN2006	96	20.00	
				Bilirubin	04AUG2004	0	0.77	
					02FEB2005	24	0.85	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	21JUL2005	48	0.52	
					21JUN2006	96	0.69	
				Creatinine	04AUG2004	0	0.74	
					02FEB2005	24	0.68	
					21JUL2005	48	0.75	
					21JUN2006	96	0.67	
				ALT	17JUL2003	0	40.00	
					09JAN2004	24	57.00	1
					25JUN2004	48	138.00	2
					27MAY2005	96	23.00	
				AST	17JUL2003	0	86.00	1
					09JAN2004	24	67.00	1
					25JUN2004	48	322.00	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	27MAY2005	96	56.00	1
				Bilirubin	17JUL2003	0	0.46	
					09JAN2004	24	0.38	
					25JUN2004	48	0.39	
					27MAY2005	96	0.68	
				Creatinine	17JUL2003	0	0.81	
					09JAN2004	24	0.90	
					25JUN2004	48	1.11	
					27MAY2005	96	0.84	
				ALT	11AUG2003	0	55.00	1
					04FEB2004	24	18.00	
					21JUL2004	48	34.00	
					22JUN2005	96	21.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		AST	11AUG2003	0	57.00	1
					04FEB2004	24	26.00	
					21JUL2004	48	27.00	
					22JUN2005	96	22.00	
				Bilirubin	11AUG2003	0	0.84	
					04FEB2004	24	2.68	3
					21JUL2004	48	3.00	3
					22JUN2005	96	0.82	
				Creatinine	11AUG2003	0	0.75	
					04FEB2004	24	0.64	
					21JUL2004	48	0.74	
					22JUN2005	96	1.09	
				ALT	15SEP2003	0	51.00	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	15MAR2004	24	33.00	
					30AUG2004	48	25.00	
					01AUG2005	96	26.00	
				AST	15SEP2003	0	63.00	1
					15MAR2004	24	26.00	
					30AUG2004	48	27.00	
					01AUG2005	96	25.00	
				Bilirubin	15SEP2003	0	0.82	
					15MAR2004	24	1.91	2
					30AUG2004	48	2.69	3
					01AUG2005	96	2.37	2
				Creatinine	15SEP2003	0	0.73	
					15MAR2004	24	1.15	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	30AUG2004	48	1.05	
					01AUG2005	96	0.93	
			15MAR2005	ALT	15SEP2003	0	30.00	
					16MAR2004	24	44.00	
					31AUG2004	48	40.00	
				AST	15SEP2003	0	41.00	
					16MAR2004	24	60.00	1
					31AUG2004	48	46.00	
				Bilirubin	15SEP2003	0	0.41	
					16MAR2004	24	0.49	
					31AUG2004	48	2.91	3
				Creatinine	15SEP2003	0	0.62	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD	15MAR2005	Creatinine	16MAR2004	24	0.83	
					31AUG2004	48	0.80	
				ALT	18SEP2003	0	47.00	
					18MAR2004	24	47.00	
					02SEP2004	48	30.00	
					04AUG2005	96	118.00	2
				AST	18SEP2003	0	46.00	
					18MAR2004	24	47.00	
					02SEP2004	48	287.00	3
					04AUG2005	96	136.00	2
				Bilirubin	18SEP2003	0	0.76	
					18MAR2004	24	1.17	1
					02SEP2004	48	1.26	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	04AUG2005	96	0.84	
				Creatinine	18SEP2003	0	1.00	
					18MAR2004	24	0.83	
					02SEP2004	48	0.96	
					04AUG2005	96	0.67	
				ALT	12AUG2004	0	37.00	
					14FEB2005	24	33.00	
					01AUG2005	48	27.00	
					03JUL2006	96	21.00	
				AST	12AUG2004	0	28.00	
					14FEB2005	24	20.00	
					01AUG2005	48	21.00	
					03JUL2006	96	19.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	12AUG2004	0	0.31	
					14FEB2005	24	0.44	
					01AUG2005	48	0.59	
					03JUL2006	96	0.18	
				Creatinine	12AUG2004	0	1.75	1
					14FEB2005	24	2.76	2
					01AUG2005	48	3.08	2
					03JUL2006	96	4.95	3
			20FEB2006	ALT	24AUG2004	0	27.00	
					17FEB2005	24	9.00	
					05SEP2005	48	25.00	
				AST	24AUG2004	0	26.00	
					17FEB2005	24	21.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	PPD	PPD	20FEB2006	AST	05SEP2005	48	17.00	
				Bilirubin	24AUG2004	0	0.29	
					17FEB2005	24	2.60	3
					05SEP2005	48	0.81	
				Creatinine	24AUG2004	0	1.13	
					17FEB2005	24	1.04	
					05SEP2005	48	0.54	
				ALT	30MAY2003	0	66.00	1
					01DEC2003	24	48.00	
					14MAY2004	48	51.00	
					15APR2005	96	338.00	3
				Bilirubin	30MAY2003	0	0.39	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	01DEC2003	24	0.73	
					14MAY2004	48	0.25	
					15APR2005	96	0.95	
				Creatinine	30MAY2003	0	0.98	
					01DEC2003	24	0.95	
					14MAY2004	48	0.86	
					15APR2005	96	0.94	
				ALT	18JUN2003	0	52.00	
					17DEC2003	24	56.00	1
					08JUN2004	48	31.00	
					04MAY2005	96	29.00	
				AST	27JUN2004	48	289.00	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	18JUN2003	0	0.41	
					17DEC2003	24	0.76	
					08JUN2004	48	1.25	
					04MAY2005	96	2.68	2
				Creatinine	18JUN2003	0	0.57	
					17DEC2003	24	0.84	
					08JUN2004	48	1.07	
					04MAY2005	96	0.95	
				ALT	21AUG2003	0	66.00	1
					23FEB2004	24	66.00	1
					02AUG2004	48	34.00	
					11JUL2005	96	50.00	
				AST	11MAR2004	24	167.00	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	21AUG2003	0	1.47	
					23FEB2004	24	0.34	
					02AUG2004	48	0.47	
					11JUL2005	96	0.53	
				Creatinine	21AUG2003	0	1.05	
					23FEB2004	24	1.15	
					02AUG2004	48	0.98	
					11JUL2005	96	1.03	
				ALT	20OCT2003	0	19.00	
					16APR2004	24	16.00	
					04OCT2004	48	20.00	
					06SEP2005	96	125.00	2
				AST	06SEP2005	96	669.00	4

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	20OCT2003	0	0.51	
					16APR2004	24	0.64	
					04OCT2004	48	0.91	
					06SEP2005	96	3.16	2
				Creatinine	20OCT2003	0	0.97	
					16APR2004	24	0.94	
					04OCT2004	48	1.05	
					06SEP2005	96	2.88	2
				ALT	05NOV2003	0	23.00	
					30APR2004	24	21.00	
					19OCT2004	48	27.00	
				AST	16NOV2004	48	4487.00	4

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	05NOV2003	0	0.32	
					30APR2004	24	0.60	
					19OCT2004	48	0.70	
				Creatinine	05NOV2003	0	0.92	
					30APR2004	24	0.90	
					19OCT2004	48	0.88	
				ALT	13NOV2003	0	332.00	3
					13MAY2004	24	16.00	
					28OCT2004	48	15.00	
					29SEP2005	96	18.00	
				Bilirubin	13NOV2003	0	0.53	
					13MAY2004	24	0.49	
					28OCT2004	48	0.34	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	29SEP2005	96	0.47	
				Creatinine	13NOV2003	0	0.86	
					13MAY2004	24	0.90	
					28OCT2004	48	0.94	
					29SEP2005	96	0.78	
				ALT	29DEC2003	0	64.00	1
					14JUN2004	24	53.00	
					29NOV2004	48	45.00	
					31OCT2005	96	26.00	
				Bilirubin	29DEC2003	0	4.39	3
					14JUN2004	24	0.32	
					29NOV2004	48	0.55	
					31OCT2005	96	0.55	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	29DEC2003	0	1.00	
					14JUN2004	24	0.93	
					29NOV2004	48	0.77	
					31OCT2005	96	0.67	
			31JAN2005	ALT	06JAN2004	0	19.00	
					19JUL2004	24	48.00	
					03JAN2005	48	20.00	
				AST	29JUL2004	24	63.00	1
				Bilirubin	06JAN2004	0	0.22	
					19JUL2004	24	4.99	3
					03JAN2005	48	0.63	
				Creatinine	06JAN2004	0	0.81	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD	31JAN2005	Creatinine	19JUL2004	24	0.55	
					03JAN2005	48	0.83	
				ALT	24JUN2003	0	166.00	2
					18DEC2003	24	228.00	3
				Bilirubin	24JUN2003	0	0.83	
					18DEC2003	24	1.21	
				Creatinine	24JUN2003	0	0.63	
					18DEC2003	24	0.79	
				ALT	08JUL2003	0	24.00	
					06JAN2004	24	19.00	
					31MAY2005	96	271.00	3
				Bilirubin	08JUL2003	0	0.46	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	06JAN2004	24	0.68	
					31MAY2005	96	0.43	
				Creatinine	08JUL2003	0	1.15	
					06JAN2004	24	0.93	
					31MAY2005	96	0.90	
				ALT	13OCT2003	0	69.00	1
					08APR2004	24	228.00	3
					23SEP2004	48	57.00	1
				Bilirubin	13OCT2003	0	0.75	
					08APR2004	24	0.58	
					23SEP2004	48	0.86	
				Creatinine	13OCT2003	0	0.96	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	PPD	PPD		Creatinine	08APR2004	24	1.04	
					23SEP2004	48	1.02	
				ALT	26JAN2004	0	18.00	
					23JUL2004	24	34.00	
					13JAN2005	48	381.00	3
				AST	13JAN2005	48	870.00	4
				Bilirubin	26JAN2004	0	0.56	
					23JUL2004	24	0.63	
					13JAN2005	48	3.15	2
				Creatinine	26JAN2004	0	0.87	
					23JUL2004	24	0.90	
				ALT	10FEB2004	0	47.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	10AUG2004	24	20.00	
					25JAN2005	48	25.00	
					27DEC2005	96	31.00	
				AST	10FEB2004	0	50.00	1
					10AUG2004	24	36.00	
					25JAN2005	48	29.00	
					27DEC2005	96	42.00	
				Bilirubin	10FEB2004	0	0.76	
					10AUG2004	24	1.76	2
					25JAN2005	48	2.63	3
					27DEC2005	96	1.82	2
				Creatinine	10FEB2004	0	1.10	
					10AUG2004	24	1.07	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	25JAN2005	48	0.75	
					27DEC2005	96	0.89	
				ALT	21AUG2003	0	15.00	
					19FEB2004	24	140.00	2
				AST	21AUG2003	0	34.00	
					19FEB2004	24	238.00	3
				Bilirubin	21AUG2003	0	0.32	
					19FEB2004	24	0.59	
				Creatinine	21AUG2003	0	1.15	
					19FEB2004	24	0.81	
				ALT	23OCT2003	0	33.00	
					22APR2004	24	300.00	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		ALT	07OCT2004	48	54.00	1
					08SEP2005	96	31.00	
				AST	23OCT2003	0	33.00	
					22APR2004	24	184.00	2
					07OCT2004	48	40.00	
					08SEP2005	96	25.00	
				Bilirubin	23OCT2003	0	0.05	
					22APR2004	24	0.47	
					07OCT2004	48	0.54	
					08SEP2005	96	0.45	
				Creatinine	23OCT2003	0	0.79	
					22APR2004	24	0.91	
					07OCT2004	48	1.16	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	08SEP2005	96	0.65	
				ALT	13NOV2003	0	17.00	
					18MAY2004	24	24.00	
					02NOV2004	48	179.00	2
					04OCT2005	96	72.00	1
				AST	13NOV2003	0	39.00	
					18MAY2004	24	35.00	
					02NOV2004	48	258.00	3
					04OCT2005	96	109.00	2
				Bilirubin	13NOV2003	0	0.21	
					18MAY2004	24	0.31	
					02NOV2004	48	0.26	
					04OCT2005	96	0.69	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Creatinine	13NOV2003	0	0.72	
					18MAY2004	24	1.00	
					02NOV2004	48	0.68	
					04OCT2005	96	0.61	
				ALT	08JAN2004	0	31.00	
					08JUL2004	24	23.00	
					23DEC2004	48	11.00	
					24NOV2005	96	21.00	
				AST	08JAN2004	0	35.00	
					08JUL2004	24	23.00	
					23DEC2004	48	14.00	
					24NOV2005	96	21.00	
				Bilirubin	08JAN2004	0	1.45	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	P P	PPD		Bilirubin	08JUL2004	24	2.15	2
					23DEC2004	48	3.29	3
					24NOV2005	96	2.05	2
				Creatinine	08JAN2004	0	0.81	
					08JUL2004	24	0.77	
					23DEC2004	48	1.03	
					24NOV2005	96	0.85	
				ALT	12FEB2004	0	46.00	
					12AUG2004	24	35.00	
					27JAN2005	48	20.00	
					29DEC2005	96	17.00	
				AST	12FEB2004	0	69.00	1
					12AUG2004	24	57.00	1

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
TDF CLcr>=50	PPD	PPD		AST	27JAN2005	48	35.00	
					29DEC2005	96	36.00	
				Bilirubin	12FEB2004	0	0.93	
					12AUG2004	24	2.88	3
					27JAN2005	48	2.96	3
					29DEC2005	96	3.41	3
				Creatinine	12FEB2004	0	0.60	
					12AUG2004	24	0.58	
					27JAN2005	48	0.76	
					29DEC2005	96	0.67	
ABC or NVP CLcr 30-49				ALT	14JAN2004	0	198.00	3
					27JUL2004	24	29.00	
					11JAN2005	48	23.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr 30-49	P P	PPD		ALT	15DEC2005	96	28.00	
				AST	14JAN2004	0	364.00	3
					27JUL2004	24	39.00	
					11JAN2005	48	38.00	
					15DEC2005	96	32.00	
				Bilirubin	14JAN2004	0	0.42	
					27JUL2004	24	0.23	
					11JAN2005	48	0.51	
					15DEC2005	96	0.30	
				Creatinine	14JAN2004	0	1.26	
					27JUL2004	24	0.79	
					11JAN2005	48	0.87	
					15DEC2005	96	0.88	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr 30-49	P P	PPD		ALT	15SEP2004	0	33.00	
					16MAR2005	24	176.00	2
					31AUG2005	48	121.00	2
					02AUG2006	96	210.00	3
				AST	15SEP2004	0	83.00	1
					16MAR2005	24	174.00	2
					31AUG2005	48	120.00	2
					02AUG2006	96	237.00	3
				Bilirubin	15SEP2004	0	0.28	
					16MAR2005	24	0.53	
					31AUG2005	48	0.37	
					02AUG2006	96	0.37	
				Creatinine	15SEP2004	0	1.10	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr 30-49	PPD	PPD		Creatinine	16MAR2005	24	0.94	
					31AUG2005	48	0.79	
					02AUG2006	96	0.86	
ABC or NVP CLcr>=50				ALT	28JUN2004	0	25.00	
					23DEC2004	24	27.00	
					13JUN2005	48	40.00	
					15MAY2006	96	20.00	
				AST	28JUN2004	0	24.00	
					23DEC2004	24	36.00	
					13JUN2005	48	52.00	
					15MAY2006	96	37.00	
				Bilirubin	28JUN2004	0	0.40	
					23DEC2004	24	0.75	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		Bilirubin	13JUN2005	48	0.92	
					15MAY2006	96	0.56	
				Creatinine	28JUN2004	0	1.04	
					23DEC2004	24	9.59	4
					13JUN2005	48	1.43	
					15MAY2006	96	1.31	
				ALT	20FEB2004	0	29.00	
					12AUG2004	24	58.00	1
					27JAN2005	48	30.00	
					22DEC2005	96	29.00	
				AST	20FEB2004	0	23.00	
					12AUG2004	24	29.00	
					27JAN2005	48	26.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		AST	22DEC2005	96	25.00	
				Bilirubin	20FEB2004	0	0.15	
					12AUG2004	24	0.26	
					27JAN2005	48	0.36	
					22DEC2005	96	3.19	3
				Creatinine	20FEB2004	0	1.06	
					12AUG2004	24	0.72	
					27JAN2005	48	0.81	
					22DEC2005	96	0.86	
				ALT	07JUL2004	0	27.00	
					18JAN2005	24	8.00	
					29JUN2005	48	20.00	
					31MAY2006	96	15.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	PPD	PPD		AST	07JUL2004	0	24.00	
					18JAN2005	24	14.00	
					29JUN2005	48	19.00	
					31MAY2006	96	15.00	
				Bilirubin	07JUL2004	0	2.54	3
					18JAN2005	24	1.32	1
					29JUN2005	48	1.19	1
					31MAY2006	96	0.74	
				Creatinine	07JUL2004	0	0.93	
					18JAN2005	24	0.89	
					29JUN2005	48	0.92	
					31MAY2006	96	1.02	
				ALT	16MAR2004	0	18.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		ALT	16SEP2004	24	73.00	1
					03MAR2005	48	148.00	2
					02FEB2006	96	112.00	2
				AST	16MAR2004	0	25.00	
					16SEP2004	24	157.00	2
					03MAR2005	48	168.00	2
					02FEB2006	96	211.00	3
				Bilirubin	16MAR2004	0	0.49	
					16SEP2004	24	0.77	
					03MAR2005	48	1.06	1
					02FEB2006	96	0.70	
				Creatinine	16MAR2004	0	0.88	
					16SEP2004	24	1.06	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		Creatinine	03MAR2005	48	1.06	
					02FEB2006	96	0.80	
				ALT	14APR2004	0	16.00	
					12OCT2004	24	30.00	
					29MAR2005	48	19.00	
					28FEB2006	96	22.00	
				AST	14APR2004	0	21.00	
					12OCT2004	24	24.00	
					29MAR2005	48	19.00	
					28FEB2006	96	20.00	
				Bilirubin	14APR2004	0	0.69	
					12OCT2004	24	0.70	
					29MAR2005	48	4.80	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		Bilirubin	28FEB2006	96	0.59	
				Creatinine	14APR2004	0	0.63	
					12OCT2004	24	1.07	
					29MAR2005	48	1.00	
					28FEB2006	96	0.79	
				ALT	27JUL2004	0	18.00	
					27JAN2005	24	399.00	3
					14JUL2005	48	17.00	
					15JUN2006	96	14.00	
				AST	27JUL2004	0	18.00	
					27JAN2005	24	411.00	4
					14JUL2005	48	28.00	
					15JUN2006	96	21.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		Bilirubin	27JUL2004	0	0.37	
					27JAN2005	24	0.41	
					14JUL2005	48	0.38	
					15JUN2006	96	0.37	
				Creatinine	27JUL2004	0	0.72	
					27JAN2005	24	0.83	
					14JUL2005	48	0.79	
					15JUN2006	96	0.63	
				ALT	27AUG2004	0	29.00	
					25FEB2005	24	18.00	
					12AUG2005	48	44.00	
					14JUL2006	96	16.00	
				AST	27AUG2004	0	27.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		AST	25FEB2005	24	20.00	
					12AUG2005	48	52.00	1
					14JUL2006	96	17.00	
				Bilirubin	27AUG2004	0	0.84	
					25FEB2005	24	0.72	
					12AUG2005	48	2.65	3
					14JUL2006	96	0.33	
				Creatinine	27AUG2004	0	0.72	
					25FEB2005	24	0.81	
					12AUG2005	48	0.50	
					14JUL2006	96	0.64	
				ALT	10JUN2004	0	28.00	
					01NOV2004	24	41.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		AST	10JUN2004	0	35.00	
					01NOV2004	24	90.00	1
				Bilirubin	10JUN2004	0	0.46	
					01NOV2004	24	4.50	3
				Creatinine	10JUN2004	0	0.95	
					01NOV2004	24	1.93	2
				ALT	18AUG2004	0	22.00	
					16FEB2005	24	11.00	
					03AUG2005	48	13.00	
					05JUL2006	96	11.00	
				AST	18AUG2004	0	28.00	
					16FEB2005	24	18.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	PPD	PPD		AST	03AUG2005	48	17.00	
					05JUL2006	96	16.00	
				Bilirubin	18AUG2004	0	0.25	
					16FEB2005	24	1.22	1
					03AUG2005	48	0.96	
					05JUL2006	96	19.19	4
				Creatinine	18AUG2004	0	0.87	
					16FEB2005	24	0.87	
					03AUG2005	48	0.62	
					05JUL2006	96	0.56	
				ALT	18MAR2004	0	14.00	
					16SEP2004	24	15.00	
					03MAR2005	48	15.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	P P	PPD		AST	20SEP2004	24	20.00	
					07MAR2005	48	25.00	
				Bilirubin	18MAR2004	0	0.39	
					16SEP2004	24	0.61	
					03MAR2005	48	6.07	3
				Creatinine	18MAR2004	0	0.63	
					16SEP2004	24	0.70	
					03MAR2005	48	0.59	
				ALT	22APR2004	0	21.00	
					21OCT2004	24	28.00	
					07APR2005	48	16.00	
					09MAR2006	96	11.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
ABC or NVP CLcr>=50	PPD	PPD		AST	27SEP2004	24	410.00	4
				Bilirubin	22APR2004	0	0.44	
					21OCT2004	24	0.50	
					07APR2005	48	0.69	
					09MAR2006	96	0.29	
				Creatinine	22APR2004	0	0.59	
					21OCT2004	24	0.53	
					07APR2005	48	1.16	
					09MAR2006	96	0.89	
Any CLcr<30				ALT	18SEP2003	0	28.00	
					18MAR2004	24	29.00	
					02SEP2004	48	13.00	

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.1
Listing of Lab Data for Subjects with at Least one G3-4 Laboratory Toxicity Grading up to 96 Weeks

Treatment	Centre	Subject ID	STI Randomisation date	Parameter	Lab date	Visit week	Result	Toxicity grade
Any CLcr<30	P P	PPD		AST	18SEP2003	0	39.00	
					18MAR2004	24	42.00	
					02SEP2004	48	21.00	
				Bilirubin	18SEP2003	0	0.35	
					18MAR2004	24	0.44	
					02SEP2004	48	0.26	
				Creatinine	18SEP2003	0	3.60	2
					18MAR2004	24	5.72	3
					02SEP2004	48	4.18	3

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	45.3/ Male/ 1.67	4/ 87/ 1.07/ 70.28	06FEB2003/ 21AUG2003/ STI pilot	NEG/ POS
PPD PPD / ZDV 3TC TDF	33.2/ Male/ 1.61	4/ 44/ 1.03/ 76.56	18FEB2003/ 05SEP2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	45.7/ Male/ 1.56	4/ 82/ 1.04/ 65.32	06MAR2003/ 18SEP2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	43.3/ Male/ 1.76	4/ 9/ 1.21/ 70.40	13MAR2003/ 25SEP2003/ STI pilot	NEG/ POS
PP PPD ZDV 3TC TDF	26.8/ Female/ 1.50	3/ 3/ 0.96/ 71.93	25MAR2003/ 08OCT2003/ STI pilot	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	50.8/ Female/ 1.66	3/ 74/ 1.00/ 65.38	10APR2003/ 23OCT2003/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	51.2/ Female/ 1.50	4/ 67/ 0.94/ 54.54	10APR2003/ 23OCT2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	34.2/ Male/ 1.67	4/ 77/ 1.16/ 69.52	15APR2003/ 28OCT2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	41.9/ Male/ 1.74	3/ 99/ 1.18/ 70.82	06MAY2003/ 18NOV2003/ STI pilot	NEG/ NEG
PP PPD ZDV 3TC TDF	52.8/ Male/ 1.81	3/ 82/ 0.90/ 95.28	08MAY2003/ 21OCT2004/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	43.0/ Female/ 1.72	4/ 96/ 1.24/ 62.34	04JUL2003/ 16JAN2004/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	34.0/ Male/ 1.85	3/ 77/ 1.13/ 88.70	09JUL2003/ 21JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	27.1/ Female/ 1.73	3/ 85/ 0.74/ 122.93	10JUL2003/ 22JAN2004/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	32.1/ Female/ 1.45	3/ 45/ 0.84/ 72.81	14JUL2003/ 23JAN2004/ STI pilot	NEG/ POS
PP PPD ZDV 3TC TDF	50.6/ Male/ 1.84	3/ 40/ 1.62/ 51.54	29SEP2003/ 27SEP2004/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	26.3/ Female/ 1.39	4/ 2/ 0.67/ 84.18	13OCT2003/ 24MAR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	29.3/ Female/ 1.53	4/ 17/ 0.86/ 79.57	14OCT2003/ 12OCT2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	49.4/ Female/ 1.56	4/ 13/ 0.90/ 67.48	11DEC2003/ 26MAY2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	34.0/ Female/ 1.59	4/ 8/ 0.88/ 73.52	19DEC2003/ 01JUN2005/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	52.5/ Male/ 1.53	3/ 69/ 0.89/ 68.15	02FEB2004/ 31JAN2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	31.3/ Female/ 1.40	3/ 28/ 0.94/ 57.22	27FEB2004/ 25FEB2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	33.8/ Female/ 1.55	4/ 8/ 0.67/ 114.28	29MAR2004/ 31MAR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	26.8/ Female/ 1.47	3/ 45/ 0.30/ 213.29	08APR2004/ 07APR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	29.8/ Male/ 1.61	3/ 28/ 1.05/ 74.40	18MAY2004/ 17MAY2005/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	60.0/ Male/ 1.69	3/ 91/ 1.20/ 53.00	28MAY2004/ 27MAY2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	38.7/ Female/ 1.42	3/ 115/ 1.00/ 55.11	13FEB2003/ 29AUG2003/ STI pilot	NEG/ POS
PPD PPD / ZDV 3TC TDF	33.2/ Female/ 1.54	2/ 192/ 1.13/ 61.13	13FEB2003/ 28AUG2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	34.7/ Female/ 1.65	2/ 132/ 0.85/ 89.10	18FEB2003/ 02SEP2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	28.0/ Female/ 1.51	3/ 166/ 1.01/ 65.01	20FEB2003/ 04SEP2003/ STI pilot	NEG/ POS
PP PPD ZDV 3TC TDF	47.6/ Female/	3/ 106/ 0.81/ 82.08	06MAR2003/ 18SEP2003/ STI pilot	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	30.7/ Female/ 1.38	4/ 133/ 0.72/ 78.33	13MAR2003/ 25SEP2003/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	42.8/ Female/ 1.51	3/ 141/ 0.88/ 64.86	25MAR2003/ 07OCT2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	40.2/ Female/ 1.70	2/ 138/ 0.96/ 78.16	27MAR2003/ 08OCT2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	26.8/ Female/ 1.50	3/ 110/ 0.36/ 186.94	10APR2003/ 23OCT2003/ STI pilot	NEG/ NEG
PP PPD ZDV 3TC TDF	45.7/ Female/ 1.48	4/ 176/ 0.90/ 58.89	15APR2003/ 28OCT2003/ STI pilot	POS/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	39.9/ Male/ 1.81	2/ 190/ 1.19/ 77.99	22APR2003/ 04NOV2003/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	38.9/ Female/ 1.58	3/ 149/ 0.92/ 71.45	24APR2003/ 06NOV2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	39.7/ Male/ 1.56	4/ 142/ 1.02/ 72.69	24APR2003/ 06NOV2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	38.5/ Male/ 1.56	2/ 127/ 1.24/ 59.06	08MAY2003/ 20NOV2003/ STI pilot	POS/ POS
PP PPD ZDV 3TC TDF	42.5/ Male/ 1.79	4/ 100/ 1.06/ 84.85	05JUN2003/ 18DEC2003/ STI pilot	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	30.0/ Female/ 1.52	2/ 114/ 1.02/ 67.79	10JUN2003/ 22DEC2003/ STI pilot	NEG/ POS
PPD PPD / ZDV 3TC TDF	38.6/ Female/ 1.65	3/ 166/ 0.78/ 79.51	17JUN2003/ 30DEC2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	26.0/ Female/ 1.41	4/ 129/ 1.01/ 62.61	23JUN2003/ 05JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	44.0/ Female/ 1.53	4/ 106/ 0.78/ 75.26	26JUN2003/ 09DEC2004/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	43.1/ Female/ 1.65	2/ 147/ 0.71/ 100.82	15JUL2003/ 30DEC2004/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	28.1/ Female/ 1.50	3/ 158/ 1.02/ 64.65	29JUL2003/ 27JUL2004/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	33.5/ Male/ 1.60	3/ 157/ 0.92/ 82.54	29JUL2003/ 27JUL2004/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	39.4/ Female/ 1.50	3/ 140/ 1.03/ 65.00	05AUG2003/ 18JAN2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	40.2/ Female/ 1.62	4/ 112/ 1.06/ 69.61	18AUG2003/ 16AUG2004/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	35.2/ Female/ 1.72	3/ 152/ 0.79/ 98.17	22AUG2003/ 04FEB2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	21.2/ Female/ 1.41	3/ 151/ 1.02/ 68.67	22AUG2003/ 20AUG2004/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	51.2/ Female/ 1.45	4/ 136/ 0.88/ 59.19	08SEP2003/ 08SEP2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	31.9/ Female/ 1.61	2/ 195/ 0.98/ 73.65	15SEP2003/ 13SEP2004/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	32.2/ Female/ 1.87	3/ 171/ 0.86/ 112.15	30SEP2003/ 28SEP2004/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	20.3/ Female/ 1.36	3/ 125/ 0.88/ 70.27	30SEP2003/ 28SEP2004/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	39.0/ Female/ 1.57	3/ 174/ 0.85/ 75.67	03OCT2003/ 01OCT2004/ STI	POS/ NEG
PPD PPD / ZDV 3TC TDF	43.6/ Female/ 1.63	2/ 175/ 1.10/ 65.12	10OCT2003/ 08OCT2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	30.1/ Female/ 1.83	4/ 195/ 0.79/ 106.99	31OCT2003/ 29OCT2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	36.2/ Female/ 1.72	4/ 199/ 1.45/ 57.78	11NOV2003/ 09NOV2004/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	35.4/ Female/ 1.57	2/ 107/ 0.80/ 81.22	14NOV2003/ 26APR2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	45.5/ Male/ 1.84	3/ 185/ 0.96/ 84.87	02DEC2003/ 30NOV2004/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	36.3/ Female/ 1.75	3/ 157/ 1.02/ 83.93	02DEC2003/ 30NOV2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	35.1/ Female/ 1.42	4/ 166/ 0.88/ 61.55	23DEC2003/ 21DEC2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	43.9/ Female/ 1.73	3/ 156/ 1.10/ 63.94	04FEB2004/ 07FEB2005/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	34.4/ Female/ 1.62	3/ 158/ 0.64/ 112.63	22APR2004/ 21APR2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	41.9/ Female/ 1.30	2/ 114/ 0.80/ 62.09	27APR2004/ 26APR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	30.1/ Female/ 1.47	3/ 169/ 0.86/ 75.24	12MAY2004/ 11MAY2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	59.0/ Female/ 1.44	2/ 192/ 0.88/ 50.79	17JUN2004/ 16JUN2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	28.1/ Female/ 1.43	3/ 162/ 0.81/ 79.21	29JUL2004/ 29JUL2005/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	35.6/ Male/ 1.71	4/ 97/ 0.41/ 224.94	03FEB2003/ 18AUG2003/ STI pilot	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	36.3/ Female/ 1.70	3/ 9/ 0.73/ 99.41	06MAR2003/ 18SEP2003/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	40.2/ Female/ 1.49	3/ 45/ 1.04/ 58.18	31MAR2003/ 13OCT2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	42.8/ Female/ 1.58	3/ 29/ 0.85/ 78.03	08APR2003/ 21OCT2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	35.6/ Female/ 1.58	4/ 69/ 0.83/ 77.69	22APR2003/ 04NOV2003/ STI pilot	NEG/ NEG
PP PPD ZDV 3TC TDF	34.9/ Female/ 1.70	4/ 62/ 1.10/ 69.72	30APR2003/ 12NOV2003/ STI pilot	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	29.8/ Female/ 1.77	3/ 70/ 0.48/ 172.93	16MAY2003/ 27NOV2003/ STI pilot	POS/ NEG
PPD PPD / ZDV 3TC TDF	40.7/ Female/ 1.56	3/ 90/ 0.92/ 74.94	27JUN2003/ 09JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	29.5/ Male/ 1.58	3/ 2/ 1.12/ 69.36	02JUL2003/ 14JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	33.6/ Female/ 1.41	3/ 66/ 0.92/ 59.85	02JUL2003/ 14JAN2004/ STI pilot	NEG/ POS
PP PPD ZDV 3TC TDF	26.3/ Female/ 1.36	3/ 98/ 0.86/ 70.02	09JUL2003/ 21JAN2004/ STI pilot	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	51.4/ Female/ 1.60	4/ 49/ 0.63/ 96.30	06AUG2003/ 04AUG2004/ CT	NEG/ NEG
PPD PPD / ZDV 3TC TDF	35.7/ Male/ 1.93	3/ 84/ 1.03/ 96.11	01SEP2003/ 14FEB2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	30.8/ Female/ 1.51	3/ 72/ 0.93/ 79.45	04SEP2003/ 17FEB2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	30.4/ Female/ 1.72	4/ 17/ 0.82/ 110.11	04SEP2003/ 02SEP2004/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	43.3/ Male/ 1.95	3/ 28/ 0.88/ 119.90	08SEP2003/ 06SEP2004/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	44.4/ Female/ 1.49	3/ 95/ 0.73/ 82.01	09SEP2003/ 07SEP2004/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	30.3/ Male/ 1.72	4/ 93/ 1.22/ 73.80	30SEP2003/ 28SEP2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	30.3/ Male/ 1.63	4/ 1/ 0.90/ 90.77	18NOV2003/ 03MAY2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	61.8/ Female/ 1.81	3/ 133/ 0.58/ 120.62	16JAN2003/ 31JUL2003/ STI pilot	NEG/ POS
PP PPD ZDV 3TC TDF	50.8/ Female/ 1.64	3/ 153/ 0.58/ 112.26	14FEB2003/ 29AUG2003/ STI pilot	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	36.4/ Male/ 1.76	3/ 128/ 1.14/ 77.16	03MAR2003/ 15SEP2003/ STI pilot	NEG/ POS
PPD PPD / ZDV 3TC TDF	41.2/ Female/ 1.48	3/ 176/ 0.70/ 86.38	10MAR2003/ 22SEP2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	31.5/ Female/ 1.74	2/ 135/ 0.27/ 293.10	18MAR2003/ 30SEP2003/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	58.8/ Female/ 1.86	2/ 126/ 0.89/ 84.21	21MAR2003/ 06OCT2003/ STI pilot	NEG/ NEG
PP PPD ZDV 3TC TDF	49.9/ Male/ 1.78	3/ 193/ 0.97/ 91.09	25MAR2003/ 07OCT2003/ STI pilot	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	37.1/ Male/ 1.84	2/ 194/ 0.99/ 112.84	03APR2003/ 16OCT2003/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	34.3/ Female/ 1.72	4/ 136/ 0.49/ 165.79	04APR2003/ 17OCT2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	40.4/ Male/ 1.70	2/ 197/ 1.59/ 50.54	02JUN2003/ 15DEC2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	32.5/ Male/ 1.67	4/ 165/ 1.50/ 56.87	16JUN2003/ 06JAN2004/ STI pilot	NEG/ NEG
PP PPD ZDV 3TC TDF	36.9/ Female/ 1.82	3/ 178/ 0.72/ 122.52	30JUN2003/ 12JAN2004/ STI pilot	/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	39.9/ Female/ 1.47	3/ 157/ 1.06/ 55.56	02JUL2003/ 14JAN2004/ STI pilot	POS/ NEG
PPD PPD / ZDV 3TC TDF	37.7/ Female/ 1.89	3/ 165/ 0.43/ 249.98	07JUL2003/ 19JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	32.5/ Female/ 2.01	4/ 162/ 0.98/ 109.75	08JUL2003/ 15JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	45.3/ Male/ 1.83	2/ 182/ 1.39/ 66.40	09JUL2003/ 21JAN2004/ STI pilot	NEG/ POS
PP PPD ZDV 3TC TDF	34.7/ Female/ 1.51	3/ 120/ 0.84/ 73.05	15JUL2003/ 27JAN2004/ STI pilot	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	46.9/ Female/ 1.46	3/ 154/ 0.63/ 83.44	28JUL2003/ 26JUL2004/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	46.0/ Male/ 1.45	3/ 129/ 0.70/ 86.76	13AUG2003/ 11AUG2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	44.2/ Female/ 1.39	3/ 192/ 0.90/ 62.13	19AUG2003/ 20AUG2004/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	43.6/ Female/ 2.00	2/ 154/ 0.70/ 144.98	28AUG2003/ 26AUG2004/ CT	NEG/ POS
PP PPD ZDV 3TC TDF	42.7/ Male/ 1.63	3/ 189/ 1.04/ 69.00	15SEP2003/ 28FEB2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	65.8/ Female/ 1.51	2/ 158/ 0.71/ 64.56	30SEP2003/ 15MAR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	35.7/ Female/ 1.46	4/ 100/ 0.96/ 61.49	06MAY2004/ 20OCT2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	45.2/ Male/ 1.58	3/ 190/ 0.97/ 72.13	10AUG2004/ 09AUG2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	41.0/ Female/ 1.59	2/ 136/ 0.71/ 87.81	24AUG2004/ 07FEB2006/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	24.2/ Female/ 1.40	3/ 108/ 1.13/ 54.24	06SEP2004/ 20FEB2006/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	43.6/ Female/ 1.68	3/ 64/ 0.53/ 129.75	18JUN2003/ 31DEC2003/ STI pilot	NEG/ POS
PPD PPD / ZDV 3TC TDF	53.3/ Male/ 1.49	2/ 74/ 0.72/ 86.00	19JUN2003/ 31DEC2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	30.1/ Female/ 1.48	3/ 66/ 0.86/ 72.24	11JUL2003/ 21DEC2004/ CT	NEG/ NEG
PPD PPD ZDV 3TC TDF	41.2/ Male/ 1.88	4/ 40/ 1.13/ 83.97	22SEP2003/ 07MAR2005/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	28.3/ Female/ 1.46	4/ 65/ 0.70/ 89.96	22SEP2003/ 20SEP2004/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	34.7/ Female/ 1.62	4/ 89/ 0.86/ 83.57	29SEP2003/ 27SEP2004/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	35.1/ Male/ 1.34	4/ 12/ 1.01/ 54.68	06OCT2003/ 21MAR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	45.6/ Male/ 1.55	3/ 47/ 1.04/ 64.77	21OCT2003/ 19OCT2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	54.2/ Male/ 1.94	4/ 24/ 1.23/ 75.30	28OCT2003/ 12APR2005/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	49.4/ Male/ 1.74	4/ 39/ 1.09/ 82.06	07NOV2003/ 22APR2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	53.2/ Female/ 1.64	3/ 25/ 1.05/ 59.07	12NOV2003/ 27APR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	37.5/ Female/ 1.61	4/ 34/ 0.83/ 87.38	27NOV2003/ 12MAY2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	38.4/ Female/ 1.78	3/ 19/ 0.68/ 121.89	04DEC2003/ 19MAY2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	25.4/ Female/ 1.43	3/ 24/ 0.81/ 74.18	02FEB2004/ 31JAN2005/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	33.9/ Male/ 1.59	4/ 1/ 1.26/ 65.56	02FEB2004/ 18JUL2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	51.3/ Male/ 1.70	3/ 38/ 0.95/ 81.83	27FEB2004/ 12AUG2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	27.3/ Female/ 2.00	2/ 197/ 0.70/ 164.56	25JUN2003/ 07JAN2004/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	32.1/ Male/ 1.99	2/ 167/ 0.89/ 138.15	27JUN2003/ 09JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	46.6/ Female/ 1.58	2/ 176/ 0.59/ 106.89	30JUN2003/ 12JAN2004/ STI pilot	/ NEG
PP PPD ZDV 3TC TDF	58.7/ Male/ 1.64	3/ 128/ 0.86/ 69.78	14JUL2003/ 26JAN2004/ STI pilot	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	46.4/ Female/ 1.66	3/ 140/ 0.85/ 75.28	15JUL2003/ 28DEC2004/ STI	NEG/ POS
PPD PPD / ZDV 3TC TDF	24.9/ Female/ 1.44	3/ 147/ 0.49/ 127.50	15JUL2003/ 27JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	48.9/ Female/ 1.55	3/ 131/ 0.49/ 119.76	22SEP2003/ 07MAR2005/ STI	/ POS
PPD PPD ZDV 3TC TDF	37.5/ Female/ 1.62	4/ 116/ 0.69/ 101.79	13OCT2003/ 22MAR2005/ STI	NEG/ POS
PP PPD ZDV 3TC TDF	22.3/ Female/ 1.41	4/ 122/ 0.76/ 79.50	14OCT2003/ 12OCT2004/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	23.3/ Female/ 1.65	4/ 134/ 0.74/ 113.94	13NOV2003/ 11NOV2004/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	37.1/ Male/ 2.25	3/ 196/ 0.85/ 193.06	12DEC2003/ 27MAY2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	31.2/ Female/ 1.76	2/ 133/ 0.67/ 135.81	12DEC2003/ 27MAY2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	35.3/ Female/ 1.73	2/ 142/ 0.90/ 89.19	30DEC2003/ 14JUN2005/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	32.0/ Male/ 1.74	3/ 192/ 0.94/ 101.53	10FEB2004/ 08FEB2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	35.2/ Female/ 1.47	2/ 152/ 1.03/ 60.87	26FEB2004/ 24FEB2005/ CT	NEG/ POS
PPD PPD / ZDV 3TC TDF	38.3/ Female/ 1.44	4/ 54/ 0.64/ 86.91	27MAY2003/ 09NOV2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	31.6/ Female/ 1.67	3/ 37/ 0.81/ 102.33	03FEB2004/ 19JUL2005/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	33.7/ Female/ 1.63	4/ 157/ 1.02/ 73.58	13MAY2003/ 26OCT2004/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	55.7/ Female/ 1.33	4/ 136/ 0.93/ 53.34	27MAY2003/ 09DEC2003/ STI pilot	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	25.9/ Female/ 1.58	3/ 100/ 0.38/ 194.20	27MAY2003/ 09DEC2003/ STI pilot	NEG/ NEG
PPD PPD / ZDV 3TC TDF	44.0/ Female/ 1.51	3/ 102/ 0.65/ 103.42	05JUN2003/ 18DEC2003/ STI pilot	NEG/ POS
PPD PPD ZDV 3TC TDF	40.0/ Female/ 1.51	3/ 185/ 0.71/ 91.15	08JUL2003/ 20JAN2004/ STI pilot	NEG/ NEG
PPD PPD ZDV 3TC TDF	35.1/ Female/ 1.59	4/ 195/ 0.49/ 156.23	08JUL2003/ 20JAN2004/ STI pilot	NEG/ NEG
PP PPD ZDV 3TC TDF	43.2/ Male/ 1.59	4/ 100/ 1.00/ 74.11	26AUG2003/ 24AUG2004/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	50.7/ Female/ 1.49	3/ 105/ 0.55/ 93.61	13NOV2003/ 11NOV2004/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	45.3/ Female/ 1.73	3/ 192/ 1.15/ 63.00	27NOV2003/ 23NOV2004/ STI	NEG/ POS
PPD PPD ZDV 3TC TDF	27.6/ Female/ 1.75	2/ 125/ 0.94/ 99.19	22JAN2004/ 20JAN2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	50.7/ Male/ 1.94	4/ 195/ 1.00/ 97.61	27JAN2004/ 25JAN2005/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	30.0/ Female/ 1.48	4/ 125/ 0.68/ 95.50	12FEB2004/ 10FEB2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	30.8/ Female/ 1.59	4/ 118/ 0.92/ 75.40	17FEB2004/ 02AUG2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	34.7/ Female/ 1.75	3/ 145/ 0.95/ 91.27	12MAR2004/ 25AUG2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: TDF CLcr 30-49

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	39.7/ Female/ 1.53	3/ 86/ 1.43/ 38.10	19DEC2003/ 17DEC2004/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	53.9/ Male/ 1.31	2/ 135/ 1.38/ 39.94	17JUL2003/ 30DEC2004/ STI	POS/ NEG
PPD PPD ZDV 3TC TDF	44.9/ Female/ 1.33	4/ 170/ 1.16/ 37.44	15SEP2003/ 28FEB2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC TDF	58.1/ Male/ 1.60	2/ 150/ 1.28/ 46.19	08OCT2003/ 11OCT2004/ STI	NEG/ NEG
PP PPD ZDV 3TC TDF	40.0/ Female/ 1.38	3/ 149/ 1.01/ 48.76	19DEC2003/ 03JUN2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: Any CLcr<30

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC TDF	29.9/ Male/ 1.45	3/ 125/ 2.40/ 28.73	18MAY2004/ 01NOV2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC TDF	61.8/ Female/ 1.54	3/ 101/ 1.83/ 28.40	21FEB2003/ 05SEP2003/ STI pilot	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	36.7/ Female/ 1.41	2/ 76/ 0.72/ 75.52	12MAR2004/ 09MAR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC NVP	32.8/ Female/ 1.61	2/ 18/ 0.86/ 86.63	22MAR2004/ 21MAR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	35.9/ Male/ 1.54	3/ 40/ 0.78/ 87.28	08APR2004/ 07APR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC ABC	41.9/ Female/ 1.35	2/ 62/ 0.80/ 62.07	07MAY2004/ 06MAY2005/ STI	NEG/ POS
PP PPD ZDV 3TC NVP	49.0/ Female/ 1.48	2/ 52/ 0.77/ 66.82	30JUN2004/ 14DEC2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	28.6/ Female/ 1.43	3/ 2/ 0.88/ 62.41	06AUG2004/ 05AUG2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC NVP	45.2/ Female/ 1.89	3/ 87/ 1.01/ 90.87	20AUG2004/ 19AUG2005/ STI	NEG/ POS
PPD PPD ZDV 3TC ABC	32.0/ Female/ 1.25	3/ 45/ 0.90/ 50.56	24AUG2004/ 07FEB2006/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	22.9/ Female/ 1.47	4/ 94/ 0.88/ 70.25	21SEP2004/ 20SEP2005/ STI	NEG/ NEG
PP PPD ZDV 3TC NVP	46.6/ Female/ 1.73	2/ 154/ 1.05/ 73.13	27JAN2004/ 25JAN2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	34.1/ Female/ 1.49	3/ 145/ 0.84/ 75.95	28JAN2004/ 26JAN2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC ABC	32.0/ Female/ 1.69	2/ 149/ 0.93/ 82.18	04MAR2004/ 03MAR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	27.9/ Female/ 1.45	3/ 171/ 1.02/ 63.47	17MAR2004/ 16MAR2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	38.2/ Female/ 1.53	4/ 195/ 1.04/ 59.83	22MAR2004/ 05SEP2005/ STI	NEG/ POS
PP PPD ZDV 3TC NVP	43.8/ Female/ 1.71	2/ 133/ 1.00/ 79.25	29MAR2004/ 30MAR2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	60.9/ Male/ 1.78	2/ 100/ 1.12/ 59.01	30MAR2004/ 29MAR2005/ STI	POS/ POS
PPD PPD / ZDV 3TC NVP	45.8/ Male/ 1.73	3/ 101/ 0.80/ 95.05	14APR2004/ 28SEP2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	37.2/ Male/ 1.72	3/ 174/ 1.40/ 63.31	22APR2004/ 21APR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	31.7/ Male/ 1.75	2/ 190/ 0.68/ 133.06	22APR2004/ 21APR2005/ STI	NEG/ POS
PP PPD ZDV 3TC NVP	40.5/ Female/ 1.78	2/ 169/ 1.07/ 81.75	12MAY2004/ 11MAY2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	32.0/ Male/ 1.81	3/ 135/ 0.98/ 97.82	02JUN2004/ 16NOV2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC ABC	30.0/ Female/ 1.60	2/ 181/ 0.93/ 75.38	04JUN2004/ 03JUN2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	30.4/ Female/ 1.77	3/ 188/ 1.06/ 83.70	04JUN2004/ 02JUN2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	37.6/ Male/ 1.63	3/ 123/ 0.79/ 97.16	17JUN2004/ 15JUN2005/ STI	NEG/ NEG
PP PPD ZDV 3TC NVP	29.7/ Female/ 1.41	3/ 128/ 1.10/ 52.02	18JUN2004/ 24JUN2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC ABC	37.2/ Male/	3/ 197/ 1.23/ 76.61	22JUN2004/ 21JUN2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC NVP	24.0/ Female/ 1.53	2/ 185/ 0.86/ 87.32	24JUN2004/ 23JUN2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	32.1/ Male/ 1.60	3/ 169/ 1.10/ 76.66	13JUL2004/ 15JUL2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	35.6/ Female/ 1.61	3/ 10/ 0.78/ 88.25	29JUL2004/ 28JUL2005/ STI	NEG/ NEG
PP PPD ZDV 3TC NVP	35.7/ Female/ 1.47	4/ 43/ 0.69/ 86.22	02SEP2004/ 01SEP2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC ABC	40.5/ Female/ 1.57	3/ 56/ 0.76/ 83.36	13SEP2004/ 12SEP2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC NVP	36.0/ Female/ 1.35	3/ 89/ 0.81/ 61.99	24SEP2004/ 23SEP2005/ STI	/ NEG
PPD PPD ZDV 3TC ABC	34.8/ Female/ 1.53	3/ 28/ 0.54/ 119.21	27SEP2004/ 13MAR2006/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	35.8/ Female/ 1.83	4/ 25/ 1.06/ 89.50	19OCT2004/ 18OCT2005/ CT	NEG/ NEG
PP PPD ZDV 3TC NVP	58.2/ Female/ 1.54	3/ 150/ 0.83/ 67.83	11MAR2004/ 10MAR2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC ABC	31.5/ Female/ 1.49	3/ 165/ 0.57/ 114.24	28APR2004/ 27APR2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC NVP	57.6/ Male/ 1.55	3/ 196/ 0.94/ 67.95	13MAY2004/ 28OCT2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	32.4/ Female/ 1.78	3/ 141/ 0.95/ 101.91	04JUN2004/ 16NOV2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	34.9/ Female/ 1.51	3/ 191/ 0.94/ 69.31	22JUN2004/ 27JUN2005/ STI	NEG/ NEG
PP PPD ZDV 3TC NVP	29.7/ Female/ 1.49	3/ 9/ 0.79/ 81.77	15APR2004/ 29SEP2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	26.3/ Female/ 1.48	3/ 67/ 0.85/ 74.13	16APR2004/ 30SEP2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC NVP	36.1/ Female/ 1.74	3/ 16/ 0.89/ 99.06	22APR2004/ 06OCT2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	40.4/ Male/ 1.62	3/ 94/ 0.85/ 86.63	17MAY2004/ 16MAY2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	35.4/ Female/ 1.58	3/ 66/ 0.79/ 88.66	07JUN2004/ 06JUN2005/ STI	NEG/ POS
PP PPD ZDV 3TC NVP	34.6/ Female/ 1.42	3/ 70/ 0.52/ 108.51	08JUN2004/ 29NOV2005/ STI	NEG/ POS

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2

Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	34.8/ Female/ 1.50	3/ 64/ 0.51/ 125.57	10JUN2004/ 08JUN2005/ STI	NEG/ NEG
PPD PPD / ZDV 3TC NVP	31.4/ Male/ 1.76	4/ 144/ 1.05/ 86.48	22MAR2004/ 21MAR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	40.0/ Female/ 1.58	4/ 109/ 0.75/ 94.23	01APR2004/ 15SEP2005/ STI	NEG/ NEG
PPD PPD ZDV 3TC NVP	27.2/ Female/ 1.63	2/ 146/ 0.92/ 83.91	06APR2004/ 05APR2005/ STI	/ POS
PP PPD ZDV 3TC NVP	48.9/ Male/ 1.80	3/ 108/ 0.94/ 92.95	08APR2004/ 05APR2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr>=50

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC NVP	40.9/ Male/ 1.88	2/ 178/ 1.02/ 96.51	15APR2004/ 14APR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC NVP	33.0/ Male/ 1.68	4/ 177/ 0.88/ 103.86	22APR2004/ 21APR2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	22.8/ Female/ 1.43	2/ 130/ 0.78/ 77.73	31MAY2004/ 30MAY2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.2
Listing of all STI patients who were censored by Treatment regimen and by CLcr at Baseline up to 96

Treatment: ABC or NVP CLcr 30-49

Centre/ Subject ID/ First ART regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ STI Randomisation date/ STI randomisation	Hepatitis C Status/ Hepatitis B Status
PPD PPD / ZDV 3TC ABC	51.8/ Female/ 1.43	3/ 183/ 1.46/ 35.59	19MAR2004/ 18MAR2005/ STI	NEG/ POS
PPD PPD / ZDV 3TC ABC	51.6/ Male/ 1.55	4/ 156/ 1.45/ 43.35	14MAY2004/ 13MAY2005/ STI	NEG/ POS
PPD PPD ZDV 3TC NVP	33.7/ Female/ 1.47	4/ 54/ 1.67/ 36.91	15APR2004/ 29SEP2005/ STI	NEG/ NEG

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	32.6/ Female/ 1.39	4/ 2/ 0.76/ 71.69	06FEB2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	36.4/ Male/ 1.83	3/ 16/ 1.15/ 89.40	29APR2003/ /	Yes/ PPD 2003	/	/
			29APR2003/ 18MAY2003/	Yes/ PPD 2003	5/ 4	Musculoskeletal/ Myalgia, pain in muscles
PPD PPD 3TC/ZDV+TDF	42.9/ Male/ 1.36	4/ 1/ 1.19/ 47.24	13MAY2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	31.4/ Female/ 1.33	4/ 27/ 1.14/ 46.99	15MAY2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.4/ Female/ 1.33	4/ 27/ 1.14/ 46.99	15MAY2003/ 17JUN2003/	Yes/ PPD 2003	1/ 5	Haematological/ Pancytopenia, bone marrow depression+Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
PP PPD 3TC/ZDV+TDF	44.2/ Male/ 1.95	2/ 15/ 0.95/ 110.88	25JUN2003/ /	Yes/ PPD 2005	/	/
			25JUN2003/ PPD 2005/	Yes/ PPD 2005	1/ 5	Other/ Death, cause unknown

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.37	3/ 3/ 1.01/ 49.11	25AUG2003/ 27JUN2005/ 11JUL2005	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	25.2/ Female/ 1.37	3/ 1/ 0.71/ 87.20	29AUG2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	41.3/ Female/ 1.32	3/ 96/ 1.05/ 45.29	12SEP2003/ /	Yes/ PPD 2003	/	/
			12SEP2003/ PPD 2003/	Yes/ PPD 2003	1/ 5	Specific Infections/ Presumed septicaemia/bacteremia - not investigated

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PP PPD 3TC/ZDV+TDF	25.3/ Male/ 1.58	3/ 6/ 0.92/ 95.88	15SEP2003/ /	Yes/ PPD 2005	/	/
PP PPD 3TC/ZDV+TDF	31.3/ Female/ 1.41	4/ 1/ 0.83/ 66.60	03OCT2003/ /	Yes/ PPD 2004	/	/
PP PPD 3TC/ZDV+TDF	33.3/ Male/	3/ 3/ 1.23/ 56.60	03OCT2003/ /	Yes/ PPD 2003	/	/
PP PPD 3TC/ZDV+TDF	36.6/ Male/	3/ 1/ 1.15/ 78.63	03OCT2003/ /	Yes/ PPD 2004	/	/
			03OCT2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Systemic/ Acute febrile episode - undiagnosed

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	28.3/ Female/	3/ 7/ 0.71/ 84.85	03OCT2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	40.7/ Female/ 1.48	3/ 49/ 0.95/ 59.03	06OCT2003/ 04OCT2004/ 29NOV2004	/	4/ 4	Haematological/ Anaemia
PPD PPD F	30.3/ Female/ 1.59	3/ 5/ 0.92/ 76.75	15OCT2003/ 05JAN2004/ 16JAN2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	39.3/ Male/ 1.69	4/ 44/ 0.92/ 90.24	20OCT2003/ /	Yes/ PPD 2004	/	/
			20OCT2003/ 01NOV2004/	Yes/ PPD 2004	1/ 5	Other/ Death, cause unknown

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
P / PPD 3TC/ZDV+TDF	32.3/ Male/ 1.61	3/ 30/ 1.05/ 78.33	20OCT2003/ 16JAN2004/ 19JAN2004	/	4/ 4	CNS/ Epilepsy, fits, convulsions
PP PPD 3TC/ZDV+TDF	34.4/ Female/ 1.49	2/ 48/ 0.87/ 68.52	22OCT2003/ 17FEB2004/ 26FEB2004	/	2/ 4	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	36.3/ Female/ 1.56	4/ 4/ 0.83/ 79.87	30OCT2003/ 23DEC2003/ 29DEC2003	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	37.5/ Female/ 1.26	3/ 99/ 0.79/ 54.83	30OCT2003/ 16AUG2004/ 09SEP2004	/	2/ 3	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	44.3/ Female/ 1.66	3/ 44/ 1.04/ 62.76	04NOV2003/ 10MAR2004/ 20APR2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PP PPD 3TC/ZDV+TDF	30.4/ Female/ 1.60	4/ 16/ 1.01/ 74.96	04NOV2003/ /	Yes/ PPD 2004	/	/
			04NOV2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Other/ Death, cause unknown
PP PPD 3TC/ZDV+TDF	35.6/ Male/ 1.71	3/ 2/ 0.88/ 103.81	10NOV2003/ 26APR2004/ 03MAY2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	25.4/ Female/ 1.67	2/ 3/ 0.95/ 87.98	17NOV2003/ 13FEB2004/ 16FEB2004	/	4/ 4	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	33.3/ Male/ 1.72	3/ 15/ 0.71/ 123.02	24NOV2003/ 04JUL2005/ 11JUL2005	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PP PPD 3TC/ZDV+TDF	24.5/ Female/ 1.62	2/ 6/ 0.75/ 100.10	27NOV2003/ 15APR2004/ 17APR2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	50.5/ Female/	2/ 77/ 1.06/ 55.49	09DEC2003/ /	Yes/ PPD 2004	/	/
P / PPD 3TC/ZDV+TDF	24.5/ Female/ 1.63	3/ 3/ 0.63/ 115.88	10DEC2003/ /	Yes/ PPD 2005	/	/
PP PPD 3TC/ZDV+TDF	39.5/ Female/ 1.23	3/ 14/ 0.61/ 67.80	12DEC2003/ /	Yes/ PPD 2004	/	/
			12DEC2003/ 26FEB2004/	Yes/ PPD 2004	1/ 5	Cardiovascular/ Pulmonary embolism+Deep vein thrombosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PP PPD 3TC/ZDV+TDF	39.0/ Female/ 1.68	3/ 75/ 0.80/ 93.65	15DEC2003/ /	Yes/ PPD 2004	/	/
PP PPD 3TC/ZDV+TDF	41.1/ Female/ 1.33	4/ 1/ 0.64/ 65.01	16DEC2003/ /	Yes/ PPD 2004	/	/
PP PPD 3TC/ZDV+TDF	28.5/ Male/ 1.72	3/ 34/ 3.01/ 33.01	18DEC2003/ 16AUG2004/ 25APR2005	/	4/ 3	Cardiovascular/ Congestive cardiac failure
PP PPD 3TC/ZDV+TDF	34.0/ Female/ 1.59	4/ 8/ 0.88/ 73.52	19DEC2003/ 11FEB2004/ 01MAR2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	34.5/ Male/ 1.68	3/ 25/ 0.84/ 101.81	13JAN2004/ 01APR2004/ 08APR2004	/	4/ 2	Renal/ Haematuria

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PP PPD 3TC/ZDV+TDF	33.2/ Female/ 1.61	3/ 96/ 0.92/ 82.27	15JAN2004/ 25JUN2004/ 27JUN2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	28.6/ Male/ 1.39	3/ 76/ 0.79/ 86.16	16JAN2004/ /	Yes/ PPD 2004	/ /	/
			16JAN2004/ PPD 2004/	Yes/ PPD 2004	1/ 5	Non HIV related deaths/ Suicide
PP PPD 3TC/ZDV+TDF	41.8/ Male/ 1.79	3/ 5/ 0.77/ 120.85	02FEB2004/ 23JUN2005/ 06JUL2005	/	5/ 3	Genitourinary/ Urinary retention
PP PPD 3TC/ZDV+TDF	34.2/ Female/ 1.30	4/ 1/ 0.96/ 50.54	23FEB2004/ /	Yes/ PPD 2004	/ /	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PP / PPD 3TC/ZDV+TDF	31.3/ Female/ 1.40	3/ 28/ 0.94/ 57.22	27FEB2004/ 19JUL2004/ 13AUG2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	47.8/ Male/ 1.75	4/ 6/ 1.07/ 71.69	26MAR2004/ 09SEP2004/ 14SEP2004	/	4/ 4	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	33.8/ Female/ 1.55	4/ 8/ 0.67/ 114.28	29MAR2004/ 23APR2004/ 29APR2004	/	4/ 4	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	28.9/ Female/ 1.24	4/ 1/ 0.65/ 68.38	27APR2004/ /	Yes/ PPD 2004	/	/
PP PPD 3TC/ZDV+TDF	54.9/ Female/ 1.41	3/ 23/ 0.83/ 58.19	19MAY2004/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	36.9/ Female/ 1.56	3/ 1/ 0.84/ 79.69	19MAY2004/ 05AUG2005/ 05OCT2005	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	35.3/ Female/ 1.52	4/ 3/ 1.18/ 56.55	01OCT2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	44.7/ Female/ 1.40	3/ 145/ 1.14/ 44.18	20FEB2003/ 25AUG2003/ 26SEP2003	/	4/ 4	Haematological/ Anaemia
			20FEB2003/ 26JUL2004/	/	1/ 5	Tumours/ Other Solid tumour
PPD PPD 3TC/ZDV+TDF	42.0/ Female/ 1.58	3/ 138/ 0.88/ 68.13	15APR2003/ 03JAN2004/ 07JAN2004	/	4/ 4	Specific Infections/ P falciparum malaria

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.1/ Female/ 1.54	3/ 161/ 0.68/ 98.26	20MAY2003/ 23MAR2004/ 26MAR2004	/	4/ 4	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	39.0/ Female/ 1.41	2/ 190/ 1.07/ 47.53	04JUL2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	27.1/ Female/ 1.72	2/ 124/ 0.79/ 117.48	16JUL2003/ 15JAN2004/ 30JAN2004	/	4/ 3	Pregnancy associated/ Other gram positive sepsis+Spontaneous abortion (complete or incomplete)
PPD PPD 3TC/ZDV+TDF	34.1/ Female/ 1.28	2/ 117/ 0.87/ 55.79	05AUG2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	34.1/ Female/ 1.28	2/ 117/ 0.87/ 55.79	05AUG2003/ 26APR2004/	Yes/ PPD 2004	1/ 5	Tumours/ Hepatocellular carcinoma
PPD PPD 3TC/ZDV+TDF	38.0/ Female/ 1.47	3/ 184/ 0.87/ 68.93	13AUG2003/ 29DEC2004/	/	1/ 5	Tumours/ Cervical carcinoma
PPD PPD 3TC/ZDV+TDF	44.0/ Male/	3/ 126/ 1.18/ 54.50	14AUG2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	35.2/ Female/ 1.38	3/ 134/ 1.03/ 51.52	03SEP2003/ 10MAR2005/ 15APR2005	/	4/ 2	Musculoskeletal/ Bone fracture

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	39.1/ Female/ 1.56	3/ 171/ 0.86/ 69.02	06OCT2003/ 19FEB2005/ 21FEB2005	/	4/ 4	Gastrointestinal / Indigestion, oesophageal reflux, gastritis, ulcerative oesophagitis
PP PPD 3TC/ZDV+TDF	34.1/ Female/ 1.68	2/ 192/ 0.88/ 88.96	27OCT2003/ /	Yes/ PPD 2004	/	/
			27OCT2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Non HIV related deaths/ Obstetric
PPD PPD 3TC/ZDV+TDF	38.2/ Female/	2/ 187/ 3.73/ 17.34	06NOV2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	38.2/ Female/	2/ 187/ 3.73/ 17.34	06NOV2003/ 20DEC2003/	Yes/ PPD 2003	1/ 5	Other/ Death, cause unknown
PPD PPD 3TC/ZDV+TDF	37.4/ Female/ 1.26	3/ 146/ 0.98/ 44.17	10NOV2003/ 18DEC2003/ 23DEC2003	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	35.4/ Female/ 1.57	2/ 107/ 0.80/ 81.22	14NOV2003/ 17MAR2004/ 02APR2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.75	3/ 100/ 0.85/ 94.71	17NOV2003/ /	Yes/ PPD 2004	/	/
			17NOV2003/ 04MAR2004/ 05MAR2004	Yes/ PPD 2004	4/ 4	Specific Infections/ P falciparum malaria

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.75	3/ 100/ 0.85/ 94.71	17NOV2003/ 03MAY2004/ 04MAY2004	Yes/ PPD 2004	1/ 5	CNS/ Epilepsy, fits, convulsions+Acute altered conscious level
PPD PPD 3TC/ZDV+TDF	35.5/ Female/ 1.36	3/ 125/ 0.96/ 55.01	09DEC2003/ /	Yes/ PPD 2004	/	/
			09DEC2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Non HIV related deaths/ Traumatic
PPD PPD 3TC/ZDV+TDF	34.0/ Female/ 1.65	3/ 110/ 0.76/ 97.13	09DEC2003/ 30MAY2005/ 04JUN2005	/	4/ 4	Haematological/ Nose bleed, epistaxis
PPD PPD 3TC/ZDV+TDF	31.5/ Male/ 1.45	4/ 164/ 1.28/ 53.16	21JAN2004/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.5/ Male/ 1.45	4/ 164/ 1.28/ 53.16	21JAN2004/ 03FEB2004/	Yes/ PPD 2004	4/ 3	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	31.7/ Female/ 1.55	3/ 192/ 3.72/ 18.83	10MAR2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	34.8/ Male/ 1.71	3/ 102/ 0.65/ 144.04	20APR2004/ 10MAR2005/ 22MAR2005	/	3/ 3	Endocrine/ Diabetes - Type II
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.62	3/ 158/ 0.64/ 112.63	22APR2004/ 13DEC2004/ 30DEC2004	/	4/ 4	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	41.9/ Female/ 1.30	2/ 114/ 0.80/ 62.09	27APR2004/ 22JUN2004/ 28JUN2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.9/ Female/ 1.41	2/ 152/ 0.70/ 76.32	07MAY2004/ /	Yes/ PPD 2006	/	/
PPD PPD 3TC/ZDV+TDF	29.0/ Male/ 1.67	4/ 130/ 1.10/ 77.44	18JUN2004/ /	Yes/ PPD 2006	/	/
PP PPD 3TC/ZDV+TDF	25.1/ Female/ 1.50	2/ 108/ 0.87/ 76.08	27JUL2004/ 23JAN2006/ 25JAN2006	/	4/ 4	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	51.2/ Male/ 1.65	4/ 148/ 0.87/ 76.88	01SEP2004/ /	Yes/ PPD 2005	/	/
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.40	3/ 46/ 0.93/ 59.13	18FEB2004/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	39.6/ Male/ 1.90	3/ 46/ 0.97/ 100.56	24FEB2004/ /	Yes/ PPD 2004	/	/
PP PPD 3TC/ZDV+NVP	38.7/ Female/ 1.64	2/ 35/ 1.02/ 72.58	10MAR2004/ 21FEB2006/ 03APR2006	/	5/ 4	Systemic/ Hypersensitivity reaction
PP PPD 3TC/ZDV+ABC	33.7/ Female/ 1.34	3/ 31/ 0.86/ 56.72	11MAR2004/ 30JAN2005/ 24FEB2005	/	5/ 4	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	32.4/ Female/ 1.52	4/ 11/ 0.90/ 71.71	28APR2004/ 08JUN2004/ 09JUN2004	/	5/ 3	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	46.0/ Male/ 1.62	3/ 82/ 1.50/ 47.98	05MAY2004/ 20JUL2004/ 30JUL2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	43.1/ Male/ 1.51	4/ 53/ 0.89/ 70.98	04JUN2004/ 01SEP2004/ 23SEP2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+ABC	31.5/ Male/ 1.67	3/ 11/ 1.04/ 78.33	12JUL2004/ 21AUG2004/ 26AUG2004	/	5/ 3	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	31.2/ Female/ 1.53	3/ 76/ 1.04/ 62.75	21JUL2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	30.8/ Female/ 1.44	4/ 36/ 1.00/ 60.71	21JUL2004/ 19AUG2004/ 02SEP2004	/	5/ 3	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	33.1/ Male/ 1.52	4/ 73/ 1.05/ 67.88	21JUL2004/ 28JUL2004/ 28AUG2004	/	5/ 2	Systemic/ Hypersensitivity reaction

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	30.0/ Female/ 1.39	3/ 82/ 1.53/ 35.56	09AUG2004/ /	Yes/ PPD 2005	/	/
			09AUG2004/ 11OCT2005/	Yes/ PPD 2005	1/ 5	Gastrointestinal / Peptic/gastric/duodenal ulcer
PPD PPD 3TC/ZDV+ABC	50.2/ Female/ 1.41	3/ 4/ 0.92/ 48.48	11AUG2004/ /	Yes/ PPD 2006	/	/
			11AUG2004/ 27NOV2005/ 01DEC2005	Yes/ PPD 2006	4/ 3	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+NVP	25.7/ Male/ 1.77	4/ 2/ 0.97/ 98.15	11AUG2004/ 10SEP2004/ 22SEP2004	/	2/ 4	Other/ Non-fatal trauma

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	32.4/ Female/ 1.49	3/ 1/ 0.97/ 63.79	18AUG2004/ 20SEP2004/ 01OCT2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	27.0/ Female/ 1.81	3/ 70/ 1.22/ 75.05	20AUG2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	50.3/ Female/ 1.32	4/ 58/ 0.89/ 44.89	30AUG2004/ /	Yes/ PPD 2004	/	/
			30AUG2004/ 18NOV2004/	Yes/ PPD 2004	1/ 5	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	30.3/ Female/ 1.53	3/ 5/ 0.83/ 78.22	14SEP2004/ 12OCT2004/ 16OCT2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	31.3/ Female/ 1.77	2/ 12/ 0.81/ 113.08	17SEP2004/ 06JAN2006/ 03FEB2006	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+ABC	30.3/ Female/ 1.66	3/ 20/ 1.05/ 73.65	20SEP2004/ 10JAN2005/ 11JAN2005	/	5/ 1	Skin/ Rash, erythematous
PPD PPD 3TC/ZDV+NVP	36.3/ Male/ 1.59	4/ 17/ 1.02/ 73.74	22SEP2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+ABC	40.3/ Female/ 1.40	4/ 1/ 0.98/ 40.56	28SEP2004/ /	Yes/ PPD 2004	/	/
			28SEP2004/ PPD 2004/	Yes/ PPD 2004	1/ 5	Other/ Death, cause unknown

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	38.1/ Female/ 1.74	4/ 145/ 0.88/ 97.84	27JAN2004/ 24MAR2004/ 19APR2004	/	5/ 3	Hepatic/ Recurrent fever - no diagnosis+Acute hepatitis
PPD PPD 3TC/ZDV+NVP	34.1/ Female/ 1.49	3/ 145/ 0.84/ 75.95	28JAN2004/ 09FEB2004/ 24FEB2004	/	5/ 2	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	37.0/ Female/ 1.56	3/ 127/ 0.93/ 71.91	28JAN2004/ 25OCT2004/	/	5/ 3	Pregnancy associated/ Still birth
PPD PPD 3TC/ZDV+NVP	36.2/ Female/ 1.72	3/ 142/ 1.06/ 85.00	26FEB2004/ 10MAY2004/ 04JUN2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	29.7/ Female/ 1.50	2/ 115/ 0.89/ 78.45	04MAR2004/ 23MAR2004/ 28MAR2004	/	5/ 2	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.75	4/ 119/ 1.04/ 74.42	10MAR2004/ 08DEC2005/ 12DEC2005	/	4/ 4	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+ABC	27.5/ Female/ 1.55	2/ 100/ 0.78/ 86.53	12MAR2004/ 14MAY2004/ 17MAY2004	/	5/ 2	Skin/ Rash, urticaria
			12MAR2004/ 09JUN2004/ 02JUL2004	/	5/ 2	Skin/ Rash, urticaria
PPD PPD 3TC/ZDV+NVP	49.8/ Male/ 1.51	4/ 100/ 1.16/ 50.67	26MAR2004/ 06APR2004/ 20APR2004	/	4/ 3	Hepatic/ Acute hepatitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	45.8/ Female/ 1.61	3/ 142/ 1.07/ 59.83	06APR2004/ /	Yes/ PPD 2005	/	/
PPD PPD 3TC/ZDV+ABC	31.8/ Female/ 1.34	3/ 157/ 0.85/ 62.93	14APR2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	37.9/ Female/ 1.46	4/ 175/ 0.83/ 74.58	23APR2004/ 14JUN2004/ 24JUN2004	/	5/ 4	Hepatic/ Acute hepatitis
PPD PPD 3TC/ZDV+ABC	37.9/ Male/ 1.66	2/ 104/ 0.90/ 85.24	04MAY2004/ 04AUG2004/ 09AUG2004	/	4/ 4	Haematological/ Anaemia+P falciparum malaria
			04MAY2004/ 31MAY2005/ 06JUN2005	/	4/ 3	Haematological/ P falciparum malaria+Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	42.0/ Female/ 1.72	3/ 108/ 0.98/ 78.58	28MAY2004/ 17NOV2004/ 10DEC2004	/	5/ 3	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	29.7/ Female/ 1.41	3/ 128/ 1.10/ 52.02	18JUN2004/ 17JUL2004/ 10SEP2004	/	5/ 1	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	34.0/ Male/ 1.75	2/ 187/ 1.32/ 65.74	25JUN2004/ /	Yes/ PPD 2006	/	/
			25JUN2004/ 06DEC2005/	Yes/ PPD 2006	1/ 5	Tumours/ Other Solid tumour
PPD PPD 3TC/ZDV+TDF	44.4/ Male/ 1.57	3/ 6/ 0.75/ 88.34	05FEB2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	44.4/ Male/ 1.57	3/ 6/ 0.75/ 88.34	05FEB2003/ PPD 2003/	Yes/ PPD 2003	1/ 5	CNS/ Epilepsy, fits, convulsions
PP PPD 3TC/ZDV+TDF	37.7/ Female/ 1.72	4/ 33/ 1.05/ 71.65	02APR2003/ 11APR2003/ 16APR2003	/	2/ 4	Gastrointestinal / Haematemesis
PPD PPD 3TC/ZDV+TDF	34.8/ Female/ 1.63	3/ 3/ 0.54/ 118.05	03APR2003/ 01JUN2004/ 30JUL2004	/	4/ 3	Cardiovascular/ Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.37	4/ 4/ 0.69/ 72.62	08MAY2003/ 11JUN2003/ 16JUN2003	/	4/ 3	Lower respiratory tract/ Bronchospasm/Asthma
PPD PPD 3TC/ZDV+TDF	33.3/ Female/ 1.67	3/ 8/ 0.78/ 93.34	12MAY2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.52	2/ 91/ 0.61/ 115.07	10JUN2003/ /	Yes/ PPD 2004	/	/
			10JUN2003/ 27OCT2004/	Yes/ PPD 2004	1/ 5	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	36.4/ Male/ 1.87	2/ 71/ 3.45/ 31.12	13JUN2003/ /	Yes/ PPD 2004	/	/
			13JUN2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Renal/ Renal failure - chronic
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.78	3/ 33/ 0.91/ 99.13	26JUN2003/ /	Yes/ PPD 2004	/	/
			26JUN2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Cardiovascular/ Hypotension/shock/toxic shock

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.7/ Male/ 1.64	2/ 92/ 0.69/ 122.02	30JUN2003/ 28AUG2003/ 26FEB2004	/	5/ 3	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+TDF	40.3/ Female/ 1.68	3/ 51/ 1.11/ 67.62	09JUL2003/ /	Yes/ PPD 2003	/	/
			09JUL2003/ 19SEP2003/	Yes/ PPD 2003	1/ 5	Hepatic/ Hepatitis cause unknown
PP PPD 3TC/ZDV+TDF	42.3/ Male/ 1.53	4/ 94/ 0.88/ 81.45	14JUL2003/ /	Yes/ PPD 2003	/	/
			14JUL2003/ 13AUG2003/	Yes/ PPD 2003	1/ 5	Tumours/ Other Solid tumour
PPD PPD 3TC/ZDV+TDF	40.4/ Female/ 1.22	3/ 43/ 0.80/ 52.47	16JUL2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	46.3/ Female/ 1.74	4/ 64/ 1.37/ 60.19	16JUL2003/ 15SEP2003/	/	1/ 5	Cardiovascular/ Congestive cardiac failure
			16JUL2003/ 17APR2004/	/	1/ 5	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+TDF	39.1/ Male/ 1.55	3/ 24/ 0.60/ 117.71	18JUL2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	40.9/ Female/ 1.50	4/ 67/ 0.93/ 68.73	21JUL2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	37.1/ Female/ 1.82	4/ 30/ 0.66/ 134.06	31JUL2003/ 24AUG2004/	/	3/ 3	Musculoskeletal/ Bone fracture

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.5/ Female/ 1.57	3/ 29/ 0.74/ 96.74	06AUG2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	41.3/ Female/ 1.66	4/ 79/ 0.94/ 80.29	08AUG2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	45.0/ Female/ 1.25	3/ 25/ 0.56/ 68.84	12AUG2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	43.3/ Female/ 1.53	3/ 79/ 0.65/ 93.59	21AUG2003/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	43.3/ Female/ 1.53	3/ 79/ 0.65/ 93.59	21AUG2003/ 09DEC2004/	Yes/ PPD 2005	1/ 5	CNS/ Stroke, cerebrovascular accident+Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	40.2/ Female/ 1.94	3/ 18/ 0.87/ 113.38	25AUG2003/ /	Yes/ PPD 2004	/	/
			25AUG2003/ 04OCT2004/	Yes/ PPD 2004	1/ 5	CNS/ Parathesia, transient numbness, tingling+Diabetes - Type I+Metabolic disorder - other

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	34.9/ Female/ 1.33	4/ 37/ 0.56/ 90.52	02SEP2003/ 24SEP2003/ 03OCT2003	/	2/ 3	Gastrointestinal / Paralitic ileus, ileitis
PPD PPD 3TC/ZDV+TDF	38.3/ Female/ 1.48	3/ 25/ 0.85/ 66.90	04SEP2003/ /	Yes/ PPD 2003	/	/
			04SEP2003/ PPD 2003/	Yes/ PPD 2003	1/ 5	Gastrointestinal / Abdominal or epigastric pain
PPD PPD 3TC/ZDV+TDF	33.7/ Female/	4/ 16/ 0.59/ 122.12	04SEP2003/ /	Yes/ PPD 2004	/	/
			04SEP2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	28.7/ Female/ 1.27	4/ 96/ 1.17/ 40.52	09SEP2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	28.7/ Female/ 1.27	4/ 96/ 1.17/ 40.52	09SEP2003/ 23SEP2003/ 02OCT2003	Yes/ PPD 2003	4/ 3	Gastrointestinal / Indigestion, oesophageal reflux, gastritis, ulcerative oesophagitis
			09SEP2003/ PPD 2003/	Yes/ PPD 2003	1/ 5	Cardiovascular/ Chest pain
PPD PPD 3TC/ZDV+TDF	61.2/ Male/ 1.87	3/ 35/ 0.95/ 76.73	11SEP2003/ 18JAN2004/ 12AUG2004	/	4/ 4	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	37.5/ Male/ 1.67	3/ 52/ 1.25/ 65.07	26SEP2003/ 16OCT2003/ 03NOV2003	/	4/ 4	Gastrointestinal / Pancreatitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.47	4/ 92/ 1.67/ 36.47	22OCT2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	32.9/ Male/ 1.65	3/ 19/ 0.84/ 97.60	29OCT2003/ /	Yes/ PPD 2003	/	/
			29OCT2003/ 15NOV2003/	Yes/ PPD 2003	1/ 5	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	34.0/ Male/ 1.70	3/ 6/ 0.83/ 105.80	29OCT2003/ /	Yes/ PPD 2004	/	/
			29OCT2003/ 18DEC2003/	Yes/ PPD 2004	1/ 5	Cardiovascular/ Congestive cardiac failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	48.8/ Female/ 1.30	4/ 18/ 1.29/ 31.35	05NOV2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	36.4/ Male/ 1.78	4/ 3/ 0.62/ 158.13	07NOV2003/ /	Yes/ PPD 2005	/	/
PPD PPD 3TC/ZDV+TDF	38.6/ Male/ 1.57	4/ 28/ 0.85/ 83.01	06APR2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	35.0/ Male/ 1.72	3/ 8/ 1.05/ 78.65	05JUL2004/ 14MAR2005/ 25MAR2005	/	4/ 3	Systemic/ Hypersensitivity reaction
			05JUL2004/ 26MAY2005/ 02JUN2005	/	5/ 3	Systemic/ Hypersensitivity reaction

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	37.2/ Female/ 1.61	4/ 47/ 1.12/ 71.81	28JUL2004/ 08DEC2005/	/	2/ 4	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	27.9/ Female/ 1.53	3/ 5/ 1.29/ 52.14	06AUG2004/ /	Yes/ PPD 2006	/	/
PPD PPD 3TC/ZDV+TDF	42.8/ Female/ 1.60	3/ 7/ 0.67/ 88.72	25AUG2004/ /	Yes/ PPD 2004	/	/
			25AUG2004/ 15SEP2004/	Yes/ PPD 2004	1/ 5	Endocrine/ Diabetes - Type I
PPD PPD 3TC/ZDV+TDF	59.3/ Male/ 1.85	4/ 101/ 1.05/ 68.47	10FEB2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	59.3/ Male/ 1.85	4/ 101/ 1.05/ 68.47	10FEB2003/ 11JUL2003/	Yes/ PPD 2003	1/ 5	Gastrointestinal / Anorexia, loss of appetite+Depression
PPD PPD 3TC/ZDV+TDF	45.9/ Female/ 1.70	4/ 105/ 0.64/ 118.52	24FEB2003/ 23JAN2004/ 19APR2004	/	5/ 2	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	31.5/ Female/ 1.74	2/ 135/ 0.27/ 293.10	18MAR2003/ 08JUL2003/	/	4/ 4	Haematological/ Anaemia+Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	32.5/ Male/ 1.67	4/ 165/ 1.50/ 56.87	16JUN2003/ 13AUG2003/ 04NOV2003	/	4/ 3	Renal/ Renal failure - acute

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	40.3/ Female/ 1.30	3/ 199/ 0.57/ 82.33	17JUL2003/ /	Yes/ PPD 2004	/	/
			17JUL2003/ 22SEP2004/	Yes/ PPD 2004	1/ 5	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	31.2/ Female/ 1.60	3/ 174/ 0.57/ 123.93	18JUL2003/ 19SEP2003/ 21NOV2003	/	5/ 3	Cardiovascular/ Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	37.9/ Female/ 1.53	3/ 169/ 1.19/ 49.77	23JUL2003/ /	Yes/ PPD 2003	/	/
PP PPD 3TC/ZDV+TDF	31.0/ Female/ 1.40	3/ 33/ 1.06/ 52.04	28JUL2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	47.1/ Female/ 1.37	3/ 136/ 0.74/ 64.53	07AUG2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	28.2/ Female/ 1.46	3/ 123/ 0.68/ 86.27	02SEP2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	44.2/ Female/ 1.56	3/ 177/ 0.72/ 89.26	03SEP2003/ /	Yes/ PPD 2003	/	/
PP PPD 3TC/ZDV+TDF	33.8/ Female/ 1.51	3/ 100/ 1.28/ 48.81	21OCT2003/ 26JUN2005/ 05NOV2005	/	4/ 3	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	52.5/ Female/ 1.62	3/ 172/ 1.06/ 66.72	25MAY2004/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	52.5/ Female/ 1.62	3/ 172/ 1.06/ 66.72	25MAY2004/ 03MAY2005/	Yes/ PPD 2005	1/ 5	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	51.6/ Male/ 1.99	2/ 120/ 1.75/ 56.44	30AUG2004/ 03JUL2006/	/	1/ 5	Renal/ Renal failure - chronic
PPD PPD 3TC/ZDV+NVP	32.8/ Female/ 1.80	2/ 67/ 0.76/ 115.34	05JAN2004/ 28JAN2004/ 01MAR2004	/	5/ 4	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	47.6/ Male/ 1.62	4/ 37/ 0.68/ 105.90	20JAN2004/ 06MAR2004/ 13MAR2004	/	4/ 2	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	39.4/ Female/ 1.65	3/ 51/ 0.74/ 113.54	05FEB2004/ 27FEB2004/ 01MAR2004	/	5/ 2	Systemic/ Hypersensitivity reaction

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	31.8/ Female/ 1.48	4/ 21/ 0.62/ 106.36	05APR2004/ 23APR2004/ 19MAY2004	/	4/ 3	Gastrointestinal / Haematemesis+Peptic/gastric/duodenal ulcer
PPD PPD 3TC/ZDV+NVP	34.9/ Female/ 1.28	3/ 51/ 0.60/ 75.84	16APR2004/ 12MAY2004/ 11JUN2004	/	5/ 2	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	34.2/ Female/ 1.72	2/ 74/ 0.95/ 92.81	19APR2004/ /	Yes/ PPD 2005	/	/
			19APR2004/ PPD 2005/	Yes/ PPD 2005	1/ 5	Lower respiratory tract/ Pneumonia no organism identified, aspiration pneumonia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	45.7/ Male/ 1.74	3/ 91/ 1.27/ 65.00	20MAY2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	42.3/ Female/ 1.73	2/ 60/ 0.73/ 115.41	25MAY2004/ 02MAY2005/ 12OCT2005	/	4/ 4	Tumours/ Cervical carcinoma
PPD PPD 3TC/ZDV+NVP	34.0/ Male/ 1.77	3/ 70/ 1.06/ 89.32	29JUN2004/ /	Yes/ PPD 2004	/	/
			29JUN2004/ 17SEP2004/	Yes/ PPD 2004	1/ 5	CNS/ Headache+Acute altered conscious level
PPD PPD 3TC/ZDV+NVP	28.1/ Female/ 1.37	3/ 16/ 0.55/ 99.36	22JUL2004/ 27SEP2005/ 07OCT2005	/	5/ 4	Systemic/ Hypersensitivity reaction

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	47.4/ Male/ 1.90	2/ 80/ 1.38/ 70.06	29JUL2004/ 31JUL2004/ 04OCT2004	/	5/ 2	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	26.9/ Female/ 1.55	4/ 52/ 0.65/ 107.47	02AUG2004/ /	Yes/ PPD 2004	/	/
			02AUG2004/ 17AUG2004/	Yes/ PPD 2004	1/ 5	Haematological/ Anaemia+Thrombocytopenia+Neutropenia
PPD PPD 3TC/ZDV+NVP	31.9/ Male/ 1.72	3/ 67/ 0.86/ 112.00	19AUG2004/ 07OCT2004/ 18OCT2004	/	5/ 4	Systemic/ Hypersensitivity reaction
PP PPD 3TC/ZDV+NVP	44.9/ Female/ 1.83	2/ 99/ 1.07/ 83.23	01SEP2004/ 20SEP2004/ 06OCT2004	/	5/ 4	Systemic/ Hypersensitivity reaction

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	24.3/ Female/ 1.41	3/ 34/ 0.65/ 106.65	23SEP2004/ 29SEP2004/ 21OCT2004	/	4/ 2	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+ABC	37.6/ Male/ 1.50	4/ 10/ 1.66/ 41.65	05OCT2004/ 03NOV2004/ 17MAY2005	/	4/ 4	Cardiovascular/ Deep vein thrombosis
PP PPD 3TC/ZDV+ABC	42.6/ Female/ 1.81	3/ 193/ 0.87/ 97.50	05JAN2004/ 30APR2005/	/	2/ 4	Tumours/ Hepatocellular carcinoma
PPD PPD 3TC/ZDV+NVP	31.4/ Male/ 1.97	4/ 174/ 1.14/ 92.14	25MAR2004/ 22APR2004/ 11MAY2004	/	2/ 4	Hepatic/ Acute hepatitis
PP D PPD 3TC/ZDV+ABC	41.9/ Female/ 1.54	3/ 109/ 0.99/ 64.52	13MAY2004/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+ABC	41.9/ Female/ 1.54	3/ 109/ 0.99/ 64.52	13MAY2004/ 04NOV2005/	Yes/ PPD 2005	1/ 5	CNS/ Epilepsy, fits, convulsions
PP PPD 3TC/ZDV+NVP	34.5/ Female/ 1.61	3/ 118/ 0.95/ 75.10	24JUN2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	50.5/ Male/ 1.47	4/ 104/ 1.00/ 56.08	03AUG2004/ /	Yes/ PPD 2004	/	/
			03AUG2004/ 10OCT2004/	Yes/ PPD 2004	1/ 5	Gastrointestinal / Haematemesis
PP PPD 3TC/ZDV+NVP	40.3/ Male/ 1.44	3/ 121/ 1.34/ 48.70	24SEP2004/ /	Yes/ PPD 2004	/	/
			24SEP2004/ 25SEP2004/	Yes/ PPD 2004	1/ 5	Other/ Death, cause unknown

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	42.2/ Female/ 1.56	2/ 97/ 0.79/ 78.46	11JUN2003/ 10SEP2003/ 16SEP2003	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	42.2/ Male/ 1.63	4/ 14/ 0.68/ 117.91	11JUN2003/ 30JUL2004/ 02AUG2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	37.2/ Male/ 1.57	3/ 54/ 2.24/ 33.21	16JUN2003/ 09DEC2003/	/	4/ 3	Renal/ Renal failure - chronic
PP PPD 3TC/ZDV+TDF	53.3/ Male/ 1.49	2/ 74/ 0.72/ 86.00	19JUN2003/ 11SEP2003/ 04DEC2003	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	35.9/ Male/ 1.61	2/ 2/ 0.66/ 124.15	23JUN2003/ 09NOV2004/ 17NOV2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	33.9/ Male/ 1.61	4/ 18/ 0.88/ 88.36	24JUN2003/ /	Yes/ PPD 2003	/	/
			24JUN2003/ 22SEP2003/	Yes/ PPD 2003	1/ 5	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	39.2/ Male/ 1.80	4/ 1/ 0.96/ 93.38	24JUN2003/ /	Yes/ PPD 2004	/	/
PP PPD 3TC/ZDV+TDF	31.1/ Male/ 1.73	2/ 25/ 0.87/ 104.79	24JUN2003/ /	Yes/ PPD 2003	/	/
PP PPD 3TC/ZDV+TDF	24.2/ Female/ 1.39	4/ 79/ 0.57/ 94.20	02JUL2003/ 04NOV2003/ 27NOV2003	/	2/ 4	Lower respiratory tract/ Pulmonary embolism
			02JUL2003/ 28JUN2004/ 17NOV2004	/	4/ 3	Musculoskeletal/ Myopathy, muscle wasting

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	41.4/ Female/ 1.59	4/ 1/ 0.46/ 139.97	10JUL2003/ 01APR2005/	/	1/ 5	Renal/ Renal failure - acute
PP PPD 3TC/ZDV+TDF	30.8/ Female/ 1.53	3/ 6/ 0.79/ 81.45	11JUL2003/ 06NOV2003/ 11NOV2003	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	44.5/ Female/ 1.75	4/ 22/ 0.64/ 126.87	11JUL2003/ /	Yes/ PPD 2004	/	/
			11JUL2003/ 03OCT2003/ 17OCT2003	Yes/ PPD 2004	4/ 4	Haematological/ Anaemia
			11JUL2003/ 10SEP2004/	Yes/ PPD 2004	1/ 5	Hepatic/ Lactic acidosis+Peripheral neuropathy - sensory & motor

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	37.1/ Male/ 1.82	3/ 78/ 1.43/ 67.43	22JUL2003/ /	Yes/ PPD 2004	/	/
			22JUL2003/ 12FEB2004/	Yes/ PPD 2004	1/ 5	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	33.6/ Female/ 1.50	3/ 23/ 1.05/ 60.26	22JUL2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.49	4/ 33/ 0.74/ 90.52	28JUL2003/ /	Yes/ PPD 2005	/	/
			28JUL2003/ 25JAN2005/	Yes/ PPD 2005	2/ 3	Cardiovascular/ Deep vein thrombosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	37.0/ Female/ 1.51	2/ 79/ 0.94/ 69.33	29JUL2003/ 14MAY2005/ 23MAY2005	/	5/ 2	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+TDF	29.4/ Female/ 1.50	2/ 25/ 0.74/ 91.53	29JUL2003/ 25JAN2005/ 31JAN2005	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.42	3/ 23/ 0.84/ 63.20	15AUG2003/ /	Yes/ PPD 2003	/	/
			15AUG2003/ 12SEP2003/	Yes/ PPD 2003	1/ 5	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	30.9/ Female/ 1.52	3/ 4/ 0.55/ 128.15	03SEP2003/ 29OCT2003/ 26NOV2003	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	32.6/ Female/ 1.55	3/ 93/ 1.03/ 68.76	05SEP2003/ 24NOV2004/	/	4/ 3	Cardiovascular/ Cardiomyopathy
PP D. J 3TC/ZDV+TDF	43.3/ Female/ 1.65	3/ 48/ 1.05/ 67.85	05SEP2003/ 06SEP2003/ 02AUG2004	/	4/ 1	Gastrointestinal / Abdominal or epigastric pain
PP PPD 3TC/ZDV+TDF	35.3/ Male/ 1.74	3/ 9/ 0.92/ 86.99	10SEP2003/ /	Yes/ PPD 2004	/	/
			10SEP2003/ 11FEB2004/ 02APR2004	Yes/ PPD 2004	3/ 3	CNS/ Peripheral neuropathy - sensory only
PPD PPD 3TC/ZDV+TDF	32.8/ Male/ 1.80	3/ 3/ 0.96/ 103.66	10SEP2003/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.38	3/ 8/ 0.87/ 64.42	12SEP2003/ /	Yes/ PPD 2003	/	/
			12SEP2003/ 17NOV2003/	Yes/ PPD 2003	1/ 5	Haematological/ Neutropenia+Thrombocytopenia
PP PPD 3TC/ZDV+TDF	55.3/ Male/ 1.51	4/ 6/ 0.77/ 73.14	19SEP2003/ 12DEC2003/ 05MAR2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	33.9/ Male/ 1.91	3/ 12/ 0.85/ 127.74	22SEP2003/ 18NOV2003/ 24NOV2003	/	5/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	55.6/ Male/ 1.86	4/ 3/ 0.94/ 86.82	22SEP2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	32.3/ Male/ 1.59	4/ 80/ 0.74/ 100.91	26SEP2003/ /	Yes/ PPD 2004	/	/
			26SEP2003/ 03NOV2003/ 19DEC2003	Yes/ PPD 2004	4/ 2	Haematological/ Anaemia
			26SEP2003/ 30JUN2004/	Yes/ PPD 2004	4/ 3	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+TDF	34.7/ Female/ 1.62	4/ 89/ 0.86/ 83.57	29SEP2003/ 18DEC2003/ 15MAR2004	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	31.7/ Male/ 1.55	3/ 7/ 0.71/ 107.46	01OCT2003/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.1/ Male/ 1.34	4/ 12/ 1.01/ 54.68	06OCT2003/ 10DEC2003/ 22MAR2004	/	4/ 3	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.7/ Female/ 1.45	4/ 40/ 0.49/ 121.78	09OCT2003/ /	Yes/ PPD 2004	/	/
			09OCT2003/ 30DEC2003/ 16JAN2004	Yes/ PPD 2004	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	31.6/ Female/ 1.36	4/ 75/ 0.93/ 51.98	10OCT2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.6/ Female/ 1.36	4/ 75/ 0.93/ 51.98	10OCT2003/ 03NOV2003/	Yes/ PPD 2003	1/ 5	Renal/ Renal failure - acute+Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+TDF	27.2/ Female/ 1.47	4/ 5/ 0.70/ 85.17	13OCT2003/ 03FEB2004/ 26MAR2004	/	4/ 4	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	38.5/ Female/ 1.49	4/ 94/ 1.03/ 56.88	15OCT2003/ 31MAR2004/ 27MAY2004	/	5/ 3	Haematological/ Anaemia
			15OCT2003/ 09FEB2005/ 08NOV2005	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	34.4/ Male/ 1.48	4/ 3/ 0.83/ 80.10	20OCT2003/ /	Yes/ PPD 2004	/	/
			20OCT2003/ 15DEC2003/ 08JAN2004	Yes/ PPD 2004	2/ 4	Haematological/ Neutropenia+Leucopenia
			20OCT2003/ 27JAN2004/	Yes/ PPD 2004	1/ 5	Haematological/ Anaemia+Thrombocytopenia
PPD PPD 3TC/ZDV+TDF	31.1/ Male/ 1.68	3/ 9/ 0.85/ 94.35	21OCT2003/ 23AUG2005/ 15NOV2005	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	42.8/ Female/ 1.90	4/ 33/ 0.93/ 103.43	22OCT2003/ 02FEB2004/ 30JUN2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	52.6/ Male/ 1.82	3/ 75/ 0.63/ 134.38	22OCT2003/ 14JAN2004/ 26JAN2004	/	4/ 4	Biochemical/ Hyperglycaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	52.6/ Male/ 1.82	3/ 75/ 0.63/ 134.38	22OCT2003/ 14JAN2004/ 07APR2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	40.9/ Female/ 1.34	3/ 16/ 1.06/ 44.12	23OCT2003/ /	Yes/ PPD 2005	/	/
			23OCT2003/ 01MAR2005/	Yes/ PPD 2005	1/ 5	CNS/ Hemiparesis
PPD PPD 3TC/ZDV+TDF	37.9/ Female/ 1.74	3/ 18/ 0.71/ 123.06	23OCT2003/ /	Yes/ PPD 2003	/	/
PPD PPD 3TC/ZDV+TDF	37.8/ Male/ 1.85	3/ 28/ 1.11/ 85.99	23OCT2003/ 15JAN2004/ 28JAN2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	40.1/ Male/ 1.50	3/ 2/ 1.00/ 67.21	27OCT2003/ /	Yes/ PPD 2004	/	/
			27OCT2003/ 01JAN2004/ 06JAN2004	Yes/ PPD 2004	2/ 4	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.7/ Male/ 1.76	3/ 3/ 0.76/ 122.77	27OCT2003/ 30JAN2004/ 15MAR2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	54.2/ Male/ 1.94	4/ 24/ 1.23/ 75.30	28OCT2003/ 07NOV2003/	/	3/ 3	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	54.2/ Male/ 1.75	2/ 32/ 0.97/ 75.24	03NOV2003/ 15SEP2005/	/	1/ 5	Renal/ Renal failure - acute

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	32.3/ Female/ 1.59	3/ 69/ 0.54/ 142.45	06NOV2003/ 28DEC2004/ 06JAN2005	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	33.9/ Male/ 1.54	2/ 10/ 1.07/ 71.21	10NOV2003/ 13SEP2004/ 11OCT2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	37.7/ Male/ 1.55	3/ 15/ 1.19/ 59.24	13NOV2003/ 06FEB2004/ 15OCT2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	39.8/ Female/ 1.76	3/ 47/ 0.81/ 110.57	14NOV2003/ 06MAR2004/ 02APR2004	/	2/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	40.6/ Female/ 1.59	3/ 4/ 0.72/ 95.05	14NOV2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	40.6/ Female/ 1.59	3/ 4/ 0.72/ 95.05	14NOV2003/ 20MAY2004/	Yes/ PPD 2004	1/ 5	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+TDF	36.0/ Male/ 1.70	3/ 43/ 0.78/ 111.68	14NOV2003/ /	Yes/ PPD 2003	/	/
			14NOV2003/ 29DEC2003/	Yes/ PPD 2003	1/ 5	Renal/ Renal failure - acute Haematological/ Pancytopenia, bone marrow depression
PP PPD 3TC/ZDV+TDF	37.7/ Male/ 1.81	3/ 32/ 1.38/ 66.26	17NOV2003/ 15JAN2004/ 18FEB2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.0/ Female/ 1.34	3/ 20/ 0.92/ 54.33	18NOV2003/ /	Yes/ PPD 2004	/	/
			18NOV2003/ 01JUN2004/ 10JUN2004	Yes/ PPD 2004	4/ 4	Haematological/ Anaemia
			18NOV2003/ 16NOV2004/	Yes/ PPD 2004	1/ 5	Hepatic/ Hepatic failure
PPD PPD 3TC/ZDV+TDF	44.2/ Male/ 1.52	3/ 31/ 0.88/ 72.10	18NOV2003/ 15JAN2004/ 01JUN2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	35.4/ Female/ 1.38	3/ 12/ 0.81/ 60.50	19NOV2003/ /	Yes/ PPD 2004	/	/
			19NOV2003/ 10MAY2004/	Yes/ PPD 2004	1/ 5	Hepatic/ Hepatic failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	33.0/ Male/ 1.62	4/ 43/ 0.96/ 86.72	24NOV2003/ /	Yes/ PPD 2005	/	/
			24NOV2003/ 10MAR2005/	Yes/ PPD 2005	1/ 5	Hepatic/ Cirrhosis
PPD PPD 3TC/ZDV+TDF	37.5/ Female/ 1.62	3/ 10/ 0.67/ 105.91	25NOV2003/ 12AUG2005/ 12OCT2005	/	4/ 4	Hepatic/ Acute hepatitis
PP PPD 3TC/ZDV+TDF	49.4/ Male/ 1.63	2/ 16/ 0.79/ 80.26	28NOV2003/ /	Yes/ PPD 2004	/	/
			28NOV2003/ 03FEB2004/	Yes/ PPD 2004	2/ 4	Haematological/ Pancytopenia, bone marrow depression

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	42.2/ Male/ 1.76	4/ 58/ 2.09/ 42.92	01DEC2003/ 17MAY2005/	/	3/ 3	Endocrine/ Diabetes - Type II
PPD PPD 3TC/ZDV+TDF	34.6/ Male/ 1.67	4/ 4/ 1.03/ 84.07	03DEC2003/ 12AUG2004/ 03NOV2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	34.2/ Female/ 1.40	3/ 6/ 0.98/ 53.65	17DEC2003/ 12FEB2004/ 10MAR2004	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.63	2/ 1/ 1.16/ 68.05	17DEC2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	50.0/ Male/ 1.67	2/ 95/ 0.95/ 76.35	19DEC2003/ 12MAR2004/ 04JUN2004	/	5/ 4	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.3/ Female/ 1.49	4/ 85/ 1.00/ 61.76	29DEC2003/ 02FEB2004/ 05FEB2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	41.5/ Female/ 1.35	3/ 48/ 0.71/ 70.10	02JAN2004/ /	Yes/ PPD 2004	/	/
			02JAN2004/ 10JAN2004/ 13JAN2004	Yes/ PPD 2004	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	35.3/ Female/ 1.36	3/ 24/ 0.87/ 59.43	06JAN2004/ 26APR2004/ 26MAY2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	37.1/ Male/ 1.92	2/ 41/ 0.93/ 116.47	12JAN2004/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	30.9/ Male/ 1.72	4/ 47/ 1.11/ 77.50	26JAN2004/ 21MAR2005/ 16MAY2005	/	2/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.62	3/ 97/ 0.90/ 77.91	28JAN2004/ 18JUN2004/ 14JUL2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	43.2/ Male/ 1.72	3/ 2/ 1.01/ 80.60	29JAN2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	25.4/ Female/ 1.43	3/ 24/ 0.81/ 74.18	02FEB2004/ 12FEB2004/ 01MAR2004	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	38.6/ Female/ 1.30	3/ 10/ 0.74/ 59.44	02FEB2004/ 29MAR2004/ 26APR2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	28.8/ Female/ 1.29	4/ 36/ 0.85/ 58.33	03FEB2004/ 03NOV2005/ 08NOV2005	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	56.1/ Female/ 1.53	3/ 30/ 0.88/ 56.42	05FEB2004/ 21JUN2004/ 14SEP2006	/	4/ 3	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+TDF	33.7/ Male/ 1.55	4/ 1/ 1.00/ 72.27	09FEB2004/ 30APR2004/ 28MAY2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	34.3/ Male/ 1.58	4/ 56/ 1.02/ 72.84	17FEB2004/ 02APR2005/ 30JUN2007	/	3/ 3	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	37.6/ Female/ 1.64	3/ 27/ 0.72/ 105.73	08MAR2004/ 26JUL2004/ 27JUL2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	38.1/ Female/ 1.51	4/ 17/ 1.06/ 54.15	18MAR2004/ /	Yes/ PPD 2004	/	/
			18MAR2004/ PPD 2004/	Yes/ PPD 2004	1/ 5	Haematological/ Anaemia+Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+TDF	28.6/ Female/ 1.84	4/ 156/ 0.63/ 151.46	08JUL2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	58.7/ Male/ 1.64	3/ 128/ 0.86/ 69.78	14JUL2003/ 08DEC2003/ 30JAN2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	31.9/ Female/ 1.50	3/ 107/ 1.03/ 64.24	17JUL2003/ 26JAN2005/ 30OCT2008	/	10/ 2	Congenital abnormality/ Club foot

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	37.2/ Male/ 1.78	4/ 118/ 0.84/ 112.10	22JUL2003/ /	Yes/ PPD 2005	/	/
PPD PPD 3TC/ZDV+TDF	42.1/ Male/ 1.89	2/ 153/ 1.01/ 108.34	24JUL2003/ 15MAR2004/ 09DEC2004	/	4/ 3	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	49.3/ Male/ 1.73	2/ 191/ 1.27/ 60.50	18AUG2003/ 10SEP2003/ 29APR2004	/	4/ 3	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+TDF	45.2/ Female/ 1.72	3/ 107/ 0.67/ 116.65	08SEP2003/ 15SEP2004/	/	3/ 3	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	57.3/ Female/ 1.71	2/ 100/ 0.80/ 81.69	08OCT2003/ 31DEC2003/	/	5/ 4	Haematological/ Anaemia+Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	41.0/ Female/ 1.52	2/ 137/ 0.98/ 63.48	14OCT2003/ 06JAN2004/ 03FEB2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	34.8/ Female/ 1.52	4/ 110/ 0.78/ 85.30	20OCT2003/ 12JAN2004/ 05APR2004	/	5/ 3	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.5/ Female/ 1.91	3/ 156/ 1.04/ 94.44	24OCT2003/ 02JAN2005/ 28MAR2006	/	4/ 4	Renal/ Renal failure - acute
PP PPD 3TC/ZDV+TDF	49.4/ Female/ 1.54	3/ 111/ 0.72/ 82.80	04NOV2003/ 11MAY2004/ 18MAY2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	39.4/ Female/ 1.38	3/ 109/ 0.89/ 55.11	18NOV2003/ 03DEC2003/ 05DEC2003	/	4/ 3	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	39.4/ Female/ 1.38	3/ 109/ 0.89/ 55.11	18NOV2003/ 27JUL2004/	/	3/ 3	CNS/ Peripheral neuropathy - sensory & motor
PP PPD 3TC/ZDV+TDF	33.6/ Female/ 1.67	4/ 110/ 0.75/ 102.97	18NOV2003/ 21FEB2005/	/	10/ 3	Congenital abnormality/ Hydrocephalus, congenital intersusception bowel
PPD PPD 3TC/ZDV+TDF	60.8/ Male/ 1.78	3/ 144/ 1.21/ 59.67	28NOV2003/ 24APR2004/ 04MAY2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	49.8/ Female/ 1.82	2/ 121/ 0.80/ 106.80	01DEC2003/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	40.2/ Male/ 1.58	2/ 187/ 1.01/ 73.83	21JAN2004/ 22JUL2004/ 29SEP2004	/	4/ 4	Haematological/ Anaemia
PP PPD 3TC/ZDV+TDF	31.9/ Male/ 1.69	4/ 110/ 1.27/ 74.82	29JAN2004/ 26NOV2004/ 21APR2005	/	4/ 4	Gastrointestinal / Pancreatitis
PPD PPD 3TC/ZDV+TDF	28.5/ Female/ 1.48	3/ 182/ 0.76/ 80.32	30JAN2004/ 04MAY2004/ 13MAY2004	/	4/ 3	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	37.7/ Female/ 1.47	3/ 177/ 0.89/ 68.22	02FEB2004/ 27APR2005/	/	5/ 3	Cardiovascular/ Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	37.9/ Female/ 1.77	4/ 168/ 0.87/ 104.42	10FEB2004/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	37.9/ Female/ 1.77	4/ 168/ 0.87/ 104.42	10FEB2004/ 13JAN2005/	Yes/ PPD 2005	1/ 5	Hepatic/ Hepatic failure
PP PPD 3TC/ZDV+TDF	35.2/ Female/ 1.47	2/ 152/ 1.03/ 60.87	26FEB2004/ 20OCT2004/ 22OCT2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	34.7/ Male/ 1.63	3/ 161/ 1.01/ 82.37	02MAR2004/ 27APR2004/ 15NOV2004	/	4/ 3	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+NVP	45.8/ Female/ 1.42	3/ 15/ 1.59/ 29.97	19MAR2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	44.4/ Female/ 1.66	3/ 96/ 0.63/ 104.98	01APR2004/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	44.4/ Female/ 1.66	3/ 96/ 0.63/ 104.98	01APR2004/ 16SEP2004/	Yes/ PPD 2005	1/ 5	Tumours/ Cervical carcinoma
					2/ 4	Cardiovascular/ Deep vein thrombosis
			01APR2004/ 22OCT2004/ 27OCT2004	Yes/ PPD 2005	4/ 3	Haematological/ Anaemia
			01APR2004/ 06JAN2005/ 10JAN2005	Yes/ PPD 2005	4/ 4	Haematological/ Anaemia
			01APR2004/ 10FEB2005/ 14FEB2005	Yes/ PPD 2005	2/ 4	Haematological/ Anaemia
			01APR2004/ 03MAR2005/	Yes/ PPD 2005	5/ 4	Hepatic/ Jaundice
			01APR2004/ 08MAR2005/	Yes/ PPD 2005	1/ 5	Hepatic/ Hepatic failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	37.5/ Female/ 1.69	3/ 61/ 0.84/ 85.64	06APR2004/ 29JUN2004/ 27JUL2004	/	5/ 3	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	48.3/ Female/ 1.37	4/ 22/ 0.87/ 52.40	13APR2004/ 11MAY2004/ 28SEP2004	/	5/ 3	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	36.6/ Male/ 1.83	2/ 69/ 1.01/ 98.96	16APR2004/ 17APR2004/ 14MAY2004	/	5/ 3	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	26.3/ Female/ 1.48	3/ 67/ 0.85/ 74.13	16APR2004/ 14MAY2004/ 26NOV2004	/	5/ 3	Cardiovascular/ Deep vein thrombosis
			16APR2004/ 07OCT2004/ 26NOV2004	/	4/ 3	Musculoskeletal/ Pyomyositis - infection

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	36.1/ Female/ 1.74	3/ 16/ 0.89/ 99.06	22APR2004/ 08SEP2005/ 23FEB2006	/	4/ 4	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+NVP	37.2/ Male/ 1.68	4/ 43/ 0.95/ 84.39	27APR2004/ 28MAY2004/ 27JUL2004	/	2/ 4	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	32.3/ Female/ 1.75	3/ 72/ 0.60/ 143.17	27APR2004/ 10MAY2004/ 24MAY2004	/	5/ 2	Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	43.1/ Male/ 1.62	3/ 16/ 0.88/ 87.45	27APR2004/ /	Yes/ PPD 2004	/	/
			27APR2004/ 27MAY2004/	Yes/ PPD 2004	1/ 5	Hepatic/ Hepatic failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	28.6/ Female/ 1.54	3/ 7/ 0.75/ 81.98	30APR2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	31.7/ Female/ 1.53	3/ 12/ 0.95/ 70.00	06MAY2004/ 14MAY2004/ 20MAY2004	/	5/ 3	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	25.6/ Female/ 1.39	3/ 30/ 0.88/ 60.76	06MAY2004/ /	Yes/ PPD 2005	/	/
			06MAY2004/ 08JUN2004/ 29JUL2004	Yes/ PPD 2005	5/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	32.3/ Male/ 1.59	3/ 23/ 0.93/ 88.09	07MAY2004/ 30JUL2004/ 01AUG2004	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	28.5/ Female/ 1.66	3/ 80/ 0.70/ 115.48	17MAY2004/ 27JUL2004/ 31AUG2004	/	5/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	46.0/ Female/ 1.94	3/ 59/ 0.81/ 107.60	31MAY2004/ 13APR2005/ 21JUL2005	/	4/ 3	Other/ Hysterectomy
PPD PPD 3TC/ZDV+NVP	36.6/ Male/ 1.78	3/ 91/ 0.75/ 110.02	01JUN2004/ 30JUN2004/ 02JUL2004	/	4/ 3	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+NVP	26.8/ Female/ 1.21	4/ 22/ 0.66/ 64.35	03JUN2004/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+NVP	50.2/ Female/ 1.52	3/ 87/ 0.83/ 62.72	04JUN2004/ 03JUN2005/ 10FEB2006	/	4/ 3	Cardiovascular/ Deep vein thrombosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	34.6/ Female/ 1.42	3/ 70/ 0.52/ 108.51	08JUN2004/ 06JUL2004/ 31AUG2004	/	5/ 4	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	31.8/ Male/ 1.86	3/ 27/ 0.81/ 122.19	10JUN2004/ /	Yes/ PPD 2005	/	/
			10JUN2004/ 17NOV2004/ 22NOV2004	Yes/ PPD 2005	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	34.8/ Female/ 1.50	3/ 64/ 0.51/ 125.57	10JUN2004/ 12MAY2005/ 16MAY2005	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	33.1/ Female/ 1.51	3/ 69/ 0.74/ 94.11	11JUN2004/ 09JUL2004/ 19JUL2004	/	5/ 3	Skin/ Rash, maculopapular

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	28.9/ Male/ 1.67	3/ 16/ 0.90/ 99.42	11JUN2004/ 23MAY2005/ 05AUG2005	/	5/ 3	Systemic/ Hypersensitivity reaction
PP PPD 3TC/ZDV+NVP	37.7/ Male/ 1.75	3/ 7/ 0.74/ 116.23	14JUN2004/ 31OCT2005/ 05JUN2008	/	3/ 3	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+NVP	28.7/ Male/ 1.43	3/ 51/ 1.04/ 64.17	30JUN2004/ 18JUL2004/ 15DEC2004	/	4/ 3	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+NVP	45.6/ Female/ 1.66	3/ 194/ 0.83/ 79.08	19MAR2004/ /	Yes/ PPD 2005	/	/
			19MAR2004/ 18AUG2005/	Yes/ PPD 2005	1/ 5	CNS/ Stroke, cerebrovascular accident

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	40.0/ Female/ 1.58	4/ 109/ 0.75/ 94.23	01APR2004/ 29APR2004/ 19AUG2004	/	5/ 3	Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	40.9/ Male/ 1.88	2/ 178/ 1.02/ 96.51	15APR2004/ 05MAY2004/ 09MAY2004	/	5/ 4	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	29.2/ Female/ 1.48	3/ 137/ 0.92/ 65.74	27APR2004/ 17MAR2005/ 29MAR2005	/	2/ 3	Gastrointestinal / Vomiting
			27APR2004/ 17MAR2005/ 13APR2005	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+NVP	53.5/ Female/ 1.41	4/ 123/ 0.74/ 67.55	04MAY2004/ 07MAR2006/ 12JUN2006	/	5/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	44.4/ Female/ 1.53	3/ 121/ 0.86/ 63.99	07MAY2004/ 28MAY2004/ 04JUN2004	/	5/ 2	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	28.0/ Female/ 1.72	2/ 174/ 0.69/ 122.83	11MAY2004/ 12JUN2004/ 06JUL2004	/	5/ 2	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	46.5/ Female/ 1.81	3/ 186/ 0.71/ 110.33	13MAY2004/ 25MAY2004/ 01JUN2004	/	5/ 2	Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	22.8/ Female/ 1.43	2/ 130/ 0.78/ 77.73	31MAY2004/ 23AUG2004/ 25AUG2004	/	4/ 4	Haematological/ Pancytopenia, bone marrow depression

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+NVP	34.3/ Female/ 1.64	3/ 156/ 0.78/ 89.91	01JUN2004/ 09JUN2004/ 27AUG2004	/	5/ 3	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	47.9/ Female/ 1.69	3/ 159/ 0.98/ 72.60	08JUN2004/ 14JUN2004/ 06JUL2004	/	5/ 2	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+TDF	36.9/ Male/ 1.58	4/ 9/ 1.00/ 76.45	27MAY2003/ /	Yes/ PPD 2003	/	/
			27MAY2003/ 10JUN2003/	Yes/ PPD 2003	1/ 5	Systemic/ Stevens-Johnson Syndrome
PPD PPD 3TC/ZDV+TDF	34.0/ Female/ 1.75	4/ 24/ 0.80/ 109.15	05JUN2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	28.9/ Female/ 1.48	2/ 27/ 0.50/ 128.10	01JUL2003/ 10MAY2005/ 31MAY2005	/	4/ 4	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.58	4/ 31/ 0.69/ 90.78	08JUL2003/ /	Yes/ PPD 2003	/	/
			08JUL2003/ 16OCT2003/	Yes/ PPD 2003	1/ 5	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	45.2/ Female/ 1.43	4/ 3/ 0.74/ 73.09	17JUL2003/ 24MAR2005/ 14APR2005	/	5/ 3	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	31.0/ Female/ 1.37	4/ 22/ 0.92/ 57.14	19AUG2003/ /	Yes/ PPD 2003	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	30.0/ Female/ 1.49	3/ 16/ 0.41/ 144.95	11SEP2003/ /	Yes/ PPD 2003	/	/
			11SEP2003/ PPD 2003/	Yes/ PPD 2003	1/ 5	Lower respiratory tract/ Pulmonary embolism
PP PPD 3TC/ZDV+TDF	35.1/ Female/ 1.41	3/ 4/ 0.69/ 84.63	30SEP2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	31.5/ Female/ 1.40	4/ 6/ 0.61/ 87.92	30SEP2003/ 23NOV2004/ 07DEC2004	/	4/ 4	Haematological/ Anaemia
			30SEP2003/ 01SEP2005/ 08NOV2005	/	2/ 4	Hepatic/ Lactic acidosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	25.0/ Female/ 1.51	4/ 45/ 0.78/ 86.71	02OCT2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	34.1/ Male/ 1.50	4/ 3/ 0.97/ 69.15	07OCT2003/ 25NOV2004/ 25DEC2004	/	4/ 4	Haematological/ Anaemia
PPD PPD 3TC/ZDV+TDF	24.8/ Female/ 1.53	4/ 21/ 0.23/ 288.82	07OCT2003/ /	Yes/ PPD 2004	/	/
			07OCT2003/ 27SEP2004/	Yes/ PPD 2004	1/ 5	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	35.7/ Female/ 1.82	3/ 18/ 0.42/ 222.15	28OCT2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	35.7/ Female/ 1.82	3/ 18/ 0.42/ 222.15	28OCT2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Other/ Death, cause unknown
PPD PPD 3TC/ZDV+TDF	26.3/ Female/ 1.66	4/ 20/ 0.56/ 148.10	28OCT2003/ 02FEB2004/	/	2/ 4	CNS/ Epilepsy, fits, convulsions+Acute focal neurological event without fever
PPD PPD 3TC/ZDV+TDF	26.0/ Female/ 1.44	4/ 25/ 0.74/ 88.84	30OCT2003/ 17MAR2005/ 14APR2005	/	4/ 4	Other/ Non-fatal trauma
PPD PPD 3TC/ZDV+TDF	31.7/ Female/ 1.59	3/ 89/ 0.10/	04NOV2003/ 14MAY2005/ 17MAY2005	/	5/ 2	Other/ Non-fatal trauma

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	52.8/ Male/ 1.61	3/ 19/ 0.52/ 123.63	04NOV2003/ /	Yes/ PPD 2005	/	/
			04NOV2003/ PPD 2005/	Yes/ PPD 2005	1/ 5	Other/ Death, cause unknown
PPD PPD 3TC/ZDV+TDF	44.1/ Female/ 1.66	4/ 2/ 0.71/ 106.53	06NOV2003/ /	Yes/ PPD 2005	/	/
			06NOV2003/ 09DEC2004/	Yes/ PPD 2005	1/ 5	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.58	4/ 10/ 0.68/ 92.35	06NOV2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	28.9/ Female/ 1.38	3/ 16/ 0.30/ 187.39	11NOV2003/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	31.4/ Female/ 1.46	4/ 6/ 0.38/ 164.75	13NOV2003/ /	Yes/ PPD 2004	/	/
			13NOV2003/ 30DEC2003/ 10FEB2004	Yes/ PPD 2004	5/ 3	Gastrointestinal / Gall stones, cholecystitis, cholelithiasis+Hepatitis B
PPD PPD 3TC/ZDV+TDF	34.3/ Male/ 1.68	3/ 3/ 0.90/ 96.44	20NOV2003/ /	Yes/ PPD 2004	/	/
PPD PPD 3TC/ZDV+TDF	29.0/ Female/ 1.59	3/ 17/ 0.42/ 186.61	20NOV2003/ 14JUL2005/ 06SEP2005	/	4/ 4	Haematological/ Anaemia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	41.5/ Female/ 1.63	4/ 11/ 0.51/ 134.12	04DEC2003/ /	Yes/ PPD 2005	/	/
			04DEC2003/ 16JUN2005/	Yes/ PPD 2005	1/ 5	Specific Infections/ P falciparum malaria
PP PPD 3TC/ZDV+TDF	42.4/ Female/ 1.41	4/ 34/ 0.98/ 52.73	09DEC2003/ 13MAY2004/ 27JAN2005	/	5/ 3	Tumours/ Cervical carcinoma
PPD PPD 3TC/ZDV+TDF	32.0/ Female/ 1.83	4/ 94/ 0.54/ 164.71	20JAN2004/ /	Yes/ PPD 2005	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	32.0/ Female/ 1.83	4/ 94/ 0.54/ 164.71	20JAN2004/ PPD 2005/	Yes/ PPD 2005	1/ 5	CNS/ Cranial nerve lesion+Jaundice+ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	34.2/ Female/ 1.70	4/ 23/ 0.71/ 117.51	22JAN2004/ 07MAR2005/ 14APR2005	/	5/ 4	Other/ Non-fatal trauma
PP PPD 3TC/ZDV+TDF	43.2/ Female/ 1.43	4/ 30/ 0.53/ 103.15	29JAN2004/ 29DEC2005/ 24JAN2006	/	2/ 3	Hepatic/ Lactic acidosis
PP PPD 3TC/ZDV+TDF	31.6/ Female/ 1.67	3/ 37/ 0.81/ 102.33	03FEB2004/ 04FEB2004/ 30MAR2004	/	5/ 3	CNS/ Epilepsy, fits, convulsions

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	37.6/ Female/ 1.59	3/ 69/ 0.68/ 97.42	12FEB2004/ /	Yes/ PPD 2004	/	/
			12FEB2004/ PPD 2004/	Yes/ PPD 2004	1/ 5	Other/ Death, cause unknown
PPD PPD 3TC/ZDV+TDF	44.0/ Male/ 1.85	3/ 101/ 1.35/ 69.27	24JUN2003/ 19JAN2004/ 19FEB2004	/	4/ 3	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	43.0/ Male/ 2.00	3/ 150/ 0.89/ 134.93	01JUL2003/ /	Yes/ PPD 2003	/	/
			01JUL2003/ PPD 2003/	Yes/ PPD 2003	1/ 5	Non HIV related deaths/ Traumatic
PP PPD 3TC/ZDV+TDF	26.1/ Female/ 1.53	3/ 123/ 0.60/ 117.24	29JUL2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.3
Listing of all Deaths and SAEs up to 96 Weeks

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)/ eGFR	Date randomised/ SAE start date/ Resolution date	Died<= STI or 96 weeks/ Date of death	Most serious ICH criteria / Grade of SAE	SAE category/ SAE
PPD PPD 3TC/ZDV+TDF	26.1/ Female/ 1.53	3/ 123/ 0.60/ 117.24	29JUL2003/ PPD 2004/	Yes/ PPD 2004	1/ 5	Non HIV related deaths/ Obstetric
PPD PPD 3TC/ZDV+TDF	30.6/ Female/ 1.63	3/ 123/ 3.60/ 20.38	02OCT2003/ /	Yes/ PPD 2005	/	/
			02OCT2003/ 21JUN2005/	Yes/ PPD 2005	1/ 5	Renal/ Renal failure - chronic+Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	38.0/ Male/ 1.59	4/ 184/ 0.78/ 94.32	30OCT2003/ /	Yes/ PPD 2004	/	/

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	45.3/ Male/ 1.67	4/ 87/ 1.07	70.28	06FEB2003/ 06MAR2003/ 29APR2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.0/ Male/ 1.52	3/ 52/ 1.01	71.31	18FEB2003/ 27OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.2/ Male/ 1.61	4/ 44/ 1.03	76.56	18FEB2003/ 18MAR2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.6/ Female/ 1.52	2/ 56/ 1.06	65.36	25FEB2003/ 25MAR2003/ 06MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.0/ Male/ 1.75	3/ 86/ 1.40	63.59	27FEB2003/ 27MAR2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	57.2/ Male/ 1.72	3/ 32/ 1.10	62.29	06MAR2003/ 30JUL2003/ 06MAR2003/ 01AUG2003/	Cardiovascular/ Congestive cardiac failure Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	45.7/ Male/ 1.56	4/ 82/ 1.04	65.32	06MAR2003/ 03APR2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.3/ Male/ 1.76	4/ 9/ 1.21	70.40	13MAR2003/ 05JUN2003/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms
				13MAR2003/ 17JUN2003/	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	46.1/ Male/ 1.64	3/ 91/ 1.29	59.79	20MAR2003/ 17APR2003/ 15MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	26.8/ Female/ 1.50	3/ 3/ 0.96	71.93	25MAR2003/ 21MAY2003/ 29MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	50.8/ Female/ 1.66	3/ 74/ 1.00	65.38	10APR2003/ 08MAY2003/ 21MAY2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	51.2/ Female/ 1.50	4/ 67/ 0.94	54.54	10APR2003/ 07MAY2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.33	3/ 55/ 1.01	54.74	10APR2003/ 15APR2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	34.2/ Male/ 1.67	4/ 77/ 1.16	69.52	15APR2003/ 13MAY2003/ 02JUN2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	25.1/ Male/ 1.55	3/ 36/ 0.63	128.7 5	15APR2003/ 13MAY2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	49.8/ Male/ 1.58	3/ 72/ 0.81	70.95	17APR2003/ 23DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	30.8/ Female/ 1.48	3/ 1/ 0.93	66.52	24APR2003/ 22MAY2003/ 27MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.4/ Male/ 1.83	3/ 16/ 1.15	89.40	29APR2003/ 30AUG2003/	Musculoskeletal/ Myalgia, pain in muscles

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	41.9/ Male/ 1.74	3/ 99/ 1.18	70.82	06MAY2003/ 20OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	51.0/ Female/ 1.45	2/ 73/ 0.90	55.58	08MAY2003/ 05JUN2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.4/ Female/ 1.46	4/ 94/ 1.56	39.43	13MAY2003/ 10JUN2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	42.9/ Male/ 1.36	4/ 1/ 1.19	47.24	13MAY2003/ 10JUN2003/ 13MAY2003/ 20MAY2003/ 10JUN2003	Biochemical/ Raised liver enzymes Lower respiratory tract/ Bronchospasm/Asthma
PP PPD 3TC/ZDV+TDF	31.4/ Female/ 1.33	4/ 27/ 1.14	46.99	15MAY2003/ 02JUN2003/ 17JUN2003	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.4/ Female/ 1.33	4/ 27/ 1.14	46.99	15MAY2003/ 17JUN2003/	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+TDF	35.6/ Female/ 1.73	3/ 36/ 0.87	90.28	15MAY2003/ 12JUN2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.51	3/ 94/ 0.68	95.20	13JUN2003/ 10JUL2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	27.0/ Female/ 1.67	3/ 98/ 0.81	96.33	17JUN2003/ 09SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.5/ Female/ 1.53	3/ 78/ 1.22	46.85	18JUN2003/ 16JUL2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.2/ Male/ 1.95	2/ 15/ 0.95	110.8 8	25JUN2003/ 05APR2005/	Lower respiratory tract/ Tuberculosis - pulmonary - smear positive

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.0/ Female/ 1.72	4/ 96/ 1.24	62.34	04JUL2003/ 01AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.1/ Female/ 1.56	3/ 99/ 0.79	87.16	04JUL2003/ 19NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	20.1/ Female/ 1.36	4/ 15/ 0.81	78.01	10JUL2003/ 04AUG2003/	Haematological/ Neutropenia
				10JUL2003/ 27NOV2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	27.1/ Female/ 1.73	3/ 85/ 0.74	122.9 3	10JUL2003/ 07AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.4/ Female/ 1.64	4/ 2/ 0.93	63.09	15JUL2003/ 08AUG2003/ 09SEP2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.5/ Male/ 1.65	3/ 1/ 1.09	79.16	18JUL2003/ 20AUG2003/ 23SEP2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.1/ Female/ 1.75	4/ 5/ 0.90	95.01	30JUL2003/ 25AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	23.8/ Female/ 1.59	2/ 42/ 1.05	76.69	31JUL2003/ 02OCT2003/ 16OCT2003	Haematological/ Anaemia with clinical symptoms
				31JUL2003/ 06FEB2004/ 31JUL2003/ 03SEP2004/ 04SEP2004	Haematological/ Neutropenia Pregnancy associated/ Still birth
PPD PPD 3TC/ZDV+TDF	38.1/ Male/ 1.46	4/ 14/ 1.02	57.11	04AUG2003/ 01SEP2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	36.4/ Female/ 1.59	2/ 72/ 0.81	83.84	06AUG2003/ 14DEC2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	26.2/ Female/ 1.50	2/ 26/ 1.01	65.21	14AUG2003/ 22APR2004/	Haematological/ Thrombocytopenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	56.6/ Male/ 1.68	3/ 78/ 1.24	57.86	15AUG2003/ 07NOV2003/ 30JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	28.7/ Female/ 1.67	4/ 3/ 0.84	97.06	18AUG2003/ 15SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.0/ Female/ 1.68	3/ 7/ 0.81	95.82	20AUG2003/ 17SEP2003/	Haematological/ Neutropenia
				20AUG2003/ 07JAN2004/ 15JAN2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	60.0/ Female/ 1.51	2/ 88/ 0.85	65.46	21AUG2003/ 27NOV2003/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	50.2/ Female/ 1.45	3/ 47/ 0.92	61.16	22AUG2003/ 30APR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.37	3/ 3/ 1.01	49.11	25AUG2003/ 22SEP2003/	Haematological/ Neutropenia
				25AUG2003/ 27JUN2005/ 12DEC2005	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	23.9/ Female/ 1.58	3/ 29/ 1.15	67.49	26AUG2003/ 23SEP2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	31.2/ Female/ 1.67	3/ 94/ 0.94	85.90	28AUG2003/ 12FEB2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	25.2/ Female/ 1.37	3/ 1/ 0.71	87.20	29AUG2003/ 30SEP2003/	CNS/ Headache
				29AUG2003/ 05DEC2003/ 29AUG2003/ 13DEC2003/	Haematological/ Neutropenia Lower respiratory tract/ Pneumothorax
PP PPD 3TC/ZDV+TDF	39.5/ Male/ 1.66	4/ 27/ 1.59	48.25	02SEP2003/ 24NOV2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	23.7/ Female/ 1.27	3/ 88/ 0.78	64.90	02SEP2003/ 09FEB2004/ 02SEP2003/ 03JUN2004/ 04JUN2004	Haematological/ Anaemia with clinical symptoms Pregnancy associated/ Still birth
PP PPD 3TC/ZDV+TDF	35.3/ Female/ 1.66	3/ 9/ 0.78	86.84	05SEP2003/ 03OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	42.1/ Male/ 1.73	3/ 16/ 1.00	82.14	08SEP2003/ 06OCT2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	24.7/ Female/ 1.45	3/ 19/ 0.70	89.95	11SEP2003/ 07OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.3/ Female/ 1.32	3/ 96/ 1.05	45.29	12SEP2003/ 23OCT2003/	Specific Infections/ Presumed septicaemia/bacteremia - not investigated

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.6/ Male/ 1.73	3/ 48/ 0.94	96.20	15SEP2003/ 13OCT2003/ 12DEC2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.0/ Female/ 1.58	3/ 8/ 0.61	119.8 1	16SEP2003/ 19JUL2005/	Fat redistribution/ Fat wasting or loss of fat
PPD PPD 3TC/ZDV+TDF	49.0/ Female/ 1.28	3/ 2/ 0.92	50.27	19SEP2003/ 28MAY2004/ 10JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.1/ Female/ 1.50	4/ 83/ 0.89	64.46	22SEP2003/ 15DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	28.0/ Male/ 1.49	3/ 1/ 1.07	71.13	22SEP2003/ 16OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	45.9/ Female/ 1.28	3/ 61/ 0.77	57.61	22SEP2003/ 20OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.3/ Male/ 1.74	3/ 4/ 0.96	84.69	24SEP2003/ 22OCT2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	44.3/ Male/ 1.68	4/ 64/ 0.87	91.80	24SEP2003/ 17DEC2003/ 08JAN2004	Hepatic/ Acute hepatitis
PPD PPD 3TC/ZDV+TDF	29.3/ Female/ 1.32	4/ 14/ 1.06	45.35	25SEP2003/ 23OCT2003/ 06NOV2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	28.3/ Male/ 1.63	3/ 21/ 0.96	88.96	29SEP2003/ 28OCT2003/ 31OCT2003	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	50.6/ Male/ 1.84	3/ 40/ 1.62	51.54	29SEP2003/ 27OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	31.3/ Female/ 1.41	4/ 1/ 0.83	66.60	03OCT2003/ 24OCT2003/	Haematological/ Neutropenia
					Systemic/ Malaise, tiredness, lethargy, fatigue, generalised body weakness

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.3/ Male/	3/ 3/ 1.23	56.60	03OCT2003/ 24OCT2003/ 03OCT2003/ 19NOV2003/ 03OCT2003/ 25NOV2003/	Haematological/ Anaemia with clinical symptoms Gastrointestinal/ Vomiting CNS/ Epilepsy, fits, convulsions
PP PPD 3TC/ZDV+TDF	36.6/ Male/	3/ 1/ 1.15	78.63	03OCT2003/ 26AUG2004/	Systemic/ Acute febrile episode - undiagnosed
PPD PPD 3TC/ZDV+TDF	28.3/ Female/	3/ 7/ 0.71	84.85	03OCT2003/ 23OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.7/ Female/ 1.48	3/ 49/ 0.95	59.03	06OCT2003/ 14JUN2004/ 12JUL2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.7/ Female/ 1.48	3/ 49/ 0.95	59.03	06OCT2003/ 04OCT2004/	Haematological/ Anaemia with clinical symptoms
				06OCT2003/ 08AUG2005/	Fat redistribution/ Fat wasting or loss of fat
PPD PPD 3TC/ZDV+TDF	32.7/ Male/ 1.67	3/ 3/ 1.13	79.20	08OCT2003/ 24MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.3/ Female/ 1.40	2/ 32/ 0.90	57.62	13OCT2003/ 10NOV2003/ 17DEC2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	62.3/ Female/ 1.51	2/ 77/ 0.97	47.00	13OCT2003/ 10NOV2003/	Haematological/ Neutropenia
				13OCT2003/ 26NOV2003/	Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+TDF	26.3/ Female/ 1.39	4/ 2/ 0.67	84.18	13OCT2003/ 05NOV2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.3/ Female/ 1.53	4/ 17/ 0.86	79.57	14OCT2003/ 07NOV2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.3/ Female/ 1.59	3/ 5/ 0.92	76.75	15OCT2003/ 05JAN2004/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms
				15OCT2003/ 15JAN2004/	Haematological/ Pancytopenia, bone marrow depression
PP PPD 3TC/ZDV+TDF	39.3/ Male/ 1.69	4/ 44/ 0.92	90.24	20OCT2003/ 17NOV2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	32.3/ Male/ 1.61	3/ 30/ 1.05	78.33	20OCT2003/ 16JAN2004/ 19JAN2004	CNS/ Epilepsy, fits, convulsions

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.3/ Male/ 1.61	3/ 30/ 1.05	78.33	20OCT2003/ 20SEP2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	31.1/ Female/ 1.33	3/ 96/ 1.09	47.18	20OCT2003/ 17NOV2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.49	2/ 48/ 0.87	68.52	22OCT2003/ 17FEB2004/ 26FEB2004 22OCT2003/ 18FEB2004/	Specific Infections/ P falciparum malaria Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	44.1/ Male/ 1.59	3/ 35/ 1.21	57.35	23OCT2003/ 11NOV2003/ 13NOV2003 23OCT2003/ 17FEB2004/ 26FEB2004 23OCT2003/ 01JUL2004/ 27JUL2004	Biochemical/ Raised AST Biochemical/ Raised liver enzymes Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.3/ Female/ 1.56	4/ 4/ 0.83	79.87	30OCT2003/ 23DEC2003/ 29DEC2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	37.5/ Female/ 1.26	3/ 99/ 0.79	54.83	30OCT2003/ 16AUG2004/ 09SEP2004	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	36.8/ Female/ 1.55	3/ 8/ 0.97	68.03	03NOV2003/ 01DEC2003/	Haematological/ Neutropenia
				03NOV2003/ 23FEB2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	31.1/ Female/ 1.57	2/ 31/ 1.32	50.37	03NOV2003/ 13JUL2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	39.9/ Female/ 1.52	3/ 2/ 0.88	69.46	03NOV2003/ 01DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	37.4/ Male/ 1.72	3/ 17/ 0.97	88.82	04NOV2003/ 27JAN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.3/ Female/ 1.66	3/ 44/ 1.04	62.76	04NOV2003/ 10MAR2004/ 20APR2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	31.4/ Female/ 1.51	3/ 95/ 0.84	87.05	05NOV2003/ 03DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	28.1/ Female/ 1.51	4/ 9/ 0.92	71.84	07NOV2003/ 22APR2005/	Biochemical/ Raised liver enzymes
PP PPD 3TC/ZDV+TDF	35.6/ Male/ 1.71	3/ 2/ 0.88	103.8 1	10NOV2003/ 08DEC2003/ 18DEC2003	Haematological/ Neutropenia
				10NOV2003/ 26APR2004/ 03MAY2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	44.9/ Female/ 1.49	4/ 83/ 1.02	53.01	10NOV2003/ 08DEC2003/ 15DEC2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.3/ Female/ 1.39	2/ 6/ 0.70	80.24	11NOV2003/ 08DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	25.4/ Female/ 1.67	2/ 3/ 0.95	87.98	17NOV2003/ 13FEB2004/ 16FEB2004	Specific Infections/ P falciparum malaria
				17NOV2003/ 26JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	27.4/ Female/ 1.31	4/ 38/ 0.77	65.46	17NOV2003/ 03MAY2004/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	54.5/ Female/ 1.45	4/ 39/ 0.79	58.44	18NOV2003/ 23JAN2004/	Haematological/ Neutropenia
					Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+TDF	26.4/ Female/ 1.61	2/ 68/ 1.16	64.80	24NOV2003/ 29JUN2005/ 24OCT2005	Musculoskeletal/ Myopathy, muscle wasting

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	45.5/ Female/ 1.48	4/ 34/ 1.35	40.50	24NOV2003/ 22DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.3/ Male/ 1.72	3/ 15/ 0.71	123.02	24NOV2003/ 22DEC2003/ 09JAN2004	Haematological/ Neutropenia
				24NOV2003/ 20JUN2005/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	24.5/ Female/ 1.62	2/ 6/ 0.75	100.10	27NOV2003/ 15APR2004/ 17APR2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	32.2/ Male/ 1.68	3/ 45/ 0.90	99.51	27NOV2003/ 10DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	46.6/ Male/ 1.47	4/ 96/ 1.46	40.09	28NOV2003/ 29NOV2003/	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	35.5/ Female/ 1.44	3/ 40/ 0.95	63.44	01DEC2003/ 01AUG2005/ 03AUG2005	Pregnancy associated/ Induced abortion

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.6/ Female/ 1.37	2/ 19/ 0.92	56.72	02DEC2003/ 30DEC2003/ 13JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	49.0/ Male/ 1.56	3/ 88/ 1.24	50.37	02DEC2003/ 06JAN2004/	Haematological/ Anaemia with clinical symptoms
					Gastrointestinal/ Vomiting Systemic/ Dehydration
				02DEC2003/ 22MAR2005/	CNS/ Parathesia, transient numbness, tingling
PPD PPD 3TC/ZDV+TDF	31.3/ Male/ 1.74	3/ 1/ 1.03	88.18	03DEC2003/ 15DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	38.1/ Male/	3/ 29/ 1.26	55.35	08DEC2003/ 05JAN2004/ 27JAN2004	Biochemical/ Raised liver enzymes

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.4/ Male/ 1.73	3/ 20/ 1.19	71.61	09DEC2003/ 06JAN2004/ 02MAR2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	25.5/ Female/ 1.39	2/ 11/ 0.90	73.32	10DEC2003/ 05JAN2004/ 14JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	24.4/ Female/ 1.56	3/ 14/ 1.02	77.48	11DEC2003/ 04MAR2004/	Haematological/ Neutropenia
				11DEC2003/ 22JUL2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	39.5/ Female/ 1.23	3/ 14/ 0.61	67.80	12DEC2003/ 26FEB2004/	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+TDF	29.5/ Female/ 1.61	4/ 10/ 0.40	176.9 7	12DEC2003/ 13MAY2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	28.5/ Female/ 1.55	3/ 3/ 1.16	58.57	12DEC2003/ 09JAN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	30.5/ Female/ 1.60	3/ 41/ 0.80	88.28	15DEC2003/ 23AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.1/ Female/ 1.33	4/ 1/ 0.64	65.01	16DEC2003/ 30DEC2003/	Haematological/ Neutropenia
				16DEC2003/ 12JAN2004/	Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+TDF	28.5/ Male/ 1.72	3/ 34/ 3.01	33.01	18DEC2003/ 16AUG2004/ 25APR2005	Cardiovascular/ Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	29.5/ Male/ 1.80	4/ 9/ 0.85	108.7 8	19DEC2003/ 16JAN2004/ 16FEB2004	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	34.0/ Female/ 1.59	4/ 8/ 0.88	73.52	19DEC2003/ 16JAN2004/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.5/ Male/ 1.59	3/ 35/ 0.96	75.44	19DEC2003/ 16JAN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.4/ Female/ 1.61	2/ 55/ 0.71	99.99	22DEC2003/ 19JAN2004/ 30JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	62.5/ Male/ 1.67	3/ 21/ 1.56	40.06	30DEC2003/ 11FEB2004/	Haematological/ Pancytopenia, bone marrow depression
				30DEC2003/ 23FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	27.6/ Female/ 1.37	2/ 9/ 1.18	47.25	12JAN2004/ 05APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.68	3/ 25/ 0.84	101.8 1	13JAN2004/ 10FEB2004/ 10MAR2004	Biochemical/ Raised ALT

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.68	3/ 25/ 0.84	101.8 1	13JAN2004/ 04MAR2004/	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
					Systemic/ Malaise, tiredness, lethargy, fatigue, generalised body weakness
				13JAN2004/ 07APR2004/	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+TDF	37.4/ Female/ 1.55	3/ 48/ 0.85	79.75	14JAN2004/ 24AUG2005/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.2/ Female/ 1.61	3/ 96/ 0.92	82.27	15JAN2004/ 12FEB2004/	Haematological/ Neutropenia
				15JAN2004/ 25JUN2004/ 27JUN2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	30.6/ Male/ 1.67	3/ 2/ 0.87	99.64	15JAN2004/ 12FEB2004/	Haematological/ Neutropenia
				15JAN2004/ 10MAR2005/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	28.6/ Male/ 1.39	3/ 76/ 0.79	86.16	16JAN2004/ 15JUL2004/	Non HIV related deaths/ Suicide
PP PPD 3TC/ZDV+TDF	26.0/ Female/ 1.40	3/ 1/ 0.84	67.33	21JAN2004/ 18FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.8/ Male/ 1.79	3/ 5/ 0.77	120.85	02FEB2004/ 01MAR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	41.8/ Male/ 1.79	3/ 5/ 0.77	120.8 5	02FEB2004/ 23JUN2005/ 06JUL2005	Genitourinary/ Urinary retention
PPD PPD 3TC/ZDV+TDF	37.3/ Male/ 1.59	3/ 59/ 1.03	76.40	04FEB2004/ 28APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.0/ Male/ 1.91	3/ 7/ 0.85	133.4 1	10FEB2004/ 02MAY2005/ 31MAY2005	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PP D PPD 3TC/ZDV+TDF	34.2/ Female/ 1.30	4/ 1/ 0.96	50.54	23FEB2004/ 22MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	48.7/ Female/ 1.53	4/ 90/ 1.82	29.50	24FEB2004/ 23MAR2004/ 24FEB2004/ 18MAY2004/ 31MAY2004	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.0/ Female/ 1.56	3/ 31/ 0.78	89.52	26FEB2004/ 25MAR2004/ 19APR2004	Haematological/ Neutropenia
				26FEB2004/ 12AUG2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	31.3/ Female/ 1.40	3/ 28/ 0.94	57.22	27FEB2004/ 19JUL2004/ 13AUG2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	33.7/ Male/ 1.65	3/ 86/ 0.97	94.29	27FEB2004/ 26MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.7/ Female/ 1.53	3/ 68/ 0.81	74.52	09MAR2004/ 08FEB2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	47.8/ Male/ 1.75	4/ 6/ 1.07	71.69	26MAR2004/ 22APR2004/	Haematological/ Neutropenia
				26MAR2004/ 09SEP2004/ 14SEP2004	Specific Infections/ P falciparum malaria

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.8/ Female/ 1.55	4/ 8/ 0.67	114.2 8	29MAR2004/ 23APR2004/ 29APR2004	Specific Infections/ P falciparum malaria
				29MAR2004/ 26APR2004/ 07MAY2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.8/ Female/ 1.62	4/ 98/ 1.41	50.32	05APR2004/ 03MAY2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	26.8/ Female/ 1.47	3/ 45/ 0.30	213.2 9	08APR2004/ 10MAR2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	28.9/ Male/ 1.65	3/ 1/ 0.93	89.77	14APR2004/ 12MAY2004/	Haematological/ Neutropenia
				14APR2004/ 01JUL2004/	Haematological/ Pancytopenia, bone marrow depression

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	30.0/ Male/ 1.74	3/ 39/ 0.80	112.9 7	15APR2004/ 13MAY2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.8/ Female/	3/ 83/ 1.36	51.06	19APR2004/ 12JUL2004/ 19JUL2004 19APR2004/ 20NOV2004/ 21NOV2004	Haematological/ Neutropenia Pregnancy associated/ Spontaneous abortion (complete or incomplete)
PPD PPD 3TC/ZDV+TDF	28.9/ Female/ 1.24	4/ 1/ 0.65	68.38	27APR2004/ 25MAY2004/ 27APR2004/ 28MAY2004/	Haematological/ Neutropenia CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	41.4/ Male/ 1.46	3/ 35/ 0.60	105.3 0	03MAY2004/ 17MAY2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	38.4/ Male/ 1.69	3/ 37/ 0.87	89.43	04MAY2004/ 01JUN2004/ 29JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.66	3/ 61/ 1.00	77.86	10MAY2004/ 07JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.1/ Female/ 1.34	3/ 5/ 0.70	69.88	12MAY2004/ 08JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.4/ Male/ 1.58	3/ 11/ 1.30	55.94	18MAY2004/ 31MAY2004/ 10JUN2004 18MAY2004/ 10JUN2004/	Biochemical/ Raised liver enzymes Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	45.9/ Female/ 1.69	2/ 39/ 0.81	88.35	18MAY2004/ 25JAN2005/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.8/ Male/ 1.61	3/ 28/ 1.05	74.40	18MAY2004/ 15JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.9/ Female/ 1.56	3/ 1/ 0.84	79.69	19MAY2004/ 16JUN2004/	Haematological/ Neutropenia
				19MAY2004/ 01AUG2005/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	38.0/ Female/ 1.38	3/ 4/ 0.90	57.01	29JUN2004/ 26JUL2004/ 21SEP2004	Haematological/ Neutropenia
				29JUN2004/ 29NOV2005/	Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+TDF	25.1/ Female/ 1.51	2/ 22/ 0.86	72.38	07JUL2004/ 16MAR2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.6/ Female/ 1.45	3/ 59/ 1.13	50.12	03AUG2004/ 31AUG2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	42.1/ Male/ 1.73	4/ 82/ 1.35	67.82	03AUG2004/ 26OCT2004/	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	35.3/ Female/ 1.52	4/ 3/ 1.18	56.55	01OCT2004/ 15NOV2004/	Haematological/ Anaemia with clinical symptoms
PP D PPD 3TC/ZDV+TDF	38.7/ Female/ 1.42	3/ 115/ 1.00	55.11	13FEB2003/ 31JUL2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	28.0/ Female/ 1.51	3/ 166/ 1.01	65.01	20FEB2003/ 26APR2003/ 10JUL2003	Cardiovascular/ Pericarditis not TB or bacterial or no cause identified
PPD PPD 3TC/ZDV+TDF	44.7/ Female/ 1.40	3/ 145/ 1.14	44.18	20FEB2003/ 07AUG2003/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	44.7/ Female/ 1.40	3/ 145/ 1.14	44.18	20FEB2003/ 26JUL2004/	Tumours/ Other Solid tumour
PPD PPD 3TC/ZDV+TDF	30.7/ Female/ 1.38	4/ 133/ 0.72	78.33	13MAR2003/ 28AUG2003/ 11SEP2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	50.0/ Female/ 1.69	4/ 133/ 1.07	65.76	18MAR2003/ 11FEB2004/ 02MAR2004	Systemic/ Malaise, tiredness, lethargy, fatigue, generalised body weakness
PPD PPD 3TC/ZDV+TDF	40.2/ Female/ 1.70	2/ 138/ 0.96	78.16	27MAR2003/ 24APR2003/ 27MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	42.0/ Female/ 1.58	3/ 138/ 0.88	68.13	15APR2003/ 03JAN2004/ 07JAN2004	Specific Infections/ P falciparum malaria

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	53.7/ Female/ 1.29	4/ 138/ 1.00	39.37	22APR2003/ 20MAY2003/ 27MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.9/ Male/ 1.81	2/ 190/ 1.19	77.99	22APR2003/ 23JUN2003/ 15JUL2003	Haematological/ Neutropenia
				22APR2003/ 04NOV2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	38.9/ Female/ 1.58	3/ 149/ 0.92	71.45	24APR2003/ 22MAY2003/ 27MAY2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	38.5/ Male/ 1.56	2/ 127/ 1.24	59.06	08MAY2003/ 27MAY2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.2/ Female/ 1.51	2/ 116/ 0.97	60.95	08MAY2003/ 05JUN2003/ 03JUL2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.1/ Female/ 1.54	3/ 161/ 0.68	98.26	20MAY2003/ 27JAN2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.1/ Female/ 1.54	3/ 161/ 0.68	98.26	20MAY2003/ 23MAR2004/ 26MAR2004	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	30.0/ Female/ 1.52	2/ 114/ 1.02	67.79	10JUN2003/ 29AUG2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	26.0/ Female/ 1.41	4/ 129/ 1.01	62.61	23JUN2003/ 15SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	44.0/ Female/ 1.53	4/ 106/ 0.78	75.26	26JUN2003/ 12DEC2003/ 18DEC2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.0/ Female/ 1.41	2/ 190/ 1.07	47.53	04JUL2003/ 01AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.2/ Male/ 1.77	3/ 115/ 1.80	45.70	08JUL2003/ 05AUG2003/ 13AUG2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.1/ Female/ 1.65	2/ 147/ 0.71	100.8 2	15JUL2003/ 07OCT2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	27.1/ Female/ 1.72	2/ 124/ 0.79	117.4 8	16JUL2003/ 14AUG2003/	Haematological/ Neutropenia
				16JUL2003/ 15JAN2004/ 30JAN2004	Pregnancy associated/ Spontaneous abortion (complete or incomplete)
PPD PPD 3TC/ZDV+TDF	28.1/ Female/ 1.50	3/ 158/ 1.02	64.65	29JUL2003/ 26AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.5/ Male/ 1.60	3/ 157/ 0.92	82.54	29JUL2003/ 26AUG2003/ 21OCT2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	38.7/ Female/ 1.49	4/ 142/ 1.90	30.74	01AUG2003/ 29AUG2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.1/ Female/ 1.28	2/ 117/ 0.87	55.79	05AUG2003/ 13APR2004/	Haematological/ Anaemia with clinical symptoms
				05AUG2003/ 26APR2004/	Tumours/ Hepatocellular carcinoma
PPD PPD 3TC/ZDV+TDF	39.4/ Female/ 1.50	3/ 140/ 1.03	65.00	05AUG2003/ 06JUL2004/ 31AUG2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	38.0/ Female/ 1.47	3/ 184/ 0.87	68.93	13AUG2003/ 14JAN2005/	Tumours/ Cervical carcinoma
PP PPD 3TC/ZDV+TDF	44.0/ Male/	3/ 126/ 1.18	54.50	14AUG2003/ 12SEP2003/	Haematological/ Neutropenia
					Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+TDF	40.2/ Female/ 1.62	4/ 112/ 1.06	69.61	18AUG2003/ 15SEP2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	21.2/ Female/ 1.41	3/ 151/ 1.02	68.67	22AUG2003/ 19SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.52	4/ 105/ 1.16	64.26	03SEP2003/ 01OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.5/ Female/ 1.99	2/ 149/ 0.95	110.92	03SEP2003/ 29OCT2003/	Gastrointestinal/ Nausea
PP PPD 3TC/ZDV+TDF	35.7/ Male/ 1.58	3/ 170/ 1.38	57.84	08SEP2003/ 06OCT2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	51.2/ Female/ 1.45	4/ 136/ 0.88	59.19	08SEP2003/ 06OCT2003/	Haematological/ Neutropenia
				08SEP2003/ 23FEB2004/	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	35.1/ Female/ 1.58	4/ 118/ 0.76	94.51	08SEP2003/ 06OCT2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.58	2/ 199/ 0.96	75.60	12SEP2003/ 02FEB2004/ 03FEB2004	Pregnancy associated/ Spontaneous abortion (complete or incomplete)
				12SEP2003/ 03FEB2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	31.9/ Female/ 1.61	2/ 195/ 0.98	73.65	15SEP2003/ 13OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.9/ Female/ 1.33	4/ 170/ 1.16	37.44	15SEP2003/ 13OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	48.3/ Female/ 1.50	2/ 128/ 1.02	55.14	16SEP2003/ 14OCT2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	49.3/ Female/ 1.57	3/ 107/ 1.10	51.61	19SEP2003/ 28MAY2004/ 10JUN2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.3/ Female/ 1.60	3/ 140/ 0.86	79.50	25SEP2003/ 29DEC2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	32.2/ Female/ 1.87	3/ 171/ 0.86	112.15	30SEP2003/ 16MAR2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	20.3/ Female/ 1.36	3/ 125/ 0.88	70.27	30SEP2003/ 28OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	31.8/ Female/ 1.63	4/ 107/ 0.88	86.60	06OCT2003/ 03NOV2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	39.1/ Female/ 1.56	3/ 171/ 0.86	69.02	06OCT2003/ 19FEB2005/ 21FEB2005	Gastrointestinal/ Peptic/gastric/duodenal ulcer
PP PPD 3TC/ZDV+TDF	31.0/ Female/ 1.63	3/ 169/ 0.63	119.47	10OCT2003/ 12AUG2005/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.6/ Female/ 1.63	2/ 175/ 1.10	65.12	10OCT2003/ 07NOV2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.3/ Female/ 1.43	3/ 142/ 0.69	80.69	10OCT2003/ 07NOV2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	25.3/ Female/ 1.40	2/ 131/ 1.23	52.52	17OCT2003/ 30JUN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	31.3/ Female/ 1.40	2/ 187/ 0.77	83.15	17OCT2003/ 30OCT2003/ 12NOV2003	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	45.7/ Male/ 1.83	3/ 138/ 0.92	97.43	27OCT2003/ 19JAN2004/ 30JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.1/ Female/ 1.68	2/ 192/ 0.88	88.96	27OCT2003/ 27SEP2004/	Non HIV related deaths/ Obstetric
PPD PPD 3TC/ZDV+TDF	48.4/ Female/ 1.67	3/ 167/ 1.02	67.25	03NOV2003/ 27JAN2004/ 10FEB2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	38.2/ Female/	2/ 187/ 3.73	17.34	06NOV2003/ 04DEC2003/	Haematological/ Neutropenia
				06NOV2003/ 20DEC2003/	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+TDF	37.4/ Female/ 1.26	3/ 146/ 0.98	44.17	10NOV2003/ 08DEC2003/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	36.2/ Female/ 1.72	4/ 199/ 1.45	57.78	11NOV2003/ 30MAR2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	32.4/ Male/ 1.71	3/ 164/ 1.03	87.29	11NOV2003/ 09DEC2003/ 22DEC2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.4/ Female/ 1.57	2/ 107/ 0.80	81.22	14NOV2003/ 17MAR2004/ 02APR2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.75	3/ 100/ 0.85	94.71	17NOV2003/ 04MAR2004/ 05MAR2004	Specific Infections/ P falciparum malaria
				17NOV2003/ 03MAY2004/ 04MAY2004	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
				17NOV2003/ 05MAY2004/	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	34.8/ Female/ 1.87	2/ 121/ 1.24	65.69	17NOV2003/ 15DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.4/ Male/ 1.95	3/ 143/ 1.10	99.18	18NOV2003/ 04MAY2004/ 12MAY2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	55.6/ Male/ 1.66	3/ 145/ 1.05	61.39	24NOV2003/ 22DEC2003/ 09JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	45.5/ Male/ 1.84	3/ 185/ 0.96	84.87	02DEC2003/ 30DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	62.0/ Male/ 1.83	3/ 163/ 1.00	78.66	02DEC2003/ 30DEC2003/ 13JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.5/ Female/ 1.36	3/ 125/ 0.96	55.01	09DEC2003/ 06JAN2004/ 09DEC2003/ 19JUN2004/	Haematological/ Neutropenia Non HIV related deaths/ Traumatic
PPD PPD 3TC/ZDV+TDF	34.0/ Female/ 1.65	3/ 110/ 0.76	97.13	09DEC2003/ 30MAY2005/ 04JUN2005	Haematological/ Nose bleed, epistaxis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.5/ Female/ 1.55	3/ 172/ 1.06	61.96	12DEC2003/ 08JUN2005/ 15JUN2005	Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+TDF	46.7/ Male/ 1.83	2/ 173/ 1.76	51.52	19DEC2003/ 16JAN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.1/ Female/ 1.42	4/ 166/ 0.88	61.55	23DEC2003/ 20JAN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	31.5/ Male/ 1.45	4/ 164/ 1.28	53.16	21JAN2004/ 03FEB2004/	Specific Infections/ P falciparum malaria
				21JAN2004/ 09FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.47	3/ 158/ 0.57	112.3 7	22JAN2004/ 29APR2004/ 05AUG2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	21.8/ Female/ 1.22	3/ 140/ 1.00	50.30	28JAN2004/ 29DEC2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.2/ Male/ 1.74	2/ 131/ 1.10	80.85	30JAN2004/ 27FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.5/ Male/ 1.81	2/ 152/ 1.30	71.79	30JAN2004/ 27FEB2004/ 24MAR2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.9/ Female/ 1.73	3/ 156/ 1.10	63.94	04FEB2004/ 03MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	42.1/ Male/ 1.69	2/ 140/ 1.24	65.71	10FEB2004/ 09MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.7/ Female/ 1.35	2/ 169/ 0.90	60.95	03MAR2004/ 08JUN2005/ 22JUN2005	Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+TDF	31.7/ Female/ 1.55	3/ 192/ 3.72	18.83	10MAR2004/ 05APR2004/	Haematological/ Neutropenia
				10MAR2004/ 13APR2004/	Renal/ Glomerulonephritis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	54.4/ Male/ 1.70	2/ 180/ 1.45	53.90	02APR2004/ 30APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	47.1/ Male/ 1.55	3/ 141/ 1.46	44.30	13APR2004/ 06JUL2004/ 03SEP2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.8/ Female/ 1.42	4/ 111/ 0.95	53.62	14APR2004/ 07JUL2004/	Haematological/ Neutropenia
				14APR2004/ 29SEP2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	24.8/ Female/ 1.49	3/ 153/ 0.80	84.72	14APR2004/ 12MAY2004/ 23JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	26.8/ Female/ 1.57	3/ 196/ 0.91	74.68	16APR2004/ 26OCT2004/ 09DEC2004	Pregnancy associated/ Spontaneous abortion (complete or incomplete)

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.8/ Male/ 1.71	3/ 102/ 0.65	144.0 4	20APR2004/ 10MAR2005/ 22MAR2005	Endocrine/ Diabetes - Type II
PPD PPD 3TC/ZDV+TDF	39.9/ Female/ 1.43	2/ 102/ 0.77	68.87	22APR2004/ 19MAY2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.62	3/ 158/ 0.64	112.6 3	22APR2004/ 13DEC2004/ 30DEC2004	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	39.9/ Female/ 1.58	3/ 147/ 0.71	91.24	27APR2004/ 25MAY2004/ 12JUL2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.9/ Female/ 1.30	2/ 114/ 0.80	62.09	27APR2004/ 26MAY2004/	Haematological/ Neutropenia
				27APR2004/ 11JUN2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	30.9/ Female/ 1.64	2/ 121/ 0.88	90.21	12MAY2004/ 03AUG2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.9/ Male/ 1.45	3/ 125/ 2.40	28.73	18MAY2004/ 15JUN2004/ 22JUN2004	Haematological/ Anaemia with clinical symptoms
				18MAY2004/ 22JUN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	24.9/ Female/ 1.57	3/ 101/ 0.86	89.79	19MAY2004/ 16JUN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	31.7/ Female/ 1.40	3/ 114/ 0.75	80.23	19MAY2004/ 08SEP2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	27.4/ Female/ 1.66	3/ 180/ 0.90	89.29	26MAY2004/ 18MAY2005/ 31MAY2005	Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+TDF	42.0/ Male/ 1.66	3/ 156/ 0.90	87.42	16JUN2004/ 14JUL2004/ 26JUL2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	59.0/ Female/ 1.44	2/ 192/ 0.88	50.79	17JUN2004/ 09SEP2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.5/ Male/ 1.89	4/ 143/ 1.24	83.36	14JUL2004/ 04OCT2004/	Haematological/ Neutropenia
				14JUL2004/ 23MAR2005/	Haematological/ Thrombocytopenia
PP PPD 3TC/ZDV+TDF	25.1/ Female/ 1.50	2/ 108/ 0.87	76.08	27JUL2004/ 23JAN2006/ 25JAN2006	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	37.1/ Male/ 1.54	3/ 183/ 1.19	57.86	04AUG2004/ 01SEP2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	51.2/ Male/ 1.65	4/ 148/ 0.87	76.88	01SEP2004/ 29SEP2004/	Haematological/ Neutropenia
					Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	44.7/ Male/ 1.64	3/ 114/ 1.11	65.83	28SEP2004/ 26OCT2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	24.6/ Male/ 1.62	2/ 26/ 1.31	72.21	27JAN2004/ 13JUL2004/ 20JUL2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	30.7/ Female/ 1.44	2/ 46/ 1.00	59.46	13FEB2004/ 05MAY2004/ 14MAY2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	39.8/ Female/ 1.63	2/ 18/ 1.18	56.16	24FEB2004/ 25JAN2005/ 22FEB2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	39.7/ Male/ 1.62	4/ 87/ 0.92	82.26	03MAR2004/ 31MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	25.7/ Female/ 1.50	3/ 23/ 1.11	60.66	03MAR2004/ 12OCT2005/ 09NOV2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	47.7/ Female/ 1.38	3/ 88/ 0.92	55.74	04MAR2004/ 02APR2004/ 24AUG2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.64	2/ 35/ 1.02	72.58	10MAR2004/ 21FEB2006/	Biochemical/ Raised liver enzymes

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.64	2/ 35/ 1.02	72.58	10MAR2004/ 21FEB2006/	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	33.7/ Female/ 1.34	3/ 31/ 0.86	56.72	11MAR2004/ 30JAN2005/ 24FEB2005	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	36.7/ Female/ 1.41	2/ 76/ 0.72	75.52	12MAR2004/ 02JUN2004/ 30JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	38.3/ Female/ 1.43	4/ 11/ 1.30	44.17	16MAR2004/ 13APR2004/ 07JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	34.8/ Female/ 1.63	4/ 60/ 1.36	57.46	01APR2004/ 28APR2004/	Haematological/ Neutropenia
				01APR2004/ 26JAN2006/ 02FEB2006	Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+NVP	35.9/ Male/ 1.54	3/ 40/ 0.78	87.28	08APR2004/ 06MAY2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	45.8/ Female/ 1.33	4/ 82/ 0.86	55.43	13APR2004/ 07JUN2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	32.4/ Female/ 1.52	4/ 11/ 0.90	71.71	28APR2004/ 08JUN2004/ 09JUN2004	Skin/ Rash, erythematous
PPD PPD 3TC/ZDV+NVP	35.9/ Male/ 1.69	4/ 20/ 1.00	86.90	03MAY2004/ 31MAY2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+ABC	47.9/ Female/ 1.25	3/ 54/ 0.80	54.22	04MAY2004/ 20OCT2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	46.0/ Male/ 1.62	3/ 82/ 1.50	47.98	05MAY2004/ 02JUN2004/ 05MAY2004/ 20JUL2004/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+ABC	36.1/ Female/ 1.72	4/ 13/ 0.80	99.41	07MAY2004/ 04JUN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	32.9/ Male/ 1.80	2/ 79/ 0.90	109.2 9	12MAY2004/ 08JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	31.9/ Male/ 1.42	3/ 46/ 1.23	53.68	14MAY2004/ 15APR2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	43.1/ Male/ 1.51	4/ 53/ 0.89	70.98	04JUN2004/ 01SEP2004/ 23SEP2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	46.1/ Male/ 1.79	3/ 99/ 3.04	26.20	11JUN2004/ 26NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	27.0/ Female/ 1.54	3/ 4/ 0.92	79.82	18JUN2004/ 16JUL2004/ 10SEP2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	37.5/ Male/ 1.57	4/ 2/ 1.28	54.71	24JUN2004/ 22JUL2004/	Haematological/ Neutropenia
				24JUN2004/ 16AUG2004/ 16SEP2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	37.5/ Male/ 1.57	4/ 2/ 1.28	54.71	24JUN2004/ 21JAN2005/ 29MAR2005	CNS/ Peripheral neuropathy - sensory & motor
PPD PPD 3TC/ZDV+ABC	36.0/ Male/ 1.80	3/ 3/ 1.24	76.75	30JUN2004/ 28JUL2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+ABC	31.5/ Male/ 1.68	2/ 49/ 1.16	75.17	05JUL2004/ 02AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	31.5/ Male/ 1.67	3/ 11/ 1.04	78.33	12JUL2004/ 09AUG2004/	Haematological/ Neutropenia
				12JUL2004/ 21AUG2004/ 26AUG2004	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	26.6/ Female/ 1.25	4/ 2/ 0.66	65.11	12JUL2004/ 05AUG2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	32.1/ Female/ 1.50	4/ 9/ 0.93	68.45	15JUL2004/ 12AUG2004/ 23SEP2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	31.2/ Female/ 1.53	3/ 76/ 1.04	62.75	21JUL2004/ 04AUG2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	30.8/ Female/ 1.44	4/ 36/ 1.00	60.71	21JUL2004/ 19AUG2004/ 02SEP2004	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	44.7/ Male/ 1.78	3/ 1/ 0.96	91.00	29JUL2004/ 25AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	32.0/ Female/ 1.62	3/ 88/ 1.07	67.35	30JUL2004/ 27AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	46.2/ Female/ 1.93	4/ 12/ 0.86	115.5 2	05AUG2004/ 02SEP2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	30.0/ Female/ 1.39	3/ 82/ 1.53	35.56	09AUG2004/ 20DEC2004/	Haematological/ Anaemia with clinical symptoms
				09AUG2004/ 11OCT2005/	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+ABC	50.2/ Female/ 1.41	3/ 4/ 0.92	48.48	11AUG2004/ 27NOV2005/ 01DEC2005	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+NVP	25.7/ Male/ 1.77	4/ 2/ 0.97	98.15	11AUG2004/ 10SEP2004/ 22SEP2004	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+ABC	32.4/ Female/ 1.49	3/ 1/ 0.97	63.79	18AUG2004/ 06SEP2004/ 20SEP2004	Haematological/ Neutropenia
				18AUG2004/ 15SEP2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	42.5/ Male/ 1.87	4/ 29/ 1.56	63.44	18AUG2004/ 29SEP2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	42.5/ Male/ 1.87	4/ 29/ 1.56	63.44	18AUG2004/ 29SEP2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	35.0/ Female/ 1.56	2/ 5/ 1.04	64.05	18AUG2004/ 15SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	27.0/ Female/ 1.81	3/ 70/ 1.22	75.05	20AUG2004/ 10SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	32.0/ Female/ 1.25	3/ 45/ 0.90	50.56	24AUG2004/ 28JUN2005/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	50.3/ Female/ 1.32	4/ 58/ 0.89	44.89	30AUG2004/ 18NOV2004/	Haematological/ Pancytopenia, bone marrow depression

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	30.3/ Female/ 1.53	3/ 5/ 0.83	78.22	14SEP2004/ 12OCT2004/ 16OCT2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	31.3/ Female/ 1.77	2/ 12/ 0.81	113.0 8	17SEP2004/ 06JAN2006/ 03FEB2006	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	22.9/ Female/ 1.47	4/ 94/ 0.88	70.25	21SEP2004/ 05OCT2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	42.3/ Male/ 1.73	3/ 2/ 1.02	80.13	29SEP2004/ 22NOV2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	29.0/ Female/ 1.34	3/ 44/ 1.10	47.51	29SEP2004/ 27OCT2004/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	29.0/ Female/ 1.34	3/ 44/ 1.10	47.51	29SEP2004/ 31AUG2005/	Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+ABC	47.3/ Female/ 1.41	3/ 99/ 0.77	62.40	30SEP2004/ 23DEC2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	43.6/ Female/ 1.51	4/ 171/ 0.94	59.81	27JAN2004/ 24FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	46.6/ Female/ 1.73	2/ 154/ 1.05	73.13	27JAN2004/ 23FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	38.1/ Female/ 1.74	4/ 145/ 0.88	97.84	27JAN2004/ 25FEB2004/ 02APR2004 27JAN2004/ 09MAR2004/ 27JAN2004/ 24MAR2004/ 19APR2004	Biochemical/ Raised liver enzymes Haematological/ Neutropenia Systemic/ Recurrent fever - no diagnosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	37.0/ Female/ 1.56	3/ 127/ 0.93	71.91	28JAN2004/ 25OCT2004/	Pregnancy associated/ Still birth
PPD PPD 3TC/ZDV+ABC	42.7/ Female/ 1.90	3/ 147/ 1.27	66.90	17FEB2004/ 16MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	39.4/ Male/ 1.63	3/ 197/ 1.16	66.12	18FEB2004/ 17MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	36.2/ Female/ 1.72	3/ 142/ 1.06	85.00	26FEB2004/ 23MAR2004/ 10MAY2004	Haematological/ Neutropenia
				26FEB2004/ 10MAY2004/ 04JUN2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	32.0/ Female/ 1.69	2/ 149/ 0.93	82.18	04MAR2004/ 27MAY2004/ 08JUL2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.75	4/ 119/ 1.04	74.42	10MAR2004/ 05APR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.75	4/ 119/ 1.04	74.42	10MAR2004/ 08DEC2005/ 12DEC2005	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+ABC	27.5/ Female/ 1.55	2/ 100/ 0.78	86.53	12MAR2004/ 04JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	27.9/ Female/ 1.45	3/ 171/ 1.02	63.47	17MAR2004/ 14APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	51.8/ Female/ 1.43	3/ 183/ 1.46	35.59	19MAR2004/ 11JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	38.2/ Female/ 1.53	4/ 195/ 1.04	59.83	22MAR2004/ 19APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	49.8/ Male/ 1.51	4/ 100/ 1.16	50.67	26MAR2004/ 06APR2004/ 20APR2004	Hepatic/ Acute hepatitis
PPD PPD 3TC/ZDV+NVP	60.9/ Male/ 1.78	2/ 100/ 1.12	59.01	30MAR2004/ 27APR2004/ 22JUN2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	60.9/ Male/ 1.78	2/ 100/ 1.12	59.01	30MAR2004/ 22JUN2004/ 09AUG2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	45.8/ Female/ 1.61	3/ 142/ 1.07	59.83	06APR2004/ 08FEB2005/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	41.4/ Female/ 1.94	2/ 152/ 0.78	133.7 8	06APR2004/ 18APR2005/ 19APR2005	Pregnancy associated/ Induced abortion
PP PPD 3TC/ZDV+NVP	45.8/ Male/ 1.73	3/ 101/ 0.80	95.05	14APR2004/ 12MAY2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+ABC	31.8/ Female/ 1.34	3/ 157/ 0.85	62.93	14APR2004/ 13MAY2004/ 14APR2004/ 06SEP2004/	Haematological/ Neutropenia CNS/ Epilepsy, fits, convulsions

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	37.2/ Male/ 1.72	3/ 174/ 1.40	63.31	22APR2004/ 20MAY2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	37.9/ Female/ 1.46	4/ 175/ 0.83	74.58	23APR2004/ 14JUN2004/ 24JUN2004	Hepatic/ Acute hepatitis
PP PPD 3TC/ZDV+ABC	27.7/ Female/ 1.79	2/ 163/ 1.20	78.71	29APR2004/ 27MAY2004/ 02JUN2004 29APR2004/ 23SEP2005/ 24SEP2005	Haematological/ Neutropenia Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+ABC	37.9/ Male/ 1.66	2/ 104/ 0.90	85.24	04MAY2004/ 24MAY2004/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	40.5/ Female/ 1.78	2/ 169/ 1.07	81.75	12MAY2004/ 08JUN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	45.0/ Male/ 1.63	2/ 122/ 1.39	51.38	19MAY2004/ 06JUL2004/	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+NVP	35.9/ Female/ 1.78	2/ 156/ 0.81	103.78	21MAY2004/ 18JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	31.9/ Female/ 1.37	3/ 173/ 0.88	59.10	27MAY2004/ 23JUN2004/	Haematological/ Neutropenia
				27MAY2004/ 22OCT2004/	CNS/ Pyogenic meningitis - organism
PPD PPD 3TC/ZDV+NVP	42.0/ Female/ 1.72	3/ 108/ 0.98	78.58	28MAY2004/ 17NOV2004/ 10DEC2004	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	32.0/ Male/ 1.81	3/ 135/ 0.98	97.82	02JUN2004/ 30JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	49.5/ Female/ 1.51	3/ 144/ 1.06	51.08	04JUN2004/ 02JUL2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	46.2/ Female/ 1.66	3/ 131/ 0.98	59.46	08JUN2004/ 06JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	37.6/ Male/ 1.63	3/ 123/ 0.79	97.16	17JUN2004/ 15JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	29.7/ Female/ 1.41	3/ 128/ 1.10	52.02	18JUN2004/ 10SEP2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+ABC	29.7/ Female/ 1.72	3/ 152/ 0.90	84.64	23JUN2004/ 17AUG2005/ 09NOV2005	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	24.0/ Female/ 1.53	2/ 185/ 0.86	87.32	24JUN2004/ 22JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	34.0/ Male/ 1.75	2/ 187/ 1.32	65.74	25JUN2004/ 06DEC2005/	Tumours/ Other Solid tumour
PPD PPD 3TC/ZDV+ABC	44.0/ Female/ 1.53	2/ 107/ 0.75	78.65	29JUN2004/ 27JUL2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	39.9/ Female/ 1.56	4/ 111/ 1.32	48.06	30JUN2004/ 22SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	33.6/ Female/ 1.44	3/ 140/ 0.88	62.45	08JUL2004/ 11MAY2006/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	32.1/ Male/ 1.60	3/ 169/ 1.10	76.66	13JUL2004/ 10AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	37.1/ Female/ 1.47	3/ 185/ 1.24	47.69	14JUL2004/ 09AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	38.4/ Female/ 1.56	3/ 110/ 0.95	68.58	19JUL2004/ 11OCT2004/	Haematological/ Anaemia with clinical symptoms
				19JUL2004/ 30MAR2005/	Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+NVP	29.6/ Female/ 1.85	2/ 102/ 0.83	116.4 1	20JUL2004/ 17AUG2004/ 14SEP2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	29.6/ Female/ 1.85	2/ 102/ 0.83	116.4 1	20JUL2004/ 12JUN2005/ 16JUN2005	Haematological/ Nose bleed, epistaxis
PPD PPD 3TC/ZDV+NVP	31.6/ Female/ 1.76	2/ 192/ 0.93	96.27	28JUL2004/ 07FEB2006/ 09FEB2006	Pregnancy associated/ Induced abortion
PPD PPD 3TC/ZDV+TDF	46.6/ Male/ 1.56	4/ 6/ 1.32	48.24	30JAN2003/ 13APR2003/ 20APR2003	Lower respiratory tract/ Pneumonia no organism identified, aspiration pneumonia
				30JAN2003/ 24APR2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	37.6/ Male/ 1.58	4/ 13/ 0.28	237.6 2	30JAN2003/ 08FEB2003/	Gastrointestinal/ Chronic diarrhoea with no pathogen

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.6/ Male/ 1.71	4/ 97/ 0.41	224.9 4	03FEB2003/ 28APR2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	44.4/ Male/ 1.57	3/ 6/ 0.75	88.34	05FEB2003/ 11MAY2003/	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	46.2/ Male/ 1.77	3/ 60/ 0.79	102.4 4	07FEB2003/ 09JAN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	36.3/ Female/ 1.70	3/ 9/ 0.73	99.41	06MAR2003/ 21AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	31.3/ Female/ 1.92	4/ 12/ 0.23	458.9 0	10MAR2003/ 31MAR2003/ 05MAY2003	Renal/ Lower urinary tract infection (UTI), cystitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.1/ Female/ 1.46	4/ 7/ 0.59	102.1 3	24MAR2003/ 17APR2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	35.1/ Male/ 1.58	3/ 10/ 0.72	103.3 8	26MAR2003/ 18JUN2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.6/ Male/ 1.78	4/ 32/ 0.83	105.5 3	28MAR2003/ 12SEP2003/ 21MAY2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.2/ Female/ 1.49	3/ 45/ 1.04	58.18	31MAR2003/ 14APR2003/ 26MAY2003	Eye/ Conjunctivitis, blepharitis, keratitis - allergic
PPD PPD 3TC/ZDV+TDF	38.5/ Female/ 1.75	3/ 35/ 0.81	95.07	31MAR2003/ 24SEP2003/	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	37.7/ Female/ 1.72	4/ 33/ 1.05	71.65	02APR2003/ 11APR2003/ 16APR2003	Gastrointestinal/ Haematemesis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.8/ Male/ 1.81	3/ 1/ 0.71	133.5 0	02APR2003/ 05MAY2003/ 23MAY2003	Hepatic/ Hepatitis cause unknown
PPD PPD 3TC/ZDV+TDF	34.8/ Female/ 1.63	3/ 3/ 0.54	118.0 5	03APR2003/ 26JUN2003/	Haematological/ Neutropenia
				03APR2003/ 01JUN2004/ 30JUL2004	Cardiovascular/ Congestive cardiac failure
PP PPD 3TC/ZDV+TDF	35.4/ Female/ 1.61	3/ 64/ 1.01	73.13	11APR2003/ 04JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.8/ Male/ 1.98	3/ 47/ 1.08	113.7 4	14APR2003/ 19APR2003/ 28APR2003	Lower respiratory tract/ Pneumonia no organism identified, aspiration pneumonia
PPD PPD 3TC/ZDV+TDF	43.4/ Male/ 1.73	3/ 4/ 1.11	71.67	23APR2003/ 20MAY2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.3/ Female/ 1.74	3/ 10/ 0.84	88.05	24APR2003/ 24OCT2003/ 19DEC2003	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	45.6/ Male/ 1.78	3/ 39/ 1.24	70.21	08MAY2003/ 01JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	32.4/ Male/ 1.70	3/ 21/ 0.66	136.59	08MAY2003/ 16DEC2004/ 06JAN2005	Haematological/ Neutropenia
				08MAY2003/ 10MAR2005/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.37	4/ 4/ 0.69	72.62	08MAY2003/ 11JUN2003/ 16JUN2003	Lower respiratory tract/ Bronchospasm/Asthma
PPD PPD 3TC/ZDV+TDF	33.3/ Female/ 1.67	3/ 8/ 0.78	93.34	12MAY2003/ 17JUL2003/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.77	3/ 70/ 0.48	172.9 3	16MAY2003/ 13JUN2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	45.4/ Female/ 1.32	3/ 14/ 0.76	62.98	27MAY2003/ 20JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.6/ Female/ 1.61	3/ 14/ 0.56	122.9 8	28MAY2003/ 20AUG2003/	Haematological/ Neutropenia
				28MAY2003/ 15OCT2003/ 17OCT2003	Cardiovascular/ Hypotension/shock/ toxic shock
PPD PPD 3TC/ZDV+TDF	37.2/ Male/ 1.95	3/ 40/ 0.66	160.4 4	05JUN2003/ 12FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.6/ Female/ 1.59	4/ 62/ 0.88	84.16	06JUN2003/ 05OCT2003/ 15OCT2003	Skin/ Rash, urticaria
PPD PPD 3TC/ZDV+TDF	28.2/ Female/ 1.46	4/ 10/ 0.68	90.92	10JUN2003/ 08JUL2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.52	2/ 91/ 0.61	115.0 7	10JUN2003/ 27OCT2004/	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	44.8/ Male/ 1.76	3/ 18/ 0.73	120.6 4	12JUN2003/ 10JUL2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	36.4/ Male/ 1.87	2/ 71/ 3.45	31.12	13JUN2003/ 19FEB2004/	Gastrointestinal/ Vomiting
				13JUN2003/ 03MAY2004/	Renal/ Renal failure - chronic
PPD PPD 3TC/ZDV+TDF	37.9/ Male/ 1.60	3/ 27/ 0.97	86.39	18JUN2003/ 03NOV2004/ 12NOV2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.6/ Female/ 1.71	2/ 24/ 0.61	151.2 1	25JUN2003/ 10DEC2003/	Haematological/ Neutropenia
				25JUN2003/ 23JUN2004/ 18AUG2004	Gastrointestinal/ Vomiting

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.6/ Female/ 1.71	2/ 24/ 0.61	151.2 1	25JUN2003/ 11FEB2005/ 14FEB2005	Haematological/ Anaemia with clinical symptoms
PP D PPD 3TC/ZDV+TDF	36.4/ Female/ 1.57	4/ 21/ 0.73	90.16	25JUN2003/ 17SEP2003/ 03OCT2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.78	3/ 33/ 0.91	99.13	26JUN2003/ 16SEP2003/ 25SEP2003	Haematological/ Anaemia with clinical symptoms
				26JUN2003/ 04APR2004/	Cardiovascular/ Hypotension/shock/ toxic shock
PPD PPD 3TC/ZDV+TDF	35.7/ Male/ 1.64	2/ 92/ 0.69	122.0 2	30JUN2003/ 28AUG2003/ 26FEB2004	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+TDF	30.9/ Female/ 1.61	3/ 48/ 0.72	103.4 0	30JUN2003/ 22SEP2003/ 26SEP2003	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.0/ Male/ 1.18	2/ 87/	72.41	30JUN2003/ 28JUL2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	42.0/ Female/ 1.48	3/ 71/ 0.38	162.5 9	30JUN2003/ 25AUG2003/ 09SEP2003	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	35.6/ Male/ 1.59	3/ 47/ 1.00	71.49	01JUL2003/ 14JAN2004/ 18JAN2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	44.1/ Male/ 1.73	3/ 1/ 0.99	83.62	02JUL2003/ 24SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.5/ Male/ 1.58	3/ 2/ 1.12	69.36	02JUL2003/ 22SEP2003/ 26SEP2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.6/ Female/ 1.41	3/ 66/ 0.92	59.85	02JUL2003/ 28AUG2003/ 01SEP2003	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	51.1/ Male/ 1.74	3/ 45/ 1.03	82.88	08JUL2003/ 04AUG2003/ 06OCT2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.6/ Male/ 1.56	3/ 30/ 1.21	61.55	08JUL2003/ 10SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	26.3/ Female/ 1.36	3/ 98/ 0.86	70.02	09JUL2003/ 03SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	40.3/ Female/ 1.68	3/ 51/ 1.11	67.62	09JUL2003/ 19SEP2003/	Hepatic/ Hepatitis cause unknown
PPD PPD 3TC/ZDV+TDF	26.8/ Female/ 1.40	4/ 3/ 1.23	49.60	11JUL2003/ 26NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	46.1/ Female/ 1.44	3/ 62/ 0.57	87.24	14JUL2003/ 01DEC2003/	Cardiovascular/ Congestive cardiac failure
				14JUL2003/ 22MAR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	37.4/ Male/ 1.65	3/ 66/ 0.86	83.51	14JUL2003/ 07AUG2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	42.3/ Male/ 1.53	4/ 94/ 0.88	81.45	14JUL2003/ 08AUG2003/	Gastrointestinal/ Gall stones, cholecystitis, cholelithiasis
				14JUL2003/ 13AUG2003/	Gastrointestinal/ Pancreatitis
PPD PPD 3TC/ZDV+TDF	35.7/ Male/ 1.68	3/ 77/ 0.95	96.13	15JUL2003/ 03NOV2003/ 07NOV2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	40.4/ Female/ 1.22	3/ 43/ 0.80	52.47	16JUL2003/ 28JAN2004/ 24MAR2004	Gastrointestinal/ Vomiting
				16JUL2003/ 02JUN2004/	CNS/ Peripheral neuropathy - sensory & motor

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	46.3/ Female/ 1.74	4/ 64/ 1.37	60.19	16JUL2003/ 15SEP2003/	Cardiovascular/ Congestive cardiac failure
				16JUL2003/ 17APR2004/	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+TDF	40.9/ Female/ 1.50	4/ 67/ 0.93	68.73	21JUL2003/ 07OCT2003/ 14OCT2003	Haematological/ Anaemia with clinical symptoms
				21JUL2003/ 22NOV2003/	Cardiovascular/ Hypotension/shock/ toxic shock
PPD PPD 3TC/ZDV+TDF	32.4/ Female/ 1.49	3/ 74/ 0.81	82.54	28JUL2003/ 25AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.1/ Female/ 1.82	4/ 30/ 0.66	134.0 6	31JUL2003/ 24AUG2004/	Musculoskeletal/ Bone fracture

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	38.1/ Female/ 1.47	4/ 70/ 0.56	104.98	06AUG2003/ 29OCT2003/ 04NOV2003	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	51.4/ Female/ 1.60	4/ 49/ 0.63	96.30	06AUG2003/ 03SEP2003/	Haematological/ Neutropenia
				06AUG2003/ 29OCT2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	41.3/ Female/ 1.66	4/ 79/ 0.94	80.29	08AUG2003/ 21JAN2004/	Haematological/ Neutropenia
				08AUG2003/ 16FEB2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.79	3/ 64/ 0.91	104.00	12AUG2003/ 11FEB2004/ 24FEB2004	Cardiovascular/ Other cardiovascular
				12AUG2003/ 23MAR2004/	Cardiovascular/ Hypotension/shock/ toxic shock

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.79	3/ 64/ 0.91	104.0 0	12AUG2003/ 23MAR2004/	Cardiovascular/ Hypertension
PPD PPD 3TC/ZDV+TDF	35.2/ Female/ 1.44	3/ 27/ 0.83	68.08	12AUG2003/ 02DEC2003/ 08DEC2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	45.0/ Female/ 1.25	3/ 25/ 0.56	68.84	12AUG2003/ 09SEP2003/	Haematological/ Neutropenia
				12AUG2003/ 27JAN2004/ 07JUL2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	53.2/ Female/ 1.42	3/ 74/ 0.74	66.98	12AUG2003/ 27OCT2003/ 03NOV2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.8/ Female/ 1.57	3/ 43/ 0.92	73.34	12AUG2003/ 09SEP2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.1/ Female/ 1.61	4/ 31/ 1.08	63.50	12AUG2003/ 07OCT2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	30.7/ Male/ 1.78	3/ 24/ 0.77	125.44	14AUG2003/ 12SEP2003/	Hepatic/ Jaundice
				14AUG2003/ 25NOV2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	25.0/ Male/ 1.50	4/ 26/ 0.83	92.54	15AUG2003/ 16SEP2003/ 06OCT2003	Haematological/ Pancytopenia, bone marrow depression
				15AUG2003/ 30SEP2003/ 06OCT2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	27.2/ Female/ 1.72	3/ 23/ 0.88	96.25	18AUG2003/ 10NOV2003/ 08DEC2003	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	48.0/ Male/ 1.58	3/ 77/ 1.15	63.44	19AUG2003/ 16SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	55.2/ Male/ 1.50	2/ 83/ 1.21	51.22	19AUG2003/ 19SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.2/ Female/ 1.41	4/ 52/ 1.37	37.42	20AUG2003/ 10NOV2003/	Haematological/ Anaemia with clinical symptoms
					Cardiovascular/ Hypotension/shock/ toxic shock
PPD PPD 3TC/ZDV+TDF	43.3/ Female/ 1.53	3/ 79/ 0.65	93.59	21AUG2003/ 09DEC2004/	CNS/ Stroke, cerebrovascular accident
				21AUG2003/ 03JAN2005/	Biochemical/ Raised liver enzymes

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.5/ Male/ 1.84	2/ 45/ 0.93	113.8 8	22AUG2003/ 10DEC2004/ 12DEC2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	40.2/ Female/ 1.94	3/ 18/ 0.87	113.3 8	25AUG2003/ 05FEB2004/ 14FEB2004	Haematological/ Anaemia with clinical symptoms
				25AUG2003/ 04OCT2004/	CNS/ Parathesia, transient numbness, tingling
PPD PPD 3TC/ZDV+TDF	33.7/ Female/ 1.41	3/ 10/ 0.70	75.97	25AUG2003/ 17NOV2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	35.0/ Female/ 1.40	3/ 25/ 0.84	66.95	29AUG2003/ 26SEP2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.4/ Female/ 1.59	3/ 81/ 0.85	82.54	01SEP2003/ 18MAR2005/	CNS/ Other neuropathy, not peripheral, not diabetic or HIV related
PPD PPD 3TC/ZDV+TDF	32.9/ Female/ 1.52	3/ 33/ 0.67	94.79	01SEP2003/ 29SEP2003/ 27OCT2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.9/ Female/ 1.33	4/ 37/ 0.56	90.52	02SEP2003/ 24SEP2003/ 03OCT2003	<Unknown>/ <Unknown>
PPD PPD 3TC/ZDV+TDF	40.4/ Male/ 1.88	3/ 59/ 0.96	104.74	03SEP2003/ 21NOV2003/ 03SEP2003/ 06JUL2005/ 03AUG2005	Biochemical/ Raised liver enzymes Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	24.2/ Female/ 1.36	3/ 14/ 0.57	97.01	03SEP2003/ 27OCT2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	30.8/ Female/ 1.51	3/ 72/ 0.93	79.45	04SEP2003/ 27NOV2003/ 01DEC2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	38.3/ Female/ 1.48	3/ 25/ 0.85	66.90	04SEP2003/ 25DEC2003/	Gastrointestinal/ Abdominal or epigastric pain
PP PPD 3TC/ZDV+TDF	33.7/ Female/	4/ 16/ 0.59	122.12	04SEP2003/ 13MAY2004/ 19MAY2004	Haematological/ Anaemia with clinical symptoms
				04SEP2003/ 08DEC2004/	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	43.3/ Male/ 1.95	3/ 28/ 0.88	119.90	08SEP2003/ 06OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.4/ Female/ 1.49	3/ 95/ 0.73	82.01	09SEP2003/ 04NOV2003/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	28.7/ Female/ 1.27	4/ 96/ 1.17	40.52	09SEP2003/ 23SEP2003/ 02OCT2003	Gastrointestinal/ Indigestion, oesophageal reflux, gastritis, ulcerative oesophagitis
				09SEP2003/ 06NOV2003/	Cardiovascular/ Chest pain
PP PPD 3TC/ZDV+TDF	61.2/ Male/ 1.87	3/ 35/ 0.95	76.73	11SEP2003/ 08OCT2003/ 05NOV2003	Haematological/ Neutropenia
				11SEP2003/ 18JAN2004/ 12AUG2004	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	40.1/ Male/ 1.51	3/ 78/ 0.97	71.67	18SEP2003/ 16OCT2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.3/ Female/ 1.60	3/ 60/ 0.75	90.93	23SEP2003/ 15NOV2003/	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
PPD PPD 3TC/ZDV+TDF	37.5/ Male/ 1.67	3/ 52/ 1.25	65.07	26SEP2003/ 16OCT2003/ 03NOV2003	Gastrointestinal/ Pancreatitis
PPD PPD 3TC/ZDV+TDF	25.3/ Female/ 1.43	3/ 23/ 0.54	106.49	29SEP2003/ 27OCT2003/	Haematological/ Neutropenia
				29SEP2003/ 17DEC2003/ 15MAR2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	28.8/ Female/ 1.67	3/ 17/ 0.58	144.41	02OCT2003/ 18MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.6/ Female/ 1.43	3/ 0/ 0.73	72.38	07OCT2003/ 30DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.6/ Female/ 1.43	3/ 0/ 0.73	72.38	07OCT2003/ 15JUN2004/	Biochemical/ Raised AST
PPD PPD 3TC/ZDV+TDF	43.3/ Male/ 1.89	3/ 10/ 1.17	87.37	17OCT2003/ 13NOV2003/ 08JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.0/ Male/ 1.57	4/ 31/ 0.38	173.1 0	20OCT2003/ 11DEC2003/ 15DEC2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	34.4/ Female/ 1.47	4/ 92/ 1.67	36.47	22OCT2003/ 03NOV2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	49.6/ Male/ 1.50	3/ 94/ 1.24	50.70	24OCT2003/ 21NOV2003/ 16JAN2004	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	36.8/ Male/ 1.71	4/ 21/ 0.92	88.99	27OCT2003/ 24NOV2003/ 10DEC2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.8/ Female/ 1.28	3/ 4/ 0.56	78.07	28OCT2003/ 24NOV2003/	Haematological/ Neutropenia
				28OCT2003/ 18AUG2005/	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	32.9/ Male/ 1.65	3/ 19/ 0.84	97.60	29OCT2003/ 15NOV2003/	Specific Infections/ P falciparum malaria
				29OCT2003/ 16NOV2003/	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+TDF	34.0/ Male/ 1.70	3/ 6/ 0.83	105.8 0	29OCT2003/ 18DEC2003/	Cardiovascular/ Congestive cardiac failure
PP PPD 3TC/ZDV+TDF	36.4/ Male/ 1.78	4/ 3/ 0.62	158.1 3	07NOV2003/ 31MAY2005/	Biochemical/ Raised AST
				07NOV2003/ 10JUN2005/	Renal/ Renal failure - acute

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	36.1/ Female/ 1.45	4/ 96/ 3.31	18.09	10NOV2003/ 05DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.2/ Female/ 1.69	3/ 67/ 0.93	77.53	10NOV2003/ 03FEB2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	37.7/ Male/ 1.72	4/ 90/ 0.84	101.6 3	14NOV2003/ 09DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	31.4/ Male/ 1.69	3/ 5/ 1.09	87.33	17NOV2003/ 10JAN2005/ 19JAN2005 17NOV2003/ 10MAY2005/ 16MAY2005	Haematological/ Neutropenia Renal/ Haematuria
PPD PPD 3TC/ZDV+TDF	30.3/ Male/ 1.63	4/ 1/ 0.90	90.77	18NOV2003/ 16DEC2003/ 13JAN2004 18NOV2003/ 19OCT2004/	Biochemical/ Raised liver enzymes Biochemical/ Raised bilirubin

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	30.6/ Female/ 1.29	3/ 69/ 0.59	87.30	19NOV2003/ 17DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	47.8/ Female/ 1.53	3/ 27/ 0.65	87.64	05APR2004/ 30MAY2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	38.6/ Male/ 1.57	4/ 28/ 0.85	83.01	06APR2004/ 01JUN2004/ 10JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.9/ Female/ 1.31	3/ 15/ 0.83	59.31	11MAY2004/ 15JUN2004/ 12JUL2004	Haematological/ Anaemia with clinical symptoms
				11MAY2004/ 05JUL2005/	Hepatic/ Lactic acidosis
PP PPD 3TC/ZDV+TDF	70.8/ Male/ 1.96	3/ 41/ 1.31	61.76	24MAY2004/ 31JAN2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.2/ Female/ 1.65	4/ 9/ 0.86	81.63	07JUN2004/ 29AUG2005/ 04NOV2005	Hepatic/ Lactic acidosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	39.3/ Female/ 1.51	3/ 27/ 0.77	72.32	24JUN2004/ 09DEC2004/	Haematological/ Neutropenia
				24JUN2004/ 10APR2006/	Biochemical/ Hyponatraemia
PPD PPD 3TC/ZDV+TDF	41.7/ Female/ 1.53	3/ 24/ 1.01	57.25	01JUL2004/ 23SEP2004/ 27SEP2004	Haematological/ Anaemia with clinical symptoms
				01JUL2004/ 30JUN2005/ 04NOV2005	Hepatic/ Lactic acidosis
PP PPD 3TC/ZDV+TDF	35.0/ Male/ 1.72	3/ 8/ 1.05	78.65	05JUL2004/ 14MAR2005/ 25MAR2005	Systemic/ Hypersensitivity reaction
PP PPD 3TC/ZDV+TDF	52.2/ Male/ 1.80	3/ 32/ 0.99	83.93	07JUL2004/ 29SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.0/ Male/ 1.65	3/ 15/ 0.85	90.92	13JUL2004/ 09AUG2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.6/ Female/ 1.43	3/ 14/ 0.56	105.3 1	22JUL2004/ 19AUG2004/ 14OCT2004	Haematological/ Neutropenia
				22JUL2004/ 06JAN2005/ 08JAN2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	30.1/ Female/ 1.27	4/ 16/ 0.46	105.1 5	23JUL2004/ 18AUG2004/ 25AUG2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.2/ Female/ 1.61	4/ 47/ 1.12	71.81	28JUL2004/ 23AUG2004/ 20SEP2004	Haematological/ Neutropenia
				28JUL2004/ 08DEC2005/	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	27.9/ Female/ 1.53	3/ 5/ 1.29	52.14	06AUG2004/ 21AUG2004/ 19OCT2004	Haematological/ Anaemia with clinical symptoms
				06AUG2004/ 01JAN2006/	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	32.0/ Female/ 1.59	3/ 65/ 0.55	141.3 9	09AUG2004/ 02JAN2006/ 20MAR2006	Hepatic/ Lactic acidosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.4/ Male/ 1.55	3/ 56/ 1.03	71.29	10AUG2004/ 07SEP2004/	Haematological/ Neutropenia
				10AUG2004/ 02NOV2004/	Biochemical/ Raised bilirubin
PPD PPD 3TC/ZDV+TDF	44.6/ Female/ 1.56	2/ 22/ 0.67	97.97	24AUG2004/ 30MAY2006/ 25JUL2006	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	42.8/ Female/ 1.60	3/ 7/ 0.67	88.72	25AUG2004/ 15SEP2004/	Endocrine/ Diabetes - Type I
PP PPD 3TC/ZDV+TDF	30.0/ Female/ 1.89	4/ 14/ 0.92	114.1 3	09SEP2004/ 26OCT2004/	Gastrointestinal/ Vomiting
				09SEP2004/ 27JUN2005/	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	31.7/ Female/ 1.53	3/ 156/ 0.23	307.6 2	15JAN2003/ 15JUN2004/	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	61.8/ Female/ 1.81	3/ 133/ 0.58	120.6 2	16JAN2003/ 03JUL2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	59.3/ Male/ 1.85	4/ 101/ 1.05	68.47	10FEB2003/ 11JUL2003/	Psychiatric/ Depression
PPD PPD 3TC/ZDV+TDF	48.5/ Female/ 1.74	3/ 178/ 0.19	405.3 4	10MAR2003/ 28MAY2003/ 22AUG2003	Haematological/ Anaemia with clinical symptoms
				10MAR2003/ 09JAN2004/ 30APR2004	CNS/ Peripheral neuropathy - sensory only
PPD PPD 3TC/ZDV+TDF	31.5/ Female/ 1.74	2/ 135/ 0.27	293.1 0	18MAR2003/ 10JUN2003/ 02SEP2004	Haematological/ Neutropenia
				18MAR2003/ 08JUL2003/	Cardiovascular/ Congestive cardiac failure
					Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	49.9/ Male/ 1.78	3/ 193/ 0.97	91.09	25MAR2003/ 22APR2003/	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+TDF	48.9/ Female/ 1.86	4/ 101/ 0.91	102.4 8	12MAY2003/ 16FEB2004/	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	46.9/ Female/ 1.54	4/ 135/ 0.75	81.81	02JUN2003/ 20OCT2003/ 27OCT2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	40.4/ Male/ 1.70	2/ 197/ 1.59	50.54	02JUN2003/ 20OCT2003/ 31OCT2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	34.9/ Male/ 1.83	3/ 106/ 1.11	89.61	06JUN2003/ 22OCT2004/ 28OCT2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	28.7/ Male/ 1.84	2/ 160/ 1.17	94.03	10JUN2003/ 02SEP2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.5/ Male/ 1.67	4/ 165/ 1.50	56.87	16JUN2003/ 05AUG2003/	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
				16JUN2003/ 13AUG2003/ 04NOV2003	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	33.4/ Female/ 1.57	3/ 177/ 0.64	119.5 7	26JUN2003/ 21AUG2003/ 18SEP2003	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	36.9/ Female/ 1.82	3/ 178/ 0.72	122.5 2	30JUN2003/ 22SEP2003/ 25SEP2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.9/ Female/ 1.70	3/ 184/ 1.02	81.96	01JUL2003/ 02JUL2003/ 15SEP2003	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	39.9/ Female/ 1.47	3/ 157/ 1.06	55.56	02JUL2003/ 24SEP2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	39.9/ Female/ 1.47	3/ 157/ 1.06	55.56	02JUL2003/ 01AUG2003/	Cardiovascular/ Pericarditis not TB or bacterial or no cause identified
PPD PPD 3TC/ZDV+TDF	37.7/ Female/ 1.89	3/ 165/ 0.43	249.98	07JUL2003/ 29SEP2003/ 03OCT2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	32.5/ Female/ 2.01	4/ 162/ 0.98	109.75	08JUL2003/ 13NOV2003/ 25NOV2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	45.3/ Male/ 1.83	2/ 182/ 1.39	66.40	09JUL2003/ 06AUG2003/ 03SEP2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	48.2/ Male/ 1.69	3/ 174/ 1.32	58.83	10JUL2003/ 12MAY2005/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.8/ Female/ 1.47	3/ 127/ 0.40	152.6 7	14JUL2003/ 01DEC2003/ 04DEC2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	43.6/ Female/ 1.63	3/ 151/ 1.18	58.85	14JUL2003/ 08OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.7/ Female/ 1.52	3/ 122/ 0.84	79.14	15JUL2003/ 11AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.8/ Female/ 1.95	3/ 104/ 0.88	120.5 3	16JUL2003/ 08OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.3/ Female/ 1.30	3/ 199/ 0.57	82.33	17JUL2003/ 22SEP2004/	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	31.2/ Female/ 1.60	3/ 174/ 0.57	123.9 3	18JUL2003/ 19SEP2003/ 21NOV2003	Cardiovascular/ Congestive cardiac failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.8/ Male/ 1.67	3/ 182/ 1.36	70.75	22JUL2003/ 19AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	46.9/ Female/ 1.46	3/ 154/ 0.63	83.44	28JUL2003/ 20OCT2003/ 27OCT2003	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	31.0/ Female/ 1.40	3/ 33/ 1.06	52.04	28JUL2003/ 20OCT2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	46.1/ Male/ 1.67	3/ 160/ 0.47	172.62	29JUL2003/ 06APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	47.1/ Female/ 1.37	3/ 136/ 0.74	64.53	07AUG2003/ 20AUG2003/	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	27.4/ Female/ 1.59	4/ 103/ 0.47	169.17	12AUG2003/ 04NOV2003/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	28.2/ Male/ 1.61	3/ 104/ 1.62	53.79	19AUG2003/ 29FEB2004/ 30MAR2004	Other/ Non-fatal trauma
PPD PPD 3TC/ZDV+TDF	31.3/ Male/ 1.70	3/ 102/ 1.26	67.48	20AUG2003/ 17SEP2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.1/ Male/ 1.64	4/ 146/ 0.75	119.0 3	20AUG2003/ 30MAR2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.4/ Female/ 1.37	4/ 117/ 0.73	62.28	26AUG2003/ 21OCT2003/ 27OCT2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	43.6/ Female/ 2.00	2/ 154/ 0.70	144.9 8	28AUG2003/ 12FEB2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	53.7/ Female/ 1.61	3/ 199/ 0.78	73.46	29AUG2003/ 25SEP2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.9/ Female/ 1.52	4/ 187/ 1.05	60.81	09SEP2003/ 02DEC2003/ 08DEC2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	47.5/ Female/ 1.55	3/ 161/ 0.68	88.05	10SEP2003/ 19MAY2004/ 25JUN2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	42.7/ Male/ 1.63	3/ 189/ 1.04	69.00	15SEP2003/ 01MAR2004/ 24MAR2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.8/ Female/ 1.51	3/ 100/ 1.28	48.81	21OCT2003/ 26JUN2005/ 05NOV2005	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	24.2/ Male/ 1.63	3/ 136/ 0.38	228.9 1	05NOV2003/ 03DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.7/ Female/ 1.46	4/ 100/ 0.96	61.49	06MAY2004/ 31MAY2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	52.5/ Female/ 1.62	3/ 172/ 1.06	66.72	25MAY2004/ 14SEP2004/ 21SEP2004	Haematological/ Anaemia with clinical symptoms
				25MAY2004/ 14APR2005/ 25MAY2004/ 03MAY2005/	Gastrointestinal/ Pancreatitis Hepatic/ Lactic acidosis CNS/ Acute altered conscious level
PPD PPD 3TC/ZDV+TDF	30.6/ Female/ 1.55	3/ 110/ 0.62	118.38	08JUN2004/ 05JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	23.5/ Female/ 1.66	4/ 107/ 0.50	178.25	04AUG2004/ 30MAR2005/ 04APR2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	41.7/ Male/ 1.60	3/ 167/ 0.78	89.46	06AUG2004/ 02SEP2004/ 09SEP2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	59.8/ Male/ 1.49	4/ 160/ 0.70	79.78	17AUG2004/ 14SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.0/ Female/ 1.59	2/ 136/ 0.71	87.81	24AUG2004/ 04NOV2004/ 07NOV2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	51.6/ Male/ 1.99	2/ 120/ 1.75	56.44	30AUG2004/ 03JUL2006/	Renal/ Renal failure - chronic Renal/ Renal colic, renal stones, uroliathiasis
PPD PPD 3TC/ZDV+TDF	41.6/ Male/ 1.73	3/ 169/ 1.61	49.67	03SEP2004/ 01OCT2004/ 29OCT2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	24.2/ Female/ 1.40	3/ 108/ 1.13	54.24	06SEP2004/ 04OCT2004/ 14OCT2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	47.7/ Female/ 1.57	3/ 150/ 1.13	51.05	06SEP2004/ 10JUL2006/ 07AUG2006	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	40.2/ Female/ 1.62	3/ 101/ 1.00	71.61	09SEP2004/ 07OCT2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	32.8/ Female/ 1.80	2/ 67/ 0.76	115.3 4	05JAN2004/ 28JAN2004/ 01MAR2004	Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+ABC	37.6/ Female/ 1.36	2/ 75/ 0.55	87.60	28JAN2004/ 21APR2004/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	39.4/ Female/ 1.65	3/ 51/ 0.74	113.5 4	05FEB2004/ 14OCT2004/ 09DEC2004	Biochemical/ Raised ALT
PPD PPD 3TC/ZDV+NVP	42.1/ Female/ 1.61	2/ 87/ 0.55	114.1 1	18FEB2004/ 17MAR2004/ 01SEP2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	31.8/ Female/ 1.48	4/ 21/ 0.62	106.3 6	05APR2004/ 03MAY2004/	Haematological/ Anaemia with clinical symptoms
				05APR2004/ 23APR2004/ 19MAY2004	Gastrointestinal/ Haematemesis
PPD PPD 3TC/ZDV+ABC	39.6/ Female/ 1.70	3/ 79/ 0.62	138.5 6	13APR2004/ 15MAR2005/ 25APR2005	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+NVP	34.9/ Female/ 1.28	3/ 51/ 0.60	75.84	16APR2004/ 05JUN2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	34.2/ Female/ 1.72	2/ 74/ 0.95	92.81	19APR2004/ 10SEP2004/ 16SEP2004	Haematological/ Anaemia with clinical symptoms
				19APR2004/ 04MAY2005/	CNS/ Acute altered conscious level

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	34.2/ Female/ 1.72	2/ 74/ 0.95	92.81	19APR2004/ 19MAY2005/	Lower respiratory tract/ Pneumonia no organism identified, aspiration pneumonia
PP PPD 3TC/ZDV+NVP	39.9/ Female/ 1.55	4/ 80/ 0.53	119.8 4	22APR2004/ 07OCT2004/ 04NOV2004	Haematological/ Neutropenia
PP PPD 3TC/ZDV+ABC	21.0/ Female/ 1.74	2/ 6/ 0.70	133.7 6	28APR2004/ 26MAY2004/ 02JUL2004 28APR2004/ 20JUL2004/	Haematological/ Neutropenia Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+NVP	33.5/ Female/ 1.50	4/ 67/ 0.51	115.9 4	07MAY2004/ 02JUL2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	41.7/ Female/ 1.66	3/ 56/ 0.81	89.00	18MAY2004/ 23JUL2004/	Haematological/ Anaemia with clinical symptoms
				18MAY2004/ 06APR2005/ 31MAY2005	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+NVP	45.7/ Male/ 1.74	3/ 91/ 1.27	65.00	20MAY2004/ 09AUG2004/	Haematological/ Anaemia with clinical symptoms
PP D PPD 3TC/ZDV+NVP	42.3/ Female/ 1.73	2/ 60/ 0.73	115.4 1	25MAY2004/ 02MAY2005/ 12OCT2005	<Unknown>/ <Unknown>
PPD PPD 3TC/ZDV+NVP	41.6/ Female/ 1.66	2/ 86/ 0.91	80.12	01JUN2004/ 05OCT2005/ 15NOV2005	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+NVP	34.0/ Male/ 1.77	3/ 70/ 1.06	89.32	29JUN2004/ 27JUL2004/	Haematological/ Neutropenia
				29JUN2004/ 17SEP2004/	CNS/ Meningitis - other

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	42.5/ Male/ 1.42	3/ 52/ 0.90	66.65	07JUL2004/ 29SEP2004/ 25NOV2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	27.1/ Female/ 1.35	3/ 33/ 0.83	67.68	09JUL2004/ 05AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	33.7/ Female/ 1.40	3/ 35/ 0.78	75.38	16JUL2004/ 13AUG2004/ 31DEC2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	35.2/ Male/ 1.57	3/ 19/ 0.65	121.2 0	21JUL2004/ 25JAN2005/ 28JAN2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	28.1/ Female/ 1.37	3/ 16/ 0.55	99.36	22JUL2004/ 19AUG2004/ 12OCT2004 22JUL2004/ 27SEP2005/ 07OCT2005	Haematological/ Neutropenia Systemic/ Hypersensitivity reaction
PPD PPD 3TC/ZDV+NVP	35.6/ Female/ 1.61	3/ 10/ 0.78	88.25	29JUL2004/ 21OCT2004/ 08NOV2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	26.9/ Female/ 1.55	4/ 52/ 0.65	107.4 7	02AUG2004/ 17AUG2004/	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+NVP	45.1/ Male/ 1.67	4/ 22/ 1.01	74.77	03AUG2004/ 05JUL2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	34.6/ Female/ 1.54	3/ 7/ 0.72	95.59	04AUG2004/ 01SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	34.6/ Female/ 1.27	4/ 98/ 0.89	51.56	06AUG2004/ 03SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	42.8/ Female/ 1.52	4/ 21/ 0.77	83.48	12AUG2004/ 09SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	31.9/ Male/ 1.72	3/ 67/ 0.86	112.0 0	19AUG2004/ 07OCT2004/ 18OCT2004	Systemic/ Hypersensitivity reaction

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	44.9/ Female/ 1.83	2/ 99/ 1.07	83.23	01SEP2004/ 20SEP2004/ 06OCT2004 01SEP2004/ 29SEP2004/ 06OCT2004	Systemic/ Hypersensitivity reaction Biochemical/ Raised liver enzymes
PP P PPD 3TC/ZDV+ABC	44.8/ Female/ 1.42	3/ 90/ 0.87	59.38	02SEP2004/ 30SEP2004/ 17FEB2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	37.2/ Female/ 1.55	3/ 97/ 1.27	51.90	07SEP2004/ 22FEB2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	28.2/ Female/ 1.65	2/ 34/ 0.72	107.0 3	10SEP2004/ 03DEC2004/ 06DEC2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	36.0/ Female/ 1.35	3/ 89/ 0.81	61.99	24SEP2004/ 10OCT2004/ 27OCT2004	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	42.7/ Female/ 2.03	2/ 32/ 0.99	113.3 4	27SEP2004/ 25OCT2004/ 22NOV2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	19.9/ Female/ 1.64	3/ 33/ 1.86	44.99	27SEP2004/ 25OCT2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	34.8/ Female/ 1.53	3/ 28/ 0.54	119.2 1	27SEP2004/ 27MAY2005/ 30MAY2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	26.8/ Female/ 1.84	4/ 28/ 1.16	87.82	27SEP2004/ 25OCT2004/ 14MAR2005	Haematological/ Neutropenia
PP D PPD 3TC/ZDV+NVP	30.8/ Female/ 1.72	4/ 16/ 0.99	81.12	01OCT2004/ 29OCT2004/	Haematological/ Neutropenia
				01OCT2004/ 15NOV2004/ 17NOV2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	37.6/ Male/ 1.50	4/ 10/ 1.66	41.65	05OCT2004/ 03NOV2004/ 17MAY2005	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+ABC	38.6/ Female/ 1.61	3/ 72/ 1.13	57.53	12OCT2004/ 09NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	37.0/ Female/ 1.59	3/ 88/ 0.90	83.51	12OCT2004/ 09NOV2004/ 07DEC2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	35.6/ Male/ 1.65	3/ 39/ 1.45	59.11	12OCT2004/ 07DEC2005/ 22DEC2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	35.8/ Female/ 1.83	4/ 25/ 1.06	89.50	19OCT2004/ 29MAR2005/ 04APR2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	36.8/ Male/ 1.63	4/ 10/ 1.09	76.54	25OCT2004/ 22NOV2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	36.8/ Male/ 1.63	4/ 10/ 1.09	76.54	25OCT2004/ 27JAN2006/ 02FEB2006	Haematological/ Anaemia with clinical symptoms
				25OCT2004/ 09MAY2006/ 15MAY2006	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+NVP	28.4/ Female/ 1.27	4/ 27/ 0.74	60.32	25OCT2004/ 02MAY2005/ 31MAY2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	35.1/ Male/ 1.51	2/ 56/ 0.81	87.01	26OCT2004/ 23NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	24.2/ Female/ 1.43	2/ 107/ 0.86	79.23	27JAN2004/ 25FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	34.8/ Female/ 1.91	2/ 178/ 0.75	135.3 6	29JAN2004/ 14APR2004/ 19APR2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	36.5/ Female/ 1.53	4/ 191/ 0.62	101.7 3	02FEB2004/ 19JUL2004/ 06APR2005	Musculoskeletal/ Myopathy, muscle wasting
PPD PPD 3TC/ZDV+ABC	48.7/ Female/ 1.99	2/ 133/ 0.65	145.5 0	09FEB2004/ 03MAY2004/	Musculoskeletal/ Myopathy, muscle wasting
PPD PPD 3TC/ZDV+NVP	28.2/ Female/ 1.60	4/ 110/ 0.83	94.12	19FEB2004/ 18MAR2004/ 23MAR2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	36.2/ Female/ 1.70	2/ 107/ 0.69	113.1 1	26FEB2004/ 25MAR2004/	Haematological/ Neutropenia
PP P PPD 3TC/ZDV+ABC	34.5/ Female/ 1.75	4/ 165/ 0.70	120.5 9	03MAR2004/ 21MAR2004/ 27MAY2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	58.2/ Female/ 1.54	3/ 150/ 0.83	67.83	11MAR2004/ 16NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	41.7/ Female/ 1.70	3/ 119/ 0.99	78.90	19MAR2004/ 23JUL2004/ 26JUL2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+ABC	41.7/ Female/ 1.70	3/ 119/ 0.99	78.90	19MAR2004/ 15APR2005/	CNS/ Peripheral neuropathy - sensory & motor
					CNS/ Peripheral neuropathy - sensory only
PPD PPD 3TC/ZDV+NVP	31.4/ Male/ 1.97	4/ 174/ 1.14	92.14	25MAR2004/ 22APR2004/ 11MAY2004	Hepatic/ Hepatic failure
PPD PPD 3TC/ZDV+ABC	44.1/ Female/ 1.68	3/ 122/ 0.91	73.14	06APR2004/ 04MAY2004/ 29JUN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	41.3/ Female/ 1.64	3/ 175/ 0.72	99.22	05MAY2004/ 02JUN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	57.6/ Male/ 1.55	3/ 196/ 0.94	67.95	13MAY2004/ 07JAN2005/ 14JAN2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	41.9/ Female/ 1.54	3/ 109/ 0.99	64.52	13MAY2004/ 04NOV2005/	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+NVP	39.5/ Female/ 1.78	3/ 117/ 1.05	82.54	20MAY2004/ 18AUG2005/ 19AUG2005	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+ABC	25.2/ Female/ 1.58	2/ 192/ 0.76	101.2 7	07JUN2004/ 16AUG2004/ 30AUG2004	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+NVP	34.9/ Female/ 1.51	3/ 191/ 0.94	69.31	22JUN2004/ 20JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	46.1/ Female/ 1.49	3/ 127/ 0.64	79.45	13JUL2004/ 17SEP2004/	Gastrointestinal/ Paralitic ileus, ileitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	39.4/ Female/ 1.63	3/ 147/ 0.60	109.5 3	22JUL2004/ 22AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	50.5/ Male/ 1.47	4/ 104/ 1.00	56.08	03AUG2004/ 10OCT2004/	Haematological/ Anaemia with clinical symptoms
					Gastrointestinal/ Haematemesis
PPD PPD 3TC/ZDV+ABC	30.2/ Female/ 1.72	3/ 132/ 0.87	106.0 1	01SEP2004/ 05JUL2006/ 08JUL2006	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	39.3/ Female/ 1.70	4/ 142/ 0.79	88.55	23SEP2004/ 21OCT2004/ 10MAR2005	Haematological/ Neutropenia
PPD 3TC/ZDV+ABC	39.4/ Male/ 1.78	3/ 175/ 0.83	108.0 0	23SEP2004/ 16DEC2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	38.7/ Female/ 1.46	4/ 141/ 1.08	52.42	23SEP2004/ 16DEC2004/ 10FEB2005	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	30.3/ Male/ 1.80	3/ 101/ 1.12	88.62	23SEP2004/ 21OCT2004/ 18NOV2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	66.8/ Male/ 1.93	3/ 104/ 1.12	72.82	24SEP2004/ 17DEC2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	40.3/ Male/ 1.44	3/ 121/ 1.34	48.70	24SEP2004/ 25SEP2004/	Other/ Overdose (not suicide attempt)
PP PPD 3TC/ZDV+ABC	41.6/ Female/ 1.57	4/ 166/ 1.14	55.88	27SEP2004/ 16DEC2004/ 14JAN2005	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	35.8/ Male/ 1.54	3/ 173/ 0.92	84.36	27SEP2004/ 25OCT2004/ 16NOV2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	39.3/ Female/ 1.75	3/ 171/ 1.01	85.70	30SEP2004/ 17MAR2005/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+ABC	38.6/ Female/ 1.65	2/ 146/ 1.04	70.55	06OCT2004/ 03NOV2004/ 29DEC2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	50.3/ Female/ 1.60	3/ 149/ 0.94	62.87	06OCT2004/ 29DEC2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	27.2/ Female/ 1.55	3/ 121/ 1.05	65.76	08OCT2004/ 04NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	37.3/ Male/ 1.70	2/ 133/ 1.08	82.16	11OCT2004/ 08NOV2004/ 06DEC2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+ABC	42.0/ Male/ 1.80	3/ 176/ 1.19	72.42	15OCT2004/ 26MAY2006/ 08JUN2006	Biochemical/ Raised liver enzymes
PPD PPD 3TC/ZDV+NVP	46.6/ Male/ 1.71	2/ 134/ 2.01	42.46	21OCT2004/ 03FEB2005/ 06FEB2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+ABC	35.8/ Male/ 1.68	3/ 125/ 1.06	77.67	28OCT2004/ 25NOV2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	42.2/ Female/ 1.56	2/ 97/ 0.79	78.46	11JUN2003/ 03SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	42.2/ Male/ 1.63	4/ 14/ 0.68	117.9 1	11JUN2003/ 30JUL2004/ 02AUG2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	58.0/ Female/ 1.52	4/ 15/ 1.18	41.03	11JUN2003/ 01OCT2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	37.2/ Male/ 1.57	3/ 54/ 2.24	33.21	16JUN2003/ 09DEC2003/	Renal/ Renal failure - chronic
PPD PPD 3TC/ZDV+TDF	43.9/ Male/ 1.70	4/ 17/ 0.79	93.27	18JUN2003/ 11AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	53.3/ Male/ 1.49	2/ 74/ 0.72	86.00	19JUN2003/ 11SEP2003/ 04DEC2003	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.9/ Male/ 1.61	2/ 2/ 0.66	124.1 5	23JUN2003/ 21JUL2003/	Haematological/ Neutropenia
				23JUN2003/ 05NOV2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	33.9/ Male/ 1.61	4/ 18/ 0.88	88.36	24JUN2003/ 22SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	44.8/ Male/ 1.57	3/ 30/ 0.81	77.12	30JUN2003/ 15NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	24.2/ Female/ 1.39	4/ 79/ 0.57	94.20	02JUL2003/ 23JUL2003/	Cardiovascular/ Cardiomyopathy
				02JUL2003/ 04NOV2003/ 27NOV2003	Lower respiratory tract/ Pulmonary embolism
				02JUL2003/ 28JUN2004/ 17NOV2004	Musculoskeletal/ Myopathy, muscle wasting

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.2/ Male/ 1.95	3/ 94/ 0.59	189.6 3	04JUL2003/ 08JUL2003/ 12JUL2003	Skin/ Rash, urticaria
PPD PPD 3TC/ZDV+TDF	32.2/ Female/ 1.53	3/ 42/ 0.67	98.25	08JUL2003/ 12SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	41.4/ Female/ 1.59	4/ 1/ 0.46	139.9 7	10JUL2003/ 23DEC2003/ 10JUL2003/ 01APR2005/	Haematological/ Neutropenia Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	30.1/ Female/ 1.48	3/ 66/ 0.86	72.24	11JUL2003/ 03OCT2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	30.8/ Female/ 1.53	3/ 6/ 0.79	81.45	11JUL2003/ 06NOV2003/ 11NOV2003	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	44.5/ Female/ 1.75	4/ 22/ 0.64	126.8 7	11JUL2003/ 03OCT2003/ 17OCT2003	Haematological/ Anaemia with clinical symptoms
				11JUL2003/ 10SEP2004/	CNS/ Peripheral neuropathy - sensory & motor
PP PPD 3TC/ZDV+TDF	37.1/ Female/ 1.65	3/ 49/ 0.80	94.38	15JUL2003/ 13AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.6/ Male/ 2.06	3/ 63/ 1.02	108.8 1	18JUL2003/ 15AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.1/ Male/ 1.82	3/ 78/ 1.43	67.43	22JUL2003/ 12FEB2004/	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	33.6/ Female/ 1.50	3/ 23/ 1.05	60.26	22JUL2003/ 14OCT2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	33.6/ Female/ 1.50	3/ 23/ 1.05	60.26	22JUL2003/ 21NOV2003/ 06DEC2003	Haematological/ Pancytopenia, bone marrow depression
				22JUL2003/ 26NOV2003/	Cardiovascular/ Deep vein thrombosis
				22JUL2003/ 03DEC2003/	Cardiovascular/ Other cardiovascular
PPD PPD 3TC/ZDV+TDF	35.8/ Male/ 1.52	3/ 2/ 0.88	81.68	24JUL2003/ 21AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.7/ Male/ 1.49	3/ 29/ 1.20	57.74	28JUL2003/ 21SEP2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.8/ Female/ 1.49	4/ 33/ 0.74	90.52	28JUL2003/ 25JAN2005/	Cardiovascular/ Deep vein thrombosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	37.0/ Female/ 1.51	2/ 79/ 0.94	69.33	29JUL2003/ 26AUG2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.4/ Female/ 1.50	2/ 25/ 0.74	91.53	29JUL2003/ 25JAN2005/ 31JAN2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.42	3/ 23/ 0.84	63.20	15AUG2003/ 12SEP2003/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	30.8/ Female/ 1.67	2/ 98/ 0.55	132.14	22AUG2003/ 30APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.9/ Female/ 1.52	3/ 4/ 0.55	128.15	03SEP2003/ 01OCT2003/ 26NOV2003	Haematological/ Neutropenia
				03SEP2003/ 29OCT2003/ 26NOV2003	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.6/ Female/ 1.55	3/ 93/ 1.03	68.76	05SEP2003/ 24NOV2004/	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	50.8/ Male/ 1.90	2/ 88/ 1.38	72.42	09SEP2003/ 02DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	35.3/ Male/ 1.74	3/ 9/ 0.92	86.99	10SEP2003/ 20OCT2003/ 30OCT2003	Haematological/ Anaemia with clinical symptoms
				10SEP2003/ 11FEB2004/ 02APR2004	CNS/ Peripheral neuropathy - sensory only
PPD PPD 3TC/ZDV+TDF	32.8/ Male/ 1.80	3/ 3/ 0.96	103.6 6	10SEP2003/ 08OCT2003/	Haematological/ Neutropenia
				10SEP2003/ 30DEC2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.5/ Male/ 1.38	3/ 8/ 0.87	64.42	12SEP2003/ 17NOV2003/	Haematological/ Neutropenia Haematological/ Thrombocytopenia Biochemical/ Hypokalaemia
PPD PPD 3TC/ZDV+TDF	55.3/ Male/ 1.51	4/ 6/ 0.77	73.14	19SEP2003/ 12DEC2003/ 05MAR2004	Haematological/ Pancytopenia, bone marrow depression
PP PPD 3TC/ZDV+TDF	33.9/ Male/ 1.91	3/ 12/ 0.85	127.7 4	22SEP2003/ 18NOV2003/ 24NOV2003	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	41.2/ Male/ 1.88	4/ 40/ 1.13	83.97	22SEP2003/ 20OCT2003/ 15DEC2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	29.9/ Male/ 1.76	4/ 95/ 0.54	178.6 9	22SEP2003/ 15NOV2004/ 22NOV2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.6/ Male/ 1.91	3/ 94/ 0.74	145.0 0	24SEP2003/ 25AUG2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	32.3/ Male/ 1.59	4/ 80/ 0.74	100.9 1	26SEP2003/ 30JUN2004/	Cardiovascular/ Deep vein thrombosis
PPD PPD 3TC/ZDV+TDF	34.7/ Female/ 1.62	4/ 89/ 0.86	83.57	29SEP2003/ 18DEC2003/ 15MAR2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	19.7/ Female/ 1.60	4/ 74/ 0.63	129.2 4	03OCT2003/ 31OCT2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.1/ Male/ 1.34	4/ 12/ 1.01	54.68	06OCT2003/ 10DEC2003/ 22MAR2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	36.7/ Female/ 1.45	4/ 40/ 0.49	121.7 8	09OCT2003/ 30DEC2003/ 16JAN2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.6/ Female/ 1.36	4/ 75/ 0.93	51.98	10OCT2003/ 03NOV2003/	Haematological/ Pancytopenia, bone marrow depression
					Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	27.2/ Female/ 1.47	4/ 5/ 0.70	85.17	13OCT2003/ 10NOV2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	38.5/ Female/ 1.49	4/ 94/ 1.03	56.88	15OCT2003/ 31MAR2004/ 27MAY2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	34.4/ Male/ 1.48	4/ 3/ 0.83	80.10	20OCT2003/ 17NOV2003/	Haematological/ Neutropenia
					Haematological/ Leucopenia
				20OCT2003/ 27JAN2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.4/ Male/ 1.48	4/ 3/ 0.83	80.10	20OCT2003/ 27JAN2004/	Haematological/ Thrombocytopenia
PPD PPD 3TC/ZDV+TDF	31.1/ Male/ 1.68	3/ 9/ 0.85	94.35	21OCT2003/ 23AUG2005/ 15NOV2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	45.6/ Male/ 1.55	3/ 47/ 1.04	64.77	21OCT2003/ 13JAN2004/ 07APR2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	42.8/ Female/ 1.90	4/ 33/ 0.93	103.4 3	22OCT2003/ 02FEB2004/ 30JUN2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	52.6/ Male/ 1.82	3/ 75/ 0.63	134.3 8	22OCT2003/ 14JAN2004/ 07APR2004	Haematological/ Anaemia with clinical symptoms Biochemical/ Hyperglycaemia
PPD PPD 3TC/ZDV+TDF	42.8/ Male/ 1.95	3/ 93/ 0.80	129.1 5	23OCT2003/ 12NOV2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.9/ Female/ 1.34	3/ 16/ 1.06	44.12	23OCT2003/ 01MAR2005/	CNS/ Hemiparesis
PPD PPD 3TC/ZDV+TDF	37.9/ Female/ 1.74	3/ 18/ 0.71	123.0 6	23OCT2003/ 06NOV2003/	Systemic/ Malaise, tiredness, lethargy, fatigue, generalised body weakness
				23OCT2003/ 07NOV2003/ 23OCT2003/ 21NOV2003/	Hepatic/ Hepatic failure Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	37.8/ Male/ 1.85	3/ 28/ 1.11	85.99	23OCT2003/ 15JAN2004/ 28JAN2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	40.1/ Male/ 1.50	3/ 2/ 1.00	67.21	27OCT2003/ 12NOV2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	38.0/ Female/ 1.50	4/ 6/ 0.88	63.28	27OCT2003/ 24NOV2003/ 19JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	41.7/ Male/ 1.76	3/ 3/ 0.76	122.7 7	27OCT2003/ 19JAN2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	54.2/ Male/ 1.94	4/ 24/ 1.23	75.30	28OCT2003/ 07NOV2003/	Cardiovascular/ Cardiomyopathy
PPD PPD 3TC/ZDV+TDF	54.2/ Male/ 1.75	2/ 32/ 0.97	75.24	03NOV2003/ 26AUG2005/ 06SEP2005	Haematological/ Anaemia with clinical symptoms
				03NOV2003/ 15SEP2005/	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	44.0/ Male/ 1.76	3/ 61/ 0.90	96.75	06NOV2003/ 26JAN2004/ 10FEB2004	Biochemical/ Raised ALT
				06NOV2003/ 22APR2004/ 15JUL2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	32.3/ Female/ 1.59	3/ 69/ 0.54	142.4 5	06NOV2003/ 28DEC2004/ 06JAN2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	49.4/ Male/ 1.74	4/ 39/ 1.09	82.06	07NOV2003/ 03DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.9/ Male/ 1.54	2/ 10/ 1.07	71.21	10NOV2003/ 13SEP2004/ 11OCT2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	41.6/ Female/ 1.35	4/ 49/ 0.90	50.05	10NOV2003/ 03JAN2005/ 23MAR2005	Haematological/ Neutropenia
PPD 3TC/ZDV+TDF	53.2/ Female/ 1.64	3/ 25/ 1.05	59.07	12NOV2003/ 10DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.7/ Male/ 1.55	3/ 15/ 1.19	59.24	13NOV2003/ 06FEB2004/ 15OCT2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	39.8/ Female/ 1.76	3/ 47/ 0.81	110.5 7	14NOV2003/ 06FEB2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	40.6/ Female/ 1.59	3/ 4/ 0.72	95.05	14NOV2003/ 20MAY2004/	CNS/ Stroke, cerebrovascular accident
PPD PPD 3TC/ZDV+TDF	36.0/ Male/ 1.70	3/ 43/ 0.78	111.6 8	14NOV2003/ 29DEC2003/	Haematological/ Pancytopenia, bone marrow depression
					Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+TDF	37.7/ Male/ 1.81	3/ 32/ 1.38	66.26	17NOV2003/ 15JAN2004/ 18FEB2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.0/ Female/ 1.34	3/ 20/ 0.92	54.33	18NOV2003/ 01JUN2004/ 10JUN2004	Haematological/ Anaemia with clinical symptoms
				18NOV2003/ 16NOV2004/	Hepatic/ Hepatic failure
PP PPD 3TC/ZDV+TDF	44.2/ Male/ 1.52	3/ 31/ 0.88	72.10	18NOV2003/ 15JAN2004/ 01JUN2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	35.4/ Female/ 1.38	3/ 12/ 0.81	60.50	19NOV2003/ 05MAY2004/ 17MAY2004	Haematological/ Neutropenia
				19NOV2003/ 10MAY2004/	Hepatic/ Hepatic failure
PPD PPD 3TC/ZDV+TDF	33.0/ Male/ 1.62	4/ 43/ 0.96	86.72	24NOV2003/ 10MAR2005/	Hepatic/ Cirrhosis
PPD PPD 3TC/ZDV+TDF	37.5/ Female/ 1.62	3/ 10/ 0.67	105.9 1	25NOV2003/ 12AUG2005/ 12OCT2005	Hepatic/ Acute hepatitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	49.4/ Male/ 1.63	2/ 16/ 0.79	80.26	28NOV2003/ 03FEB2004/	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+TDF	42.2/ Male/ 1.76	4/ 58/ 2.09	42.92	01DEC2003/ 17MAY2005/	Endocrine/ Diabetes - Type II
PPD PPD 3TC/ZDV+TDF	34.6/ Male/ 1.67	4/ 4/ 1.03	84.07	03DEC2003/ 31DEC2003/	Haematological/ Neutropenia
				03DEC2003/ 28JAN2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	29.2/ Male/ 1.70	3/ 3/ 0.85	108.8 9	09DEC2003/ 06JAN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	40.0/ Male/ 1.43	3/ 41/ 1.37	43.94	15DEC2003/ 12JAN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	51.0/ Male/ 1.60	4/ 18/ 1.00	62.25	16DEC2003/ 13JAN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.2/ Female/ 1.40	3/ 6/ 0.98	53.65	17DEC2003/ 12FEB2004/ 10MAR2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	34.5/ Male/ 1.63	2/ 1/ 1.16	68.05	17DEC2003/ 12JAN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	50.0/ Male/ 1.67	2/ 95/ 0.95	76.35	19DEC2003/ 12MAR2004/ 04JUN2004	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	35.3/ Female/ 1.49	4/ 85/ 1.00	61.76	29DEC2003/ 02JAN2004/ 23FEB2004	Haematological/ Anaemia with clinical symptoms
				29DEC2003/ 27JAN2004/ 23FEB2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	41.5/ Female/ 1.35	3/ 48/ 0.71	70.10	02JAN2004/ 09JAN2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	32.6/ Female/ 1.42	3/ 17/ 0.63	86.01	05JAN2004/ 30JAN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	35.3/ Female/ 1.36	3/ 24/ 0.87	59.43	06JAN2004/ 30MAR2004/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	30.9/ Male/ 1.72	4/ 47/ 1.11	77.50	26JAN2004/ 21MAR2005/ 16MAY2005	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	34.4/ Female/ 1.62	3/ 97/ 0.90	77.91	28JAN2004/ 16JUN2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.2/ Male/ 1.72	3/ 2/ 1.01	80.60	29JAN2004/ 22APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	25.4/ Female/ 1.43	3/ 24/ 0.81	74.18	02FEB2004/ 12FEB2004/ 01MAR2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	38.6/ Female/ 1.30	3/ 10/ 0.74	59.44	02FEB2004/ 29MAR2004/ 26APR2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	33.9/ Male/ 1.59	4/ 1/ 1.26	65.56	02FEB2004/ 09FEB2004/ 29MAR2004	Hepatic/ Jaundice
PP PPD 3TC/ZDV+TDF	28.8/ Female/ 1.29	4/ 36/ 0.85	58.33	03FEB2004/ 04OCT2005/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	56.1/ Female/ 1.53	3/ 30/ 0.88	56.42	05FEB2004/ 04MAR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	56.1/ Female/ 1.53	3/ 30/ 0.88	56.42	05FEB2004/ 21JUN2004/ 14SEP2006	CNS/ Stroke, cerebrovascular accident
PP PPD 3TC/ZDV+TDF	33.7/ Male/ 1.55	4/ 1/ 1.00	72.27	09FEB2004/ 30APR2004/ 28MAY2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	42.4/ Female/ 1.57	3/ 2/ 0.88	73.13	10FEB2004/ 09MAR2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	47.7/ Female/ 1.53	2/ 19/ 0.75	82.08	12FEB2004/ 14JAN2005/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	27.5/ Female/ 1.43	4/ 72/ 0.80	73.37	13FEB2004/ 12DEC2005/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	34.3/ Male/ 1.58	4/ 56/ 1.02	72.84	17FEB2004/ 02APR2005/ 30JUN2007	Cardiovascular/ Cardiomyopathy

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	51.3/ Male/ 1.70	3/ 38/ 0.95	81.83	27FEB2004/ 26MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.2/ Female/ 1.53	3/ 83/ 0.62	106.74	01MAR2004/ 29MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	32.0/ Female/ 1.35	4/ 1/ 0.76	69.23	04MAR2004/ 01APR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	37.6/ Female/ 1.64	3/ 27/ 0.72	105.73	08MAR2004/ 26JUL2004/ 27JUL2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	28.8/ Female/ 1.36	3/ 58/ 0.97	54.24	09MAR2004/ 24AUG2004/ 16NOV2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	38.1/ Female/ 1.51	4/ 17/ 1.06	54.15	18MAR2004/ 19MAY2004/	Haematological/ Pancytopenia, bone marrow depression

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	38.1/ Female/ 1.51	4/ 17/ 1.06	54.15	18MAR2004/ 19MAY2004/	Hepatic/ Hepatic failure
PPD PPD 3TC/ZDV+TDF	34.6/ Male/ 1.80	4/ 188/ 0.78	126.9 1	23JUN2003/ 21JUL2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	27.3/ Female/ 2.00	2/ 197/ 0.70	164.5 6	25JUN2003/ 17SEP2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	32.1/ Male/ 1.99	2/ 167/ 0.89	138.1 5	27JUN2003/ 30JUN2003/ 15JUL2003	Skin/ Rash, urticaria
PP PPD 3TC/ZDV+TDF	46.6/ Female/ 1.58	2/ 176/ 0.59	106.8 9	30JUN2003/ 15DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	58.7/ Male/ 1.64	3/ 128/ 0.86	69.78	14JUL2003/ 08DEC2003/ 30JAN2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	51.0/ Male/ 1.79	3/ 149/ 1.09	73.85	17JUL2003/ 31DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	49.3/ Male/ 1.84	3/ 145/ 0.88	104.4 6	18JUL2003/ 17AUG2003/	Skin/ Rash, urticaria
PPD PPD 3TC/ZDV+TDF	37.2/ Male/ 1.78	4/ 118/ 0.84	112.1 0	22JUL2003/ 24JAN2005/ 02FEB2005	Biochemical/ Hypocalcaemia - clinically symptomatic
				22JUL2003/ 05MAR2005/	Hepatic/ Hepatic failure
PPD PPD 3TC/ZDV+TDF	42.1/ Male/ 1.89	2/ 153/ 1.01	108.3 4	24JUL2003/ 21AUG2003/	Haematological/ Neutropenia
				24JUL2003/ 15MAR2004/ 09DEC2004	Musculoskeletal/ Bone fracture
PPD PPD 3TC/ZDV+TDF	31.2/ Female/ 1.53	2/ 115/ 0.76	91.25	04AUG2003/ 19JAN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.6/ Male/ 1.75	3/ 122/ 0.81	111.3 2	08AUG2003/ 31OCT2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	49.3/ Male/ 1.73	2/ 191/ 1.27	60.50	18AUG2003/ 10SEP2003/ 29APR2004	Cardiovascular/ Deep vein thrombosis
PP PPD 3TC/ZDV+TDF	45.2/ Female/ 1.72	3/ 107/ 0.67	116.65	08SEP2003/ 15SEP2004/	Cardiomyopathy
PP PPD 3TC/ZDV+TDF	54.2/ Female/ 1.87	3/ 125/ 1.01	78.19	19SEP2003/ 17OCT2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	44.8/ Male/ 1.69	3/ 104/ 1.09	71.30	03OCT2003/ 08DEC2003/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	57.3/ Female/ 1.71	2/ 100/ 0.80	81.69	08OCT2003/ 31DEC2003/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	37.5/ Female/ 1.62	4/ 116/ 0.69	101.7 9	13OCT2003/ 10NOV2003/	Biochemical/ Raised ALT
PPD PPD 3TC/ZDV+TDF	41.0/ Female/ 1.52	2/ 137/ 0.98	63.48	14OCT2003/ 06JAN2004/ 03FEB2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	34.8/ Female/ 1.52	4/ 110/ 0.78	85.30	20OCT2003/ 17NOV2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	37.5/ Female/ 1.91	3/ 156/ 1.04	94.44	24OCT2003/ 02JAN2005/ 28MAR2006	Renal/ Renal failure - acute
PP PPD 3TC/ZDV+TDF	34.8/ Male/ 1.74	3/ 151/ 1.27	70.99	27OCT2003/ 05JUL2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	49.4/ Female/ 1.54	3/ 111/ 0.72	82.80	04NOV2003/ 02DEC2003/	Haematological/ Neutropenia
				04NOV2003/ 20APR2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	39.4/ Female/ 1.38	3/ 109/ 0.89	55.11	18NOV2003/ 03DEC2003/ 05DEC2003 18NOV2003/ 12DEC2003/	Haematological/ Anaemia with clinical symptoms CNS/ Peripheral neuropathy - sensory & motor
PP PPD 3TC/ZDV+TDF	36.8/ Female/ 1.66	4/ 140/ 1.02	69.92	18NOV2003/ 16DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	60.8/ Male/ 1.78	3/ 144/ 1.21	59.67	28NOV2003/ 24APR2004/ 04MAY2004	Haematological/ Anaemia with clinical symptoms
P PPD 3TC/ZDV+TDF	37.1/ Male/ 2.25	3/ 196/ 0.85	193.06	12DEC2003/ 20AUG2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	31.2/ Female/ 1.76	2/ 133/ 0.67	135.81	12DEC2003/ 09JAN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.2/ Male/ 1.58	2/ 187/ 1.01	73.83	21JAN2004/ 07JUL2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	31.9/ Male/ 1.69	4/ 110/ 1.27	74.82	29JAN2004/ 26NOV2004/ 21APR2005	Gastrointestinal/ Pancreatitis
PPD PPD 3TC/ZDV+TDF	44.1/ Female/ 1.49	3/ 137/ 1.03	56.60	30JAN2004/ 04JUN2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	28.5/ Female/ 1.48	3/ 182/ 0.76	80.32	30JAN2004/ 23APR2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	37.7/ Female/ 1.47	3/ 177/ 0.89	68.22	02FEB2004/ 27APR2005/	Cardiovascular/ Congestive cardiac failure
PPD PPD 3TC/ZDV+TDF	37.9/ Female/ 1.77	4/ 168/ 0.87	104.4 2	10FEB2004/ 13JAN2005/	Hepatic/ Hepatic failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.2/ Female/ 1.47	2/ 152/ 1.03	60.87	26FEB2004/ 20OCT2004/ 22OCT2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	34.7/ Male/ 1.63	3/ 161/ 1.01	82.37	02MAR2004/ 27APR2004/ 15NOV2004	Cardiovascular/ Deep vein thrombosis
PP PPD 3TC/ZDV+NVP	42.2/ Male/ 1.77	3/ 4/ 0.71	132.1 7	19MAR2004/ 02APR2004/ 16APR2004	Skin/ Rash, erythematous
PP PPD 3TC/ZDV+NVP	38.8/ Male/ 1.99	4/ 8/ 1.04	112.9 7	22MAR2004/ 20APR2004/ 18MAY2004	Biochemical/ Raised ALT
PP PPD 3TC/ZDV+NVP	44.4/ Female/ 1.66	3/ 96/ 0.63	104.9 8	01APR2004/ 16SEP2004/	Cardiovascular/ Deep vein thrombosis
					Tumours/ Cervical carcinoma
				01APR2004/ 22OCT2004/ 27OCT2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	44.4/ Female/ 1.66	3/ 96/ 0.63	104.9 8	01APR2004/ 03MAR2005/	Hepatic/ Jaundice
				01APR2004/ 08MAR2005/	Hepatic/ Hepatic failure
PP PPD 3TC/ZDV+NVP	46.3/ Male/ 1.70	3/ 22/ 1.84	43.36	01APR2004/ 24JUN2004/ 09DEC2004	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	37.5/ Female/ 1.69	3/ 61/ 0.84	85.64	06APR2004/ 29JUN2004/ 27JUL2004	Haematological/ Neutropenia
PP P, D 3TC/ZDV+NVP	40.1/ Male/ 1.66	3/ 6/ 0.79	102.7 2	13APR2004/ 12MAY2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	48.3/ Female/ 1.37	4/ 22/ 0.87	52.40	13APR2004/ 11MAY2004/ 28SEP2004	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	29.7/ Female/ 1.49	3/ 9/ 0.79	81.77	15APR2004/ 13MAY2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	36.6/ Male/ 1.83	2/ 69/ 1.01	98.96	16APR2004/ 17APR2004/ 14MAY2004	Skin/ Rash, maculopapular
PPD PPD 3TC/ZDV+NVP	26.3/ Female/ 1.48	3/ 67/ 0.85	74.13	16APR2004/ 14MAY2004/ 26NOV2004	Cardiovascular/ Deep vein thrombosis
				16APR2004/ 28JUN2004/ 09JUL2004	Haematological/ Anaemia with clinical symptoms
				16APR2004/ 07OCT2004/ 26NOV2004	Musculoskeletal/ Myopathy, muscle wasting
PP PPD 3TC/ZDV+NVP	36.1/ Female/ 1.74	3/ 16/ 0.89	99.06	22APR2004/ 08SEP2005/ 23FEB2006	Cardiovascular/ Deep vein thrombosis
PP PPD 3TC/ZDV+NVP	37.2/ Male/ 1.68	4/ 43/ 0.95	84.39	27APR2004/ 24MAY2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	43.1/ Male/ 1.62	3/ 16/ 0.88	87.45	27APR2004/ 27MAY2004/	Hepatic/ Hepatic failure

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	28.6/ Female/ 1.54	3/ 7/ 0.75	81.98	30APR2004/ 24JUN2004/ 28JUN2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	31.7/ Female/ 1.53	3/ 12/ 0.95	70.00	06MAY2004/ 14MAY2004/ 20MAY2004	Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	33.9/ Female/ 1.36	3/ 73/ 0.81	66.22	06MAY2004/ 07DEC2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	35.0/ Female/ 1.41	2/ 6/ 0.59	92.84	06MAY2004/ 24SEP2004/ 21OCT2004	Biochemical/ Raised liver enzymes
PP PPD 3TC/ZDV+NVP	25.6/ Female/ 1.39	3/ 30/ 0.88	60.76	06MAY2004/ 07JUN2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	32.3/ Male/ 1.59	3/ 23/ 0.93	88.09	07MAY2004/ 04JUN2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	32.3/ Male/ 1.59	3/ 23/ 0.93	88.09	07MAY2004/ 30JUL2004/ 01AUG2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	31.9/ Male/ 2.12	3/ 28/ 1.04	130.1 0	11MAY2004/ 12JAN2005/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	31.2/ Female/ 1.53	4/ 6/ 1.01	60.88	13MAY2004/ 07JUL2005/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	40.4/ Male/ 1.62	3/ 94/ 0.85	86.63	17MAY2004/ 11JUN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	28.5/ Female/ 1.66	3/ 80/ 0.70	115.4 8	17MAY2004/ 27JUL2004/ 31AUG2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	35.8/ Female/ 2.00	4/ 6/ 0.78	139.0 2	20MAY2004/ 12AUG2004/	Haematological/ Neutropenia Haematological/ Leucopenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	36.6/ Male/ 1.78	3/ 91/ 0.75	110.0 2	01JUN2004/ 30JUN2004/ 02JUL2004	Renal/ Renal failure - acute
PPD PPD 3TC/ZDV+NVP	25.9/ Female/ 1.60	3/ 22/ 0.69	105.8 5	01JUN2004/ 02JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	26.8/ Female/ 1.21	4/ 22/ 0.66	64.35	03JUN2004/ 02JUL2004/ 05JUL2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	33.4/ Female/ 1.48	3/ 7/ 0.62	94.78	03JUN2004/ 30JUN2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	27.6/ Male/ 1.60	4/ 88/ 0.85	91.65	04JUN2004/ 02JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	40.2/ Female/ 1.61	4/ 6/ 0.71	94.62	04JUN2004/ 02JUL2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	50.2/ Female/ 1.52	3/ 87/ 0.83	62.72	04JUN2004/ 03JUN2005/ 10FEB2006	Cardiovascular/ Deep vein thrombosis
PP PPD 3TC/ZDV+NVP	40.5/ Male/ 1.68	3/ 32/ 0.81	92.71	04JUN2004/ 19NOV2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	25.2/ Male/ 1.65	3/ 10/ 1.21	72.62	07JUN2004/ 05JUL2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	34.6/ Female/ 1.42	3/ 70/ 0.52	108.51	08JUN2004/ 06JUL2004/ 31AUG2004	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	31.8/ Male/ 1.86	3/ 27/ 0.81	122.19	10JUN2004/ 02SEP2004/ 10JUN2004/ 17NOV2004/	Haematological/ Neutropenia Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	34.8/ Female/ 1.50	3/ 64/ 0.51	125.5 7	10JUN2004/ 12MAY2005/ 16MAY2005	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+NVP	33.1/ Female/ 1.51	3/ 69/ 0.74	94.11	11JUN2004/ 09JUL2004/ 19JUL2004	Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	28.9/ Male/ 1.67	3/ 16/ 0.90	99.42	11JUN2004/ 23MAY2005/ 05AUG2005	Systemic/ Hypersensitivity reaction
PP PPD 3TC/ZDV+NVP	35.2/ Male/ 1.85	3/ 91/ 1.04	97.95	11JUN2004/ 09FEB2006/ 12APR2006	Hepatic/ Acute hepatitis
PPD PPD 3TC/ZDV+NVP	37.7/ Male/ 1.75	3/ 7/ 0.74	116.2 3	14JUN2004/ 31OCT2005/ 05JUN2008	Cardiovascular/ Deep vein thrombosis
				14JUN2004/ 01NOV2005/ 21NOV2005	Hepatic/ Acute hepatitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	28.7/ Male/ 1.43	3/ 51/ 1.04	64.17	30JUN2004/ 18JUL2004/ 15DEC2004	Cardiovascular/ Deep vein thrombosis
PP PPD 3TC/ZDV+NVP	45.6/ Female/ 1.66	3/ 194/ 0.83	79.08	19MAR2004/ 18AUG2005/	CNS/ Stroke, cerebrovascular accident
PP PPD 3TC/ZDV+NVP	35.0/ Female/ 1.45	3/ 117/ 0.85	67.31	30MAR2004/ 27APR2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	40.0/ Female/ 1.58	4/ 109/ 0.75	94.23	01APR2004/ 29APR2004/	Skin/ Rash, erythematous
					Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	27.2/ Female/ 1.63	2/ 146/ 0.92	83.91	06APR2004/ 04MAY2004/	Haematological/ Neutropenia
				06APR2004/ 10MAY2004/	Hepatic/ Acute hepatitis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	48.9/ Male/ 1.80	3/ 108/ 0.94	92.95	08APR2004/ 01JUL2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	48.7/ Male/ 1.58	3/ 152/ 0.85	82.97	08APR2004/ 30APR2004/ 03JUN2004 08APR2004/ 04MAY2004/	Systemic/ Hypersensitivity reaction Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	48.5/ Female/ 1.57	2/ 169/ 1.03	63.18	13APR2004/ 06JUL2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	40.9/ Male/ 1.88	2/ 178/ 1.02	96.51	15APR2004/ 05MAY2004/ 09MAY2004	Skin/ Rash, maculopapular
PP PPD 3TC/ZDV+NVP	33.0/ Male/ 1.68	4/ 177/ 0.88	103.8 6	22APR2004/ 26MAY2004/	Hepatic/ Hepatitis cause unknown
PPD PPD 3TC/ZDV+NVP	29.2/ Female/ 1.48	3/ 137/ 0.92	65.74	27APR2004/ 20JUL2004/	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	29.2/ Female/ 1.48	3/ 137/ 0.92	65.74	27APR2004/ 17MAR2005/ 13APR2005	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+NVP	53.5/ Female/ 1.41	4/ 123/ 0.74	67.55	04MAY2004/ 07MAR2006/ 12JUN2006	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+NVP	43.7/ Female/ 1.43	3/ 173/ 0.67	83.35	07MAY2004/ 22OCT2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+NVP	43.4/ Male/ 1.69	3/ 110/ 0.89	91.60	31MAY2004/ 15NOV2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+NVP	22.8/ Female/ 1.43	2/ 130/ 0.78	77.73	31MAY2004/ 23AUG2004/ 25AUG2004	Haematological/ Pancytopenia, bone marrow depression
PPD PPD 3TC/ZDV+NVP	34.3/ Female/ 1.64	3/ 156/ 0.78	89.91	01JUN2004/ 09JUN2004/ 27AUG2004	Skin/ Rash, maculopapular

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+NVP	46.3/ Female/ 1.63	3/ 115/ 0.63	118.5 8	01JUL2004/ 10MAR2005/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	33.5/ Female/ 1.51	4/ 57/ 0.61	106.7 9	20MAY2003/ 07OCT2003/ 16OCT2003	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	45.0/ Female/ 1.47	4/ 22/ 1.53	37.24	20MAY2003/ 11SEP2003/	Gastrointestinal/ Vomiting
				20MAY2003/ 02OCT2003/	Cardiovascular/ Hypotension/shock/ toxic shock
PP PPD 3TC/ZDV+TDF	41.2/ Female/ 1.55	3/ 14/ 0.71	84.32	20MAY2003/ 17JUN2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	36.9/ Male/ 1.58	4/ 9/ 1.00	76.45	27MAY2003/ 10JUN2003/	Systemic/ Stevens-Johnson Syndrome
PP PPD 3TC/ZDV+TDF	40.9/ Male/ 1.54	4/ 13/ 0.67	102.9 4	27MAY2003/ 24JUN2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.9/ Male/ 1.54	4/ 13/ 0.67	102.9 4	27MAY2003/ 19AUG2003/	Haematological/ Leucopenia
PPD PPD 3TC/ZDV+TDF	34.0/ Female/ 1.75	4/ 24/ 0.80	109.1 5	05JUN2003/ 26AUG2003/ 30SEP2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	37.9/ Female/ 1.45	4/ 43/ 0.79	71.45	17JUN2003/ 02DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	31.0/ Male/ 1.92	4/ 83/ 0.98	105.2 4	17JUN2003/ 09SEP2003/ 04NOV2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	33.0/ Female/ 1.71	3/ 40/ 0.74	113.1 3	17JUN2003/ 09SEP2003/ 02OCT2003	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.4/ Female/ 1.52	2/ 81/ 0.55	126.5 3	24JUN2003/ 16SEP2003/ 06NOV2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	28.9/ Female/ 1.48	2/ 27/ 0.50	128.1 0	01JUL2003/ 23SEP2003/ 28OCT2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	28.9/ Female/ 1.48	2/ 27/ 0.50	128.1 0	01JUL2003/ 10MAY2005/ 31MAY2005	Hepatic/ Lactic acidosis
PPD PPD 3TC/ZDV+TDF	34.5/ Female/ 1.65	3/ 32/ 0.38	192.7 9	08JUL2003/ 27JUL2003/	Haematological/ Thrombocytopenia
PP PPD 3TC/ZDV+TDF	33.5/ Female/ 1.58	4/ 31/ 0.69	90.78	08JUL2003/ 05AUG2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	40.0/ Male/ 1.52	2/ 86/ 0.96	75.34	08JUL2003/ 05AUG2003/ 02DEC2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	29.1/ Female/ 1.36	4/ 52/ 0.52	100.4 1	08JUL2003/ 05AUG2003/ 02SEP2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	45.2/ Female/ 1.43	4/ 3/ 0.74	73.09	17JUL2003/ 30DEC2003/	Haematological/ Neutropenia
				17JUL2003/ 24MAR2005/	Hepatic/ Lactic acidosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	45.2/ Female/ 1.43	4/ 3/ 0.74	73.09	17JUL2003/ 24MAR2005/	CNS/ Peripheral neuropathy - sensory only
PP PPD 3TC/ZDV+TDF	29.1/ Female/ 1.70	3/ 10/ 0.94	82.61	17JUL2003/ 12AUG2003/ 11SEP2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	25.7/ Female/ 1.38	4/ 14/ 0.74	81.80	29JUL2003/ 03AUG2003/	Gastrointestinal/ Abdominal or epigastric pain
PP PPD 3TC/ZDV+TDF	48.1/ Male/ 1.47	3/ 58/ 0.87	65.42	19AUG2003/ 12OCT2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	36.0/ Female/ 1.39	4/ 52/ 0.89	57.67	21AUG2003/ 31MAR2005/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	30.0/ Female/ 1.60	4/ 21/ 1.08	71.92	21AUG2003/ 22JAN2004/ 27JAN2004	Haematological/ Anaemia with clinical symptoms
				21AUG2003/ 06JAN2005/	CNS/ Peripheral neuropathy - sensory only
PP PPD 3TC/ZDV+TDF	31.6/ Male/ 1.59	4/ 38/ 1.14	72.14	02SEP2003/ 03OCT2003/ 21OCT2003	Musculoskeletal/ Myalgia, pain in muscles
PP PPD 3TC/ZDV+TDF	42.2/ Female/ 1.41	3/ 11/ 1.12	48.27	09SEP2003/ 07OCT2003/ 13NOV2003	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	30.0/ Female/ 1.49	3/ 16/ 0.41	144.95	11SEP2003/ 15DEC2003/	Lower respiratory tract/ Pulmonary embolism
PP PPD 3TC/ZDV+TDF	40.6/ Male/ 1.65	4/ 34/ 0.90	89.94	11SEP2003/ 26FEB2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.1/ Female/ 1.41	3/ 4/ 0.69	84.63	30SEP2003/ 16DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	31.5/ Female/ 1.40	4/ 6/ 0.61	87.92	30SEP2003/ 23NOV2004/ 07DEC2004	Haematological/ Anaemia with clinical symptoms
				30SEP2003/ 01SEP2005/ 08NOV2005	Hepatic/ Lactic acidosis
PP PPD 3TC/ZDV+TDF	43.3/ Female/ 1.70	4/ 47/ 1.62	43.20	30SEP2003/ 23DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	41.1/ Male/ 1.48	3/ 2/ 1.00	71.55	02OCT2003/ 10JUN2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	34.1/ Male/ 1.50	4/ 3/ 0.97	69.15	07OCT2003/ 25NOV2004/ 25DEC2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	24.8/ Female/ 1.53	4/ 21/ 0.23	288.8 2	07OCT2003/ 04NOV2003/ 13JAN2004	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	24.8/ Female/ 1.53	4/ 21/ 0.23	288.8 2	07OCT2003/ 27SEP2004/	Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	36.3/ Female/ 1.44	4/ 24/ 1.31	45.63	14OCT2003/ 11NOV2003/ 09DEC2003	Cardiovascular/ Other cardiovascular
PP PPD 3TC/ZDV+TDF	34.9/ Male/ 1.62	3/ 30/ 0.81	102.9 1	16OCT2003/ 13NOV2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	26.3/ Female/ 1.66	4/ 20/ 0.56	148.1 0	28OCT2003/ 02FEB2004/	CNS/ Epilepsy, fits, convulsions
PP PPD 3TC/ZDV+TDF	26.0/ Female/ 1.44	4/ 25/ 0.74	88.84	30OCT2003/ 17MAR2005/ 14APR2005	Other/ Non-fatal trauma
PP PPD 3TC/ZDV+TDF	41.8/ Male/ 1.56	3/ 25/ 0.98	67.89	30OCT2003/ 15APR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	41.4/ Female/ 1.71	4/ 16/ 0.50	149.4 7	30OCT2003/ 15APR2004/ 09JUL2004	Haematological/ Anaemia with clinical symptoms
				30OCT2003/ 03OCT2004/ 04OCT2004	CNS/ Epilepsy, fits, convulsions
PP PPD 3TC/ZDV+TDF	27.0/ Female/ 1.74	4/ 14/ 0.47	193.2 1	30OCT2003/ 01MAR2005/	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
PPD PPD 3TC/ZDV+TDF	52.8/ Male/ 1.61	3/ 19/ 0.52	123.6 3	04NOV2003/ 02DEC2003/ 27JAN2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.1/ Female/ 1.66	4/ 2/ 0.71	106.5 3	06NOV2003/ 02DEC2003/	Haematological/ Neutropenia
				06NOV2003/ 09DEC2004/	Hepatic/ Lactic acidosis

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.58	4/ 10/ 0.68	92.35	06NOV2003/ 04DEC2003/	Haematological/ Neutropenia
					Haematological/ Leucopenia
PP PPD 3TC/ZDV+TDF	32.2/ Female/ 1.58	4/ 6/ 0.66	111.5 1	11NOV2003/ 13SEP2005/ 06DEC2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	28.9/ Female/ 1.38	3/ 16/ 0.30	187.3 9	11NOV2003/ 03FEB2004/	Haematological/ Neutropenia
				11NOV2003/ 02MAR2004/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	32.2/ Female/ 1.58	4/ 47/ 0.48	155.8 4	13NOV2003/ 15MAY2005/ 02MAR2006	CNS/ Peripheral neuropathy - sensory only

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	31.4/ Female/ 1.46	4/ 6/ 0.38	164.7 5	13NOV2003/ 30DEC2003/	Haematological/ Anaemia with clinical symptoms
					Gastrointestinal/ Gall stones, cholecystitis, cholelithiasis
					Hepatic/ Jaundice <Unknown>/ <Unknown>
				13NOV2003/ 02JAN2004/ 24FEB2004	Biochemical/ Raised creatinine
PP PPD 3TC/ZDV+TDF	40.5/ Female/ 1.67	3/ 4/ 0.30	234.2 3	18NOV2003/ 16DEC2003/ 10FEB2004	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	44.4/ Male/ 1.60	3/ 4/ 0.76	89.25	20NOV2003/ 18DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	40.3/ Female/ 1.50	3/ 8/ 0.84	64.23	20NOV2003/ 12FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	34.3/ Male/ 1.68	3/ 3/ 0.90	96.44	20NOV2003/ 19FEB2004/	Gastrointestinal/ Acute diarrhoea no pathogen, idiopathic AIDS enteropathy
PPD PPD 3TC/ZDV+TDF	41.0/ Male/ 2.02	4/ 4/ 0.83	139.3 9	20NOV2003/ 30JUN2005/ 22SEP2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.0/ Female/ 1.59	3/ 17/ 0.42	186.6 1	20NOV2003/ 30JUN2005/	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	35.0/ Female/ 1.48	3/ 50/ 0.67	95.53	20NOV2003/ 18DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	28.0/ Male/ 1.85	4/ 89/ 0.88	116.4 7	25NOV2003/ 11MAY2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	32.1/ Female/ 1.48	4/ 49/ 0.57	115.7 9	27NOV2003/ 07JUL2005/ 29SEP2005	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.9/ Female/ 1.50	4/ 24/ 0.77	86.68	27NOV2003/ 03DEC2003/ 21DEC2003	Gastrointestinal/ Vomiting
PPD PPD 3TC/ZDV+TDF	41.5/ Female/ 1.63	4/ 11/ 0.51	134.1 2	04DEC2003/ 02JAN2004/ 29JAN2004 04DEC2003/ 12AUG2004/ 04DEC2003/ 16JUN2005/	Hepatic/ Hepatitis cause unknown Hepatic/ Acute hepatitis Specific Infections/ P falciparum malaria
PPD PPD 3TC/ZDV+TDF	33.5/ Male/ 1.54	4/ 8/ 0.69	110.6 4	09DEC2003/ 02MAR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	29.0/ Female/ 1.55	4/ 46/ 0.60	106.6 8	11DEC2003/ 15APR2004/	<Unknown>/ <Unknown>
PPD PPD 3TC/ZDV+TDF	33.4/ Female/ 1.39	4/ 17/ 0.87	69.21	23DEC2003/ 16MAR2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	32.0/ Female/ 1.83	4/ 94/ 0.54	164.7 1	20JAN2004/ 17FEB2004/	Haematological/ Neutropenia
				20JAN2004/ 31MAY2005/	CNS/ Epilepsy, fits, convulsions
PPD PPD 3TC/ZDV+TDF	34.2/ Female/ 1.70	4/ 23/ 0.71	117.5 1	22JAN2004/ 19FEB2004/	Haematological/ Neutropenia
				22JAN2004/ 07MAR2005/ 14APR2005	Other/ Non-fatal trauma
PP PPD 3TC/ZDV+TDF	39.4/ Male/ 1.52	4/ 5/ 0.87	78.88	27JAN2004/ 18MAY2004/ 15JUN2004	Haematological/ Anaemia with clinical symptoms

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	43.2/ Female/ 1.43	4/ 30/ 0.53	103.1 5	29JAN2004/ 26FEB2004/	Biochemical/ Raised liver enzymes
				29JAN2004/ 24MAR2005/	Haematological/ Neutropenia
				29JAN2004/ 29DEC2005/ 24JAN2006	Hepatic/ Lactic acidosis
PP PPD 3TC/ZDV+TDF	31.6/ Female/ 1.67	3/ 37/ 0.81	102.3 3	03FEB2004/ 04FEB2004/ 30MAR2004	CNS/ Epilepsy, fits, convulsions
				03FEB2004/ 27APR2004/	Haematological/ Neutropenia
				03FEB2004/ 06JUL2004/ 17AUG2004	Haematological/ Anaemia with clinical symptoms
PPD PPD 3TC/ZDV+TDF	52.1/ Female/ 1.57	4/ 34/ 1.17	50.36	03FEB2004/ 02MAR2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	34.1/ Female/ 1.45	3/ 88/ 1.32	46.25	05FEB2004/ 04MAR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.1/ Female/ 1.45	3/ 88/ 1.32	46.25	05FEB2004/ 29SEP2005/	Fat redistribution/ Fat wasting or loss of fat
PPD PPD 3TC/ZDV+TDF	32.0/ Female/ 1.50	3/ 45/ 0.74	92.22	10FEB2004/ 09MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	39.5/ Female/ 1.24	4/ 8/ 0.53	75.89	12FEB2004/ 11MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	32.7/ Female/ 1.48	3/ 5/ 0.70	86.55	12FEB2004/ 11MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	35.8/ Female/ 1.44	4/ 3/ 0.78	72.33	17FEB2004/ 16MAR2004/	Haematological/ Neutropenia
				17FEB2004/ 22NOV2005/ 14MAR2006	CNS/ Peripheral neuropathy - sensory only

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	28.4/ Female/ 1.60	4/ 58/ 0.52	146.4 1	17FEB2004/ 16MAR2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	29.2/ Female/ 1.41	3/ 85/ 0.89	64.46	24FEB2004/ 17MAR2004/ 26MAR2004	Haematological/ Anaemia with clinical symptoms
PP 'PPD 3TC/ZDV+TDF	25.9/ Female/ 1.58	3/ 100/ 0.38	194.2 0	27MAY2003/ 27JUN2003/	Haematological/ Anaemia with clinical symptoms
PP 'PPD 3TC/ZDV+TDF	44.0/ Male/ 1.85	3/ 101/ 1.35	69.27	24JUN2003/ 19JAN2004/ 19FEB2004	Musculoskeletal/ Bone fracture
				24JUN2003/ 02MAR2004/	Haematological/ Anaemia with clinical symptoms
				24JUN2003/ 23OCT2004/ 04JAN2005	CNS/ Peripheral neuropathy - sensory only

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.
PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	34.8/ Female/ 1.31	3/ 131/ 0.55	107.9 9	01JUL2003/ 29JUL2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	43.0/ Male/ 2.00	3/ 150/ 0.89	134.9 3	01JUL2003/ 06SEP2003/	Non HIV related deaths/ Traumatic
PP D PPD 3TC/ZDV+TDF	30.9/ Female/ 1.67	4/ 117/ 0.74	111.0 3	22JUL2003/ 19AUG2003/	Haematological/ Neutropenia
PP D PPD 3TC/ZDV+TDF	26.1/ Female/ 1.53	3/ 123/ 0.60	117.2 4	29JUL2003/ 25AUG2003/	Haematological/ Neutropenia
				29JUL2003/ 23SEP2003/ 07OCT2003	Haematological/ Anaemia with clinical symptoms
				29JUL2003/ 01MAR2004/	Non HIV related deaths/ Obstetric
PP T PPD 3TC/ZDV+TDF	37.1/ Female/ 1.56	3/ 165/ 0.71	93.76	05AUG2003/ 28AUG2003/ 28OCT2003	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	51.1/ Male/ 1.71	4/ 156/ 1.15	62.91	04SEP2003/ 19FEB2004/	Biochemical/ Raised AST
PPD PPD 3TC/ZDV+TDF	30.6/ Female/ 1.63	3/ 123/ 3.60	20.38	02OCT2003/ 30OCT2003/	Biochemical/ Raised creatinine
				02OCT2003/ 23DEC2003/	Renal/ Renal failure - chronic
				02OCT2003/ 15APR2004/	Biochemical/ Hyperkalaemia
				02OCT2003/ 21JUN2005/	Cardiovascular/ Congestive cardiac failure
PP PPD 3TC/ZDV+TDF	38.0/ Male/ 1.59	4/ 184/ 0.78	94.32	30OCT2003/ 27NOV2003/ 30DEC2003	Haematological/ Neutropenia
				30OCT2003/ 11MAR2004/	Cardiovascular/ Congestive cardiac failure
PP PPD 3TC/ZDV+TDF	50.7/ Female/ 1.49	3/ 105/ 0.55	93.61	13NOV2003/ 11DEC2003/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Protocol: COL30515
Population: DART Subjects

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	25.4/ Female/ 2.11	3/ 137/ 0.75	195.0 2	18NOV2003/ 16DEC2003/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	30.5/ Female/ 1.50	3/ 147/ 1.22	54.20	25NOV2003/ 23DEC2003/	Haematological/ Neutropenia
				25NOV2003/ 20JAN2004/	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	45.3/ Female/ 1.73	3/ 192/ 1.15	63.00	27NOV2003/ 23DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	48.6/ Female/ 1.84	4/ 174/ 0.57	151.8 2	04DEC2003/ 30DEC2003/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	40.0/ Male/ 1.83	4/ 176/ 0.84	109.3 0	20JAN2004/ 17FEB2004/ 13APR2004	Biochemical/ Raised ALT
				20JAN2004/ 13APR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Listing 2.4
Listing of All Clinical Grade 3 or 4 AEs

Centre/ Subject ID/ Regimen	Age (yrs)/ Sex/ Body Surface Area	WHO Stage/ CD4 count (x10^6/l)/ Creatinine (mg/dL)	eGFR	Date randomised/ Event date/ Resolution date	Event category/ Adverse Event
PPD PPD 3TC/ZDV+TDF	55.5/ Male/ 1.61	3/ 137/ 0.91	71.08	22JAN2004/ 19FEB2004/	Haematological/ Neutropenia
PPD PPD 3TC/ZDV+TDF	27.6/ Female/ 1.75	2/ 125/ 0.94	99.19	22JAN2004/ 15APR2004/ 13MAY2004	Haematological/ Anaemia with clinical symptoms
PP PPD 3TC/ZDV+TDF	50.7/ Male/ 1.94	4/ 195/ 1.00	97.61	27JAN2004/ 13JUL2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	30.0/ Female/ 1.48	4/ 125/ 0.68	95.50	12FEB2004/ 16MAR2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	30.8/ Female/ 1.59	4/ 118/ 0.92	75.40	17FEB2004/ 16MAR2004/	Haematological/ Neutropenia
PP PPD 3TC/ZDV+TDF	34.7/ Female/ 1.75	3/ 145/ 0.95	91.27	12MAR2004/ 08APR2004/	Haematological/ Neutropenia

NOTE: Baseline CLcr was measured by eGFR using CGF and reported in mL/min unless otherwise specified. All subjects received 3TC/ZDV ZDV (COMBIVIR) with a 3rd ART of either ABC or NVP or TDF. CLcr<30 means any ART regimen with baseline CLcr<30 mL/min. CLcr units are mL/min.

PPD

Development of AntiRetroviral Therapy in Africa

ACRONYM: DART

Full Title of trial:

A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa

ISRCTN13968779

Protocol number 1.4

Protocol date 29 March 2007

PPD

..... 17/4/07 .....

Authorised signature Date

Name Professor PPD

(Chair of TSC for final protocols and amended final protocols)

Name of person authorised to sign final protocol and protocol amendments for the sponsor (Chair of TSC)

Professor PPD
Department of Sexually Transmitted Diseases
Mortimer Market Centre
off Capper Street
London WC1E 6AU

PPD
Tel: PPD
Fax: PPD

Trial Sponsor
Medical Research Council (MRC, UK)

Principal Investigators and Co-PIs (in bold) and Investigators responsible for conducting trial

Professor PPD
PPD

PPD
Tel: PPD
Fax:

Professor PPD
Dr PPD **(Co-PI)**
Dr PPD (Trial Manager)
PPD
PPD
PPD Uganda.

PPD
Tel: PPD
Fax:

Professor PPD

Dr PPD **(Co-PI)**

Dr PPD (Project Leader)

PPD (Trial Manager)

PPD
PPD
PPD Uganda

PPD

Tel: PPD
Fax:

Prof PPD
Prof PPD
PPD
PPD Uganda

PPD

Tel: PPD
Fax:

Professor PPD
PPD
Professor PPD **(Co-PI)**
Prof PPD
Dr PPD **(Project Leader)**

PPD

PPD
PPD
PPD Zimbabwe
PPD (Trial Manager)

Tel: PPD
Fax:

PPD

Professor PPD
Professor PPD **(Co-PI)**
Professor PPD
PPD

PPD

Tel: PPD
Fax:

Trial manager and monitors

PPD
PPD

PPD
Tel: PPD
Fax:

Dr PPD

PPD

The trial will be conducted in compliance with the protocol, GCP and regulatory requirements.

Trial statisticians

Professor PPD

Dr PPD

PPD
Tel: PPD
PPD
Tel: PPD

MRC Clinical Trials Unit
222 Euston Road
London NW1 2DA

Fax: PPD

Trial Funders

The trial is funded by the Medical Research Council (MRC UK), Rockefeller Foundation, US and Department for International Development, UK (DFID) and the drugs are supplied by Boehringer Ingelheim, Gilead, GlaxoSmithKline and Abbott Labs.

SUBSTANTIVE CHANGES FROM DART PROTOCOL V1.3 TO V1.4 (important changes in bold)

- **Extension of the trial by one calendar year: the DART trial will have a nominal end date of 31 December 2008, though in fact there will be a phased transition to national programmes from late 2008 and the last DART clinic visit will occur in the first quarter of 2009.**
- **The bPI monotherapy section of the second-line randomisation that was added in version 1.3 is removed again in this amendment, having been transferred (largely unchanged, except for the addition of separate informed consent at the point of randomisation to bPI monotherapy maintenance or continued combination ART) to a separate Protocol (the SARA study).**
- **Added an explicit statement that DART participants may co-enrol in any other study provided this does not compromise the integrity of the DART trial. Specifically the restrictions relating to laboratory monitoring must be maintained, section 6.5, page 31.**
- **Addition of sample size calculations for the trial extension, section 10.1, page 43.**
- **Amendment of sample size calculations for second line randomisation, section 10.1, page 43.**
- **Addition of Aluvia to Appendix 3.0 (details of ARVs), page 66.**
- **Amendment of the patient information sheet for the second-line feasibility study to remove bPI monotherapy, Appendix 6.4, page 83.**
- **Addition of Abbott as a donor of ARVs (Aluvia) for second-line.**

SUBSTANTIVE CHANGES FROM DART PROTOCOL V1.2 TO V1.3 (important changes in bold)

- **Termination of STI randomisation throughout. Note that several amendments relating to the STI randomisation for safety had already been implemented and were in draft for Protocol amendment when the STI randomisation was terminated on 15 March 2006. These changes are included for completeness but are no longer being applied as the whole STI arm has been closed with all participants moving to the CT arm.**
- Explicit statement of MRC as Sponsor of the DART Trial.
- Change of contact details and personnel.
- **Amendment of Trial Summary – Abstract, page 13, and Schema, page 14, to include feasibility second line randomisation.**
- **Amendment of flow sheets, section 1.3, page 16**

- **Amendment of rationale to include second line randomisation feasibility study, section 2.5, page 24.**
- **Amendment of DART trial objectives – that STIs will only be evaluated during first line ART, section 3.1, page 25**
- **Addition of section on second line feasibility study to objectives, section 3.4, page 26.**
- **Addition of endpoints for second line feasibility study, section 4.0, page 26.**
- **Amendment of STI/CT randomisation throughout to allow randomisation at week 76 for patients not randomised at week 52 for any reason.**
- **Amendment to criteria for modifying the STI regimen and restarting ART early, section 7.5.2, page 36.**
- **Amendment of criteria for deferring STI - section 7.5.3, page 36.**
- **Addition of information on second line ART to section 2.4, page 22.**
- **Addition of 2nd line ART feasibility randomisation to design, section 5.1.4, page 28.**
- **Amendment of section 7.3.1, page 31, to include 2nd line feasibility randomisation.**
- **Addition of details of 2nd line feasibility randomisation - section 7.3.4, page 33.**
- **Amendment of** Table 5**, page 39, for second line regimens.**
- **Amendment of section 7.6.2, page 37 on switching at failure of first line to include option to switch when the CD4 count is between 100 and 50 cells/mm^3 (LCM only)**
- **Amendment of section 8.1.2, page 40 for second line ART**
- **Addition of section on second line randomisation feasibility study to sample size, section 10.1, page 43**
- **Addition of section on second line randomisation feasibility study to analysis plan, section 10.2, page 46**
- **Additional references, section 14.0, page 47**
- **Addition of lactate, cardiomyopathy and lipodystrophy to AE grading table, appendix 4.1,page 70**
- **Addition of Patient Information Sheet for second line randomisation feasibility study - appendix 6.4, page 83**
- **Addition of Consent Form for second line randomisation feasibility study – appendix 6.5, page 87**
- **Update of section on post-trial issues, Appendix 9.0, page 90**

SUBSTANTIVE CHANGES FROM DART PROTOCOL V1.1 TO V1.2 (important changes in bold)

- Change of various contact details.
- **Amendment of CD4 threshold for STI randomisation to 300 cells/mm^3, throughout.**
- **Amendment of time for STI randomisation to week 52 (using week 48 CD4 count for eligibility), throughout.**
- **Amendment of recruitment target for STI/CT randomisation to 600, throughout.**
- **Recruitment target revised to 3300, throughout.**
- **Recruitment period for CMO/LCM extended into 2nd year, throughout.**
- **Recruitment period for STI/CT extended into 3rd year, throughout.**
- Trial schema revised, section 1.2, page 14.
- **Flow sheets revised for STI changes, section 1.3, page 16.**
- **Flow sheets revised to make 12 weekly plasma storage mandatory and addition of plasma storage at (or near) time of delivery, section 1.3, page 16.**
- NORA will not take place in Zimbabwe, throughout.
- **Addition of specific eligibility criteria for STI randomisation, section 7.3.3, page 32.**
- **Addition of intensive monitoring of first 100 patients randomised to STI/CT, section 7.3.3, page 32.**
- **Revision of criteria for restarting ART early during an STI, section 7.5.2, page 36.**
- **Revision of criteria and procedure for deferring an STI, section 7.5.3, page 36.**
- **Revision of CD4 threshold and time on ART for resuming STIs after switch to second line, removal of recurrent bacterial infection for clinical reason for switching and reduction of time for repeating CD4 counts if <50, section 7.6.2, page 37.**
- **Updating of sample size calculations, section 10.1, page 43.**

SUBSTANTIVE CHANGES FROM DART PROTOCOL V1.0 TO V1.1 (important changes in bold)

- Change of PI details at PPD
- Addition of contact details for Project Leader at PPD
- Addition of Investigators at PPD and PPD
- Update of various contact details.
- Addition of details of trial managers at sites and at CTU.

- **Section 4.2: addition of 2 extra secondary endpoints.**
- Section 5.1.2: CD4 monitoring should not be open for CMO patients in the STI pilot
- **Section 6.2 point 5: replacement of WBC as example exclusion criterion with neutrophils <0.50x10^9/l.**
- **Section 6.3: inclusion of PPD site in the NORA substudy.**
- Section 7.1: removal of cell percentages from required cell counts.
- Section 7.3.1: CMO/LCM stratification corrected to 0-99 and 100-199 CD4 not 1-99 and100-200.
- Section 7.3.1: STI/CT stratification by week number at entry.
- Section 7.3.3: remove requirement to fax CTU.
- Section 7.3.3: extend period on other ARVs from 5 to 7 days on stopping NVP.
- Section 7.3.6: clarification about families and NORA.
- **Section 7.4: change to reporting of grade 4 biochemistry in CMO arm.**
- Section 7.5.1: extend period on other ARVs from 5 to 7 days on stopping NVP.
- Section 7.6.2: allowance for some clinical discretion about reasons for switching ART.
- Section 7.9: clarification of reporting of protocol violations.
- Section 7.9.1: clarification of definition of SAEs and reporting.
- Section 8.1 Table 5: second line ART specified as containing 2 NRTIs rather than limiting to ddI+d4T.
- **Section 8.1.1: revision to allow NORA in PPD**
- Section 8.1.2: second line ART specified as containing 2 NRTIs rather than limiting to ddI+d4T and removal of reference to Zimbabwe as only country where NVP will be first line.
- Sections 9.1 & 9.4: a subgroup of TSC (not of DSMC) will monitor STI pilot and STI.
- Section 9.5: Endpoint Review Committee structure revised.
- Section 12.0: requirement for locked file cabinets replaced with locked locations.
- Section 14.0 ref 10: update of reference to WHO guidelines from draft to final.
- **Appendix 1.0: monitoring of STI pilot revised.**
- Appendix 1.5: pregnancy test corrected to week 48 from 52.
- Appendix 2.4: NORA schema clarified.
- **Appendix 2.5.1: NORA primary endpoint revised.**
- **Appendix 2.5.2: NORA secondary endpoints clarified.**
- **Appendix 2.6.2 pt 5: replacement of WBC as example exclusion criterion with neutrophils <0.50x10^9/l.**

- Appendix 2.9: management of adverse events in NORA expanded.
- Appendix 2.9.5: revision of safety monitoring in NORA.
- Appendix 2.11: NORA flowsheet revised - removal of extra pregnancy test at week 12 and adherence assessment at week 0.
- **Appendix 2.12: NORA patient information sheet revised for inclusion of** PPD
- **Appendix 2.13: NORA consent revised for inclusion of** PPD
- Appendix 3.0: removal of restriction for TDF to be taken with food.
- Appendix 3.0: footnote added to ZDV contraindications to note revised eligibility criteria on neutrophils.
- Appendix 5.0: correction of performance scale 3 to bed-ridden <50% of time.

TABLE OF CONTENTS

1.0 Summary 13
1.1 Abstract 13
1.2 Trial Schema 14
1.3 Flow Sheets 16
1.3 Flow Sheets 16

2.0 Background and Rationale 20
2.1 Introduction 20
2.2 Monitoring for efficacy and toxicity 20
2.3 Structured Treatment Interruptions (STIs) 21
2.3.1 STI randomisation termination 21
2.4 Antiretroviral Therapy Regimens 22
2.5 Rationale 24

3.0 Objectives 25
3.1 Main DART Trial Objectives 25
3.2 STI Pilot Study Objectives 25
3.3 Abacavir Safety Substudy Nevirapine OR Abacavir (NORA) Objectives 25
3.4 Second line feasibility study objectives 26

4.0 Endpoints 26
4.1 Primary Endpoints (CMO/LCM and STI/CT): 26
4.2 Secondary Endpoints (CMO/LCM and STI/CT): 26
4.3 Primary Endpoints (second-line randomisation feasibility study): 27
4.4 Secondary Endpoints (second-line randomisation feasibility study): 27

5.0 Design 27
5.1 Type of design 27
5.1.1 Randomisation to CMO or LCM arm 27
5.1.2 STI Pilot 27
5.1.3 STIs or continuous ART 27
5.1.4 Feasibility randomisation for second line ART for those failing first line ART 28
5.2 Antiretroviral Therapy 29

6.0 Patient Population 29
6.1 Inclusion Criteria (CMO/LCM) 29
6.2 Exclusion criteria (CMO/LCM) 29
6.3 Number and source of subjects (CMO/LCM and STI/CT) 30
6.4 Number and source of subjects (second-line feasibility study randomisation) 30
6.5 Co-enrolment in other studies 31

7.0 Procedures and Management of Subjects 31
7.1 Screening Procedure for CMO/LCM 31
7.2 Baseline procedure (Week 0 for CMO/LCM) 31
7.3 Randomisation and Enrolment 31
7.3.1 Randomisation List 31
7.3.2 First Randomisation to CMO or LCM 32
7.3.3 Second Randomisation – STIs or continuous ART 32
7.3.4 Third randomisation – second line regimen feasibility study 33
7.3.5 Pregnancy 34

7.3.6 Enrolment of family members into the trial....34
7.4 Follow-up Evaluations....34
7.5 Management of patients allocated to the STI arm....36
7.5.1 Timing of STIs....36
7.5.2 Modifying the STI regimen....36
7.5.3 Cessation of STIs....36
7.5.4 Deferring STI during follow-up....37
7.5.5 Termination of the STI study....37
7.6 Changing ART....37
7.6.1 Substituting for Toxicity....37
7.6.2 Switching for failure of first-line therapy....37
7.7 Assessment of adherence....38
7.8 Withdrawal from allocated strategy....38
7.9 Recording and reporting of Adverse Events, Death, HIV progression and protocol violations....38
7.9.1 Serious Adverse Events (SAE):....39

8.0 Drug Regimens....39
8.1 Antiretroviral Therapy....39
8.1.1 First-line antiretroviral drugs....40
8.1.2 Second-line antiretroviral drugs....40
8.1.3 Provision of trial drugs....40
8.1.4 Modification of therapy for toxicity....40
8.2 Prophylaxis against Opportunistic Infections....41
8.3 Medications not permitted/ Precautions....41
8.4 Data on concomitant medications....41

9.0 Management of the Trial....41
9.1 Trial Steering Committee....41
9.2 Trial Management Groups....42
9.3 Data Management and Monitoring....42
9.4 Data and Safety Monitoring Committee (DSMC)....43
9.5 Endpoint Review Committee....43

10.0 Statistics....43
10.1 Sample Size....43
10.2 Analysis Plan....46

11.0 Regulatory/ Ethics Approval....46

12.0 Confidentiality....46

13.0 Publication....47

14.0 References....47

Appendices

Appendix 1.0 Structured Treatment Interruptions (STI) Pilot Study....49
1.1 Monitoring of individual patients 49
1.2 Monitoring of the group data 49
1.3 Guidelines for management during STI pilot. 50
1.4 Guidelines for the DSMC and Steering Committees. 50

1.5 Flow Sheet for STI pilot 51

Appendix 2.0 Nevirapine OR Abacavir (NORA) Substudy 52

2.1 Objective 52
2.2 Background and Rationale 52
2.2.1 Hypersensitivity reaction to Abacavir.....52
2.2.2 Adverse reactions to NVP.....53
2.3 Trial Design 53
2.4 NORA Trial Schema 54
2.5 Endpoints 54
2.5.1 Primary endpoint:.....54
2.5.2 Secondary Endpoints.....55
2.6 NORA Criteria for Inclusion/Exclusion 55
2.6.1 Inclusion Criteria.....55
2.6.2 Exclusion criteria 55
2.7 Sample size 56
2.8 Analysis Plan 56
2.9 Management of Adverse reactions 56
2.9.1 Management of reactions to combivir 56
2.9.2 Management of reactions to blinded drug.....56
2.9.3 Management of nevirapine reactions 57
2.9.4 Management of abacavir reactions 57
2.9.5 Safety monitoring.....57
2.10 Hypersensitivity reaction to abacavir and management of safety - as provided by GSK. 58
2.10.1 Description of hypersensitivity to Abacavir 58
2.10.2 Information for patients 59
2.10.3 Medical management for possible hypersensitivity to abacavir 59
2.10.4 Medical management for Abacavir rash not accompanied by systemic symptoms 60
2.10.5 Fever and hypersensitivity to Abacavir 60
2.10.6 Special considerations following an interruption of abacavir therapy.....60
2.11 NORA SUBSTUDY FLOW SHEET 62
2.12 DART NORA Substudy Patient Information sheet 63
2.13 DART NORA Substudy Patient consent form 65

Appendix 3.0 Details of Antiretroviral Therapy.....66

Appendix 4.0 Toxicity Grading and Management 70

4.1 Table of Common Toxicity Criteria 70
4.2 Table of Clinical Signs, Symptoms, Monitoring and Management of Symptoms of Serious Adverse Effects of Antiretroviral Drugs that Require Drug Discontinuation (adapted from WHO guidelines [ref 10] Annex 11B) 74
4.3 Guide to management of toxicities 75
4.3.1 Grade 1 (clinical or laboratory (LCM arm only)):.....75
4.3.2 Grade 2 (clinical or laboratory (LCM arm only)):.....75
4.3.3 Grade 3 (clinical or laboratory (LCM arm only)):.....75
4.3.4 Grade 4*(clinical or laboratory):.....75

Appendix 5.0 Clinical progression and WHO Definitions.....76

Appendix 6.0 Patient Information sheet and Consent Forms (Templates)..77

6.1 Patient information sheet for DART study 77
6.2 Consent for Screening for the DART Trial 81
6.3 Patient consent form for DART Trial 82
6.4 Patient information sheet for the second line randomisation feasibility study 83
6.5 Patient consent form for the feasibility second line randomisation 87

Appendix 7.0 Handling and Storage of Specimens.....88
7.1 Bloods 88
7.1.1 Processing of EDTA blood for Plasma and cell store.....88
7.1.2 Storage of samples 88

Appendix 8.0 Adherence protocol 89

Appendix 9.0 Post DART Trial issues.....90

Tables

Table 1 Laboratory and Clinical Monitoring (LCM) group (+/- STI co-enrolment) 16
Table 2 LCM group (+/- STI co-enrolment): weeks 84-180 17
Table 3 Clinical Monitoring Only (CMO) Group (+/- STI co-enrolment) 18
Table 4 CMO Group (+/- STI co-enrolment): weeks 84 - 180 19
Table 5 First and second-line drug regimens for DART (For details see Appendix 3.0, page 67) 39
Table 6 Guidelines for Substituting for Toxicity in First-Line 41
Table 7 STI Pilot for 100 patients (completed 24 weeks in CMO or LCM and with CD4 cell counts at week 24 of 200 cells/mm^3 or higher. 51
Table 8 NORA flow sheet 62

1.0 Summary

1.1 Abstract

The DART protocol describes an open-label randomised trial evaluating two strategic approaches for management of antiretroviral therapy (ART) in symptomatic HIV infected adults in Africa. The first strategy compares **clinical monitoring only** (CMO) with **laboratory plus clinical monitoring** (LCM). The second approach compares structured treatment interruptions (STIs: 12 weeks on, 12 weeks off ART) with continuous ART in patients who achieve CD4 cell counts ≥ 300 cells/mm^3 after 48 weeks on continuous ART.

Eligible patients will have symptomatic HIV disease (WHO stage 2, 3 or 4) and CD4 cell counts <200 cells/mm^3, no prior ART and no clinical or laboratory abnormalities contra-indicating start of ART. 3300 patients will be enrolled over 1-2 years into the CMO/LCM comparison from 3 African sites (2 in Uganda, 1 in Zimbabwe) and followed for 3-5 years. In both CMO and LCM arms, patients will have haematology and liver function tests performed but the results will not be returned to clinicians caring for patients in CMO arm unless indicative of a grade 4 adverse event. CD4 counts will be performed both in CMO and LCM arms with results not returned to physicians in the CMO arm but monitored independently by a subgroup of the Data Safety and Monitoring Committee (DSMC).

Following the pilot STI study in 100 patients, it is expected at least 600 will achieve CD4 ≥300 cells/mm^3 by 48 weeks after trial entry and will undergo a second randomisation to structured treatment interruption (STI) or to continuous ART. The second randomisation will open after a non-randomised pilot study of a 100 patients assigned to STIs (see Appendix 1.0, page 49) has been completed and the DSMC and Trial Steering Committees have assessed STIs as safe. During the pilot study and during the first phase of the STI randomisation, all patients (in both CMO and LCM arms) will undergo monthly CD4 cell monitoring.

Patients will initially receive zidovudine (ZDV) and lamivudine (3TC) in combination (combivir, CBV) plus tenofovir (TDF, 2,400 patients) or nevirapine (NVP, 300 patients). In addition, 600 patients enrolled early in the trial will be offered co-enrolment (for which they will consent separately) to a double blind 24-week comparison of the safety of abacavir (ABC) versus NVP for first line therapy (see Appendix 2.0, page 52). These patients will continue to receive ABC or NVP, respectively, after the blinded period is over. For toxicity or intolerance of any individual drug, another drug from the same class will be substituted.

The primary efficacy endpoint will be progression to a new WHO HIV stage 4 disease or death. The decision to change to second-line ART will be based on clinical criteria alone for the CMO arm and on clinical plus laboratory criteria for the LCM arm. Second-line ART consisting of a ritonavir boosted protease inhibitor (bPI) plus (initially at least) either nucleoside or non-nucleoside reverse transcriptase inhibitors or both will be provided according to the feasibility study randomisation detailed in section 7.3.4, page 33 (anyone not consenting to enter this feasibility study will still be offered a bPI containing second line regimen). Patients who fail the second-line regimen will be offered the best combination available from the first and second line drugs.

DART is a six-year trial. Recruitment into the trial will take place over two years for the first randomisation to the 2 monitoring strategies, with follow-up of 4 years after the last patient is randomised. For the second randomisation to STIs or continuous ART, recruitment will occur during the second and third years, to be completed by the end of the third year and follow-up will be for up to 2 years after the last patient is randomised.

1.2 Trial Schema

CMO/LCM and STI/CT



* Once second randomisation has opened after STI pilot study. **Note STI randomisation terminated 15th March 2006**

Second-line feasibility study randomisation:



* Note: any patient who did not disclose prior NNRTI experience before entering DART & is considered to have failed immunologically and/or clinically whilst taking NNRTI should be enrolled in strata 1.

† patients with previous adverse reaction to ZDV will receive bPI+TDF+3TC only

1.3 Flow Sheets

Note that the STI arm has been terminated (15 March 2006) so no STIs will be taken after this date.

Table 1 Laboratory and Clinical Monitoring (LCM) group (+/- STI co-enrolment)

EVENTS	WEEK IN TRIAL																							
Doctor/Nurse visit * ☐ Nurse visit ☐ Doctor only visit * ■	Screening Week-2	Start therapy Week 0	2	4	8	12	16	20	24	28	32	36	40	44	48	52	56	60	64	68	72	76	80	Switch[7]
CD4>=300 at week 48																Start STI			Restart ART			Start STI		
Adherence assessment and 4 weeks ART supply *		X		X	X	X	X	X	X	X	X	X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	X
Consent to screening and patient information sheet	X																							
Informed Consent		X																						X
History & Physical[1]	X	X	X	X	X	X			X	X		X			X	X		X			X			X
Symptom check list		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pregnancy Test[2]	X								X						X						X			
Haematology[3]	X			X		X			X			X			X			X			X			X
Biochemistry[4]	X			X		X			X			X			X			X			X			X
Lymphocyte Subsets [5]	X					X			X			X			X			X			X			X
Plasma storage[6]	X	X		X		X			X			X			X			X			X			X

* **Patients will return 4-weekly to see the nurse or doctor, return used drug containers and receive 4 weeks of ART (except for STI).** Nurse should check if patient has any new symptoms since the last visit. If yes, patient should see the trial doctor BEFORE PROCEEDING with structured treatment interruption (STI). The doctor will prescribe antiretroviral therapy and make decisions on any modifications of therapy as necessary.

[1] Clinical: including weight, WHO staging for HIV.

[2] At screening, and subsequently at start of STI in those randomised to STI; see section 7.3.4 if positive.

[3] Haematology: Hb, MCV, WBC, Lymphocytes, Neutrophils, and Platelets.

[4] Biochemistry: Urea, Creatinine, AST or ALT, Bilirubin

[5] CD4, CD8, CD3 percentage and absolute, total lymphocyte count

[6] Take 6 ml EDTA blood. Store DNA pellet at week –2, 0, 24, 48 and then every 48 weeks (if feasible). See Appendix 7.0 for instructions about storage. Take plasma (DNA pellet if feasible) at time of switch. Take plasma as near as possible to time of delivery for any women giving birth in DART

[7] At time of switch to 2nd line reset flow sheet to visit week 0.

Table 2 LCM group (+/- STI co-enrolment): weeks 84-180

EVENTS	WEEK IN TRIAL																											
Doctor/Nurse visit * ■ Nurse visit □	84	88	92	96	100	104	108	112	116	120	124	128	132	136	140	144	148	152	156	160	164	168	172	176	180	12 weekly	Switch[7]
CD4>=300 at week 48		Restart ART			Start STI			Restart ART			Start STI			Restart ART			Start STI			Restart ART			Start STI				
Adherence assessment and 4 weeks ART supply*	STI or X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	STI or X		X
Informed Consent																											X
History & Physical[1]	X			X			X			X			X			X			X			X			X	X	X
Symptom check list	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pregnancy Test[2]				X						X						X						X					
Haematology[3]	X			X			X			X			X			X			X			X			X	X	X
Biochemistry[4]	X			X			X			X			X			X			X			X			X	X	X
Lymphocyte Subsets [5]	X			X			X			X			X			X			X			X			X	X	X
Plasma storage[6]	X			X			X			X			X			X			X			X			X	X	X

*** Patients will return 4-weekly to see the nurse or doctor, return used drug containers and receive 4 weeks of ART (except for STI).**

The doctor will prescribe antiretroviral therapy and make decisions on any modifications of therapy as necessary.

1 Clinical: including weight, WHO staging for HIV

2 At screening, and subsequently at start of STI in those randomised to STI; see section 7.3.4 if positive.

3 Haematology: Hb, MCV, WBC, Lymphocytes, Neutrophils, and Platelets

4 Biochemistry: Urea, Creatinine, AST or ALT, Bilirubin

5 CD4, CD8, CD3 percentage and absolute, total lymphocyte count

6 Take 6 ml EDTA blood. Store DNA pellet at week 96 and then every 48 weeks (if feasible). See Appendix 7.0 for instructions about storage. Take plasma (DNA pellet if feasible) at time of switch. Take plasma as near as possible to time of delivery for any women giving birth in DART

7 At time of switch to 2nd line reset flow sheet to visit week 0.

Table 3 Clinical Monitoring Only (CMO) Group (+/- STI co-enrolment)

EVENTS	WEEK IN TRIAL																						
Doctor/Nurse visit* ☐ Nurse visit ☐ Doctor only visit* ■	Screening Week-2	Start therapy Week 0	2	8	12	16	20	24	28	32	36	40	44	48	52	56	60	64	68	72	76	80	Switch[7]
CD4>=300 at week 48															Start STI			Restart ART			Start STI		
Adherence assessment and 4 weeks drug supply*		X		X	X	X	X	X	X	X	X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI OR X	X
Consent for screening and patient information	X																						
Informed consent		X																					X
History & Physical[1]	X	X	X	X	X			X	X		X			X	X		X			X			X
Symptom check list		X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pregnancy Test[2]	X							X						X						X			
Haematology[3]	X				X			X			X			X			X			X			X
Biochemistry[4]	X				X			X			X			X			X			X			X
Lymphocyte Subsets – results returned to clinician [5a]	X													X									
Lymphocyte Subsets –results not returned to clinician[5b]					X			X			X						X			X			X
Plasma storage	X	X			X			X			X			X			X			X			X

* Patients will return 4-weekly to see the nurse or doctor, return used drug containers and receive 4 weeks of ART (except for STI). **Nurse should check if patient has any new symptoms since the last visit, if yes patient should see the trial doctor BEFORE PROCEEDING with structured treatment interruption (STI)** The doctor will prescribe antiretroviral therapy and make decisions on any modifications of therapy as necessary.

[1] Clinical: including weight, WHO staging for HIV.

[2] At screening, and subsequently at start of STI in those randomised to STI; see section 7.3.4 if positive

[3] **Blinded** Haematology: Hb, MCV, WBC, Lymphocytes, Neutrophils, Platelets, except at screening (week –2) when results returned to clinician.

[4] **Blinded** Biochemistry: Urea or Creatinine, AST or ALT, Bilirubin, except at screening (week –2) when results returned to clinician

[5a] Return results at baseline. At week 48 return result as </>=300 cells/mm^3. If result at week 48 is >=300 cells/mm^3, randomise to STI or no STI . A result taken at time of switch to second-line therapy should not be made available to clinician. After switch, all patients receive at least 48 weeks of continuous ART. At the next scheduled visit where lymphocyte subsets are taken prior to a scheduled STI but at least 48 weeks post switch, CD4 cell count will again be made available to the clinician (as </>=300 cells/mm^3). If this result is >=300 cells/mm^3, patients in the STI arm may recommence STI. If CD4 count is <300 cells/mm^3, then patient continues ART with no further STI.

[5b] **Blinded** CD3, CD4, CD8 percentage and absolute, total lymphocyte count.

[6] Take 6 ml EDTA blood. Store DNA pellet at week –2, 0, 24, 48 and then every 48 weeks (if feasible). See Appendix 7.0 for instructions about storage. Take plasma at time of switch (and DNA pellet if feasible). Take plasma as near as possible to time of delivery for any women giving birth in DART

[7] At time of switch to 2nd line reset flow sheet to visit week 0.

Table 4 CMO Group (+/- STI co-enrolment): weeks 84 - 180

EVENTS	WEEK IN TRIAL																										
Doctor/Nurse visit * ☐ Nurse visit ☐	84	88	92	96	100	104	108	112	116	120	124	128	132	136	140	144	148	152	156	160	164	168	172	176	180	12 Weekly	Switch[7]
CD4>=200 at week 48		Restart ART			Start STI			Restart ART			Start STI			Restart ART			Start STI			Restart ART			Start STI				
Adherence assessment and 4 weeks drug supply*	STI or X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	STI or X	X	X	X	STI or X	STI or X	STI or X		X
Informed Consent																											X
History & Physical[1]	X			X			X			X			X			X			X			X			X	X	X
Symptom check list	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Pregnancy Test[2]				X						X						X						X					
Haematology[3]	X			X			X			X			X			X			X			X			X	X	X
Biochemistry[4]	X			X			X			X			X			X			X			X			X	X	X
Lymphocyte Subsets- return results to clinician[5a]																											
Lymphocyte Subsets- do not give results to clinician[5b]	X			X			X			X			X			X			X			X			X	X	X
Plasma storage[6]	X			X			X			X			X			X			X			X			X	X	X

*** Patients will return 4-weekly to see the nurse or doctor return used drug containers and receive 4 weeks of ART (except for STI).** The doctor will prescribe antiretroviral therapy and make decisions on any modifications of therapy as necessary.

1 Clinical: including weight, WHO staging for HIV.

2 At screening, and subsequently at start of STI in those randomised to STI; see section 7.3.4 if positive

3 **Blinded** Haematology: Hb, MCV, WBC, Lymphocytes, Neutrophils, Platelets, except at screening (week –2) when results returned to clinician

4 **Blinded** Biochemistry: Urea or Creatinine, AST or ALT, Bilirubin, except at screening (week –2) when results returned to clinician

5a Return results at baseline. At week 48 return result as </>=300 cells/mm^3. If result at week 48 is >=300 cells/mm^3, randomise to STI or no STI. A result taken at time of switch to second-line therapy should not be made available to clinician. After switch, all patients receive at least 48 weeks of continuous ART. At the next scheduled visit where lymphocyte subsets are taken prior to a scheduled STI but at least 48 weeks post switch, CD4 cell count will again be made available to the clinician (as </>=300 cells/mm^3). If this result is >=300 cells/mm^3, patients in the STI arm may recommence STI. If CD4 count is <300 cells/mm^3, then patient continues ART with no further STI.

5b **Blinded** CD3, CD4, CD8 percentage and absolute, total lymphocyte count. .

6 Take 6 ml EDTA blood Store DNA pellet at week –2, 0, 24, 48 and then every 48 weeks (if feasible). See Appendix 7.0 for instructions about storage. Take plasma at time of switch and DNA pellet if feasible. Take plasma as near as possible to time of delivery for any women giving birth in DART

7 At time of switch to 2nd line reset flow sheet to visit week 0.

2.0 Background and Rationale

2.1 Introduction

The prevalence of HIV infection is very high (>20%) and still rising in many Sub-Saharan African countries. Prevention messages in the absence of treatment appear to have limited impact and the effect of the epidemic on the social and physical well-being of individuals and on the economy of these countries is devastating. Combination antiretroviral therapy (ART) has had a dramatic effect on the morbidity and mortality of HIV-infected adults and children in well-resourced countries. It may also reduce transmission of HIV, through reduction in HIV viral load. Until recently very high costs were an absolute barrier to the introduction of ART on a wide scale in resource-poor countries. However, these have recently been reduced substantially, making the provision of ART to HIV-infected persons in Africa a realistic possibility. However, the costs and infrastructure required for monitoring patients taking these drugs for efficacy and toxicity, as carried out in developed countries, are also extremely high. There are concerns about the lack of infrastructure to administer ART and to sustain adherence and monitor toxicity in developing country settings. Trials are needed to evaluate strategies for using ART, which are tailored to the circumstances of developing countries.

DART aims to address two major questions. The first is whether ART can be safely given with clinical monitoring alone, in the absence of regular viral load and CD4 measurements and laboratory monitoring for toxicity. The second question concerns the use of pulse compared with continuous ART, the hypothesis being that pulse therapy would reduce the cost and toxicity of ART and may improve adherence, without increasing the risk of developing resistance or disease progression.

2.2 Monitoring for efficacy and toxicity

In persons starting ART in well-resourced countries, monitoring of prognostic markers of HIV disease (HIV RNA viral load and CD4 cell counts) is routinely undertaken in order to make decisions about starting and switching therapy. In addition, routine monitoring of laboratory markers is undertaken in order to detect bone marrow, liver and other toxicities to ART.

Although trials have been carried out, and others are currently ongoing, to ascertain the value of resistance testing in the management of HIV, no trials have been undertaken in developed countries to determine the efficacy and cost-effectiveness or the optimum frequency of HIV RNA viral load or CD4 count monitoring. There have been no studies evaluating the need for, or frequency of laboratory tests required for monitoring toxicity of ART. HIV RNA and CD4 count tests are particularly expensive (although the cost may come down), and unavailable outside major centres in Africa. In addition there are important issues of quality control. Requirements for monitoring schedules similar to those in developed countries are likely to be a barrier to the administration of ART to large numbers of persons in the African setting. Although HIV RNA viral load is an important prognostic marker and is widely used to monitor therapy when first introduced, recently greater emphasis has been placed on monitoring CD4 cell counts as these are better predictors of the immediate risk of clinical disease progression and mortality, particularly in late disease. Furthermore, with the current therapeutic options, it is difficult to maintain HIV RNA below the limit of detection of current assays, over a long period of time, although CD4 count increases may be maintained.

Many would therefore agree that HIV-RNA viral load monitoring is unlikely to be cost-effective or necessary in the African setting. However, it is unclear whether decisions about management of ART toxicity or switching ART can be made on the basis of clinical signs and symptoms alone, or should be on the basis of clinical monitoring plus regular laboratory monitoring for toxicity and CD4 cell counts.

2.3 Structured Treatment Interruptions (STIs)

Structured Treatment Interruptions (STIs), whereby periods on ART are followed by periods off treatment, are being explored in a number of circumstances in developed countries. First, following recent infection with HIV, there is some evidence from small uncontrolled studies that STIs lead to control of viral replication even during periods of no therapy in some patients [1-4]. Second, in patients who have failed several ART regimens and have resistant virus, there is some evidence that an STI leads to the re-emergence of wild-type sensitive virus which may result in a better response to a subsequent new ART regimen [5, 6]; this is being explored in ongoing randomised trials (e.g. OPTIMA Trial). Finally, in chronically infected patients, the possibility of reducing toxicity, improving adherence and reducing costs, while maintaining the clinical and immunological well-being of patients has been reported in observational studies of STI [7,8].

Different periods of interruption of ART are being explored in a number of trials of pulse compared with continuous ART in patients with suppressed viral replication in developed countries. One approach is to cycle on and off ART rapidly (7-days on, 7-days off). This has been reported in small studies to prevent an increase in viral load and the re-emergence of resistance, but may be difficult to implement. Other approaches being evaluated include longer cycles (e.g. 1, 2, 3 or 4 months on and off therapy), and trials where the length of treatment interruption is individualised and driven by the rate of fall in CD4 cell count after stopping ART (e.g. TILT Trial). To date, no evidence is available to define the most appropriate approach. This may anyway be different in the African setting, where many patients are likely to start ART with much lower CD4 cell counts than in developed countries and where CD4 count monitoring is expensive and not readily available. The limited data available from STI studies suggest that the average fall in CD4 count is about 20 cells a month, but may be faster, up to 50-60 cells/month [9], in patients starting ART with a very low CD4 count.

STI trials in developed countries aim to keep CD4 cell counts above a threshold of 200 cells/mm^3. However, most opportunistic infections occur when the CD4 count falls below 50 cells/mm^3. It would be unreasonable not to start ART in patients in most need in Africa, nearly all of whom will have symptomatic disease and many of whom will have CD4 counts below 50 cells/mm^3. It could be argued that it would not be appropriate to interrupt ART until CD4 has increased to above 200 cells/mm^3.

2.3.1 STI randomisation termination

On 15th March 2006 following the recommendation of the DSMC the STI randomisation was terminated early. All patients were transferred to continuous therapy.

2.4 Antiretroviral Therapy Regimens

The role of regular CD4 count monitoring could not be evaluated if the trial did not incorporate a second line ART regimen. The choice of first-line therapy is in line with recently developed WHO guidelines on the use of antiretroviral therapy in resource-poor settings [10]. These recommend use of a double NRTI plus an NNRTI or a triple NRTI regimen, preserving PI-containing regimens for a second-line regimen. The key questions being addressed in the DART trial do not necessitate the use of the same first-line regimen for all patients in the trial. Further, including more than one first-line regimen would enhance the generalisability of results.

2NRTI + NNRTI Regimens

Possible options for this first-line regimen include combivir (zidovudine and lamivudine, CBV plus an NNRTI; e.g. nevirapine (NVP) or efavirenz (EFZ). Both combinations have proven first line efficacy. EFZ may be teratogenic if used in pregnancy, which would be a major issue for women of childbearing age. NVP is being used increasingly as a single dose in women during labour (and one dose to the baby at birth) to reduce mother-to-child HIV transmission (MTCT) and it is unclear to what extent the widespread use of NVP for treatment could impact MTCT programs. Further, if women have already received NVP during a previous pregnancy, it is possible (although unproven) that its subsequent efficacy as part of a treatment regimen may be reduced, as it is known that resistance can develop rapidly. Both NVP and EFZ have long half-lives and resistance develops rapidly. Stopping the NNRTI some days before the NRTIs during treatment interruptions therefore needs to be considered. It is planned to obtain additional pharmacokinetic data to facilitate best management of this issue.

Triple NRTI Regimens

The formulation of a triple NRTI combination of zidovudine, lamivudine and abacavir (Trizivir, TZV), given as one tablet twice a day, provides the possibility of a well-tolerated, simple regimen with the advantage that there is a reduced possibility of developing resistance (as all drugs are in one tablet) and there are likely to be fewer interactions with other drugs (e.g. anti-tuberculosis drugs) than with other anti-HIV drugs, particularly protease inhibitors. However, TZV has potential hazards related to abacavir (ABC), which is associated with hypersensitivity in about 3% of patients. This can be fatal if the patient is re-challenged after stopping the drug for symptoms of hypersensitivity. There is no evidence that interruption of therapy not preceded by hypersensitivity symptoms leads to problems but there are relatively few data on this. Any patient stoppingABC for hypersensitivity would need to receive a replacement drug and would then have to take therapy as separate formulations (two formulations if using CBV or three if all three drugs are provided separately). Giving ABC as part of a regimen with STIs will require close monitoring, particularly in the early phase of treatment. However, the symptoms of hypersensitivity to ABC are predominantly clinical (fever and rash) and careful monitoring will ensure safety of patients.

Information on whether symptoms of immune reactivation post ART or symptoms of tropical diseases could be mistaken for the toxicity of ABC, when used in combination with CBV or as TZV, will be valuable in terms of the widespread use of this combination in developing countries and will be obtained from the NORA substudy in the DART trial (see Appendix 2.0, page 52).

Other possible triple NRTI regimens include CBV plus didanosine (ddI) or CBV plus a nucleotide reverse transcriptase inhibitor, tenofovir (TDF). TDF is available as a single tablet to be taken once daily. It has an excellent safety profile, and has recently been shown to have efficacy at least similar to NRTIs in a 48-week trial comparing the effect on HIV RNA of D4T+3TC+EFV with that of TDF+3TC+EFV [11]. In addition, HIV resistance against TDF develops very slowly, making it an attractive drug to use in resource-poor settings in the absence of HIV RNA resistance testing.

Second line ART

Following the WHO public health approach to ART in resource limited settings, patients in DART continue on first-line ART to clinical/immunological failure rather than switching to second-line at virological failure, as in industrialised countries. There is considerable interest in determining the most appropriate second-line strategies for such patients who may have acquired significant resistance whilst continuing first-line treatment to clinical/immunological failure. There are currently no robust data on the optimal treatment strategy for such patients, because clinical practice in industrialised countries is to switch patients earlier for virological failure based on frequent, routine viral load tests which are currently both technically complex and expensive. (Of note, there are no data comparing switch at virological versus clinical/immunological failure to determine the long-term impact in any setting.)

Further, the number of patients who have taken the most commonly used DART regimen of CBV plus TDF (3 NRTI drugs) world-wide is small, and so there are even fewer data to inform possible choice of second-line therapies for the majority of the DART population. Triple NRTI regimens such as CBV plus TDF are attractive for resource limited settings because of their low pill burden, low frequency of adverse reactions and compatibility with other drugs including anti-tuberculosis therapy, and are being viewed as increasingly important in the WHO Public Health approach.

The first 20 patients identified as failing clinically/immunologically on CBV plus TDF in DART were switched to a second line regimen (bPI+NNRTI+-NRTI) based on clinical opinion at the time. Genotyping was carried out on these patients and revealed extensive nucleoside/nucleotide resistance mutations. This is not unexpected as clinical/immunological failure is likely to occur after many months of viral replication, with accumulation of resistance mutations. It should be noted however that these early failures may not be representative and could have had baseline resistance from undisclosed ART before entry to the DART trial. As yet there are no genotype data from patients failing on 2NRTI plus NNRTI first line in DART, but from other studies in resource-limited settings it is likely that similar extensive NRTI mutations will be seen as well as key NNRTI mutations (rendering this class ineffective).

Therefore, in many patients with clinical or immunological failure of first-line therapy, there may be at best limited activity from any NRTIs included in second line. Expert opinion agrees that a boosted PI (bPI) based regimen will be the most effective second line, but the value of adding NRTIs or NNRTIs is less clear. The use of a new currently licensed NNRTI following failure of a first line regimen containing an NNRTI is unlikely to be beneficial as there is cross-resistance among all currently licensed NNRTIs (which also have a low genetic barrier to resistance). However, two drug, two class, NNRTI plus PI regimens have been used successfully in NNRTI naïve patients (the BIKS study [12]). Non-inclusion of an NRTI in second line could preserve any residual activity for a third line/salvage regimen and would reduce the pill burden and possibly the toxicity from the second line regimen. Of note,

changing to a bPI as part of a regimen is a substantial increment in regimen complexity and tolerability compared to the first line regimens used in DART.

Another question about second-line ART is whether potency of either a bPI or bPI plus NNRTI (for those that have not failed on a NNRTI containing regimen) could be augmented by the addition of new NRTIs, or alternatively by continuing one or more of the NRTI(s) used in first-line therapy, in order to maintain the presence of a highly resistant, but less fit virus with significantly reduced potency. Such viruses with large numbers of nucleoside associated mutations (NAMs) have been reported to have increased susceptibility to NNRTIs. Thus there are interesting questions around the effect of resistance on viral fitness and induction of NNRTI hypersusceptibility which could be addressed if one or more additional NRTI(s) were added to either a bPI or PI/NNRTI regimen. This concept could be particularly valuable for patients failing an NNRTI regimen, who are likely to have extensive NNRTI and NRTI resistance at clinical/immunological failure.

2.5 Rationale

The DART trial is addressing a very important question about safe management of patients taking ART in an environment where routine toxicity and efficacy tests may not be available in compliance with the principles of Good Clinical Practice and the Declaration of Helsinki.

In the African setting, many patients adopt a practice of interrupting therapy because of limited funds. However, this is usually done in a haphazard way and it is unclear whether it is safe. STI trials are being undertaken in chronic HIV infection in developed countries with the aims of reducing toxicity, costs, and possibly improving adherence, without compromising efficacy. In Africa reduction of costs, in particular, would have major advantages. However, as the natural history of HIV in Africa differs from that in developed country settings (e.g. a much higher proportion of TB) and patients are likely to start ART later in the course of HIV disease, it is necessary to evaluate the safety of STI in an African setting. The optimum period for STI is not yet known but rapid cycling of drugs would be too complex. A 3-month cycle has been chosen for DART but may be altered following data from the pilot phase (see Appendix 1.0, page 49).

ART administration in developed countries is accompanied by tests for monitoring ART efficacy and toxicity. However, no trials evaluating the need for laboratory monitoring over and above clinical monitoring alone have been undertaken in developed countries. The cost of tests to measure CD4 cell count, and also of haematology and liver function tests is a major barrier to administration of ART to large numbers of persons in resource-poor settings. Even if costs are reduced, these tests are unlikely to be available outside major centres. Therefore there is a need to explore the question of the necessity of these laboratory tests with the introduction of ART in Africa.

The advantages of combining both the STIs and monitoring questions into a three-centre trial are 3-fold: first, a larger trial can be undertaken than would be possible in a single clinical centre; second, the logistics of supplying drugs for a single trial to address both questions, rather than two separate trials, would be simpler and cheaper; thirdly, collaboration across sites in Africa would be likely to build capacity and enhance regional knowledge about the use of ART.

A simple ART regimen is important for use in the African setting. At a recent meeting of HIV experts at WHO to develop guidelines on use of ART in resource-poor countries, the combination of ZDV, 3TC and ABC in one preparation (trizivir) was considered as a front-

runner for first-line therapy because of ease of administration (one pill twice daily), and lack of interaction with other drugs, in particular anti-TB drugs [10]. However, although there is good data to guide the management of hypersensitivity reactions to ABC in developed countries, this may be different in the African setting because immune reconstitution syndromes may be more common after starting ART in patients with advanced disease living in areas with high prevalence of other infectious diseases. A 600-patient, double blind substudy comparing the toxicity of ABC and NVP (both given with combivir) will therefore be undertaken within the DART trial (see Appendix 2.0, page 52). (This will require placebos for both NVP and ABC.) For the remaining patients in the main study (2700 patients), combivir + TDF will be the first-line regimen for 2400 patients and combivir + NVP for 300 patients.

DART provides an important opportunity to address issues around second-line regimens. In view of the paucity of data on this issue in these settings, the aim would be to capitalise on the infrastructure of DART to conduct a feasibility study to explore the activity of a number of such regimens, using surrogate endpoints (CD4) to identify the most appropriate second-line regimens to take forward into a clinical endpoint trial to assess their **clinical** effectiveness, while minimising resistance and preserving options for third-line (salvage) regimens. All strategies considered will include a boosted PI, in combination with either an NNRTI (with or without a NRTI) or with 2 NRTIs.

3.0 Objectives

3.1 Main DART Trial Objectives

To compare, in terms of clinical HIV disease progression or death:

1. Clinical monitoring only (CMO) versus routine regular laboratory and clinical monitoring (LCM)
2. Structured Treatment Interruptions during first line ART (STIs: 12 weeks on, 12 weeks off therapy) versus continuous ART, initiated if the CD4 count has increased to above 300 cells/mm^3 (after 48 weeks on ART).

The hypothesis is that CMO will result in similar outcomes to LCM, and that ART administered as pulse therapy (STI) will result in similar outcomes to continuous ART, in terms of progression of clinical HIV disease or death.

3.2 STI Pilot Study Objectives

The initial non-randomised pilot study of STIs will inform on the safety of the 12 weeks on, 12 weeks off STI strategy (see Appendix 1.0, page 49) and only after the completion of this substudy will the second randomisation commence.

3.3 Abacavir Safety Substudy Nevirapine OR Abacavir (NORA) Objectives

This randomised sub-study of 600 patients will address issues of safe administration of abacavir (ABC) in resource poor settings and will compare the safety of ABC with that of NVP when used in combination with combivir (see Appendix 2.0, page 52).

3.4 Second line feasibility study objectives

This randomised feasibility study of patients failing first-line regimens of DART will provide preliminary, surrogate endpoint (CD4) data to select the most promising second-line regimens/strategies to be evaluated in a large-scale clinical endpoint trial. Specifically, the feasibility study aims to compare, in terms of CD4 response

1. Strategies of using bPI+NNRTI or all three classes following clinical/immunological failure of regimens not containing an NNRTI
2. Strategies of using bPI plus either new NRTIs (potential residual activity despite possible cross-resistance) or recycled NRTIs (to maintain drug pressure and presence of variants with lower fitness) following clinical/immunological failure of NNRTI containing regimens.

4.0 Endpoints

4.1 Primary Endpoints (CMO/LCM and STI/CT):

- *Efficacy*: Progression to a new WHO stage 4 HIV event or death (see Appendix 5.0, page 76).
- *Safety*: Any serious adverse event, which is not HIV related (see section 7.9, page 38 and 0, page 70).

4.2 Secondary Endpoints (CMO/LCM and STI/CT):

- Progression to a new or recurrent WHO stage 4 HIV event or death
- Progression to a new WHO stage 4 HIV event or death from 6 weeks after randomisation
- Progression to a new or recurrent WHO stage 4 HIV event or death from 6 weeks after randomisation
- Any grade 3 or 4 adverse events (see 0, page 70)
- Number and class of anti-HIV drugs received by 3 years
- Time to cessation of first-line regimen for failure
- Adherence as measured by questionnaire and pill counts
- CD4 count at 3 years (provided that it is at least 2 months after restarting ART for those in the STI group)
- HIV RNA viral load (performed retrospectively) at 3 years (providing that it is at least 2 months after restarting ART for those in the STI group)
- HIV resistance profiles at 3 years in those with detectable viral load (providing that it is at least 2 months after restarting ART for those in the STI group)

4.3 Primary Endpoints (second-line randomisation feasibility study):

- *Efficacy*: change in CD4 count from time of switch to second-line to 24 weeks.
- *Safety*: Any serious adverse event, which is not HIV related (see section 7.9, page 38 and 0, page 70).

4.4 Secondary Endpoints (second-line randomisation feasibility study):

- Progression to a new or recurrent WHO stage 4 HIV event or death
- Progression to a new or recurrent WHO stage 3 or 4 HIV event or death
- Change in CD4 count from time of switch to second-line to 48, 72 and 96 weeks
- Any grade 3 or 4 adverse events (see 0, page 70)
- HIV RNA viral load (performed retrospectively) at 48, 72 and 96 weeks
- Adherence as measured by questionnaire and pill counts
- Health economic outcomes

5.0 Design

5.1 Type of design

DART is an international, three-centre open-label randomised trial in symptomatic HIV infected adults in Africa. There will be two randomisations and the total duration of the trial will be 6 years.

5.1.1 Randomisation to CMO or LCM arm

3300 patients will be randomised to CMO or LCM over a period of -two years. Randomisation will be stratified by CD4 count (0-99, 100-199) and by clinical sites.

5.1.2 STI Pilot

Because there are no data on STI in the African setting, where patients are likely to have low CD4 cell counts before starting ART, a non-randomised pilot study of the first 100 patients eligible for the STI randomisation will be undertaken (see Appendix 1.0, page 49). This would be expected to delay the onset of the second randomisation by a minimum of 6 months (the time taken to enrol patients (estimated to be 2-3 months), and at least 3 months follow-up). During this 24-week period the patients will be seen by the doctor every 4 weeks and 4-weekly CD4 cell counts will be performed on all 100 patients and reported to the clinicians in the LCM arm and to the subgroup of DSMC in the CMO arm

5.1.3 STIs or continuous ART

Of the 3300 patients randomised to CMO or LCM, we would expect at least 600 to be eligible for the second randomisation (STIs versus continuous ART) commencing after the STI pilot (see section 5.1.2 above and Appendix 1.0, page 49), which should be completed by

about 12 months after the start of the trial. Randomisation to STIs or continuous ART would be completed by the end of year 3.

5.1.4 Feasibility randomisation for second line ART for those failing first line ART

As data on optimal treatment of patients failing clinically and/or immunologically on a first-line regimen do not exist, all patients switching to second-line therapy in DART will be invited to consent to be randomised within a feasibility study using surrogate (CD4) endpoints to identify the most appropriate strategies to take forward into a clinical endpoint trial.

Patients failing first-line ART in DART and switching to second-line, who are eligible and consent, will be randomised to one of the following arms:

Strata 1: failure on an NNRTI containing regimen*

(A) bPI + ABC + ddI

(B) bPI + TDF + CBV†

Strata 2: failure on a regimen not containing an NNRTI

(C) bPI + NNRTI

(D) bPI + NNRTI + 3TC

(E) bPI + NNRTI + ddI

*Note: any patient who did not disclose prior NNRTI experience before entering DART & is retrospectively considered to have failed immunologically and/or clinically whilst taking NNRTI should be enrolled in strata 1

† patients with previous adverse reaction to ZDV may receive bPI+TDF+3TC only

Patients failing first line ART will be randomised 1:1 across arms A and B in strata 1 and 1:1:1 across arms C, D and E in strata 2. The decision of whether a patient has failed on an NNRTI (likely to have led to resistance) will be left up to the treating clinician. For example a patient failing immunologically/clinically whose only NNRTI experience is single dose NVP for PMTCT should go into strata 2.

As currently available NNRTIs (NVP, EFZ) are not active against NNRTI-resistant strains, and as NNRTIs have a low genetic barrier to resistance, the majority of patients failing NNRTI-containing regimens will have NNRTI-resistant virus. Therefore such patients in DART will be randomised between A and B only (Strata 1). For most DART patients that have failed an NNRTI regimen the first line NRTIs will have been ZDV and 3TC, the NRTIs with most residual activity are likely to be ABC, ddI and TDF (note that co-treatment with ddI and TDF is contraindicated) – arm A. However, rather than maximising residual activity an alternative strategy is to maintain virus with lower fitness due to extensive TAMs and M184V – arm B.

In contrast NNRTIs are likely to be highly active in patients who have failed on a triple NRTI first line regimen: therefore bPI+NNRTI will be the backbone for all such patients (Strata 2). Patients initiating second line with bPI+NNRTI will not have used ddI in DART. Although there is likely to be some resistance to this drug arising from cross-resistance to the first line NRTIs it is not known whether adding ddI to a 2-drug, 2-class regimen improves outcome or merely increases regimen complexity – arm E. An alternative strategy is to maintain virus with lower fitness due M184V by keeping 3TC in the regimen – arm D. A third strategy is

not to use an NRTI, to reduce pill-burden and retain any residual activity for salvage therapy – arm C.

In view of contraindications for EFZ in pregnancy, NVP should be used as the NNRTI wherever possible for women of childbearing age.

5.2 Antiretroviral Therapy

See section 8.0, page 39 and Appendix 3.0, page 66 for full details. First and second-line regimens will be available for all patients as well as the option of changing individual drugs (within the same class) for toxicity (see sections 7.6, page 37 and 8.0, page 39, Appendix 3.0, page 66 and 0, page 70). For patients in whom second-line therapy fails, the most appropriate combination of available drugs will be offered (see section 8.0, page 39). Every effort will be made to make further ART available after the trial but it is agreed that local health authorities will commit to providing adequate care for the participating patients (see Appendix 9.0, page 90).

6.0 Patient Population

6.1 Inclusion Criteria (CMO/LCM)

1. Documentation of HIV-1 infection: antibody positive serology by ELISA test (confirmed by licensed second ELISA or Western Blot).
2. Age $\geq$ 18 years
3. Symptomatic WHO stage 2, 3 or 4 HIV disease ***and*** CD4 < 200 cells/mm^3
4. ART naïve (except for ART use during pregnancy for the prevention of mother-to-child HIV transmission).
5. Agreement and documented informed consent to be randomised to CMO or LCM and to STI or continuous ART, if eligible.
6. Life expectancy of at least 3 months.

6.2 Exclusion criteria (CMO/LCM)

1. Cannot, or unlikely to attend regularly (e.g. usual residence too far from Study Centre)
2. Likelihood of poor compliance
3. Presence of acute infection (e.g. malaria, acute hepatitis, pneumococcal pneumonia, non-typhoid salmonella septicaemia, cryptococcal meningitis). Patients may be admitted after recovery of an acute infection. Patients with tuberculosis (TB) will not be enrolled while on the intensive phase of anti-tuberculosis therapy, but should be re-evaluated after the intensive phase and a decision made then about starting ART. Patients starting ART whilst on anti-tuberculosis therapy after the intensive phase will not receive NVP, nor will they be randomised into the NORA substudy.
4. On chemotherapy for malignancy
5. Laboratory abnormalities which are a contra-indication for the patient to start ART (e.g. Haemoglobin <8g/dl, neutrophils <0.50x10^9/l, AST or ALT >5 x the upper limit

of normal (ULN), grade 3 renal dysfunction – creatinine >360 µmol/l and/or urea >5 x ULN).

6. Pregnancy or breast-feeding

6.3 Number and source of subjects (CMO/LCM and STI/CT)

Patients will be recruited from three sites: PPD Uganda, PPD Uganda; and PPD Zimbabwe. It is expected that approximately 1000 patients will be recruited from each site, plus 300 from a satellite clinic in PPD The STI pilot (see Appendix 1.0, page 49) will be conducted in all three sites. The NORA substudy (see Appendix 2.0, page 52) will be conducted in PPD and PPD

This trial requires that patients commit to long-term follow-up. Therefore priority will be given to those who can regularly attend for follow-up. Patients will be recruited from 3 sources:

1. patients who have been tested for HIV infection in the past and are in regular follow-up;
2. following ***recovery*** from a hospital admission during which HIV infection has been diagnosed, and followed by attendance at a follow-up outpatient clinic (N.B. no patient should be recruited during a hospital admission);
3. from outpatient clinics (e.g. general medical, TB clinics). For newly HIV diagnosed patients, the HIV counselling and testing process will be fully carried out.

To avoid inequity in access to the trial, the recruitment will be carried out as eligible patients visit the outpatient clinics to consult over a recent health problem or who come for a previously scheduled follow up visit.

6.4 Number and source of subjects (second-line feasibility study randomisation)

All patients failing first-line therapy in DART and switching to second-line will be eligible. Although additional informed consent will be sought for this randomisation, it is anticipated that refusal rates will be low, as the alternative is for the clinician to choose between the randomised arms based on no data.

The sample size available for this feasibility study is therefore constrained by the fact that only patients failing first-line therapy in DART and switching to second-line therapy will be enrolled. Currently the failure rate is approximately 5% per annum after the first year on first-line therapy. Assuming this rate increases at 2% per annum until the end of the trial, we estimate that 240 patients will switch to second-line therapy during 2007 (and will have 48 weeks follow-up by the end of 2008), although the exact numbers and split between NNRTI and NRTI failures are unknown – and could increase dramatically if the failure rate increased.

6.5 Co-enrolment in other studies

DART participants may co-enrol in any other study provided this does not compromise the integrity of the DART trial. Specifically the restrictions relating to laboratory monitoring must be maintained.

7.0 Procedures and Management of Subjects

7.1 Screening Procedure for CMO/LCM

At screening, HIV infected adults will be given an information sheet about the DART trial and asked to give consent to screening (see Appendix 6.0, page 77). Interested patients will have clinical information including medical history, examination, confirmation of WHO stage 2, 3, or 4, and weight recorded, and T cell subsets (CD4, CD8, CD3 and total lymphocyte count), haematology, biochemistry and pregnancy tests performed. Plasma and DNA pellets will be saved. Women of reproductive age will be given information about the risks of pregnancy in the trial and encouraged to avoid pregnancy.

7.2 Baseline procedure (Week 0 for CMO/LCM)

The time between screening and randomisation should preferably be within 2 weeks and not exceed 4 weeks.

Patients eligibility for enrolment will be confirmed. Patients with CD4 ≥200 cells/mm^3 can be enrolled later if the CD4 count falls to <200 cells/mm^3 and they are still in follow up. Those in whom the CD4 count is <200 cells/mm^3, with no haematological or biochemistry contraindications to starting ART, will be eligible for the trial.

Fully informed signed consent will be obtained just before randomisation (see Appendix 6.0, page 77). The patient must consent to both randomisations and agree to participate in the STI pilot if required (see Appendix 1.0, page 49). Consent forms should be kept securely at the clinical site and be available for monitoring.

When possible, and particularly if there is doubt about the place of residence of a patient, a study nurse/field worker, preferably the same nurse who gave information about the trial to the patient, will accompany the patient home and draw a map indicating the place of residence.

A trial register should be kept at the clinical site and will record all patients who are eligible and invited to join the trial. Those accepting will have name, date of birth (DOB), date of randomisation and trial number recorded. Those who refuse will have name, DOB, and reason for refusal recorded. The register will be kept in a secure place in each clinical site and will be the responsibility of the trial investigator at that site.

7.3 Randomisation and Enrolment

7.3.1 Randomisation List

A randomisation list for CMO/LCM will be prepared, by computer staff at MRC CTU under the direction of the trial statistician. Patient randomisation numbers will be prepared

separately for each centre and further stratified within centre by baseline CD4 cell count (0-99, 100-199). A single member of staff at each site who is not directly involved in patient care will be responsible for carrying out the randomisation process using a secure electronic system. A reliable back-up system will also be available. Randomisation will not take place until after the patient has given informed consent and is ready to receive therapy.

A randomisation list will be similarly prepared for STI/continuous ART after completion of the STI pilot. This will be stratified by centre, by week number at entry (52 or 76, see section 7.3.3 below), and by first randomisation to CMO/LCM.

Another randomisation list will be prepared for the second line feasibility study randomisation; this will be stratified by centre and CMO/LCM.

7.3.2 First Randomisation to CMO or LCM

The first randomisation is to CMO or LCM. The patient's eligibility for enrolment will be reviewed by the doctor at baseline (week 0, see Flow Sheets, section 1.3, page 16), having completed the screening CRF, including all laboratory results. Patients should start ART and be told their allocation on the day of randomisation. Those allocated to LCM will have CD4 cell counts undertaken 12-weekly and haematology and biochemistry tests undertaken at 4, and 12 weeks, and 12-weekly thereafter (see Flow Sheets, section 1.3, page 16).

7.3.3 Second Randomisation – STIs or continuous ART

The second randomisation **will not commence** until the pilot STI study has been completed (see Appendix 1.0, page 49). To determine whether a patient is eligible for the second randomisation, CD4 counts will be undertaken in all patients irrespective of the monitoring arm, at 48 weeks (or at 72 weeks if the patient was not randomised at week 52) and the results will be returned to the clinician. For patients allocated to CMO, these results will be reported as CD4<300 or ≥300 cells/mm^3. Eligibility for the second randomisation will depend on the CD4 cell count being 300 cells/mm^3 or higher. If the CD4 count is <300 cell/mm^3 at 48 weeks (72 weeks if the patient was not randomised at week 52), the patient will **not be eligible** for the second randomisation, but will continue to be followed for the evaluation of the monitoring strategies (see Trial Schema, section 1.2, page 14).

As the results of the STI pilot study have been reviewed by the Trial Steering Committee and Data and Safety Monitoring Committee (DSMC), and STI is still deemed to be safe (see Appendix 1.0, page 49), subsequent patients who are clinically well with CD4 cell counts of 300 cells/mm^3 or higher at 48 weeks (72 weeks if the patient is was not randomised at week 52) will be allocated in a 1:1 ratio to continuous ART or to ART with STI (12 weeks off followed by 12 weeks on ART, repeating the schedule until the end of the trial).

Inclusion Criteria:

1. CD4 count 4 weeks prior to STI randomisation visit ≥300 cells/mm^3

Exclusion criteria:

1. Pregnant or breast-feeding
2. WHO stage 3 or 4 illness in the 12 weeks prior to STI randomisation visit
3. Other illness at the STI randomisation visit such that the clinician believes it could be harmful to stop ART at this timepoint

4. Participation in the STI pilot study

Patients will return to the clinic at week 52 (or week 76 if the patient was not randomised at week 52), four weeks after the week 48 (or 72) CD4 cell count has been taken. Eligible patients will see the doctor at this visit (see Flow Sheets, section 1.3, page 16). They will be told that they are eligible to be included in the second randomisation, and will be randomised at that visit to the continuous ART arm or the STI arm. They will be requested to bring all unused medication with them, which will be taken from them if they are in the STI arm. If the doctor has clinical concerns about the patient at this visit, such that he/she feels that the STI should not commence despite the CD4 cell count being ≥300 cells/mm^3 four weeks previously, then he/she may defer randomisation and record using the appropriate form. In all patients undergoing the second randomisation and randomised to STI, this should commence immediately and should be within 5 weeks of the week 48 (or 72) CD4 cell count test (see Trial Schema, section 1.2, page 14 and Flow Sheets, section 1.3, page 16). NVP will be stopped seven days before combivir to avoid the risk of developing NVP resistance because of its long half-life. In practice NVP will be stopped on the day of commencement of STI and combivir alone continued for 7 more days.

The first 100 patients randomised to STI or CT will have plasma stored and CD4 cells measured 4 weekly, including at the time of randomisation; these counts will only be returned to clinicians for LCM patients. Two members of the TSC who are not involved with clinical management of DART patients will closely monitor individual CD4 counts and any WHO 3 and 4 events for these 100 patients on a monthly basis, **without** knowledge of CMO/LCM allocation. They could decide whether they need to inform the DSMC and TSC immediately, prompting a full analysis of all data accrued in the STI randomisation to this point in time for urgent consideration by the DSMC.

Note that the STI randomisation was terminated on 15th March 2006; all patients were offered continuous therapy.

7.3.4 Third randomisation – second line regimen feasibility study

Prior to randomisation to the second line feasibility study patients will go through counselling and information sessions and signed, informed consent will be obtained. A trial register for the second-line feasibility study should be kept at the clinical sites and will record all patients who are eligible (failing first-line therapy clinically/immunologically) and invited to join the feasibility study. Those accepting will have name, date of birth (DOB), date of randomisation in the second-line feasibility study and main DART trial number recorded. Those who refuse will have name, DOB, and reason for refusal recorded. The register will be kept in a secure place in each clinical site and will be the responsibility of the trial investigator at that site.

Randomisation to a second line regimen may be carried out at any clinic visit (scheduled or extra) beyond week 48 after enrolment in DART. Randomisation will be stratified by clinical site and CMO/LCM allocation.

Inclusion Criteria:

1. Completed 48 weeks in DART
2. Clinical and/or immunological assessment of failure whilst currently receiving first line regimen following section 7.6.2, page 37 and decision made that patient is to be switched to second-line

Exclusion criteria:

1. Continuing or starting treatment with any medications incompatible with any arm of the randomisation to which the patient could be assigned. [Note: it is recommended that patients remain on first-line therapy whilst tuberculosis treatment is received, but may be enrolled in the second line study if not taking rifampicin]

7.3.5 Pregnancy

Eligible women who are found to be pregnant at screening may be re-screened to ascertain eligibility to be enrolled in the trial after the baby is born and breast-feeding has finished, provided that enrolment is still open in that site.

7.3.6 Enrolment of family members into the trial

If more than one person from the same family is eligible and gives consent to enrolment in the trial, they will be allocated to CMO or LCM without consideration as to the randomisation of the family member already enrolled. The same will be true for the STI/continuous ART randomisation. This must be fully explained to family members where more than one is recruited into the trial.

No patient will be enrolled into NORA if there is already a household member in NORA.

7.4 Follow-up Evaluations

After randomisation to CMO/LCM (week 0) all patients will have follow-up visits to see both the study doctor and study nurse at weeks 2, 4, 8, 12 and then every 12 weeks from randomisation. The patient will collect a supply of drugs every 4 weeks from the nurse at the follow-up and intermediate visits (see Flow Sheets, section 1.3, page 16). For patients randomised to the STI arm, for the first 2 visits at start of STIs (weeks 52 and 76 or 76 and 100), patients will see both a doctor and a nurse at an extra visit, in order for decisions to be endorsed by the doctor about undertaking the next STI (see Flow Sheets, section 1.3, page 16).

At each full assessment, the following will be undertaken (see Flow Sheets, section 1.3, page 16):

- Administration of a symptom checklist by a nurse to detect intercurrent illness, HIV disease progression or adverse events to ART. The severity and likely relationship of events to ART, will be documented by a doctor.
- Medical history since last visit including signs and symptoms of HIV disease and WHO stage.
- Weight.
- Haematology and biochemistry (as at baseline). However, for patients in the CMO arm; for haematology grade 4 results (see 0, page 70), only the grade 4 result will be returned to the clinic; for biochemistry, if any of AST/ALT/bilirubin are grade 4, all 3 results will be returned to the clinic and, if either of urea/creatine are grade 4, both will be returned to the clinic. Clinicians may request biochemistry and/or haematology investigations for patients in the CMO arm who experience symptoms suggestive of severe toxicity to antiretroviral drugs they are receiving if the test result is essential in order to make decisions about clinical management (including switching drugs for

toxicity, e.g. suspected hepatitis (biochemistry), renal disease (biochemistry), pancreatitis (biochemistry)). Reasons for requesting laboratory tests must be clearly stated on the appropriate form.

- CD4 cell counts (in the CMO arm, results will not be returned to the clinician except at 48 weeks (72 weeks if the patient was not randomised at week 52) as <300 or ≥300).
- Plasma store and DNA pellets (see Appendix 7.0, page 88); stored plasma samples and DNA pellets may be used subsequently for HIV RNA viral load measurements, measurements of cell associated HIV DNA, HIV/HLA typing and analyses of drug levels.
- Assessment of adherence by pill counts and nurse administered questionnaire (see Appendix 8.0, page 89).
- Changes in ART, OI prophylaxis and other concomitant medication.
- For females of childbearing age allocated to the STI group, pregnancy tests will be performed one month before commencement of STI (see Flow Sheets, section 1.3, page 16).
- All women of childbearing age will be given continuing advice about avoiding pregnancy.
- If a woman becomes pregnant during the course of the trial, she will continue in the LCM or CMO arm like other patients, but if randomised in the STI arm, will ***NOT undergo*** a STI at any time during pregnancy, for 24 weeks after the end of pregnancy or while breast-feeding (STIs would be deferred until after the baby has been weaned). Advice on breast-feeding will be given according to national guidelines.
- Recording of compliance with the allocated management strategies on the follow-up form

At each 'drug collection' visit, the study nurse will:

- Administer the symptom check-list
- Assess adherence by questionnaire (see Appendix 8.0, page 89) and record numbers of returned pills
- Administer the next 4 weeks supply of drugs

If the study nurse has any clinical concerns at these visits, the patient should be referred to see a study doctor.

Patients switching to second-line (including those randomised in the second-line feasibility study) will have the visit schedule reset to week 0 at the time of switch. They will have the same visits as early after first randomisation primarily to provide additional checks for any adverse events associated with new drugs and to identify any problems with dosing etc.

7.5 Management of patients allocated to the STI arm

More details of management for the STI arm have been developed after the pilot phase of STI (see Appendix 1.0, page 49). Of note, STIs will take place during first-line ART only and patients in the STI arm will revert to continuous ART when they switch to second-line ART. For patients in the STI arm, there are two issues to consider: first, when to shorten an STI; second, when not to recommence an STI during follow-up.

7.5.1 Timing of STIs

Among patients randomised to STIs, follow-up visits will be due 4 weeks before commencing a STI. Thus CD4 count results at weeks 48 will be available at the week 52 visit and, after review by the study doctor, the STI will commence from week 52 (see Flow Sheets, section 1.3, page 16). For patients taking CBV+NVP, at each STI, CBV will be continued for 7 days after NVP is stopped.

7.5.2 Modifying the STI regimen

Criteria for early restart of ART include:

- Always restart for CD4 cell count <50 cells/mm^3, 8 weeks into STI (LCM only)
- Always restart for development of a WHO stage 3 or 4 diagnosis (Appendix 5.0, page 76).
- Consider restart for development of HIV related symptoms that do not meet the criteria for WHO stage 3 or 4 events, at the discretion of the treating clinician

If a patient develops clinical symptoms during a planned STI (detected at a nurse visit), then the nurse will refer the patient to be seen by the doctor. If the doctor assesses that the patient has a WHO stage 3 or 4 event, ART should be restarted. If the doctor assesses that the patient has clinical symptoms that do not meet the criteria for WHO stage 3 or 4 events, ART *may* be restarted at the discretion of the treating clinician but if the patient is in LCM, then the decision to restart therapy may also be deferred to take account of the CD4 cell count result (depending on the patient's health status).

For patients restarting ART early during a planned STI, consideration will be given to switching to second line ART if symptoms persist after ART is re-initiated, or CD4 count criteria (<50 cells/mm^3) continue to be met (LCM only), at the next scheduled CD4 count after recommencing ART (see section 7.6.2, page 37), because any symptoms or low CD4 count are likely to be a consequence of the interruption rather than failure of ART (which the patient was not receiving).

Patients who undergo a shortened STI for reasons other than WHO stage 3 or 4 or CD4<50 (LCM) may be reconsidered for further STIs at the next scheduled STI start: however, patients should only interrupt again if the clinician is confident that the patient has made a good recovery.

7.5.3 Cessation of STIs

Patients who experience a WHO stage 3 or 4 event or LCM patients who have a CD4 count <50 at any time after STI randomisation will not have any further STIs in the DART trial.

Patients who have switched to second line will not have any further STIs in the DART trial.

7.5.4 Deferring STI during follow-up

In the following situations an STI should always be deferred:

- CD4 count is <200 cells/mm^3 at 4 weeks before the scheduled STI start (for those who are randomised to LCM)
- Patient is pregnant, breastfeeding or within 24 weeks of the end of a pregnancy.
- The patient has not received 12 weeks back on continuous ART e.g. did not attend clinic for ART restart as scheduled.

In the event of any of the above, STI will be deferred until the next scheduled STI start (24 weeks later) before reassessment for consideration of another STI (or consideration of switching ART regimen – see section 7.6.2, page 37).

7.5.5 Termination of the STI study

On 16th March 2006, following a review of the STI data to 15 January 2006 by the DSMC and its subsequent report to the TSC, the STI randomisation was terminated and it was recommended that all clients randomised to STI be transferred to CT.

7.6 Changing ART

7.6.1 Substituting for Toxicity

Switching for severe clinical or laboratory toxicity will follow guidelines, based on clinical and laboratory grading of toxicities (0, page 70). A symptom checklist will include questions on nausea/vomiting, rash, headache, fever, jaundice, abdominal pain etc. In the CMO arm, laboratory tests will be done (at 4 and 12 weeks and then 12-weekly) but results will ***not be given back to clinicians*** unless a laboratory grade 4 adverse event occurs. A system will be set up at each site (with standard operating procedures (SOPs)) for feedback of grade 4 results only to clinicians for patients in the CMO group. Clinicians caring for patients allocated to CMO may request laboratory tests if indicated by clinical symptoms, as in routine practice. For guidelines on switching of individual drugs for toxicity, see section 8.1.4, page 40.

7.6.2 Switching for failure of first-line therapy

Physicians will be ***encouraged not to switch*** ART before 48 weeks on continuous ART, or within 12 weeks after recommencing ART after a planned STI. Every attempt should be made to ensure that patients are adherent to ART before a switch of ART is considered.

After 48 weeks, switching therapy can be considered at any time for those on continuous ART, and after at least 8 weeks back on ART for those on STI arm.

Clinical criteria for consideration of switching therapy include:

- The development of a new WHO stage 4 diagnosis (see Appendix 5.0, page 76)

CD4 cell count criteria (LCM arm only):

- CD4 cell count <50 cells/mm^3 on 2 occasions, while on ART (at least 8 weeks after restarting ART). I.e. if a CD4 cell count is <50 cells/mm^3 then it should be repeated as soon as practical and if still <50 cells/mm^3, the patient should switch ART.
- Consideration should be given to switching if the CD4 count on 2 consecutive occasions is below 100 cells/mm^3.

When a decision to change therapy has been taken, blood will be taken for haematology and biochemistry screens from all patients (CMO and LCM) to ensure there is no laboratory toxicity that would preclude the patient from taking the second-line therapy. A CD4 cell count will also be taken, but the result will not be returned to the clinician in the CMO arm, and a plasma specimen for future evaluation of HIV-RNA viral load and drug resistance will be collected.

When the clinical decision to switch has been made the patient (if they consent and are eligible) will be randomly assigned to a second line regimen/strategy according to section 7.3.4, page 33.

7.7 Assessment of adherence

A study nurse will assess adherence at each 4-weekly visit by pill counts and a nurse administered adherence questionnaire (see Appendix 8.0, page 89).

7.8 Withdrawal from allocated strategy

Patients may voluntarily withdraw from the allocated trial treatment for any reason. If this occurs, the trial researchers are not under obligation to provide ART. The patient's withdrawal from the trial will not affect their access to the best standard of care within the national health system. Follow-up for documentation of any clinical endpoints should continue, if possible.

Clinical data, including weight, presence of signs or symptoms, and other concomitant medications should be recorded at the time of withdrawal. In addition, a blood sample for plasma storage should be taken for storage (for subsequent viral load and possible resistance testing). Blood should also be taken for FBC, biochemistry and T-cell subsets (not returned to clinicians of patients in the CMO arm).

If a patient has an unscheduled period off treatment or not in follow-up, this should be fully recorded on follow-up forms.

7.9 Recording and reporting of Adverse Events, Death, HIV progression and protocol violations

If the patient has died, experienced any new or recurrent WHO stage 4 illness or experienced an adverse event (serious, Grade 3 or 4, or one leading to a modification of ART) since the last visit, the investigator/study co-ordinator will complete specific case report forms.

If there is any violation of the protocol for any reason, this should be fully recorded.

7.9.1 Serious Adverse Events (SAE):

According to the ICH Harmonised Tripartite Guidelines for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (1994), a Serious Adverse Event (SAE) is defined as 'any untoward medical occurrence' that:

1. **results in death**
2. **is life-threatening** (patient was actually at risk of death at the time of the event)
3. **requires unplanned inpatient hospitalisation** or **prolongation of existing hospitalisation**
4. **results in persistent or significant disability/incapacity** or is a congenital anomaly/ birth defect
5. any **other important medical condition, which, though not included in the above,** may jeopardise the subject and may require medical or surgical intervention to prevent one of the outcomes listed (e.g. intensive treatment in hospital or at home for allergic bronchospasm; blood dyscrasia or convulsions that do not result in hospitalisation, or the development of drug dependency)

In the context of the DART trial SAEs need only be reported if considered **not** HIV-related **only.** All such SAEs must be recorded on the Serious Adverse Event form and reported to the MRC CTU as soon as possible after the event.

The MRC CTU will report SAEs that are definitely or probably related to antiretrovirals to the relevant pharmaceutical companies and/or to the regulatory authorities in timely fashion, as appropriate.

National requirements for reporting of SAEs will be followed.

Data on SAEs will be tabulated and presented to the Data and Safety Monitoring Committee (DSMC; see section 9.4, page 43).

Other grade 3 and 4 adverse events (see 0, page 70) should be reported on the next scheduled follow-up.

8.0 Drug Regimens

8.1 Antiretroviral Therapy

Table 5 First and second-line drug regimens for DART (For details see Appendix 3.0, page 66)

Patient numbers	First-line treatment	Second-line treatment
2700	CBV plus TDF or ABC (and no evidence of prior failure on an NNRTI)	boosted PI* plus NNRTI** ±ddI/3TC
600	CBV plus NVP	boosted PI* plus ABC+ddI or TDF+CBV

* boosted PI will normally be Lopinavir/r (Aluvia or Kaletra)

** NNRTI will preferably be nevirapine for women of childbearing age.

8.1.1 First-line antiretroviral drugs

All patients will receive a triple combination of ART throughout the trial. All patients will receive combivir as part of their first-line regimen. The third drug for 600 patients enrolled in the NORA substudy will be blinded ABC or NVP plus placebo (see Appendix 2.0, page 52). For all patients not enrolled in the substudy TDF and NVP will be available as the third first-line drug for patients. Patients with any absolute (e.g. on concomitant anti-tuberculosis therapy) or relative (e.g. receipt of previous NVP in pregnancy) contra-indications to receipt of NVP, should receive TDF as the third drug.

TDF and NVP will be allocated equally between Zimbabwe and Uganda. It is expected that patients will stay for about 2.5 years on each regimen. Upon failure of a second-line regimen, the best possible combination will be selected from first and second-line drugs for the remaining duration of the trial. After trial completion follow-up healthcare will be provided by the national health systems (see Appendix 9.0, page 90, and letters from the Ministries of Health).

8.1.2 Second-line antiretroviral drugs

Second-line ART will be provided according to the feasibility randomisation strategy assigned (section 7.3.4, page 33). For those patients who have already switched to second-line ART prior to the introduction of the second line randomisation or are not eligible or choose not to consent for randomisation, second line ART will be provided according to the decision of the treating clinician from the regimens included in the feasibility study

8.1.3 Provision of trial drugs

Patients will be provided with a 4-weekly supply of drugs throughout the trial. Patients will be requested to return all empty bottles and to bring any bottles in use to the follow-up clinic.

On no account should any drug assigned to one patient be used by another patient. Unused drug must be returned to the site if a patient withdraws from treatment.

All drug dispensed and returned to the site should be documented on a treatment log for each patient. At each site, a named person (trial pharmacist or research nurse) will be required to maintain complete records of all study medication dispensed. The procedures to be followed will adhere to the Good Clinical Practices (GCP) guidelines on drug accountability. MRC CTU will monitor drug accountability at site visits.

8.1.4 Modification of therapy for toxicity

For reactions where the cause may be attributed to one or more trial drugs, all drugs should be stopped temporarily and may be restarted if the symptoms resolve and this is appropriate. If the symptoms are intolerable or do not resolve, an alternative drug **of the same class** may be substituted if this is considered appropriate by the investigator (see Table 6 below) and other drugs restarted. ZDV and 3TC will be available as separate drugs for patients who need to stop one drug for toxicity. See also 0, page 70.

Table 6 Guidelines for Substituting for Toxicity in First-Line

Event	Switch
ZDV toxicity	Substitute ZDV with d4T (replace combivir with d4T + 3TC)
3TC toxicity	Substitute 3TC with ddI (replace combivir with ZDV + ddI)
NVP toxicity	Substitute NVP with TDF
ABC toxicity	Substitute ABC with NVP or TDF
TDF toxicity	Substitute TDF with NVP
ddI toxicity	likely to be 3TC (individual judgement)
d4T toxicity	likely to be ZDV (individual judgement)

Note: due to potential for lymphopenia ddI and TDF should not be used together. If absolutely necessary to use them together the dose of ddI should be reduced. Substitutions in second-line will follow this where possible, but will depend on individualised drug history.

8.2 Prophylaxis against Opportunistic Infections

Decisions on prophylaxis strategies will be made taking into account National guidelines. All prophylaxis therapy should be recorded on forms.

8.3 Medications not permitted/ Precautions

Patients should not be co-enrolled in other ART trials or receive ART outside the trial. Patients will be encouraged to seek advice prior to taking any other medication. See Appendix 3.0, page 66 for details of drug interactions.

8.4 Data on concomitant medications

At each visit, information on other medications, including start dates, and reason(s) for taking should be documented on follow-up forms.

9.0 Management of the Trial

9.1 Trial Steering Committee

The trial will be managed by a Trial Steering Committee (TSC) with an independent chairperson (Professor PPD independent members and one Principal Investigator or key investigator from each site and from the MRC CTU and Imperial College.

A subgroup of the TSC will undertake monitoring of the STI pilot data, see Appendix 1.0, page 49.

In addition to the above, a subcommittee of the TSC will be formed to undertake close monitoring of CD4 cell counts on a monthly basis among patients in the CMO and STI arms of the study (after completion of the STI pilot). The reason for this is to ensure that asymptomatic patients with very low CD4 cell counts are not continuing on STIs and therefore being at high risk of developing clinical progression. Should this occur, the subcommittee could convene a meeting of the DSMC to consider its findings and would advise the Trial Steering Committee about appropriate action, e.g. change of trial design to shorten the period of STIs.

9.2 Trial Management Groups

An International Co-ordinating Group (ICG) of principal and key investigators from each site, as well as members from MRC CTU will communicate regularly to ensure that the trial is proceeding well across all 3 sites. Local Trial Management Committees (LTMCs) composed of investigators at each site will meet regularly. There will be regular teleconferences to ensure good communication across sites and with MRC CTU and Imperial College.

9.3 Data Management and Monitoring

An Analysis and Data Management Committee will be set up with data management, computing and statistician members from each site and the MRC-CTU, chaired by the Trial Statistician. This Committee will be responsible for setting up the databases at each site and for co-ordination of timely merging of data from each site at MRC CTU, where the central database will be held. The committee will be responsible for ensuring that the system for data collection is working consistently across the sites, for developing the trial analysis plan and 'shell' tables to be provided to the DSMC, and for making decisions about analyses.

Each site will be responsible for maintaining its own database and for timely transfer of checked data to the MRC CTU for merging of data with those from the other sites. Staff from MRC CTU will visit clinical sites to validate and monitor data and this may also be done across sites (e.g. a data manager from Zimbabwe may visit Uganda), under the oversight of the Analysis and Data Management Committee. The clinical investigators and participants, by giving consent, agree that within the host country's Data Protection Law, the MRC CTU may consult and /or copy source records (clinical notes, laboratory values) in order to do this. Such information will be treated as strictly confidential and will in no circumstances be made publicly available. The monitoring will adhere to MRC Good Clinical Practice guidelines (based on ICH guidelines). The following data should be verifiable from source documents: signed consent forms; dates of visits including laboratory results; eligibility and baseline values for all patients; all clinical endpoints; all serious/severe adverse events; an ongoing random 10% sample of routine patient clinical and laboratory data; drug compliance; dates drug dispensed and (if necessary) drugs returned; pharmacy/clinic drug logs; concomitant medication.

9.4 Data and Safety Monitoring Committee (DSMC)

An independent Data and Safety Monitoring Committee (DSMC) will be established and will monitor all aspects of the trial including the NORA substudy (see Appendix 2.0, page 52). The DSMC will consider findings from any other relevant studies and review trial data on recruitment, safety, adherence to randomised strategies and efficacy, in strict confidence approximately every 6 months. The DSMC will report to the DART Trial Steering Committee and to the Ethics Committee in each country, if in their view the data provide proof beyond reasonable doubt that one of the allocated strategies is better than its comparator in terms of a difference of clinically significant magnitude in a primary outcome. The guiding statistical criteria for "proof beyond reasonable doubt" is a Haybittle-Peto type rule based on the 99.9% confidence interval of the relative hazard of disease progression in each interim analysis. The DART Trial Steering Committee will then decide whether to amend or stop the trial before the end of the planned follow-up. In addition, the DSMC will meet with the DART Trial Steering Committee to consider results from the STI pilot study. The decision whether to go ahead with the evaluation of the planned STI strategy or an amended strategy will be taken jointly by the two committees in that meeting. The MRC CTU will undertake the organisation of the DSMC meetings.

9.5 Endpoint Review Committee

An Endpoint Review Committee will be appointed whose remit will be to determine the validity of potential endpoints that do not clearly satisfy the standard criteria, as defined by the protocol. It will have an independent Chair and will include Project Leaders from each site as well as other clinicians. No member will review endpoints from their own site. Terms of reference for the Endpoint Review Committee will be drawn up.

10.0 Statistics

10.1 Sample Size

The aim is to recruit 3000 patients (1000 from each of the 3 sites – 2 in Uganda, 1 in Zimbabwe) during the first year. Patients will be allocated in a 1:1 ratio to LCM or CMO. Data from several studies co-ordinated by the MRC Clinical Trials Unit (CTU) in the UK in adults show that among patients starting triple ART with CD4 counts <50, 50-99, 100-199, the proportions with CD4 >200 cells/mm^3 are 20%, 43%, 73% respectively at 6 months after starting ART and 33%; 68%, 77% respectively at 12 months. Thus if the proportions of patients with CD4 counts in these three ranges are equal, we would expect 60% of patients to have CD4≥200 cells/mm^3 and to qualify for the second randomisation to STI or no STI, based on a threshold of 200 cells/mm^3 (n=1800).

The estimation of the sample size is based on the following assumptions:

1. Progression rate to a new stage 4 disease or death is 15% per year in the LCM arm. This is based on data from the PPD cohort which suggest that the cumulative proportion of untreated patients with CD4 count less than 200 cells/mm^3 progressing to WHO stage 4 or death is 0.55, equivalent to a progression rate of 80% per year. A progression rate of 15% per year therefore represents a reduction of more than 80% under ART.

2. Progression rate to a new stage 4 disease or death in patients eligible for the second randomisation on continuous ART is 10% per year (this is lower than the overall progression rate as these patients have achieved CD4 cell counts >200 cells/mm^3).
3. Recruitment is over 1 year and follow-up for a further 4 years. For the second randomisation recruitment is over 2 years and follow-up for at least 3 years.
4. Loss to follow-up rate 3.3% per year, equivalent to approximately 15% cumulative proportion of patients lost to follow-up by 5 years.
5. Type I error probability (alpha) 0.05 (two sided)
6. A progression rate of up to 17.5% per year in the CMO arm would be considered 'equivalent' to that in LCM (15%).
7. A progression rate of up to 13% per year in the STI arm would be considered 'equivalent' to that in the no STI arm (10%).
8. Power 80% to detect equivalence of LCM and CMO, i.e. the upper limit of the 95% confidence interval of the hazard ratio (CMO relative to LCM) will be no greater than 1.17 (a relative increase of 17%, equivalent to an annual rate of progression of 17.5% in the CMO arm compared to 15% in the LCM arm) with probability 0.80 if CMO and LCM were truly equivalent.
9. Power 80% to detect equivalence of STI and no STI, i.e. the upper limit of the 95% confidence interval of the hazard ratio (STI relative to no STI) will be no greater than 1.3 (a relative increase of 30%, equivalent to an annual rate of progression of 13% in the STI arm compared to 10% in the no STI arm) with probability 0.80 if STI and no STI were truly equivalent.

Under these assumptions, a total of 2862 would be required for the LCM versus CMO comparison and 1520 for the STI versus no STI comparison. The target number of events (progression to a new stage 4 event or death) is 1392 for the LCM versus CMO comparison and 501 for the STI versus no STI comparison. An additional 100 patients would be required for the STI pilot study.

Assuming that recruitment into the LCM versus CMO comparison takes place through the first two years rather than one year, a total of 3101 patients (rather than 2862) would be required for the LCM versus CMO comparison.

Assuming the STI versus CT randomisation is based on a threshold of 300 CD4 cells/mm^3 rather than 200 cells/mm3, thus in DART so far we would expect around 20% of patients to be eligible for the second randomisation at 48 weeks. Excluding those already included in the STI pilot this would leave at least 600 patients eligible for the second randomisation.

Assuming:

10. A progression rate of up to 16% per year in the STI arm would be considered 'equivalent' to that in the no STI arm (10%).
11. Power 80% to detect equivalence of STI and no STI, i.e. the upper limit of the 95% confidence interval of the hazard ratio (STI relative to no STI) will be no greater than 1.6 (a relative increase of 60%, equivalent to an annual rate of progression of 16% in the STI arm compared to 10% in the no STI arm) with probability 0.80 if STI and no STI were truly equivalent.

Then 556 patients would be required for the STI versus no STI comparison (target number of events 159).

Sample size for trial extension to end 2008

At the time the trial was designed (2001) there were no data on likely rates of disease progression/death in patients in Africa receiving effective ART: the 15% progression rate per year described above represented a 80% reduction from the rates observed in patients with CD4 <200 cells/mm^3 in the (natural history) PPD cohort, similar reductions to those observed on a population level in cohorts in industrialised countries (e.g. CASCADE, EuroSIDA).

However, it has become apparent that the overall rate for the primary endpoint - progression to new WHO stage 4 or death - is considerably lower than predicted (approx 10% rather than 15% per year for the randomised groups combined), reducing the power from 80% to only 65% with the existing sample size and a 5 year trial. The one year extension of total trial duration (from 5 to 6 calendar years, to end 2008), maintains 80% power to demonstrate equivalence with a definition of 10% per year ±1.8% (hazard ratio 1.18) (or to demonstrate equivalence according to the original design (10% per year ±1.7%, hazard ratio 1.17) with power of 72%).

***Trial closeout*:** the power calculations above are based on an additional year follow-up for each participant (i.e. until end 2008). However, given the size of DART, it will not be possible for the trial to close quickly in December 2008 as participants will need to be transferred into national ART programmes. Therefore, participants who have been in the trial longest will start to move onto national ART programmes through the last quarter of 2008, with final transfer of all participants by the end of the first quarter of 2009 (which would retain the total number of additional person years of follow-up required).

Second-line randomisation feasibility study:

The sample size available for this feasibility study is constrained by the fact that only patients failing first-line therapy in DART and switching to second-line therapy will be eligible. Thus the sample size calculation below shows the differences that could be detected given the expected number of patients failing first-line during mid-2007 to last quarter 2008 and thus having at least 24 weeks follow-up. **The intention of the feasibility study is to identify the most promising regimens, based on CD4 response, to potentially take forward into a larger, subsequent clinical endpoint trial.** Currently the failure rate is approximately 5% per annum after the first year on first-line therapy. Assuming this rate increases at 2% per annum until the end of the trial, we estimate that at least 240 patients will switch to second-line therapy during mid-2007 to 2008 (and will have 24 weeks follow-up by the end of 2008), although the exact numbers and split between NNRTI and NRTI failures are unknown (estimated 15-20% versus 85-80%) – and could increase dramatically if the failure rate increased.

Optimal HAART regimens

If we assume (as observed from 0 to 24 weeks in DART) that the standard deviation for the change in CD4 from switch to second-line to 24 weeks is 100, a total of 190 participants that had not failed on an NNRTI, randomised between 3 arms (C,D,E), would provide at least

80% power to detect a difference in change of CD4 from baseline of more than 55 cells/mm^3 between any 2 of the 3 groups (based on 2-sided alpha=0.025 to allow for multiple testing of 3 pairwise comparisons) assuming 5% missing data (loss to follow-up/death during the first year after randomisation to second-line therapy plus failure to attend the week 48 visit/missing sample). A total of 50 patients that had failed on an NNRTI, randomised between 2 arms (A&B) would provide 80% power to detect a difference of 80 cells/mm^3 between these 2 arms as significant at the 2-sided 5% level, again assuming 5% missing data. The choice of 24 weeks as endpoint is based on large increases in CD4 observed at initiation of 2^{nd} line in DART, therefore any ineffective regimens are likely to be identified quickly.

10.2 Analysis Plan

The primary analysis will compare LCM with CMO and STI with no STI as allocated (intention to treat (ITT)) in terms of:

a) Progression to a new HIV stage 4 event or death and

b) Drug-related grade 4 serious adverse events

Time-to-event methods (Kaplan-Meier plots, stratified log rank test and Cox proportional hazard regression) will be used for these comparisons. The frequency of grade 4 adverse events will be tabulated by body systems and randomised group and the groups will be compared using the X^2 test. Wilcoxon's rank-sum test will be used to compare median CD4 cell counts at 3 years in the different allocated strategies.

For the second-line feasibility study, the primary analysis will compare

(1) Arm A versus Arm B (optimised HAART: NNRTI failures)

(2) Arm C versus Arm D versus Arm E (optimised HAART: NRTI failures)

(All analyses will be conducted based on all randomised patients (ITT).

11.0 Regulatory/ Ethics Approval

This document, along with any subsequent modifications and with the sample informed consent documents will be reviewed by the Ethics Committee from each participating site as well as by Ethics Committees in the UK (Liverpool School of Tropical Medicine and Imperial College).

Regulatory approval for conduct of the trial and use of antiretrovirals in the trial will be obtained.

12.0 Confidentiality

A unique trial number will identify all laboratory specimens, case record forms, and other records and no names will be used, in order to maintain confidentiality. All records will be kept in locked locations. Clinical information will not be released without written permission, except as necessary for monitoring by the trial monitors.

13.0 Publication

The ICG will develop guidelines for the preparation of papers (including abstracts) for presentation at national and international meetings, as well as the preparation of manuscripts for peer-reviewed publication. Any publication or presentation during the active phase of the study must have prior approval of the TSC. The TSC will define the strategy for, and resolve any problems of authorship and maintain the quality of publications. All publications will acknowledge appropriate funding sources. The DART TSC is the custodian of the data and specimens generated from the DART trial; DART trial data are not the property of individual participating investigators or health care facilities where the data were generated.

14.0 References

1. Altfeld M, Rosenberg ES, Walker BD. Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection**.** *J. Exp. Med.* 2001 193: 169-180.
2. Lori I, Maserati R, Foli A et al. Structured treatment interruptions to control HIV-1 infection. *Lancet* 2000, 354, 287.
3. Lisziewicz J, Rosenburg E, Lieberman J et al. Control of HIV despite the discontinuation of antiretroviral therapy. *N Engl J Med*, 1999, 340, 1683.
4. Rosenburg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. *Nature* 2000, 407: 523-526.
5. Amie C et al. Treatment interruptions in heavily antiretroviral pre-treated patients: clinical and genotypic evolution. *First International AIDS Society Conference on HIV Pathogenesis and Treatment*, Buenos Aires, abstract 445, 2001.
6. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann N, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. Virologic and Immunologic Consequences of Discontinuing Combination Antireroviral-Drug Therapy in HIV-Infected Patients with Detectable Viremia. *N Eng J Med*, Feb 2001; 344:472-480.
7. Ruiz L, Martinez-Picardo J, Romeu J, Paredes R, Khalil Zayat M, Marfil S, Negredo E, Sirera G, Tural C and Clotet B. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. *AIDS* 2000, 14: 397-403
8. Wallace M et al. Structured treatment interruption: effect on triglyceride levels. *First International AIDS Society Conference on HIV Pathogenesis and Treatment*, Buenos Aires, abstract 448, 2001.
9. Youle M, Janossy G, Turnbull W, Tilling R, Loveday C, Mocroft A, Tyrer M, Madge S, Wilson D, Dykhoff A, Johnson M, Phillips A, for the Royal Free Centre for HIV Medicine. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens *AIDS* 2000, 14(12): 1717-20
10. Scaling up antiretroviral therapy in resource limited settings: guidelines for a public health approach. 2002. http://www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf ISBN 92 4 154570 4

11. Schooley RT, Ruane P, Myers RA et al for the Study 902 Team. TDF DF in antiretroviral-experience patients: results from a 48-week, randomised, double-blind study. *AIDS* 2002, 16: 1257-1263.

12. C Allavena et al. 2-Year Follow-Up Lopinavir/ritonavir (LPV/r-Efavirenz (EFV) Combination. Abstract WePe6.3C06 (poster). Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24-27, 2005. Rio de Janeiro, Brazil

Appendix 1.0 Structured Treatment Interruptions (STI) Pilot Study

A pilot study will be undertaken to provide preliminary data on the safety of STI in this patient population in whom antiretroviral therapy is started at a relatively late stage of HIV disease. Therefore, ***before commencing the second randomisation to either structured treatment interruption (STI) or to continuous ART (no STI),*** the first 100 patients (from either the CMO arm or the LCM arm, at any of the three study sites) with CD4 cell counts >=200 cells/mm^3 at week 24 will be enrolled into a non-randomised pilot study and undergo a treatment interruption of 12 weeks, followed by restarting therapy for 12 weeks.

1.1 Monitoring of individual patients

During this 24-week period the patients will be seen by the doctor every 4 weeks and 4-weekly CD4 cell counts will be performed on all 100 patients and reported to the clinicians in the LCM arm.For CMO patients in the STI pilot the Trial Manager at each site will check all CD4 counts while on STI and if any are <50 cells/mm^3 they will report the result to the clinic as <50 cells/mm^3). These 100 patients will subsequently be excluded from the analysis of the STI versus continuous ART randomisation, **but not from the CMO versus LCM randomisation.** At the end of the 24 weeks, patients will remain in their original LCM/CMO arm and will continue with STIs. Patients will continue to receive drugs and follow-up as in the main DART study.

1.2 Monitoring of the group data

Two members of the TSC who are not involved with clinical management of DART patients will look at individual CD4 counts for all patients enrolled in the STI pilot after each 2-weekly data merge, **without** knowledge of CMO/LCM allocation.

The data will be summarised by CD4 at baseline (before ART) and before the STI, to describe the following:

- the rate of decline of CD4
- the proportion with new stage 3 or 4 WHO events,
- the proportion of patients with CD4 <50 cells/mm^3
- the proportion with a reduction in CD4 of 150 cells/mm^3 or greater from the start of the STI.

If the rate of decline were considered too fast (given baseline and pre-STI values) by the 2 TSC members, or if, for example, >10% patients in the STI experienced any of the above outcomes, this would be further discussed with the chair of the TSC. They could decide whether they need to inform the DSMC and TSC immediately, prompting a full analysis of all data accrued in the STI pilot to this point in time in the STI pilot for urgent consideration by the DSMC.

After the 100th patient has been enrolled and completed 12 weeks STI, the data will immediately be analysed and considered jointly by the Trial Steering Committee and the DSMC, to determine whether it is safe to start the second randomisation (STI or continuous ART). The Committees may be satisfied about the safety of STI either after reviewing data

on 12 weeks of STI on all 100 patients, or they may recommend waiting until the results of the effect on CD4 count of restarting ART for a further 12 weeks after the STI are available on all 100 patients before making a decision about commencing the second randomisation.

1.3 Guidelines for management during STI pilot.

1. If CD4 count falls to <50 cells/mm^3, repeat within 2 weeks, and if still <50 cells/mm^3, then the patient should be restarted on ART for LCM arm
2. Clinical criteria (see Appendix 5.0, page 76) for restarting ART during a STI would include for LCM and CMO arms:
    - the development of a new WHO stage 3 or 4 diagnosis

(NB. if CD4 cell count is not low (e.g. >150 cells/mm^3), despite the presence of symptoms consistent with stage 3 or 4 disease, the clinician may decide to continue STI, and repeat CD4 cell count in 4 weeks. If by then the CD4 count has declined or if symptoms do not resolve, ART should be restarted.

1.4 Guidelines for the DSMC and Steering Committees.

If any of the following occurred during the pilot STI study, this would be of concern to the TSC and DSMC and would suggest that a revision of the STI trial design would be necessary:

1. If a significant number of patients (e.g. >10%) develop the following during an STI:
    a. Progression to new stage 3 or stage 4 event
    b. CD4 count <50 cell/mm^3
    c. Reduction in CD4 cell count of 150 cells or more from the value at the start of the STI

2. Analyses would be undertaken to explore the relationship between development of the above and baseline characteristics, including baseline CD4 cell count. The committees may recommend a change to the trial design, depending on the group of patients in whom this occurs. For example, they could recommend:
    a. Only enrol those with CD4 cell counts above 100 cells/mm^3 at baseline into the trial
    b. Shorten the period of STI e.g. 12 weeks on and 8 weeks off ART
    c. In any event, they may recommend continuation of the pilot study with the new design.

1.5 Flow Sheet for STI pilot

Table 7 STI Pilot for 100 patients (completed 24 weeks in CMO or LCM and with CD4 cell counts at week 24 of 200 cells/mm^3 or higher.

EVENTS	WEEK of STI pilot study						
	Start of STI 0 (Week 28 in trial)	4 (32)	8 (36)	Restart ART 12 (40)	16 (44)	20 (48)	Restart STI 24 (52)
History & Physical[1]	**X**	**X**	**X**	**X**	**X**	**X**	**X**
Symptom check list	**X**	**X**	**X**	**X**	**X**	**X**	**X**
Pregnancy Test[2]	**X**					**X**	
Haematology[3]	**X**	**X**	**X**	**X**	**X**	**X**	**X**
Biochemistry[4]	**X**		**X**	**X**		**X**	**X**
Lymphocyte Subsets [5]	**X**	**X**	**X**	**X**	**X**	**X**	**X**
Plasma storage[6] + DNA pellet	**X**	**X**	**X**	**X**	**X**	**X**	**X**
Adherence assessment[7]	**X**				**X**	**X**	**X**

1 Clinical: including weight, WHO staging for HIV. Doctor sees patient at every visit.

2 If positive, exclude from STI pilot study.

3 Haematology: Hb, MCV, WBC, Lymphocytes, Neutrophils, and Platelets.

4 Biochemistry: Blood Urea Nitrogen or Creatinine, AST or ALT, Bilirubin,– results to be given back for all patients in the pilot.

5 CD4, CD8, CD3, percentage and total lymphocyte count.

6 Take 6 ml blood into EDTA. Store DNA pellet (if feasible) See Appendix 7.0, page 88 for instructions about storage.
Take plasma at the time of change to second-line regimen (and DNA pellet if feasible).

7 See Appendix 8.0, page 89.

Appendix 2.0 Nevirapine OR Abacavir (NORA) Substudy

A randomised, double-blind, phase II (substudy) trial to evaluate the toxicity of Abacavir compared with Nevirapine, both in combination with ZDV+3TC (combivir), as first-line antiretroviral therapy in patients participating in the DART trial

2.1 Objective

To assess the safety of abacavir (ABC) compared with nevirapine (NVP), (both in combination with ZDV+3TC (combivir)) in African patients.

2.2 Background and Rationale

2.2.1 Hypersensitivity reaction to Abacavir

In clinical studies, approximately 3-5% of patients receiving ABC develop a hypersensitivity reaction. This is characterised by symptoms which usually appear within the first six weeks of initiation of treatment with ABC (median time to onset is 11 days) and most often include fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhoea, or abdominal pain), and lethargy or malaise. Other signs and symptoms may include respiratory symptoms (dyspnoea, sore throat, cough), musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia), headache, paraesthesiae and oedema. Some patients with hypersensitivity reactions were initially thought to have respiratory disease (pneumonia, bronchitis, pharyngitis) or a flu-like illness.

The rash is variable and may be absent, but often appears maculopapular or urticarial. Laboratory abnormalities that may accompany ABC hypersensitivity include abnormal liver function tests or elevated creatinine phosphokinase or creatinine or lymphopenia.

Symptoms related to the hypersensitivity reaction worsen with continued therapy but usually resolve upon discontinuation of ABC. Restarting ABC following a hypersensitivity reaction results in a prompt return of symptoms within hours. This recurrence of the hypersensitivity reaction may be more severe than on initial presentation and may include life-threatening hypotension and death. Subjects who develop a hypersensitivity reaction must not be re-challenged with ABC.

As ABC hypersensitivity is heralded by the onset of relatively vague symptoms and signs, it could be mistaken for an acute intercurrent infection (e.g. malaria or flu), or be confused with immune reconstitution disease. Standard practice in the West (where rates of intercurrent infection are much lower, and there is likely to be less endemic sub-clinical infection to precipitate immune reconstitution disease), is to stop ABC for symptoms consistent with hypersensitivity and not to restart the drug. High rates of possible reactions that cannot be delineated further clinically could render ABC difficult to use in Africa, or substantially reduce its role. However, it is possible that even if ABC is difficult to use as first-line therapy because of difficulties distinguishing hypersensitivity from immune reconstitution disease, it might be possible to use it sometime after 3 or more months into ARV treatment when the risk of immune reconstitution (IR) disease is lower. Reasons for doing this might include the desire to switch to a simpler regimen (ABC is available in combination with ZDV and 3TC as a single formulation, taken as 1 tablet twice daily) or the need to start antituberculosis therapy. It could also be useful in a second-line regimen. No study has been carried out to address these questions and no data are available.

2.2.2 Adverse reactions to NVP

Signs and symptoms of NVP reaction include rash with or without fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, and/or hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.

The most common clinical toxicity of NVP is rash, which occurred in 15-20% of subjects in phase I/II trials. Severe and life-threatening skin reactions, including fatal cases, have occurred in 2-5% subjects treated with NVP. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterised by rash, constitutional findings and organ dysfunction.

Rashes are usually mild to moderate, maculopapular erythematous cutaneous eruptions, with or without pruritus, located on the trunk, face and extremities. The majority of rashes occur within the first 6 weeks of therapy, and severe rashes occur earlier, usually within the first 28 days of treatment; 25% of the patients with severe rashes required hospitalisation. Overall, 7% of patients in clinical trials discontinued NVP due to rash.

In one clinical trial, concomitant use of prednisone to prevent NVP-associated rash increased the incidence and severity of rash during the first 6 weeks of NVP therapy. The use of prednisone to prevent NVP-associated rash is not recommended.

Elevation of liver enzyme levels frequently occurs during drug therapy with NVP. Hepatitis and cases of fatal hepatic toxicity have been reported but are rare.

2.3 Trial Design

It is proposed to undertake this substudy in 600 patients enrolled in the DART trial. Separate consent will be sought for the substudy. Patients will be randomised to ABC (plus NVP placebo) or NVP plus ABC placebo in a 1:1 ratio, stratified by allocation to CMO/LCM arms. The blinded part of the trial will take place over 6 months, during which no patients will undergo STIs.

The trial sites will be in PPD Uganda and PPD Uganda. These are 2 of the 3 sites for the DART trial.

2.4 NORA Trial Schema



2.5 Endpoints

2.5.1 Primary endpoint:

- Any serious adverse event that is definitely/probably or uncertainly related to blinded trial drugs (blinded ABC or blinded NVP) where the adverse event occurs while on ART or within 30 days of receiving ART. A SAE in the context of the DART trial is defined as any untoward medical occurrence that is not definitely HIV related only and either:
    - results in death
    - is life-threatening (patient was actually at risk of death at the time of the event)
    - requires unplanned inpatient hospitalisation or prolongation of existing hospitalisation
    - results in persistent or significant disability/incapacity
    - is any other important medical events considered serious by the investigator (e.g. intensive treatment in an emergency room or at home

for allergic bronchospasm; blood dyscrasia or convulsions that do not result in hospitalisation)

All suspected hypersensitivity reactions must be reported as a SAE, these should be categorized as "other important medical conditions" unless they fall into one of the more specific categories.

2.5.2 Secondary Endpoints

- Adverse events of any grade leading to permanent stopping of trial drug:
- Fever, rash or raised liver enzymes (blinded in CMO except grade 4) leading to discontinuation of trial drug.
- Grade 4 events irrespective of whether they result in stopping trial drug

Adverse events will be classified by whether they are definitely/probably related, uncertainly related or unrelated/unlikely to be related to trial drug.

2.6 NORA Criteria for Inclusion/Exclusion

2.6.1 Inclusion Criteria

1. Documentation of HIV-1 infection: antibody positive serology by ELISA test (confirmed by licensed second ELISA or Western Blot)
2. Age > 18 years
3. Symptomatic WHO stage 2, 3 or 4 HIV disease and CD4 < 200 cells/mm3
4. ART naïve (except for ART use during pregnancy for the prevention of mother-to-child HIV transmission)
5. Agreement and documented informed consent to participate in DART main study and willingness to be randomised to ABC or NVP, if eligible
6. Life expectancy of at least 3 months

2.6.2 Exclusion criteria

1. Cannot or unlikely to attend regularly (e.g. usual residence too far from Study Centre)
2. Likelihood of poor compliance
3. Presence of acute infection (e.g. malaria, acute hepatitis, pneumococcal pneumonia, non-typhoid salmonella septicaemia, cryptococcal meningitis, acute hepatitis). Patients may be admitted after recovery of an acute infection. Patients with tuberculosis (TB) will not be enrolled while on the intensive phase of anti-tuberculosis therapy, but should be re-evaluated after the intensive phase and a decision made then about starting ART. Patients starting ART whilst on anti-tuberculosis therapy after the intensive phase will not receive NVP, nor will they be randomised into the NORA substudy.
4. On chemotherapy for malignancy
5. Laboratory abnormalities which are a contra-indication for the patient to start ART (e.g. Haemoglobin <8g/dl, neutrophils $<0.50x10^9$/l, AST or ALT >5 x the upper limit of normal (ULN), grade 3 renal dysfunction - creatinine >360 μmol/l and /or urea >5 x ULN).
6. Pregnancy or breast-feeding

7. Family/household members already enrolled in NORA

Patients included in this substudy should not be included in the STI pilot substudy

2.7 Sample size

Data from a cohort of 70 patients on ddI/d4T/NVP, over an average follow-up of 6 months; suggest a cumulative proportion of 15% of patients experiencing an SAE during the first 24 weeks (unpublished data from Cascade). 300 patients per arm will be sufficient to detect a difference between 15% in one arm and 8% in the other arm with power 80% using a two-sided chi-square test of difference in proportions with alpha = 0.05.

The substudy will last for 6 months. After that patients will switch to unblinded drug and will remain on the monitoring arm they were randomised to before the substudy and will become eligible for the STI randomisation, providing their CD4 count is 200cells/mm^3 or higher. Drug supply, patient management and follow-up will continue as in the main DART study.

2.8 Analysis Plan

The frequency of SAEs, all grade 4 adverse events and all adverse events leading to discontinuation of trial drug will be tabulated by body systems and the two randomised groups will be compared in terms of the proportion of patients experiencing any of the primary and secondary outcomes of the substudy by week 24, using the X^2 test, stratified by allocation to CLM or CMO. Kaplan-Meier plots and log-rank test will be used to compare the two groups in terms of time to first SAE.

2.9 Management of Adverse reactions

All patients will be followed up as in the main DART trial and given advice about reactions to ZDV, 3TC and NVP. They will also be given standard advice and warnings about possible reactions to ABC.

2.9.1 Management of reactions to combivir

Patients developing adverse reactions that can reasonably be attributed to CBV (e.g. anaemia or neutropenia as reaction to ZDV) may switch the responsible drug to an alternative as in the main part DART trial (e.g. ZDV to d4T). In such a case there would be no need for unblinding and the appropriate CRFs should be completed as in the main part of the trial.

2.9.2 Management of reactions to blinded drug

Patients will be instructed to seek advice from the clinic within 12-24 hours if they develop any of the following symptoms: fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhoea, or abdominal pain), fatigue, lethargy, malaise, respiratory symptoms (dyspnoea, sore throat, cough), musculoskeletal symptoms (myalgia, myolysis, arthralgia), headache, paraesthesia, oedema, oral lesions, conjunctivitis, blisters, general ill feeling or "flu-like" symptoms, dark urine, tiredness, pale stools, pain, ache, or sensitivity to touch on the right side below the ribs, lack of appetite, yellowing skin or whites of the eyes.

On attending the clinic they should be assessed clinically with the standard symptom checklist and examination and CRFs completed as appropriate. In the CMO arm, results of scheduled laboratory tests can be requested if indicated by symptoms; documented approval for this should be obtained from the Project Leader as in the main DART trial. As with standard management of adverse reactions, if a reaction is felt to be possible but other causes have not been excluded, the patient may be maintained on treatment under close observation. However, if, after investigations and discussion with the Project Leader, the clinical event is considered a potential reaction to ABC or NVP, it is likely that unblinding will be necessary for patient management (after completion of SAE and Hypersensitivity CRFs). This would avoid the possibility of restarting ABC or NVP in a patient who is experiencing a drug-related reaction. It will also facilitate allowing for the long half-life of NVP when stopping drugs.

2.9.3 Management of nevirapine reactions

NVP should be discontinued and not restarted if patients experience hypersensitivity characterized by rash with constitutional symptoms (such as fever, blistering, oral lesions, conjunctivitis, swelling, muscles or joint aches or general malaise) plus visceral involvement such as hepatitis, eosinophilia, granulocytopenia and renal dysfunction.

Patients experiencing mild to moderate rash without constitutional symptoms or visceral involvement during the 14-day lead-in period of 200 mg/day should not have their NVP dose increased until the rash has resolved.

If stopping NVP, if the patient is well enough to tolerate any drugs, CBV should be continued and TDF added as soon as possible. Note that if the reaction is mild it may be possible to start with TDF immediately. If necessary, all drugs should be stopped and CBV/TDF started soon after toxicity symptoms resolve.

2.9.4 Management of abacavir reactions

If, on unblinding, a patient is found to have experienced a reaction to ABC, ABC should be permanently discontinued and not restarted after recovery. If the patient is well enough to take medication, CBV should be continued and TDF added as soon as possible. If necessary, all drugs should be stopped and CBV/TDF started soon after toxicity symptoms resolve.

See also section 2.10 below for further guidelines on the management of ABC reactions.

2.9.5 Safety monitoring

All serious adverse events must be recorded on the Serious Adverse Event Form and reported to the Local Trials Centre and MRC CTU. Grade 3 adverse events should be reported on the next scheduled follow-up unless they lead to treatment modification.

Data on SAEs will be reported, if required, to ethics committees (treatment assignment blinded) and will be tabulated and presented to the Data Safety Monitoring Committee (DSMC) (treatment assignment unblinded).

2.10 Hypersensitivity reaction to abacavir and management of safety - as provided by GSK.

Fatal hypersensitivity reactions have been associated with therapy with ABC. Patients developing signs or symptoms of hypersensitivity (which include fever; skin rash; fatigue; gastrointestinal symptoms such as nausea, vomiting, diarrhoea, or abdominal pain; and respiratory symptoms such as pharyngitis, dyspnoea, or cough) should discontinue ABC as soon as a hypersensitivity reaction is suspected. To avoid a delay in diagnosis and minimize the risk of a life-threatening hypersensitivity reaction, ABC should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible (e.g., acute onset respiratory diseases, gastroenteritis, or reactions to other medications). There have been infrequent reports of hypersensitivity reaction following reintroduction of ABC, where the interruption was preceded by a single symptom (e.g., rash, fever or gastrointestinal symptoms). On very rare occasions, hypersensitivity reactions have been reported in subjects who have stopped and restarted therapy, and who had no preceding symptoms of a hypersensitivity reaction.

ABC must not be restarted following a hypersensitivity reaction because more severe symptoms will recur within hours and may include life-threatening hypotension and death.

2.10.1 Description of hypersensitivity to Abacavir

In clinical studies, approximately 5% of patients receiving ABC develop a hypersensitivity reaction that in rare cases has proved fatal. This is characterized by the appearance of symptoms indicating multi-organ/body system involvement. The reaction can occur at any time during treatment with ABC, but the symptoms usually appear within the first six weeks of initiation of treatment (median time to onset is 11 days) and most often include fever, rash, gastrointestinal symptoms (nausea, vomiting, diarrhea, or abdominal pain), and lethargy or malaise. Other signs and symptoms may include respiratory symptoms (dyspnoea, sore throat, cough), musculoskeletal symptoms (myalgia, rarely myolysis, arthralgia), headache, paraesthesiae and oedema. Some patients with hypersensitivity reactions were initially thought to have acute onset respiratory diseases, gastroenteritis, or reactions to other medications. This delay in diagnosis of hypersensitivity has resulted in ABC being continued or re-introduced, leading to more severe hypersensitivity reactions or death. Therefore, the diagnosis of hypersensitivity reaction should be carefully considered for patients presenting with symptoms of these diseases. Renal failure, hepatic failure and anaphylaxis have also been reported in association with hypersensitivity reactions.

Physical findings include lymphadenopathy and, occasionally, mucous membrane lesions (conjunctivitis and/or mouth ulceration) and hypotension. The rash is variable and may be absent, but often appears maculopapular or urticarial. Laboratory abnormalities that may accompany ABC hypersensitivity include elevated liver function tests, creatinine phosphokinase, creatinine or lymphopenia.

Symptoms related to this hypersensitivity reaction worsen with continued therapy and usually resolve upon discontinuation of ABC. Restarting ABC following a hypersensitivity reaction results in a prompt return of symptoms within hours. This recurrence of the hypersensitivity reaction may be more severe than on initial presentation and may include life-threatening hypotension and death. Subjects who develop a hypersensitivity reaction must discontinue ABC and must NEVER be re-challenged with ABC (ziagen or trizivir).

2.10.2 Information for patients

Subjects must be informed of the risk of a hypersensitivity reaction to ABC and provided with information to help them recognize the symptoms and signs associated with possible hypersensitivity reactions. Patients must be advised to contact the clinic immediately if they experience such symptoms.

Warning Card - All subjects receiving ABC should receive a wallet-size warning card provided by GlaxoSmithKline (GSK). As each subject is enrolled, the study site must assure that:

a) The subject receives the warning card.(Information will be translated into local languages where necessary)

b) The designated health care provider (e.g., physician, study nurse-coordinator, or pharmacist) reviews the signs and symptoms of hypersensitivity with the subject.

c) The subject verbalizes an understanding of the steps to take in the event of a suspected hypersensitivity, including contacting the study site.

2.10.3 Medical management for possible hypersensitivity to abacavir

If a subject reports symptoms consistent with the diagnosis of ABC hypersensitivity, s/he should be instructed not to take any additional doses of ABC and should be evaluated at the clinic within 12 to 24 hours. All possible, suspected, implied, and/or probable cases of "ABC hypersensitivity" are to be reported as a SAE on the SAE pages of the CRF. ABC hypersensitivity CRF pages (Abacavir Hypersensitivity Reaction Record for Non-GlaxoSmithKline Clinical Trials Only) should also be completed and reported to GSK.

If the clinical presentation cannot be differentiated between hypersensitivity and another medical event (e.g. respiratory infection, gastroenteritis, or reaction to another medication), ABC must be discontinued.

Once the diagnosis of a hypersensitivity reaction has been made, the investigator should take the following steps:

- The patient should permanently discontinue ABC study medication
- Counsel the patient that ABC should never be re-started, as a life-threatening reaction may occur within hours. The patient should never be prescribed any ABC-containing product (e.g. ziagen or trizivir)
- Complete the Hypersensitivity CRF provided by GSK
- Complete the SAE form
- Obtain all hypersensitivity laboratory evaluations including chest x-ray if respiratory symptoms are present.
- The patient should return all unused ABC for disposal to prevent an accidental re-challenge.
- Symptomatic support for the acute reaction may include antihistamines and corticosteroids.
- Symptoms usually start to resolve within 24 hours after stopping therapy. Symptomatic support, such as intravenous fluids for those who develop hypotension, is advised. There are no clinical data demonstrating the benefit of antihistamines or

corticosteroids in the management of hypersensitivity. Nevertheless, symptomatic and/or supportive treatment may be reasonable.

2.10.4 Medical management for Abacavir rash <u>not</u> accompanied by systemic symptoms

The following guidance is provided for clinical management of subjects who experience rash alone in the absence of accompanying diagnosis of ABC hypersensitivity, systemic or allergic symptoms or signs of mucosal or target lesions. The toxicity ratings must be used to appropriately grade cutaneous events when recording AEs.

- For grade 1 or 2 rash, antihistamines or topical corticosteroids may be prescribed. Use of a Medrol pack is not allowed.
- Study medications should be continued. The patient's symptoms should be evaluated and followed aggressively for one week or until symptoms resolve or change. If additional symptoms develop, the patient should be re-evaluated in clinic.
- If the etiology of the rash can be definitively diagnosed as due to concurrent illness or other medical event, routine management should be performed and the documentation of the diagnosis provided.
- Subjects who develop a grade 3 or 4 rash (e.g., exfoliation, mucosal involvement, or target lesions [erythema multiforme]) or any evidence of Stevens - Johnson syndrome should have all study drugs discontinued and assessed further.
- Patients should be followed, even though study medications have been discontinued.

2.10.5 Fever and hypersensitivity to Abacavir

The onset of fever may herald hypersensitivity. Subjects reporting fever should be evaluated as above for the possibility of a hypersensitivity reaction to ABC. In the event of a clinical presentation consistent with hypersensitivity, ABC should be discontinued permanently, and the steps taken as stated above.

2.10.6 Special considerations following an interruption of abacavir therapy

If therapy with ABC has been discontinued and restarting therapy is under consideration, the reason for discontinuation should be evaluated to ensure that the subject did not have symptoms of a hypersensitivity reaction. Subjects who have stopped ABC due to possible adverse reactions or illness should be advised to contact their doctor before restarting**.**

<u>If hypersensitivity reaction cannot be ruled out, ABC should not be restarted.</u>

There have been infrequent reports of hypersensitivity reaction following reintroduction of ABC, where interruption was preceded by a **<u>single symptom</u>**. When subjects who have discontinued ABC present with an indeterminate diagnosis of hypersensitivity (single symptom: rash, fever, malaise/fatigue, gastrointestinal symptoms or a respiratory symptom), the investigator should:

- Assess the probability that hypersensitivity preceded the interruption. It may be difficult to fully assess a patient's signs and symptoms if there has been a delay of more than a day between the patient stopping therapy and presenting to the physician. If there is doubt about the diagnosis, ABC should not be restarted.
- Assess the risk:benefit of reinitiating ABC

On very rare occasions hypersensitivity reactions have been reported in subjects who have stopped and restarted ABC therapy and who **had no apparent preceding symptoms** of a hypersensitivity reaction. If a decision is made to restart ABC in this setting, it should be assured that the subject can readily contact the site in the event that symptoms develop. Single missed doses require no special precautions. Subjects should be instructed to resume their normal treatment schedule. If an interruption of 3 or more days is noted, the subject should contact the study investigator. If it is determined that a hypersensitivity reaction is not present, the subject may resume treatment.

2.11 NORA SUBSTUDY FLOW SHEET

Table 8 NORA flow sheet

EVENTS		SUBJECT'S WEEK OF TREATMENT							
	Screening Week -2	Entry Week 0	2	4	8	12	16	20	24
Signed Consent		X							
History & Physical[1]	X	X	X	X	x	X	X	X	X
Symptom check list	X	X	X	X	X	X	X	X	X
Pregnancy Test[2]	X								X
Haematology[3]	X			X*		X*			X*
Biochemistry[4]	X			X*		X*			X*
Lymphocyte Subsets [5]	X					X*			X
Plasma storage[6]	X	X		X		X			X
Adherence Determination[7]				X	X	X	X	X	X

* Not returned to clinician in CMO arm.

1 Clinical: including weight, WHO staging for HIV.

2 See section 7.3.4 if positive.

3 Haematology: Hb, MCV, WBC, Lymphocytes, Neutrophils, Platelets.

4 Biochemistry: Blood Urea Nitrogen or Creatinine, AST or ALT, Bilirubin.

5 CD4, CD8, CD3 percentage and total lymphocyte count.

6 Take 6 ml blood into EDTA. Store DNA pellet (if feasible) See Appendix 7 for storage instructions.

7 See Appendix 8.0.

NB In addition to the above, patients will return 4-weekly to see the nurse, return used drug containers, and receive 4 weeks of ART

2.12 DART NORA Substudy Patient Information sheet

(to be given in addition to the DART information sheet for those eligible to participate in the NORA substudy. Patients participating in this substudy should not take part in the STI pilot)

Patient Information sheet for

Nevirapine or Abacavir (NORA) Substudy

You have already been invited to take part in the DART study. If you consent you may be asked if you would like to be enrolled in the nevirapine (NVP) or abacavir (ABC) substudy (NORA). This information sheet gives you details about the substudy. Discuss it with others if you wish. Ask us if anything is not clear or if you would like more information. You will be given a copy of this information sheet to keep.

What is the purpose of NORA?

The purpose of this substudy is to compare the safety of abacavir (ABC) with nevirapine (NVP), both in combination with combivir (ZDV & 3TC) in 600 patients.

What will happen if I wish to take part in the substudy?

You will be required to give separate signed consent to take part. You will first be assigned to one of the two main DART study monitoring arms and then to either combivir with ABC and NVP placebo (inactive drug) or combivir with NVP and ABC placebo. Both allocations will be done by a computer programme to ensure an even balance of patients in each group. You and your doctor will not know which combination of drugs you are going to take (although if your doctor needs to find out s/he can do so). You will take the drugs and placebo every day for 6 months, following the instructions given and after 6 months you will continue taking drugs but without placebo.

How often will I need to attend the clinic?

You will have to come to the clinic 2 and 4 weeks after enrolment. After that you will be followed every 4 weeks. You will be asked if you have any problems and if you have taken all the drugs you were given (you must return any drugs you have not taken). You can ask questions and discuss any problems you have at these visits. Blood tests will be taken after the first 4 weeks and then at 12 and 24 weeks.

What are the disadvantages and risks of taking part?

All anti-HIV drugs can cause side-effects. If you experience what could be a side effect you should tell your doctor at your next clinic visit. Rarely, a reaction or hypersensitivity to ABC may develop. The earliest signs are mild fever, weakness and nausea. A rash may then develop, followed by vomiting, diarrhoea and muscle pain.

If you think you may have this hypersensitivity you must not take any more of your anti-HIV drugs and must come to the next weekday clinic. Your doctor will keep you under close observation. If it is found that your symptoms are due to a particular drug, that drug will be replaced with another anti-

HIV drug. If your doctor thinks you may have had hypersensitivity to abacavir, you will be told NEVER to take abacavir again.

What are the possible benefits of taking part?

The information we get from the substudy will help us to make the best use of these anti-HIV drugs for you and other people with HIV infection.

What happens at the end of the substudy?

The substudy will last for 6 months. After that, if you have improved with the treatment you will continue on your drugs and remain on the monitoring arm you were randomised to before the substudy. If you had any problems with treatment, your doctor would have changed your treatment and you will remain on your new drugs. You will continue to receive drugs and follow-up as in the main DART study.

2.13 DART NORA Substudy Patient consent form

Fill in with Forms 2-4 at Enrolment	DART TRIAL **DART NORA CONSENT**

Centre: PPD

	Day	Month	Year		
Trial Consent Date			2 0 0	Clinic/Hospital Number	
Date/Year of Birth			1 9	Age at Screening (if DOB not available)	Initials: Male ○ Female ○

DART Trial Number

DART NORA SUBSTUDY CONSENT

A randomised double-blind phase II substudy trial to evaluate the toxicity of Abacavir compared with Nevirapine in combination with Combivir as first-line therapy in patients participating in the DART trial

NORA

(Nevirapine OR Abacavir)

Please initial (or mark) box if you agree:

1. I have read/been read the information sheet for the NORA substudy and I understand what will be required of me if I participate in the substudy.
   My questions concerning this substudy have been answered by:
   _____
2. I understand that I will be given anti-HIV drugs for 4-5 years while I am in the DART study. After the study, my healthcare will be provided by the national health system.
3. I understand that my participation is voluntary and that I am free to withdraw at any time, without giving a reason and without affecting my normal care and management.
4. I agree to allow blood samples to be taken and stored for testing later. I understand that I may not be given results of tests performed on stored samples.
5. I am willing to allow access to my medical notes to check that the trial is being carried out correctly but understand that strict confidentiality will be maintained.
6. **I agree to take part in the NORA substudy.**

Individual's signature (or thumbprint)	Print name	Date

Witness's signature	Print name	Date

Doctor's signature	Print name	Date

IMPORTANT: **One signed original to be given to patient**
One signed original to be kept on file by the researcher
One signed original to be kept in the clinic notes

CRF Version 1.4, December 2003

Appendix 3.0 Details of Antiretroviral Therapy

Detailed information on all drugs will be provided on regularly updated disk from EMEA website and in individual drug brochures

Drug (recommended dosing)	Class and major toxicities	Contraindications	Drug interactions
Zidovudine (Retrovir) 300mg twice daily (600mg daily)	NRTI Anaemia, leucopenia, neutropenia, nausea, vomiting	Cannot be used in patients with abnormally low neutrophil counts (< 0. 75 x 10^9/litre) or abnormally low haemoglobin levels (< 7.5 g/dL) * Switch to another drug recommended if patient experiences grade 3 or 4 haematological toxicity. No co-administration with stavudine!	Co-administration with rifampicin decreases AUC of ZDV by 48%: in clinical practice doses are not adjusted. Products inhibiting glucuronidation or directly inhibiting hepatic microsomal metabolism (eg codeine, morphine, indomethacin, naproxen, oxazepam, cimetidine, dapsone) should be administered with caution.
Lamivudine (Epivir) 150mg twice daily or 300 mg once daily (300 mg daily)	NRTI Can be administered with or without food Nausea, vomiting , abdominal pain or cramps, headache, arthralgia	In moderate to severe renal impairment with creatinine clearance 30-50 ml/min change to 150mg once daily and if <30ml/min: dose reduction recommended to below 150mg daily using oral solution. Switch to another drug is often practised.	High doses of co-trimoxazole for treatment of PCP should be avoided Co-administration with intravenous ganciclovir or foscarnet is not recommended
Combivir 300mg zidovudine/ 150mg lamivudine twice daily	See Retrovir and Epivir	Dosage reduction recommended in reduced renal function (creatinine clearance <50ml/min) In severe hepatic impairment separate Epivir and Retrovir recommended to facilitate Retrovir dose adjustment. Switch to alternative drug is often practised.	See Retrovir and Epivir

* Note that, in DART, patients should not be recruited if neutrophils <0.5x10^9/litre; patients with counts 0.5-0.75x10^9/litre may be included (see section6.2, page 29).

Drug (recommended dosing)	Class and major toxicities	Contraindications	Drug interactions
DDI (Didanosine, Videx) **200 mg twice daily (or 400mg once daily)** **if <60kg: 125mg twice daily (or 250mg once daily)**	Ingestion with food reduces the amount of didanosine absorbed by approximately 50%. Major toxicities: pancreatitis, peripheral neuropathy, abnormal liver function tests; cases of lactic acidosis (in the absence of hypoxemia), sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis	Extreme caution in patients with a history of pancreatitis	Medicines which can be affected by stomach acidity (eg. oral azoles such as ketoconazole and itraconazole), should be given at least 2 hours prior to dosing with Videx Co-administration of ddI with medicines that are known to cause peripheral neuropathy or pancreatitis may increase the risk of these toxicities. If treatment with other drugs known to cause pancreatic toxicity is required (e.g. i.v. pentamidine), didanosine should be suspended during such therapy wherever possible Plasma concentrations of some quinolone antibiotics (eg. ciprofloxacin) are decreased by administration with antacids contained in or administered with Videx. Tetracycline antibiotics (e.g.doxycycline) should not be taken with Videx.
D4T (Stavudine, Zerit) **40mg twice daily** **if <60kg, use 30mg twice daily**	NRTI Should be taken on empty stomach Headache, chills, fever, abdominal pain, nausea, vomiting, myalgia, arthralgia, malaise, insomnia, depression Peripheral neuropathy, lactic acidosis, pancreatitis, hepatic impairment	In patients with ALT/AST >5 x ULN, D4T should be discontinued Patients with previous history of pancreatitis should be carefully monitored Treatment with D4T should be interrupted in peripheral neuropathy and re-introduced after resolution of symptoms (50% dose level may be considered) No co-administration with ZDV.	

Drug (recommended dosing)	Class and major toxicities	Contraindications	Drug interactions
Tenofovir (Viread) 245 mg once daily 245 mg tablet is equivalent to 300mg of tenofovir disoproxil (as fumarate)	NRTI Consider interruption of TDF therapy if serum creatinine > 2.0 mg/dl (177umol/l) or serum phosphate < 1.0 mg/dl (0.32 umol/l) Most common side effects: diarrhoea, nausea, vomiting, flatulence (1 % discontinuance rate for GI side effects); grade 1 and 2 serum phosphate decreases requiring phosphate supplementation is some patients	Tenofovir should not be administered to patients with severe renal impairment. No data on patients with mild or moderate renal impairment: caution advised.	Nephrotoxic agents should be avoided but if they have to be administered concomitantly, weekly monitoring of renal toxicity should be considered. No interaction with lamivudine, indinavir or efavirenz In co-administration: AUC for ddI increased by 44%, with lopinavir/ritonavir: 30% increase in Cmax and AUC for tenofovir and about 15% decrease in the same parameters for lopinavir. However, in clinical practice dose adjustments are not made.
Nevirapine (Viramune) 200mg once daily for 14 days, followed by 200mg twice daily After treatment interruptions lasting >7days, restart with 200mg once daily	NNRTI Within first 6 weeks: Potential severe and life threatening skin reactions: Stevens Johnsons syndrome and toxic epidermal necrolysis or serious hepatitis/hepatic failure The majority of NVP associated rashes appear within first 6 weeks: dose escalation should NOT be instituted till rash resolves.	Severe hepatic failure NVP should not be re-administered to patients who discontinued this drug for severe rash, rash accompanied by constitutional symptoms, NVP induced hypersensitivity or clinical hepatitis. If AST or ALT > 5xULN, NVP should be stopped	Oral contraceptives should not be used as sole method of contraception as NVP co-administration may decrease the concentration of these agents. Ketoconazole should not be co-administered (replace with fluconazole) Compounds that are enzyme substrates for Cyp3A and CYP2B6 may have altered metabolism when co-administered with NVP and need to be carefully monitored: clarithromycin, cimetidine Rifampicin is Not recommended: rifabutin can be used instead Prednisone DOES NOT decrease NVP related rash.
Hard gel Saquinavir (Fortovase) (boosted) 1600mg plus 100mg ritonavir once daily	Protease Inhibitor Major toxicities: Hyperglycaemia and fat redistribution	Do not administer in severe renal or hepatic impairment	Should not be co-administered with rifabutin or rifampicin . Due to inhibition of CYP3A4, saquinavirshould not be administered with compounds that are substrates for this enzyme; e.g. terfenadine, , midazolam, pimozide, ergot derivatives

Drug (recommended dosing)	Class and major toxicities	Contraindications	Drug interactions
Lopinavir/ Ritonavir (Kaletra) 133mg/33.3mg capsules, three capsules twice daily	Protease Inhibitor Major toxicities: Hyperglycaemia and fat redistribution Pancreatitis has been reported in patients with hyperglycaemia	Do not administer in severe hepatic impairment. Caution with severe renal impairment	No co-administration with rifampicin! Due to inhibition of CYP3A4, Kaletra should not be administered with compounds that are substrates for this enzyme; e.g. terfenadine, midazolam, pimozide, ergot derivatives Caution required when used with products known to induce GT internal prolongation e.g. clarithramycin, erythromycin Oral contraception effectiveness may be decreased.
Lopinavir/ Ritonavir (Aluvia) 200mg/50mg tablets, 2 tablets twice daily	Protease Inhibitor Major toxicities: Hyperglycaemia and fat redistribution Pancreatitis has been reported in patients with hyperglycaemia	Do not administer in severe hepatic impairment. Caution with severe renal impairment	No co-administration with rifampicin! Due to inhibition of CYP3A4, Aluvia should not be administered with compounds that are substrates for this enzyme; e.g. terfenadine, midazolam, pimozide, ergot derivatives Caution required when used with products known to induce GT internal prolongation e.g. clarithramycin, erythromycin Oral contraception effectiveness may be decreased.
Indinavir (Crixivan) 800mg three times daily	Protease Inhibitor Major toxicities: nephrolithiasis (adequate hydration of patients taking the drugs is recommended); Fat redistribution and hyperglycaemia	Do not administer in severe renal or hepatic impairment	No co-administration with rifampicin! Dose increase of rifabutin and dose reduction of indinavir are recommended when two compounds are co-administered. Due to inhibition of CYP3A4, Indinavir should not be administered with compounds that are substrates for this enzyme; e.g. terfenadine, midazolam, pimozide, ergot derivatives

Appendix 4.0 Toxicity Grading and Management

4.1 Table of Common Toxicity Criteria

Note: ULN denotes upper limit of local reference range ("upper limit of normal")

	Grade 1	Grade 2	Grade 3	Grade 4
HAEMATOLOGICAL				
Haemoglobin	8.0-9.4 g/dl	7.0-7.9 g/dl	6.5-7.0 g/dl	<6.5 g/dl
Leucopenia	3.0-3.9 $x10^3$ cells/μl	2.0-2.9 $x10^3$ cells/μl	1.9-1.0 $x10^3$ cells/μl	<1.0 $x10^3$ cells/μl
Neutrophils	1.00-1.50 $x10^3$ cells/μl	0.75-0.99 $x10^3$ cells/μl	0.50-0.74 $x10^3$ cells/μl	<0.50 $x10^3$ cells/μl
Platelets	75-99 $x10^3$ cells/μl	50-74 $x10^3$ cells/μl	20-49 $x10^3$ cells/μl	<20 $x10^3$ cells/μl
Prothrombin time	>1.0-1.25 x ULN	>1.25-1.5 x ULN	>1.5-3.0 x ULN	>3.0 x ULN
Partial prothrombin time	>1.0-1.66 x ULN	>1.66-2.33 x ULN	>2.33-3.0 x ULN	>3.0 x ULN
Methaemoglobin	5-10.0 %	10.1-15.0 %	15.1-20.0 %	>20 %
BIOCHEMISTRY				
Hyponatraemia	130-135 mmol/l	123-129 mmol/l	116-122 mmol/l	<116 mmol/l
Hypernatraemia	146-150 mmol/l	151-157 mmol/l	158-165 mmol/l	>165 mmol/l
Hypokalaemia	3.0-3.4 mmol/l	2.5-2.9 mmol/l	2.0-2.4 mmol/l	<2.0 mmol/l
Hyperkalaemia	5.6-6.0 mmol/l	6.1-6.5 mmol/l	6.6-7.0 mmol/l	>7.0 mmol/l
Hypocalcaemia (corrected for albumin)	1.95-2.10 mmol/l 7.8-8.4 mg/dl	1.75-1.94 mmol/l 7.0-7.7 mg/dl	1.53-1.74 mmol/l 6.1-6.9 mg/dl	<1.53 mmol/l <6.1 mg/dl
Hypercalcaemia (corrected for albumin)	2.70-2.93 mmol/l 10.8-11.7 mg/dl	2.94-3.19 mmol/l 11.8-12.7 mg/dl	3.20-3.44 mmol/l 12.8-13.7 mg/dl	>3.44 mmol/l >13.7 mg/dl
Hypomagnesaemia	0.47-0.59 mmol/l 1.2-1.4 mg/dl	0.35-0.46 mmol/l 0.9-1.1 mg/dl	0.25-0.34 mmol/l 0.6-0.8 mg/dl	<0.25 mmol/l <0.6 mg/dl
Hypophosphataemia	0.58-0.72 mmol/l 2.0-2.4 mg/dl	0.44-0.57 mmol/l 1.5-1.9 mg/dl	0.30-0.43 mmol/l 1.0-1.4 mg/dl	<0.3 mmol/l <1.0 mg/dl
Hypoglycaemia	3.1-3.6 mmol/l 55-64 mg/dl	2.2-3.0 mmol/l 40-54 mg/dl	1.7-2.1 mmol/l 30-39 mg/dl	<1.7 mmol/l <30 mg/dl
Hyperglycaemia (fasting)	6.5-9.0 mmol/l 118-164 mg/dl	9.1-14.0 mmol/l 165-255 mg/dl	14.1-28.0 mmol/l 256-509 mg/dl	>28.0 mmol/l >509 mg/dl or ketoacidosis
Triglycerides (fasting)	1.8-2.2 mmol/l 150-190 mg/dl	2.3-5.6 mmol/l 191-470 mg/dl	5.7-10.0 mmol/l 471-830 mg/dl	>10.0 mmol/l >830 mg/dl
Triglycerides (non-fasting)	-	4.8-8.9 mmol/l 400-750 mg/dl	9.0-14.4 mmol/l 751-1200 mg/dl	>14.4 mmol/l >1200 mg/dl
Albumin	26-30 g/l 2.6-3.0 g/dl	20-25 g/l 2.0-2.5 g/dl	<20 g/l <2.0 g/dl	-
Bilirubin	>1.0-1.5 x ULN	>1.5-2.5 x ULN	>2.5- 5.0 x ULN	>5.0 x ULN
AST or ALT or GGT	1.25-2.5 x ULN	>2.5-5.0 x ULN	>5.0-10.0 x ULN	>10.0 x ULN
Alkaline phosphatase	1.25-2.5 x ULN	>2.5-5.0 x ULN	>5.0-10.0 x ULN	>10.0 x ULN
Amylase (total or pancreatic or salivary)	>1.0-1.5 x ULN	>1.5-2.5 x ULN	>2.5-5.0 x ULN	>5.0 x ULN
Creatinine	>1.0-1.5 x ULN	>1.5-3.0 x ULN	>3.0-6.0 x ULN	>6.0 x ULN
Creatinine kinase	>1.0-2.0 x ULN	>2.0-4.0 x ULN	>4.0-6.0 x ULN	>6.0 x ULN
Lactate	>1.0- 2.0 x ULN without acidosis	≥2 x ULN without acidosis	>1.0 XULN with acidosis , without life threatening consequenses	>1.0 XULN with acidosis and life threatening consequences
Urea	1.25-2.5 x ULN	>2.5-5.0 x ULN	>5.0-10.0 x ULN	>10.0 x ULN
URINALYSIS				

	Grade 1	Grade 2	Grade 3	Grade 4
Proteinuria	1+ or <0.3% or <3g/l or 200mg-1g loss/day	2-3+ or 0.3-1.0% or 3-10g/l or 1-2g loss/day	4+ or >1.0% or >10g/l or 2-3.5g loss/day	nephrotic syndrome or >3.5 g loss/day
Haematuria	microscopic only	gross, no clots	gross and clots	obstruction or requiring transfusion
GASTROINTESTINAL				
Stomatitis/mouth ulcers	mild discomfort, no limits on activity	some limits on eating or talking	eating/ talking very limited	requiring IV fluids
Nausea	mild or transient discomfort, maintains reasonable intake	moderate discomfort or significantly decreased intake for <3 days	severe discomfort or minimal intake for ≥3 days	hospitalisation required
Vomiting	mild or transient; 2-3 episodes per day or mild vomiting lasting <1 week	moderate or persistent; 4-5 episodes per day or vomiting lasting ≥1 week	severe vomiting of all food/fluids in 24 hours or orthostatic hypotension or IV fluids required	hypotensive shock or hospitalisation required for IV fluids
Diarrhoea	mild or transient; 3-4 loose stools/day or mild diarrhoea lasting <1 week	moderate or persistent; 5-7 loose stools/day or diarrhoea lasting ≥1 week or nocturnal loose stools	bloody diarrhoea or orthostatic hypotension or >7 loose stools/day or requiring IV fluids	hypotensive shock or hospitalisation required for IV fluids
Clinical pancreatitis	mild abdominal pain, amylase <2.5x ULN, other causes excluded	moderate abdominal pain, amylase <2.5x ULN, other causes excluded	severe abdominal pain, amylase >2.5x ULN, hospitalisation required	severe abdominal pain, shock/ hypovolaemia, amylase>5x ULN, hospitalisation required
NEUROLOGICAL				
Headache	mild, no treatment	moderate or requires non-narcotic analgesia	severe or responds to first narcotic	intractable or requiring repeated narcotics
Consciousness	difficulty in concentration or memory	mild confusion or lethargy <50% waking hours	disoriented or stupor >50% waking hours	coma or seizures
Mood	mild anxiety or depression	treatment required for anxiety or depression	treatment and assistance required, severe depression, mania or anxiety	acute psychosis or hospitalisation
Psychosis	mild agitation or confusion	some limitation in activities of daily living and minimal treatment required	treatment and assistance required, severe agitation or confusion	toxic psychosis or hospitalisation
Cerebellar	slight incoordination or dysdiadochokinesia	intention tremor or dysmetria or slurred speech or nystagmus	ataxia requiring assistance to walk or arm incoordination interfering with activities of daily living	unable to stand
Motor	mild weakness in muscle of feet but able to walk or mild increase or decrease in reflexes	moderate weakness in feet (unable to walk on heels or toes), mild weakness in hands but still able to do most hand tasks, or loss of previously present reflex or development of hyperreflexia or unable to do deep knee bends due to weakness	marked distal weakness (unable to dorsiflex toes or foot drop) and moderate proximal weakness (eg in hands interfering with activities of daily living or requiring assistance to walk or unable to rise from chair unassisted)	confined to bed or wheelchair because of muscle weakness
Clinical myopathy	minimal findings	moderate myalgia or difficulty climbing stairs or rising from sitting position, able to walk, may need NSAID	moderate to severe myalgia needing NSAID, assistance required for walking or general activities	severe myalgia unrelated to exercise requiring narcotics, unable to walk or necrosis or oedema

	Grade 1	Grade 2	Grade 3	Grade 4
Sensory	mild impairment (decreased sensation eg vibratory, pinprick, hot/cold in great toes) in focal area or symmetric distribution	moderate impairment (moderately decreased sensation eg vibratory, pinprick, hot/cold to ankles) or joint position or mild impairment that is not symmetrical	severe impairment (decrease or loss of sensation to knees or wrists) or loss of sensation of moderate degree in multiple different body areas (eg upper and lower extremities)	sensory loss involves limbs and trunk
Parathaesia (burning, tingling etc)	mild discomfort, no treatment	moderate discomfort, requiring non-narcotic analgesia	severe discomfort or symptoms respond to narcotic analgesia	incapacitating or not responsive to narcotics
Peripheral neuropathy	mild paraesthesia, numbness, pain or weakness, not treated	moderate paraesthesia, numbness or pain, objective weakness, requires analgesic	severe, narcotic required, interferes with normal activity	intolerable, incapacitating, unable to walk despite narcotics, paralysis
RESPIRATORY				
Bronchospasm	transient, no treatment, 70-80% peak flow or FEV1	requires treatment, normalises with bronchodilator, 50-<70% peak flow or FEV1	no normalisation with bronchodilator, 25-<50% peak flow or FEV1, retractions	cyanosis, intubated or <25% peak flow or FEV1
CARDIOVASCULAR				
Cardiac arrhythmia	-	asymptomatic, transient dysrhythmia, no treatment	recurrent or persistent dysrhythmia, symptomatic treatment required	unstable dysrhythmia, hospitalisation and treatment required
Hypertension	transient, increase >20mm/Hg, no treatment	recurrent, chronic increase >20mm/Hg, requires treatment	acute treatment required, outpatient hospitalisation possible	hospitalisation required
Hypotension	transient, orthostatic hypotension no treatment	symptoms correctable with oral fluid treatment	IV fluid required, no hospitalisation required	hospitalisation required
Pericarditis	minimal effusion	mild/moderate asymptomatic effusion, no treatment	symptomatic effusion, pain, ECG changes	tamponade or pericardiocentesis or surgery required
Haemorrhage	microscopic or occult	mild, no transfusion	gross blood loss or transfused 1-2 units	massive blood loss or transfused >2 units
Cardiomyopathy	Asymptomatic, therapy not indicated	Asymptomatic, therapy indicated	Symptomatic CHF responsive to intervention	Refractory CHF, poorly controlled; intervention such as ventricular assist device, or heart transplant indicated
OTHER				
Fever, oral, >12 hours	37.7-38.5^{0}C	38.6-39.5^{0}C	39.6-40.5^{0}C	>40.5^{0}C
Fatigue	normal activity reduced by <25%	25-50% decrease in normal activity	>50% decrease in activity, cannot work	unable to care for self
Hypersensitivity	pruritus without rash	localised urticaria	generalised urticaria or angioedema	anaphylaxis
Rash	erythema or pruritus	diffuse maculopapular rash or dry desquamation	vesiculation or moist desquamation or ulceration	exfoliative dermatitis or mucous membrane involvement or suspected Stevens-Johnson or erythema multiforme or necrosis requiring surgery
Lipodystrophy	Detectable by study participant	Detectable on physical exam by healthcare provider	Disfiguring OR Obvious on casual visual inspection	
General	mild, transient, easily tolerated, no treatment	moderate, discomfort, interrupts usual activity, may require minor treatment	severe, considerable interference with usual activity, requires treatment or medical intervention	incapacitating or life-threatening, requires treatment and/or hospitalisation

4.2 Table of Clinical Signs, Symptoms, Monitoring and Management of Symptoms of Serious Adverse Effects of Antiretroviral Drugs that Require Drug Discontinuation (adapted from WHO guidelines [ref 10] Annex 11B)

Adverse Effect	Possible Offending Drug(s)	Clinical Signs / Symptoms	Management
Acute hepatitis	Nevirapine (NVP); more uncommon with zidovudine (ZDV), didanosine (ddI), stavudine (d4T) (<1%); and protease inhibitors (PI), most frequently with ritonavir (RTV)	Jaundice, liver enlargement, gastrointestinal symptoms, fatigue, anorexia; NVP-associated hepatitis may have hypersensitivity component (drug rash, systemic symptoms, eosinophilia)	Monitor serum transaminases, bilirubin. All ARV should be stopped until symptoms resolve. NVP may need to be permanently discontinued.
Acute pancreatitis	ddI, d4T	Nausea, vomiting, and abdominal pain	If possible, monitor serum pancreatic amylase, lipase. All ART should be stopped until symptoms resolve. Restart ART with change to different NRTI, preferably one without pancreatic toxicity (e.g., ZDV)
Lactic acidosis	All nucleoside analogue reverse transcriptase inhibitors (NRTIs)	Initial symptoms are variable: a clinical prodromal syndrome may include generalized fatigue and weakness, gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain, hepatomegaly, anorexia, and/or sudden unexplained weight loss), respiratory symptoms (tachypnea and dyspnea) or neurologic symptoms (including motor weakness).	Discontinue all ARV; symptoms may continue or worsen after discontinuation of ART. Supportive therapy. Regimens that can be considered for restarting ART include a PI combined with an NNRTI and tenofovir
Hyper-sensitivity reaction	Abacavir (ABC) Nevirapine (NVP)	ABC: Constellation of acute onset of symptoms including: fever, fatigue, myalgia, nausea/vomiting, diarrhea, abdominal pain, pharyngitis, cough, dyspnea (with or without rash). While these symptoms overlap those of common infectious illness, the combination of acute onset of both respiratory and gastrointestinal symptoms after starting ABC is more typical of a hypersensitivity reaction. NVP: Systemic symptoms of fever, myalgia, arthralgia, hepatitis, eosinophilia with or without rash.	Discontinue all ARVs until symptoms resolve. The reaction progressively worsens with drug administration and can be fatal. Administer supportive therapy. Do not rechallenge with ABC (or NVP), as anaphylactic reactions and death have been reported. Once symptoms resolve, restart ARVs with change to different NRTI if ABC-associated or to PI- or NRTI-based regimen if NVP-associated.
Severe rash / Stevens-Johnson syndrome	Non nucleoside reverse transcriptase inhibitors (NNRTIs): nevirapine (NVP)	Rash usually occurs during the first 2-4 weeks of treatment. The rash is usually erythematous, maculopapular, confluent, most prominent on the body and arms, may be pruritic and can occur with or without fever. Life-threatening Stevens-Johnson Syndrome or toxic epidermal necrolysis (SJS/TEN) has been reported in ~0.3% of infected individuals receiving NVP	Discontinue all ARVs until symptoms resolve. Permanently discontinue NVP for rash with systemic symptoms such as fever, severe rash with mucosal lesions or urticaria, or SJS/TEN; once resolves, switch ART regimen to different ARV class (e.g., 2 NRTIs and tenofovir or 2 NRTIs and PI).

Adverse Effect	Possible Offending Drug(s)	Clinical Signs / Symptoms	Management
Severe peripheral neuropathy	ddI, d4T, (3TC – unusual)	Pain, tingling, numbness of hands or feet; distal sensory loss, mild muscle weakness, and areflexia can occur.	Stop suspect NRTI and switch to different NRTI that does not have neurotoxicity (e.g., ZDV, ABC). Symptoms usually resolve in 2-3 weeks.
Severe anaemia	ZDV	Severe pallor, tachycardia at rest Shortness of breath on exertion (SOBOE)	Stop ZDV and switch to another drug

4.3 Guide to management of toxicities

4.3.1 Grade 1 (clinical or laboratory (LCM arm only)):

- Continue study drugs

4.3.2 Grade 2 (clinical or laboratory (LCM arm only)):

- Continue study drugs
- If relevant, monitor more closely, and for LCM arm only, consider more frequent laboratory assessments.
- Work-up to exclude other causes

4.3.3 Grade 3 (clinical or laboratory (LCM arm only)):

- Repeat clinical observation within 72 hours for confirmation.
- LCM arm: if relevant, obtain repeat confirmatory laboratory results within 72 hours
- CMO arm: if clinically indicated, laboratory results can be requested
- Work-up to exclude other causes
- Clinician has the option of immediately stopping the study drugs if a confirmatory laboratory test cannot be performed within 72 hours, or if the clinician determines that the continuation of study drugs is unsafe while awaiting test results

4.3.4 Grade 4(clinical or laboratory):*

- If relevant, obtain confirmatory laboratory results within 72 hours and fill in adverse event form
- Work-up to exclude other causes
- Clinician has the option of immediately stopping the study drugs if a confirmatory laboratory test cannot be performed within 72 hours, or if the clinician determines that the continuation of study drugs is unsafe while awaiting test results
- For all confirmed Grade 4 toxicities that can be clearly attributable to one or more antiretroviral drug(s), consider stopping relevant drug(s) and switching to alternative drug(s) as indicated in section 8.1.4, page 40. If therapy needs to be stopped, stop all drugs until toxicity resolves to ≤Grade 2. Then, restart therapy but discontinue the implicated drug(s) permanently and replace as indicated in section 8.1.4, page 40. If any doubt about management, discuss with the principal trial investigator

Appendix 5.0 Clinical progression and WHO Definitions

WHO clinical staging for HIV/AIDS

Clinical Stage 1: Asymptomatic Persistent generalised lymphadenopathy (PGL) Performance scale 1: asymptomatic, normal activity
Clinical Stage 2: Weight loss, <10% of body weight Minor mucocutaneous manifestations (seborrheic dermatitis, prurigo, fungal nail infections, recurrent oral ulcerations, angular cheilitis) Herpes Zoster, within the last 5 years Recurrent upper respiratory tract infections (e.g. bacterial sinusitis) And/or performance scale 2: symptomatic, normal activity.
Clinical stage 3: Weight loss, >10% of body weight Unexplained chronic diarrhoea, >1 month Unexplained prolonged fever (intermittent or constant), > 1 month Oral candidiasis (thrush) Oral hairy leukoplakia Pulmonary tuberculosis, within the past year. Severe bacterial infections (e.g. pneumonia, pyomyositis) And/or Performance scale 3: bed-ridden, <50% of the day during the last month
Clinical stage 4: HIV wasting syndrome, as defined by CDC[1] Pneumocystis carinii pneumonia Toxoplasmosis of the brain Cryptosporidiosis with diarrhoea, >1 month Cryptococcosis, extra pulmonary Cytomegalovirus (CMV) disease of an organ other than liver, spleen or lymph nodes Herpes Simplex Virus (HSV) infection, mucocutaneous >1 month, or visceral any duration Progressive multifocal leukoencephalopathy (PML) Any disseminated endemic mycosis (e.g. histoplasmosis, coccidioidomycosis) Candidiasis of the oesophagus, trachea, bronchi or lungs Atypical mycobacteriosis, disseminated Non-typhoid Salmonella septicaemia Extra Pulmonary tuberculosis Lymphoma Kaposi's sarcoma (KS) HIV encephalopathy, as defined by CDC[2] And/or Performance scale 4: bed-ridden, >50% of the day during the last month

(note: Both definitive and presumptive diagnoses are acceptable)

[1] HIV wasting syndrome: weight loss of >10% of body weight, plus either unexplained chronic diarrhoea (>1 month), or chronic weakness and unexplained prolonged fever (>1 month).

[2] HIV encephalopathy: clinical finding of disabling cognitive and/or motor dysfunction interfering with activities of daily living, progressing over weeks to months, in the absence of a concurrent illness or condition other than HIV infection that could explain the findings.

Appendix 6.0 Patient Information sheet and Consent Forms (Templates)

6.1 Patient information sheet for DART study

DART

Development of AntiRetroviral Therapy in Africa for adults infected with HIV.

Patient information sheet

You are being invited to take part in a research study. Please read this information carefully or have someone read it to you. You will be given a copy of this form to keep. Discuss it with others if you wish. Ask us if you would like more information. Take time to decide whether or not you wish to take part. If you are already registered with a current health system provider (e.g. TASO in Uganda), joining this work will not affect your rights to any other benefits it offers.

If you decide not to take part now or to withdraw from the study later, this will not influence the care you receive now (e.g. if you are a TASO member you will still get all your benefits from TASO).

What is the reason for doing the study?

HIV infection cannot be cured, but taking anti-HIV (antiretroviral) drugs can control it. We want to find out how best to use anti-HIV drugs so that the treatment is safe and effective. At present doctors use regular blood tests to see how the drugs are working and to check for side-effects. We want to find out whether the drugs can be taken without doing many blood tests. We also want to find out if the drugs need to be taken all the time or can they safely be taken with breaks (3 months on drugs, 3 months off).

How can I join the study?

After reading this information sheet you will be asked to give consent to be screened, which will involve being seen by the doctor and giving a blood sample. After two weeks you will be told whether you are eligible for the study and asked to sign a DART study consent form if you choose to participate.

What will happen if I take part?

You will be started on 3 anti-HIV drugs and you will be assigned to one of two groups:

- **clinical monitoring-only group**

  or

- **clinical and laboratory monitoring group**

In the **clinical monitoring-only group** your doctor will make decisions about your treatment based only on your symptoms. The results of your blood tests will be monitored independently and your doctor will be informed if there is a problem.

In the **clinical and laboratory-monitoring group** your doctor will make decisions about your treatment based on your symptoms and the results of your blood tests.

You will be asked to attend clinics 2 and 4 weeks after entry to the study, then every 4 weeks to see the nurse and every 3 months to see the doctor and to provide blood. At each visit you will be given a supply of anti-HIV drugs and asked to follow exact instructions on how to take these drugs.

It is very important that you do not miss any doses and do not share your medication with others.

If anti-HIV drugs are not taken properly, they will lose their effect, as the virus becomes resistant. Other medicines should only be taken on the advice of your doctor. You will be counselled to practice safe sex, as anti-HIV drugs cannot prevent transmission of HIV infection to sexual partners. If you do not attend your clinic visit, we would like to send a field-worker to your home to find out how you are.

After you have been taking anti-HIV drugs for 6 months, if your immune system has improved (CD4 count greater than 200cells/mm^3) you will be assigned into one of two groups (by computer):

- interrupted treatment (3 months on and 3 months off treatment)

  or

- continuous treatment

If your immune system has not improved enough at 6 months, you will be examined again at 12 months. If your CD4 count then is greater than 200 cells/mm^3, you will be eligible to be assigned to either interrupted or continuous treatment.

Treatment interruption pilot study

The first 100 patients who interrupt treatment will have blood tests and visits every month. Independent experts will look at the results on these 100 patients and if they find that treatment interruption is safe, all other patients with good response to treatment at 6 or 12 months will be assigned to either interrupted or continuous treatment. The pilot study will last for 6 months. After that, if you have no problems with interrupted treatment you will continue to interrupt drugs. If you had any problems with interrupted treatment, your doctor may suggest you take drugs continuously. After the pilot, you will continue on the monitoring arm you were assigned before the pilot. You will continue to receive drugs and follow–up as in the main DART study.

Blood samples

Blood tests may be done whenever you see the doctor. This may cause some discomfort and/or bruising in some patients. About two tablespoons of blood will be taken at one time. Some blood may be stored for later testing and you may not be given these results.

What drugs will be used in the DART study?

1. combivir (zidovudine + lamivudine in one pill)
2. tenofovir
3. nevirapine
4. didanosine
5. stavudine
6. saquinavir with ritonavir or other similar drugs from the same group

When you start the trial you will be given combivir with a third drug. The third drug will be tenofovir in Uganda and tenofovir or nevirapine in Zimbabwe. We will supply drugs for the duration of the study (4-5 years). After the study, your care will be provided by the national health system (or TASO in Uganda) including provision of anti-HIV drugs in line with current government plans.

Side effects

Anti-HIV drugs, like all drugs, have side effects, which are sometimes serious (less than 5%). If you experience symptoms tell your clinic doctor at your next visit, or if you are worried you should come to the clinic as soon as possible. It may be necessary to stop the drug(s) after which the problem usually goes away. We can replace drugs causing problems with other drugs.

Effects of drug interruption

During drug interruption it is possible that your HIV disease may get worse. If you get symptoms between visits you should come to the clinic. Your doctor may restart your treatment early (before the end of 3 months) and if problems continue when you are back on treatment, your drugs may be changed.

Pregnancy

HIV treatment given early in pregnancy may harm the unborn child. Pregnant and breastfeeding women will not be entered into this trial. A pregnancy test will be carried out at screening and at regular intervals during the study and women will be encouraged to avoid becoming pregnant during the trial. If a woman does becomes pregnant while in the trial, treatment will be continued without interruptions.

Confidentiality

Information about you will be kept confidential and will not be made available to anyone who is not connected with the study without your consent.

If you would like more information about this work please ask the doctors, nurses or counsellors. If you still need more information, call:

Insert names and telephone numbers as appropriate for each trial site

Name: ……..

Telephone Number: …….

6.2 Consent for Screening for the DART Trial

fill in with Forms 0 & 1	DART TRIAL **DART SCREENING CONSENT**

Centre: PPD

	Day	Month	Year		
Screening Consent Date			2 0 0	Clinic/ Hospital Number	
Date/Year of Birth			1 9	Age (if DOB not available)	Initials

Male ❍ Female ❍

DART TRIAL SCREENING CONSENT

I have read the information sheet for the DART trial and would like to be screened to see whether I am eligible for this trial.

I understand this will involve being seen by the doctor, who will ask questions about my health and my household, and having some blood taken.

Individual's signature (or thumbprint)	Print name	Date

Witness's signature	Print name	Date

Doctor's signature	Print name	Date

6.3 Patient consent form for DART Trial

fill with Forms 2-4 at Enrolment	**DART TRIAL** **DART TRIAL CONSENT**

Centre: PPD

	Day	Month	Year			
Trial Consent Date			2 0 0	Clinic/ Hospital Number		
Date/Year of Birth			1 9	Age at Screening (if DOB not available)	Initials	Male ❍ Female ❍

DART TRIAL CONSENT

A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa

DART

(Development of Anti-Retroviral Therapy in Africa)

Please initial box if you agree:

1. I have read/been read the information sheet for the DART study and I understand what will be required of me if I participate in the study.
   My questions concerning this study have been answered by:
   _____
2. I understand that I will be given anti-HIV drugs for 4-5 years while I am in the DART study. After the study, my healthcare will be provided by the national health system.
3. I understand that I may withdraw from the study at any time, without giving a reason and without affecting my normal care and management.
4. I agree to allow blood samples to be taken and stored for testing later. I may not be given results of tests performed on stored samples.
5. I am willing to allow access to my medical notes to check that the trial is being carried out correctly but understand that strict confidentiality will be maintained.
6. **I agree to take part in the DART study.**
7. I also agree to take part in the treatment interruption pilot study if asked to do so.

Individual's signature (or thumbprint)	Print name	Date

Witness's signature	Print name	Date

Doctor's signature	Print name	Date

IMPORTANT: **One signed original to be given to patient**
One signed original to be kept on file by the researcher
One signed original to be kept in the clinic notes

6.4 Patient information sheet for the second line randomisation feasibility study

DART

Development of AntiRetroviral Therapy in Africa

2nd Line Feasibility study

Patient information sheet

You are already taking part in DART but are being invited to additionally join an extra part of the study. This is because the anti-HIV drugs you have been taking are no longer working as well and need to be changed to different ones. Please read this information carefully or have someone read it to you. You will be given a copy of this form to keep. Discuss it with others if you wish. Ask us if you would like more information. Take time to decide whether or not you wish to take part.

If you decide not to take part in the DART 2nd line feasibility study, this will not affect the continuing care and treatment you receive now in the DART study.

What is the reason for doing the study?

With your recent clinical history it is now clear that the anti-HIV medicines that you are taking are no longer working as well as they have. It is now necessary to change to a new combination of anti-HIV/AIDS medicines. We call this second-line treatment.

We will provide the new second-line medicines within the current DART study and everything else will continue as before, except for the change of medication. You will continue to receive the same care and have the same access to the trial staff and clinic. We will continue to offer exactly the same level of services and support.

Much of the power in second-line treatment comes from Aluvia (also called Kaletra). Drugs like these are called "protease inhibitors" (PIs). They are made more powerful by adding small amounts of another drug (Ritonavir) and are then called "boosted" PIs. Although there are several different PIs available and Aluvia is currently the recommended boosted PI in Uganda and Zimbabwe.

We normally use anti-HIV drugs in combination to work together to attack the virus in different ways. Aluvia will therefore be supported by other drugs, at least for the first 24 weeks. Which other drugs you need will depend on what you have already been using up to now in your initial or first-line treatment in DART.

There are several different ways of using the new powerful second-line medicines; and it is not clear which is the best.

- One question is exactly which combination of other drugs best supports Aluvia. The options have different strengths and possible side-effects and may not be as effective when used in second-line as in first-line. The best balance between these factors is not known in second-line treatment anywhere yet.

This second-line feasibility study is therefore evaluating different combinations of the drugs to support Aluvia.

In DART, we continue to try to work out the best ways of treating HIV in Africa which is why we want to evaluate these different second line approaches - to see if all are the same or find out if some ways are better than others. The DART team emphasise that it is completely unclear to experts whether all approaches are ultimately the same for you; or whether one second line approach is in fact better for you than another.

What are the possible risks & benefits of different drug combinations to support Aluvia?

NOTE THAT FOR CLARITY DIFFERENT VERSIONS OF THE SHEET WILL BE PRODUCED WITH ONLY ONE OF THESE SECTIONS ON EACH. THE PARTICIPANT WILL BE GIVEN THE VERSION RELEVANT TO THEIR PRVIOUS TREATMENT HISTORY.

NNRTI FAILURES

You have already taken at least 2 drugs from the class called "nucleosides" (NRTIs, Combivir – actually Zidovudine and Lamivudine), together with a "non-nucleoside" (NNRTI, Nevirapine). Your HIV will have at least some resistance to these NRTI drugs and it is likely that the NNRTIs would not work at all. Therefore most of the power from your second-line drugs will come from Aluvia.

There are 2 options for support drugs we will use in DART are:

1. To use 2 new NRTI drugs that you have not taken before (Abacavir and Didanosine), even though we believe that these drugs are not likely to be fully effective because of resistance the virus has developed to the NRTIs you have taken before.
2. To exploit the idea that in becoming resistant to the drugs you have been taking the virus has probably also become weaker (less "fit"). By continuing to take Combivir we hope to keep the virus weaker. As you have already been taking Combivir this should give no new side-effects. You will also take one new NRTI (Tenofovir), which should have some activity against the virus.

NRTI FAILURES

You have only taken drugs from one class of HIV drugs – the "nucleoside" (or "nucleotides", NRTI), so we expect drugs from the other 2 classes to be as active as if you had not already taken any HIV drugs. So you will be given a boosted PI (Aluvia) and a "non-nucleoside" (NNRTI, Nevirapine or Efavirenz). It is not clear if added a third drug, another NRTI, will add any extra benefit or may increase side-effects.

The 3 options we will use in DART are:

1. To just take a boosted PI and an NNRTI
2. To take a boosted PI, an NNRTI and lamivudine. You have already taken lamivudine and your HIV will be resistant to it but is likely to also be weaker (less "fit"). By continuing to take lamivudine we hope to keep this weakness
3. To take a boosted PI, an NNRTI and Didanosine. Didanosine is an NRTI that you have not already taken, so may have some beneficial activity

How can I join the study?

After reading this information sheet you will be asked to give consent and to sign a DART 2nd Line feasibility study consent form if you choose to participate.

What will happen if I take part?

You will be allocated by chance to receive:

1. one of two or three different ART combination regimens to support Aluvia (or another PI).

All participants in the second-line study of DART trial will continue to be followed up in the DART clinic and receive exactly the same standards of care, provided free of charge.

An independent group of international experts will also continue regularly to monitor the progress of all patients in the second line feasibility study and should it be apparent that one approach or trial arm is better or worse than another then that arm or part of the trial will be stopped and all patients move to the better treatment option.

What will happen if I do not to take part?

If you do not wish to join the second line study in DART that is fine - we will still provide drugs for your second-line therapy and you will continue in current DART follow-up for the duration of the first part of DART. Declining to participate in the evaluation of second-line treatment in DART does not in any way or form affect your abilities or rights to continue to be part of the DART trial.

Whether or not you choose to take part in this study, after you have received 24 weeks of Aluvia based second-line therapy, you will be approached about co-enrolment into another study looking at the maintenance phase of second-line treatment.

If you have already switched to a second line regimen

If you have already switched to a second line regimen in DART you will not be able to join this feasibility study.

Blood samples

Blood tests may be done whenever you see the doctor, you will see the doctor as often as when you started in DART. This may cause some discomfort and/or bruising in some patients. About two tablespoons of blood will be taken at one time. Some blood may be stored for later testing and you may not be given these results. There will be no difference in the amount of blood taken if you join the DART 2nd Line Feasibility study or just continue in the main DART trial.

Side effects

Anti-HIV drugs, like all drugs, have side effects, which are sometimes serious (less than 5%). If you experience symptoms tell your clinic doctor at your next visit, or if you are worried you should come to the clinic as soon as possible. It may be necessary to stop the drug(s) after which the problem usually goes away. We can replace drugs causing problems with other drugs.

Pregnancy

Some HIV drugs (but not all) given early in pregnancy may harm the unborn child. A pregnancy test will be carried out at regular intervals during DART. If you think you might become pregnant please tell your doctors so that they can work out which drugs you should take. If a woman does become pregnant while in the trial, treatment will be continued.

Will joining this feasibility study have any effect on my treatment after the DART trial ends?

At the end of DART, all participants will be transferred into national programmes. Your government has promised that you will continue to be treated.

Confidentiality

Information about you will be kept confidential and will not be made available to anyone who is not connected with the study without your consent.

We have tried to explain clearly the different approaches being evaluated. If you feel that you still do not fully understand the different issues then it is fine to pause and ask for further information now. You also do not need to decide now but can come back later.

If you would like more information about this work please ask the doctors, nurses or counsellors. If you still need more information, call:

Insert names and telephone numbers as appropriate for each trial site

Name: ……..

Telephone Number: …….

6.5 Patient consent form for the feasibility second line randomisation

DART TRIAL

DART 2ND LINE FEASIBILITY STUDY CONSENT

Centre: PPD

	Day	Month	Year		
Consent Date			2 0 0	Clinic/Hospital Number	
Date/Year of Birth			1 9	Age at Screening (if DOB not available)	Initials

Male ❍ Female ❍

DART Trial Number

DART 2nd LINE FEASIBILITY STUDY CONSENT

A randomised trial of monitoring practice and structured treatment interruptions in the management of antiretroviral therapy in adults with HIV infection in Africa

DART

(Development of Anti-Retroviral Therapy in Africa)

Please initial (or mark) box if you agree:

1. I have read/been read the information sheet for the 2nd Line Feasibility Study of the DART Trial and I understand what will be required of me if I participate in the study.

   My questions concerning this study have been answered by:

   _____

2. I understand that I may withdraw from the 2nd Line Feasibility Study at any time and that if I still stay in DART I will be offered treatment with whichever combination of DART drugs my doctor decides.

3. I understand that I will continue to be given anti-HIV drugs in the DART study. After the study, my healthcare will be provided by the national health system.

4. **I agree to take part in the DART 2nd Line Feasibility Study.**

Individual's signature (or thumbprint)	Print name	Date

Independent witness's signature (only required if patient is unable to read)	Print name	Date

Doctor's signature	Print name	Date

IMPORTANT: **One signed original to be given to patient**
One signed original to be kept on file by the researcher
One signed original to be kept in the clinic notes

Appendix 7.0 Handling and Storage of Specimens

7.1 Bloods

7.1.1 Processing of EDTA blood for Plasma and cell store

For best results, centrifuge within 2 hours of drawing blood. If the time to processing is not within the same working day, **do not proceed**.

1. Centrifuge at 1500g for 15 minutes to separate cells from plasma.

2. Using a sterile pipette, collect the plasma more than 5mm above the buffy cell coat layer (grey layer above red cell layer).

3. Place the plasma, using up to three aliquots, in the cryovials provided for the trial. A minimum of two aliquots is required Routinely three cryovials of plasma and one cryovial containing the DNA pellet (if feasible) should be stored at each visit.

4. Label the cryovials with the patient "PLASMA" identification labels

5. Store cell pellet for later DNA isolation (if feasible). After plasma has been removed transfer the cell pellet into cryovial

6. Label the cryovials with the patient "CELLS" identification label and store at $^{-}$80°C (if not possible then $^{-}$20°C)

7.1.2 Storage of samples

1. Store within 4- 6 hours of drawing blood at -70°C (temperatures to -50°C allowed if this is not available). Place upright in the cryobox provided for the trial.

2. Add the Patient ID label to the Specimen Storage Log for sample. Complete the details for type of specimen processed, visit month, total number of tubes and storage temperature. Start a new log sheet when either the sheet is full or when starting to fill a new cryobox.

Appendix 8.0 Adherence protocol

FORM 14	DART TRIAL **ADHERENCE**

Centre: PPD

	Day	Month	Year		
Date Form Completed			2 0 0	Clinic/ Hospital Number	
Date/Year of Birth			1 9	Age at Screening (if DOB not available)	Initials

Male ❍ Female ❍

DART Trial Number | **CMO ☐ LCM ☐**

Please tell us if you have been able to take your anti-HIV treatment as planned.
You do not have to answer all the questions if you do not want to.
A NURSE SHOULD HELP YOU COMPLETE THIS FORM

1. **Are you late for this scheduled visit?** (tick box) Yes ☐ No ☐ If yes, specify number of days late ☐☐

2. **During the past 4 days, on how many days have you missed taking all (or part) of your HIV drug doses?**
   1 day ☐ 2 days ☐ 3 days ☐ 4 days ☐ No days ☐

3. **Indicate in the box below when you took your drugs.** Write the names of anti-HIV drugs in the first column. Put an 'X' if you took your drugs and put '0' if you missed a dose on each day.

Name of HIV drug	Did you take your drug?							
	Yesterday		2 days ago		3 days ago		4 days ago	
	am	pm	am	am	am	pm	am	pm
	am	pm	am	pm	am	pm	am	pm
	am	pm	am	pm	am	pm	am	pm
	am	pm	am	pm	am	pm	am	pm

4. **Some people find that they forget to take their pills on the weekends.**
   Did you miss any of your anti-HIV drugs last weekend (Saturday or Sunday)? (tick box)..... Yes ☐ No ☐

5. **Do any of your anti-HIV drugs have special instructions, such as "take with food", or "on an empty stomach"?** (tick box) ..... Yes ☐ No ☐
   If yes, how often did you follow these special instructions over the last 4 days? (tick box)
   Never ☐ Some of the time ☐ About half of the time ☐ Most of the time ☐ All of the time ☐

6. **Which one (if any) of your anti-HIV drugs is the easiest to take?** (write in here): _____

7. **Which one (if any) of your anti-HIV drugs is the most difficult to take?** (write in here):_____

8. **When was the last time you missed any of your anti-HIV drugs?** (tick box):
   Within the last week ☐ 1- 2 weeks ago ☐ 2- 4 weeks ago ☐ 1- 3 months ago ☐
   More than 3 months ago ☐ Never ☐

9. **(Complete at scheduled doctor visit only) People may miss taking their anti-HIV drugs for many reasons. Here is a list of possible reasons.** If you never miss your drugs do not answer this question

In the past month how often have you missed taking your anti-HIV drugs because you:	Never	Rarely	Sometimes	Often
a) Were away from home?	☐	☐	☐	☐
b) Were too busy with other things?	☐	☐	☐	☐
c) Simply forgot?	☐	☐	☐	☐
d) Had too many pills to take?	☐	☐	☐	☐
e) Wanted to avoid side-effects?	☐	☐	☐	☐
f) Did not want other people to notice you taking pills?	☐	☐	☐	☐
g) Had a change in daily routine?	☐	☐	☐	☐
h) Felt like the drug was toxic or harmful?	☐	☐	☐	☐
i) Were asleep through the dose time?	☐	☐	☐	☐
j) Felt sick or ill?	☐	☐	☐	☐
k) Felt depressed or overwhelmed?	☐	☐	☐	☐
l) Had a problem taking pills at a specified time (with meals or on an empty stomach)?	☐	☐	☐	☐
m) Ran out of pills?	☐	☐	☐	☐
n) Felt good?	☐	☐	☐	☐

Appendix 9.0 Post DART Trial issues

The DART trial, as with all clinical trials, is funded for a specific time-limited period by the funding bodies involved. Drugs will be provided for the duration of the trial for up to 6 years for each patient.

It may be expected that as all patients in the trial will be receiving HAART, many patients will be alive at the end of the trial, and still be benefiting from ART. For them cessation of therapy would not be appropriate. The various study sites in Uganda and Zimbabwe have made this dilemma clear in their ethical submissions. The DART team has initiated collaboration with the governments in Uganda and Zimbabwe and external sponsors to address these concerns and ensure that DART trial is entirely ethically sound and acceptable to the countries. Both Zimbabwe and Uganda have applied to the Global Fund and access to ARV has expanded substantially. It is expected that post-trial healthcare for the patients will be obtained within the framework of this partnership. There will be a phased transition of DART participants to other programmes over a period of up to 6 months covering quarter 4 of 2008 and quarter 1 of 2009.

This partnership with local health authorities also includes collaborations with:

- The Ugandan Ministry of Health Task Force set up to deliver more drug treatment for Ugandan citizens and to establish the mechanisms of drug provision by the Government.
- The PPD which has recently been established in PPD has set up a large treatment centre for ART.
- The large and medium sized businesses to seek to derive support from the companies for long-term ART after the trial of their employees.
- Medical insurance companies who are taking an active interest in the issues around ART and are considering ways to provide ART for their clients.